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 Disulfide-bonding cysteine residues perform critical roles in the structural 
stabilization and redox regulation of protein function. Secreted proteins are often 
enriched for structural disulfide bonds conferring conformational stability in the 
oxidizing extracellular environment. The controlled formation of disulfide bonds 
in secreted proteins is regulated in the endoplasmic reticulum (ER) by the protein 
disulfide isomerase (PDI) family. To investigate disulfide-bond formation in the 
ER, quantitative chemical-proteomic methods were coupled to subcellular-
fractionation-based ER enrichment. Cysteine reactivity studies identified highly 
reactive post-translationally modified cysteine residues including disulfide-
bonding cysteines. Upon discovering a highly reactive population of traditionally 
oxidized cysteines, the percentage of oxidation for cysteines localizing to the ER 
was determined. Next, ER function was chemically perturbed to evaluate changes 
to cysteine oxidation following upregulation of the unfolded protein response 
(UPR). Disulfide bond formation was specifically disrupted in the ER by CRISPR-
Cas9-mediated PDIA1 and PDIA4 knockout. The effects of PDI knockout on 
cancer cell phenotype and changes to cysteine oxidation states were evaluated. 
Finally, in vitro studies were performed to evaluate PDIA4 oxidase activity and 
identify potential PDIA4-selective inhibitors. In the future, the platforms 
developed within may be applied to profiling changes to cysteine oxidation in 
other biological systems such as other organelles and disease states.
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SKOV-3 cells. A) Cellular proliferation following PDIA1KO or PDIA4KO 
was characterized. Cells were compared to a WT control. Data is presented 
as a mean +/- SEM, n = 5. B) Cellular serum-free survival in PDIA1KO and 
PDIA4KO cells was evaluated and compared to a WT control. Data is 
presented as a mean +/- SEM, n = 5. * P value <0.05. 
 
Figure 3-12. Activation of UPR target genes was evaluated by qRT-PCR in 
WT, PDIA1KO, and PDIA4KO cells. Transcripts were normalized to a 
housekeeping gene, RPLP2, and relative mRNA expression levels were 
calculated. Data represents the mean ± s.d. of two replicates. * P value <0.05. 
 
 
Figure 3-13. Quantifying changes in secretory pathway protein abundance 
following PDIA1 and PDIA4 knockout in SKOV-3 cells. A) Schematic 
representation of a ReDiMe MS platform design to quantify changes to 
protein abundance in the isolated ER of PDIA1KO an PDIA4KO cells. B) 
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ReDiMe MS analysis was performed to evaluate changes in protein 
abundance following knockout of PDIA1. Changes to protein abundance 
are shown as a log2 ratio plot (PDIA1KO:WT) of identified ER and secretory 
pathway Uniprot/Go annotated proteins. C) ReDiMe MS analysis was 
performed to evaluate changes in protein abundance following knockout 
of PDIA4. Changes to protein abundance are shown as a log2 ratio plot 
(PDIA4KO:WT) of identified ER and secretory pathway Uniprot/Go 
annotated proteins. 
 
Figure 3-14. Schematic representation of an OxICAT MS platform designed 
to capture and quantify cysteine oxidation states in isolated ER. 
 
Figure 3-15. Statistical analyses of changes to cysteine oxidation following 
genetic depletion of PDIA1 or PDIA4. ER was isolated from WT, PDIA1KO, 
and PDIA4KO SKOV-3 cell lines and subjected to OxICAT MS methods. A) 
Volcano plot displaying differences in average percent oxidized (WT-
PDIA1KO) for 930 ER and secretory pathway annotated cysteines against -
log(P-value). B) Volcano plot displaying difference in average percent 
oxidized (WT-PDIA4KO) for 944 ER and secretory pathway annotated 
cysteines against -log(P-value). (A,B) Differences in average percent 
oxidized (WT- PDIA1KO or WT - PDIA4KO) were assessed for statistical 
significance using unpaired t tests, n = 3. A P-value of 0.05 was set for 
statistical significance (horizontal dotted line). Cysteine residues with a 
difference (WT - PDIA1KO or WT - PDIA4KO) greater than 10% (sensitive 
cysteine residues) are plotted to the left and right of the vertical dotted lines. 
 
Figure 3-16. Evaluating changes to secretory pathway cysteine oxidation 
states following depletion of PDIA1 or PDIA4 in SKOV-3 cells. A) Plot 
comparing secretory pathway cysteine oxidation states in the isolated ER of 
WT and PDIA1KO cells. B) Plot comparing secretory pathway cysteine 
oxidation states in the isolated ER of WT and PDIA4KO cells. 
 
Figure 3-17. Cysteine oxidation state sensitivity is predominantly unique to 
PDIA1KO or PDIA4KO. A) Venn Diagram illustrating unique and 
overlapping changes in cysteine oxidation states following genetic 
depletion of PDIA1 or PDIA4. B) Extracted ion chromatogram from 
OxICAT analysis for Cys296 in SEC63, a residue found to be sensitive to 
PDIA1 knockout. C) Extracted ion chromatogram from OxICAT analysis 
for Cys342 in ERBB2, a residue found to be sensitive to PDIA4 knockout. D) 
Extracted ion chromatogram from OxICAT analysis for Cys645 in HSP90B1, 




Figure 4-1. Small molecule inhibitors of PDIA1. Non-covalent inhibitors are 
highlighted in blue and covalent inhibitors are highlighted in red. 
 
Figure 4-2. Structure of 1,2-dihydroxytrideca-5,7,9,11-tetrayne (DHTT) a 
small molecule inhibitor of PDIA4. 
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Figure 4-3. RNase A oxidation activity assay to measure PDI family oxidase 
activity. The refolding of reduced RNase A by PDIs is coupled to the 
hydrolysis of cCMP by RNase A. 
 
Figure 4-4. Evaluation of PDIA1 and PDIA4 oxidase activity. A) 
Recombinant PDIA1 and PDIA4 were expressed and purified. B) Purified 
PDIA1 and PDIA4 were subjected to an RNase A oxidative activity assay, 
demonstrating each PDIs relative oxidase activity. 
 
Figure 4-5. Schematic representation of cysteine to alanine PDIA4 active-
site mutants used to independently study the role of each active site in 
PDIA4’s oxidase activity. 
 
Figure 4-6. Screening of triazine and 4-aminopiperidine small molecule 
libraries against purified recombinant PDIA4. A) Library members that 
demonstrated the most potent covalent modification of PDIA4. B) 0.2 
mg/mL purified recombinant PDIA4 was incubated with various library 
members (10 µM) for 1 hour and analyzed by in-gel fluorescence. 
 
Figure 4-7. Screening of SMC-19, SMC-20, and RB-9-ca (10 µM) against 
SKOV-3 lysates (2 mg/mL), recombinant purified PDIA4 (0.2 mg/mL), or 
SKOV-3 lysates (2 mg/mL) spiked with recombinant purified PDIA4 (0.2 




List of abbreviations 
Standard 3-letter and 1-letter codes are used for the 20 natural amino acids. 
  
1,3-BPG 1,3-bisphosphoglycerate 
2DE two-dimensional electrophoresis 
ABHD12 lysophosphatidylserine lipase 
ABHD12 
 
AIDS acquired immunodeficiency 
syndrome 
 
ALS amyotrophic lateral sclerosis 
ANPEP aminopeptidase N 
APEX engineered ascorbate peroxidase 
aRNase A active RNase A 
ATF6 activating transcription factor-6α 
ATP13A1 manganese-transporting ATPase 13A1 
ATPIF1 ATPase inhibitor 
BioGEE biotinylated glutathione ethyl ester 
BioGSH biotinylated GSH 
BioGSSG biotinylated GSSG 
BioID proximity-dependent biotin 
identification 
 
Bip  binding-immunoglobulin protein 
BPTI bovine pancreatic trypsin inhibitor 





Cas9 CRISPR associated protein 9 
CBS cystathionine β-synthase 
cCMP 2’,3’-cyclic cytidine monophosphate 
CCR5 C-C chemokine receptor type 5 
CD circular dichroism 
CD151 cluster of differentiation 151 
CD4 T-cell surface glycoprotein CD4 
CHOP C/EBP-homologous protein 
CJD Creutzfeldt-Jakob disease 
CKAP4 cytoskeleton-associated protein 4 
CM cell membrane 
CoA coenzyme A 
COL18A collagen alpha-1 (XVIII) chain 
COPI coated protein complex I 
COPII coated protein complex II 
Cox17 cytochrome c oxidase copper 
chaperone 
 
CRISPR clustered regularly interspaced short 
palindromic repeats 
 
CRMP2 collapsing response mediator protein 
2  
 




CXCR4 chemokine C-X-C receptor 4 
Cyto. cytosol 
Cyto. Ves. cytoplasmic vesicle 
Cytoskel. cytoskeleton 
DHTT 1,2-dihydroxytrideca-5,7,9,11-tetrayne 
DJ-1 protein/nucleic acid deglycase DJ-1 
DMSO dimethyl sulfoxide 
DNAJC3 DnaJ homolog subfamily C member 3 
DRM detergent-resistant membrane 
DSM detergent-soluble membrane 
DTNB 5,5’-dithiobis-(2-nitrobenzoic acid) 
DTT dithiothreitol 
E10R probable FAD-linked sulfhydryl 
oxidase E10 
 
EC2 extracellular loop 2 
Endo. endosome 
ER endoplasmic reticulum 
ERAD endoplasmic reticulum associated 
degradation 
 
ERBB2  receptor tyrosine-protein kinase erbB-
2 
 
ERDJ4 endoplasmic reticulum DNA J 
domain-containing protein 4 
 
ERM ER-localizable reactive molecules 
ERM ezrin, radixin, and moesin 
Ero1 oxidoreductin 1 
	 	 	xxii	
ERp29 endoplasmic reticulum resident 
protein 29 
 
ERp44 endoplasmic reticulum resident 
protein 44 
 
ERp5 endoplasmic reticulum protein 5 
ERp57 endoplasmic reticulum resident 
protein 57 
 
ERp72 endoplasmic reticulum resident 
protein 72 
 
Erv1 sulfhydryl oxidase 
FAD flavin adenine nucleotide 
FALS familial amyotrophic lateral sclerosis 
FERM 4.1 protein, ezrin, radixin, and 
moesin) 
G3P glyceraldehyde 3-phosphate 
G4L glutaredoxin-2 (viral) 




GLRX-10 glutaredoxin (C. elegans) 
GNP 5’-guanylyl imidodiphosphate 
GO Gene Ontology 
gp120 envelope glycoprotein gp120 
gp160 envelope glycoprotein gp160 
gp41 envelope glycoprotein gp41 
GPT GlcNAc phosphotransferase 
GR glutathione reductase 
GRP94 94 kDa glucose-regulated protein 
	 	 	xxiii	
Grx glutaredoxin 
Grx1 glutaredoxin 1 
Grx2 glutaredoxin 2 
GS glutathione synthetase 
GSH glutathione (reduced) 
GSSG glutathione (oxidized) 
GTP guanosine-5’-triphosphate 
H3FA histone H3 
HER2 receptor tyrosine-protein kinase erbB-
2 
	
HIV human immunodeficiency virus 
HSA human serum albumin 
HSP heat shock protein 
HSP90B1 endoplasmin 
HSPA13 heatshock protein 70 kDa protein 13 
HSPA5 heat shock protein family A member 5 
HSV-1 herpes simplex virus 1 
HUVEC human umbilical vein endothelial 
cells 
 
HYOU1 hypoxia up-regulated protein 1 




ICAT isotope-coded affinity tags 




IMS intermembrane space 
IPTG isopropyl-β-D-thiogalactoside 
IRE1α inositol-requiring 1α 
isoTOP-ABPP isotopic tandem orthogonal 
proteolysis – activity based protein 
profiling 
 
ITGAV integrin alpha-V 
KO knockout 
L1CAM neural cell adhesion molecule L1 
LC liquid chromatography 
Lyso. lysosome 
MEF murine embryonic fibroblast 
MHCII major histocompatibility complex 
class II 
 
Mia40 mitochondrial intermembrane space 




MS mass spectrometry 
MYH10 myosin-10 
N3GSH azide containing GSH 








OxICAT oxidation ICAT 
P4H prolyl 4-hydroxylase 
P4HA1 prolyl 4-hydroxylase subunit alpha-1 
P4HA2 prolyl 4-hydroxylase subunit alpha-2 
P4HB prolyl 4-hydroxylase subunit beta 
PAM protospacer adjacent motif 
PC photocleavable 
PCR polymerase chain reaction 
PD Parkinson’s disease 
PDI protein disulfide isomerase 
Pdi1P protein disulfide isomerase (S. 
cerevisiae) 
 
PDIA1 protein disulfide isomerase A1 
PDIA13 protein disulfide isomerase A13 
PDIA14 protein disulfide isomerase A14 
PDIA18 protein disulfide isomerase A18 
PDIA1KO PDIA1 knockout 
PDIA2 protein disulfide isomerase A2 
PDIA3 protein disulfide isomerase A3 
PDIA4 protein disulfide isomerase A4 
PDIA4KO PDIA4 knockout 
PDIA6 protein disulfide isomerase A6 
PDIA8 protein disulfide isomerase A8 
PDIA9 protein disulfide isomerase A9 
	 	 	xxvi	




Prp prion protein 
PrpC prion protein (non-pathogenic) 
PrpSC prion protein (protease resistant) 
PTM post-translational modification 
PTP protein tyrosine phosphatase 
PTP1B protein tyrosine phosphatase 1B 
qPCR quantitative polymerase chain 
reaction 
 
QSOX Quiescin-sulfhydryl oxidase 
ReDiMe isotopic reductive dimethylation 
Ribo. ribosome 
RNase ribonuclease 
RNase A ribonuclease A 
ROS reactive oxygen species 
RPN1 ribophorin I 
RPS6 40s ribosomal protein S6 
rRNase A reduced RNase A 
SAR structure-activity relationship 
Sec. secreted 
SEC63 translocation protein SEC63 homolog 
SEM standard error of the mean 
	 	 	xxvii	
SERCA sarco/endoplasmic reticulum Ca2+-
ATPase 
 
sgRNA single guide RNA 
shRNA short hairpin RNA 
SILAC stable isotope labeling by amino acids 
in cell culture 
	
siRNA small interfering RNA 
SN supernatant 
SOD1 superoxide dismutase 1 
STT3A dolichyl-diphophooligosaccharide-
protein glycosyltransferase subunit 
STT3A 
 
TCA trichloroacetic acid 
TCEP tris(2-carboxyethyl)phosphine 
Tg thapsigargin 
TIM translocase of the inner membrane 
Tim40 mitochondrial import inner 
membrane translocase 
 
TM9S3 transmembrane 9 superfamily 
member 3 
 
TMX3 thioredoxin-related transmembrane 
protein 3 
 





TrxR thioredoxin reductase 
TSA tumor-specific antigen 
	 	 	xxviii	
TSE transmissible spongiform 
encephalopathies 
 




Txnip Trx-interacting protein 
UL32 packaging protein UL32 
UPR unfolded protein response 
UV ultra violet 
VWF von Willebrand factor 
WC whole-cell 
WT wild-type 
XBP1 X-box binding protein 1 



















































Bechtel, T.J. and Weerapana, E. From structure to redox: The diverse functional 
roles of disulfides and implications in disease. Proteomics. 2017, 17. 
	 2	
Introduction 
 Disulfide bonds have classically been shown to stabilize proteins by 
maintaining overall structure via intermolecular and intra-domain covalent bonds 
between two cysteine residues1. These structural disulfide bonds are essential for 
the stability of secreted and plasma-membrane proteins destined for the harsh 
oxidizing extracellular environment. Disulfide-bond formation on secreted 
proteins is tightly regulated by oxidoreductases in the endoplasmic reticulum 
(ER), including members of the protein disulfide isomerase (PDI) family1-3. Recent 
studies have shown that structural disulfide-bond formation may occur in other 
cellular compartments such as the mitochondria, due to the presence of 
oxidoreductase machineries (Erv1/Mia40) similar to the PDIs4. Dysregulated 
structural disulfide-bond formation is a hallmark of diseases such as Creutzfeldt-
Jakob disease (CJD), amyotrophic lateral sclerosis (ALS) and various cancers5-6.  
The functional roles of disulfide bonds extend beyond the well-
characterized role in protein structure stabilization (Figure 1-1). Importantly, 
redox-active disulfide bonds regulate protein activity and localization in response 
to cellular redox potentials and comprise intramolecular protein disulfides and 
mixed disulfides with small-molecule thiols such as glutathione. Unlike static 
structural disulfides, redox-active disulfides are highly dynamic and are regulated 
by oxidative or reductive changes in the local environment7. Dysregulation of 
cellular redox potentials and the resulting aberrant formation or reduction of 
redox-active disulfides contributes to diseases such as thrombosis and 
Parkinson’s8-11. In addition, dynamic disulfide switches are essential mediators of 
viral entry as demonstrated by HIV-112.  
	 3	
This chapter will focus on the diverse functional roles of disulfide bonds in 
eukaryotic cells. The mechanisms for disulfide-bond formation in various 
organelles and the roles of structural and redox-active disulfide bonds in protein 
stabilization and regulation of activity and localization will be described. Special 
emphasis will be placed on the contributions of dysregulated disulfide-bond 
formation to human disease. Lastly, current proteomic methodologies for globally 
identifying structural and redox-active disulfide bonds will be surveyed. 
 
 
Figure 1-1. The known functional roles of disulfides: structural and redox 
disulfides. Redox disulfides may be further characterized as small molecule, 
catalytic and allosteric disulfides. 
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Evolution of Disulfide Bonds 
Cysteine residues on proteins play a variety of functional roles including 
metal binding, nucleophilic and redox catalysis, protein regulation and disulfide-
bond formation13. Given the unique ability of cysteine to fulfill these diverse 
functional roles, it is unsurprising that cysteine is the second most conserved 
amino acid during protein evolution, surpassed only by tryptophan14. 
Furthermore, although cysteine is a late evolutionary addition to the genetic code, 
cysteine residues on proteins have accrued with higher frequency, alluding to the 
preferential incorporation of cysteine residues at functional loci15. Importantly, 
within a given organism, approximately 50% of cysteines are involved in 
disulfide-bond formation and these disulfide bonds are highly conserved. In fact, 
cysteines that form disulfide bonds are the most highly conserved of the amino 
acids (even more conserved than tryptophan), whereby 96.9% of disulfide-bonded 
cysteines are conserved once acquired in H. sapiens16. Interestingly, up to 99% of 
disulfide cysteine pairs are mutated in concert and it is rare for only one cysteine 
to be replaced by evolution16-17. Lastly, as organismal complexity increases, there 
is an increased rate of accrual for disulfide-bonded cysteine residues16, which 
likely reflects the need for more intricate mechanisms by which to modulate 
protein structure and function. In summary, the high conservation and increased 
rate of accrual of disulfide bonds underscores the fundamental importance of the 
acquisition and maintenance of disulfide bonds to eukaryotic evolution.   
 
Properties of a Disulfide Bond 
Protein disulfide bonds are covalent linkages between the thiol groups of 
two cysteine residues, which are formed via a two-electron oxidation that is often 
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coupled to the reduction of oxygen, flavin cofactors, oxidized glutathione, and 
other disulfides. Disulfide-bond formation between two thiolate anions (RS-) may 
occur spontaneously in vitro with molecular oxygen as the final electron acceptor1. 
In contrast, within biological systems, disulfide bonds are predominately formed 
via thiol-disulfide exchange reactions1, whereby a thiol nucleophile attacks an 
existing disulfide bond (RSSR) to yield a new mixed disulfide and free thiol 
species. For example, due to the high (mM) concentrations of oxidized and 
reduced forms of glutathione (GSSG/GSH) in the cell, the GSSG/GSH couple 
frequently control the formation and reduction of cellular disulfides through thiol-
disulfide exchange reactions. Furthermore, oxidoreductases in eukaryotic cells 
including protein disulfide isomerases18 and thioredoxin9, accelerate the rate of 
disulfide-bond formation and reduction.  
The redox potential of a disulfide bond, which specifies the tendency to be 
reduced, dictates the formation and stability of that species in a given redox 
environment19. Typically, for cellular disulfides, redox potentials are measured 
relative to glutathione as a standard; therefore, disulfide bonds with negative 
redox potentials are considered more stable and less likely to undergo thiol-
disulfide exchange in the presence of glutathione. The redox potentials that have 
been measured for protein disulfides range from -95 to -470 mV, varying by at least 
375 mV7.  These variations in redox potential are attributed to several factors 
including pKa, entropy and bond-strain energy, as discussed below9, 19-21.  
  
Thiol pKa.   
The kinetics of thiol-disulfide exchange are dependent on the pKa of both 
the nucleophilic-cysteine thiol and the leaving-group thiol. The standard pKa for a 
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thiol is 8.5, resulting in protonation at physiological pH. However, cysteine pKa 
values are known to range from 3.5 to greater than 12 depending on the local 
protein microenvironment3. Decreased cysteine pKa is attributed to stabilization of 
the thiolate by electron withdrawing groups or nearby positive charges and results 
in an increase in the rate of thiol-disulfide exchange22-23. Low thiol pKa values that 
are significantly below the pH of the solution, however, render decreased 
nucleophilicity of the thiolate. Therefore, the rate constant peaks when the thiol 
pKa is equivalent to the pH of the solution23. In contrast, decreased pKa of the 
leaving-group thiol increases the rate of thiol-disulfide exchange, regardless of the 
pH of the solution. Thiol addition to an asymmetrical disulfide (RSSR’), results in 
the thiol with the lowest pKa acting as the leaving group24.  
 
Entropy. 
Entropic barriers, including rotation and translation, affect the stability of 
disulfide bonds and the rate of formation. Intermolecular disulfide bonds are 
entropically disfavored, but the entropic costs of intramolecular disulfide bonds 
are more complex. In denatured proteins, with large distances between cysteines, 
the entropic barriers to disulfide-bond formation are high due to the rotational and 
translational freedom characteristic of a denatured protein. As two cysteines 
become closer in the primary sequence, the amount of conformational freedom 
decreases and orientations that permit disulfide formation increases, reducing the 
entropic costs of disulfide-bond formation25.   
The rigid tertiary structure of a folded protein can potentially bring cysteine 
residues into close proximity, resulting in more thermodynamically favorable and 
faster disulfide-bond formation, relative to a denatured protein. For example, a 
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disulfide bond in bovine pancreatic trypsin inhibitor (BPTI) is stabilized by tertiary 
structure and therefore has been measured to display an exceptionally low redox 
potential of -470 mV26.  
 
Strain. 
 Disulfide bonds may be unstable if the disulfide introduces strain into the 
protein structure. The ideal dihedral angle for disulfides is ± 90o, and studies show 
that distortion away from this preferred angle can increase redox potential by as 
much as 10-100 mV27. While observed in nature28-29, vicinal disulfides between two 
neighboring cysteines, and disulfides in loops, are associated with higher levels of 
structural strain than cysteines within more distal and less rigid regions of the 
protein. Furthermore, vicinal disulfide bonds reverse the direction of the peptide 
chain, and distort the trans-planar conformation of the peptide backbone to a cis 
conformation, which introduces further strain on the protein structure30. 
 
Structural Disulfide Bonds 
Disulfide bonds confer structural stability to proteins destined for the 
secretory pathway. Importantly, secreted and plasma-membrane proteins are 
exposed to highly oxidizing environments (~ -140 mV more than intracellular 
organelles)31. This highly oxidizing extracellular environment induces 
spontaneous inter- and intramolecular disulfide-bond formation2 that disrupts 
protein structure. The controlled formation of structural disulfide bonds within 
the ER and other cellular compartments prior to secretion minimizes potential 
structural damage to proteins due to spontaneous extracellular disulfide 
formation.  
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Structural disulfide bonds exist as intramolecular or inter-domain disulfide 
bonds, which are generated in a highly controlled fashion by families of dedicated 
oxidoreductases32. Disulfide-forming oxidoreductases are abundant and essential 
components of the endoplasmic reticulum and include members of the PDI 
family3, 33. Similar oxidoreductase systems, comprised of MIA40/Erv1, have also 
been identified in the intermembrane space (IMS) of the mitochondria4. 
Furthermore, recent studies have identified mechanisms for controlled disulfide-
bond formation in the most reducing organelle of the cell, the cytoplasm34, where 
viruses co-opt an oxidative folding pathway for protein biogenesis35. The efficient 
and controlled formation of structural disulfide bonds is essential to maintaining 
protein integrity, and dysregulation of structural disulfides contributes to various 
types of diseases including CJD, ALS, and many cancers5-6, 36.  
 
Disulfide-bond formation in the ER; the protein disulfide isomerase family.  
 Proteins destined for the secretory pathway are subjected to 
posttranslational modification (e.g. glycosylation), folding and disulfide-bond 
formation in the ER. The redox potential of the ER is between -150 to -180 mV with 
a GSH to GSSG ratio of 1:1 to 3:1, thereby rendering the ER one of the most 
oxidizing organelles within the cell37. The PDI protein family catalyzes the 
controlled formation and rearrangement of disulfide bonds for structural 
stabilization of nascent proteins. Each of the 22 PDI members contain at least one 
thioredoxin-like (Trx-like) domain with a thioredoxin fold6. These Trx-like 
domains may be catalytically active (a-domain), possessing a CXXC motif, or 
inactive (b-domain). PDIs also possess an acidic C-terminal extension (c-domain) 
that terminates with an ER retention sequence6, 38. The PDI family members vary 
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in the number of a and b domains that they contain39. For example, PDIA1 
(commonly referred to as PDI), is the most abundant (~ 0.8% of all cellular 
protein40) PDI, and possesses four Trx-like domains (a, b, b’, and a’) and a c-domain 
with a KDEL ER retention sequence41-42.  
In PDIA1, the redox state of the CGHC active-site motifs in the a-domains 
dictate if oxidase (disulfide form of PDIA1) or isomerase (dithiol form of PDIA1) 
chemistry is performed43. The non-catalytic b’ domain is responsible for 
identifying unfolded and improperly folded proteins through exposed 
hydrophobic patches on the nascent protein44. Oxidation of nascent proteins is 
accompanied by the concomitant reduction of the CGHC active-site motifs of 
PDIA145. Subsequent re-oxidation of the PDIA1 active sites is carried out by ER 
oxidoreductin 1 (Ero1), a flavin adenine nucleotide (FAD) binding oxidase46. Ero1 
contains two cysteine pairs; one located on a flexible loop and the other two as part 
of a CXXC motif proximal to the FAD cofactor47. Oxidation of PDIA1 is first 
achieved through thiol-disulfide exchange with the flexible-loop cysteines, 
followed by transfer of electrons to the FAD cofactor via the CXXC cysteines. 
Lastly, these electrons are shuttled from FADH2 to O2, producing H2O2 and 
regenerating the FAD cofactor (Figure 1-2)47-48. In contrast to PDIA1 oxidase 
activity, substrate isomerization does not result in a net change in the PDIA1 redox 
state, therefore, Ero1 is not required for continued isomerase activity. Isomerase 
chemistry occurs via the formation of a mixed-disulfide through nucleophilic 
attack of PDIA1 active-site cysteines on the substrate disulfide bond. The N-
terminal cysteine in each CGHC active-site motif is stabilized by the adjacent 
histidine residue, thereby reducing the thiol pKa (~4.5 – 5.6)49-50 and enabling this 
cysteine to act as a nucleophile in isomerase reactions. In comparison, the C-
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terminal cysteine has an observed pKa of 12.851. A thiolate on the substrate 
subsequently resolves the mixed disulfide to produce a new disulfide whilst 
restoring PDIA1 to its reduced state52. Lastly, it is proposed that PDIA1 can also 
reduce disulfide bonds on substrates via formation of a mixed disulfide that is 
resolved by the C-terminal cysteine within the CGHC motif53 32. This reductase 
activity may prove important for removing an incorrect disulfide when 
isomerization is not feasible.  
In addition to PDIA1, other members of the PDI family have been shown to 
display oxidase and isomerase activity, including: PDIA2, PDIA3 (ERp57), PDIA4 
(ERp72) and PDIA6 (ERp5)54. The functional redundancy of each PDI member in 
vivo has not been fully determined. It has been shown that PDIA4 expression is 
increased in cells in which PDIA3 levels are reduced, suggesting some functional 
overlap between these two PDIs55. Additionally, PDIA3 interacts with calnexin 
and calreticulin and is thought to aid in the folding of glycoproteins54. Future 
studies into the substrate specificities of the PDI members are likely to establish 










Figure 1-2. The Ero1α-PDI mediated oxidative folding pathway. PDI is reoxidized 
by Ero1α a FAD binding oxidase. Ero1α transfers electrons from PDI to FAD with 





Disulfide-bond formation in the mitochondria; Mia40. 
Since mitochondrial proteins are translated in the reducing environment of 
the cytoplasm and the mitochondria itself is a reducing environment (-280 to -340 
mV), the presence of structural disulfides is surprising56. However, numerous 
mitochondrial proteins, including the Tim proteins that comprise the translocase 
of the inner membrane (TIM) complex57-58, and the copper chaperone Cox1759, are 
known to contain structural disulfide bonds. Structural disulfides are introduced 
during translocation of proteins through the inter mitochondrial space (IMS), 
which is the most oxidizing (~-255 mV) of the mitochondrial compartments60. 
Disulfide-bond formation in the IMS uses a disulfide-relay system, Mia40 and 
Erv1, which is similar to the PDI/Ero1 system in the ER61. Mia40 (Tim40) contains 
a unique catalytic CPC-motif and two twin CX9C segments that form structural 
disulfides with one another62. The catalytic CPC-motif has a redox potential of -
200 mV63, and in contrast to PDIA1, the C-terminal cysteine of the CPC-motif is the 
more nucleophilic of the catalytic cysteines63. Mia40 is responsible for disulfide-
bond formation on several Tim proteins and Cox174, and similar to PDIA1, re-
oxidation of Mia40 is required upon disulfide-bond formation on a substrate 
protein. Erv1, a Quiescin-sulfhydryl oxidase (QSOX), is an electron acceptor for 
reduced Mia4064. Erv1 contains two CXXC motifs; one located on a flexible-tail 
segment while the second is proximal to the FAD cofactor64. Electrons are 
transferred from Mia40 to FAD on Erv1 via the CXXC motifs, with oxidation of 
FADH2 occurring through transfer of electrons to two equivalents of Cytochrome 
c65-66. 
The Mia40/Erv1 system in the mitochondria share similarities with the ER 
PDI/Ero1 system. However, several differences exist between the two systems; 
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notably Mia40 does not contain Trx-like domains and furthermore, Erv1 belongs 
to a protein family (QSOX) divergent from Ero1. The substrate repertoire of Mia40 
in the IMS is not fully established and it is currently unknown whether or not other 
disulfide-relay systems exist in the IMS. 
 
Disulfide-bond formation in the cytoplasm; viral proteins. 
 Similar to the mitochondria, the cytoplasm is considered to be highly 
reducing, with a redox potential of -200 to -260 mV67, and cytoplasmic disulfide-
bond formation is unanticipated. However, disulfide-bond formation occurs in 
keratinization as well as in in viral-protein biogenesis and has been recently 
reviewed34. Vaccinia virus was the first identified to introduce disulfide bonds on 
viral protein substrates in the cytoplasm35. A viral protein complex comprising a 
redox-active protein, A2.5L, and sulfhydryl oxidase, E10R, together with an 
accessory protein, G4L, are responsible for disulfide-bond formation34-35. This 
disulfide-bond forming machinery is shared by several other nucleocytoplasmic 
large DNA viruses34. Additionally, the herpes simplex virus 1 (HSV-1) chaperone 
UL32 contains three CXXC motifs and is thought to regulate disulfide-bond 
formation on capsid proteins to ensure structural integrity68. Absence of UL32 
resulted in the formation of non-native disulfide bonds, likely due to spontaneous 
and uncontrolled disulfide-bond formation during infection and capsid 
maturation68-70. While disulfide-bond formation in the cytoplasm is rare and only 
demonstrated for non-host viral proteins, it serves to exemplify that even reducing 
compartments of the cell are capable of hosting oxidoreductases for  controlled 
disulfide formation.  
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Dysregulation of structural disulfide-bond formation in disease. 
Transmissible spongiform encephalopathies (TSEs). TSEs are rare and fatal disorders 
characterized by neurodegeneration and classified into three forms: infectious 
(kuru), sporadic (Creutzfeldt-Jakob disease (CJD)) and familial (fatal familial 
insomnia). These disorders are the result of prion protein, PrPC, misfolding into a 
protease-resistant form, PrPSC, which is prone to aggregation (Figure 1-3A)71-72. 
PrPC contains a globular domain composed of three α-helices, with a disulfide 
linkage connecting two of these helices73-74. Upon conversion of PrPC to PrPSC, these 
α-helices are replaced by 𝛽-sheets75. The disulfide bridge has been shown to 
contribute to stabilization of the native and non-pathogenic PrPC structure. When 
the disulfide bond on the mouse prion protein was reduced and capped, circular 
dichroism (CD) studies showed that the resulting reduced PrP possessed 
decreased α-helical content, increased β-content and larger exposed hydrophobic 
regions relative to its oxidized counterpart76. These data suggest that the disulfide 
bond is important to stabilize the α-helical structure of PrP and prevents exposure 
of hydrophobic regions that promote aggregation. 
Upon translation in the ER, approximately 10% of PrPC is misfolded and 
removed by ER-associated degradation (ERAD)77-78. An increase in misfolded PrP 
in TSEs causes ER stress and activation of the unfolded protein response (UPR)78-
80. UPR activation increases expression of a variety of pro-survival genes including 
the PDIs81 (Figure 1-3B). For example, PDIA3 is upregulated in CJD brain tissue 
and protects cells from the toxicity of infectious PrP82-83. PDIA3-deficient murine 
embryonic fibroblasts (MEFs) show increased PrP aggregation, which was further 
augmented by treatment with a reducing agent, suggesting that reduced disulfide-
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bond content correlates with increased aggregation. Furthermore, PDIA3 was 
shown to directly interact with PrP via co-immunoprecipitation studies84, 
suggesting that either the chaperone or oxidoreductase activity of PDIA3 is 
important to prevent PrP aggregation. 
 
 
Figure 1-3. Structural disulfides in prion protein related diseases. A) A reduced 
form of Prp, PrpSC, is protease resistant. (B) Misfolded Prp may be removed from 
the ER via ERAD.  Activation of the UPR results in increased expression of folding 
chaperones such as ERp57. ERp57 interacts with misfolded Prp and may refold 
Prp, preventing Prp aggregation.   
 
Amyotrophic lateral sclerosis (ALS). Familial ALS (FALS) is caused by mutations in 
superoxide dismutase 1 (SOD1) resulting in the misfolding and aggregation of 
SOD1 into cross-β-amyloid fibrils that ultimately lead to cell death (Figure 1-4)85-
86. The first step in cross-β-amyloid fibril formation is referred to as initiation. The 
“nucleus” that is formed during initiation may fragment and produce fibril seeds 
that convert soluble SOD1 to insoluble β-rich structures and thus elongate the 
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fibril. The process following initiation is termed seeded amyloid growth87-88. 
Fragmented fibrils may be transmitted to new cells where they seed further 
aggregation89-90. SOD1 exists as a homodimer with each monomer containing a β-
barrel, binuclear Cu/Zn site, and an intramolecular disulfide bond91. The mature 
form of SOD1 is highly stable and therefore does not initiate aggregation92. 
Recently, fibrillation-induced fluorescence measurements identified the 
structural-disulfide bond in wild-type (WT) SOD1 as an important contributor to 
fibril formation88. The reduced form of SOD1 showed increased rates of seeded 
amyloid growth and spontaneous fibrillation, whereas  no fibril initiation was 
observed for oxidized SOD1. Importantly, the disulfide bond in mutant SOD1 was 
more easily reduced than WT SOD1 and small quantities of the reduced form of 
mutant SOD1 were sufficient to initiate the fibrillation of WT SOD1. During seeded 
growth, reduced WT SOD1 was recruited faster by growing fibrils than oxidized 
WT SOD1, which is attributed to the conformational flexibility of the disulfide-
reduced state88. These data identify the disulfide bond of SOD1 as an important 






Figure 1-4. The role of structural disulfides in seeded growth in ALS. Immature 
and reduced apo-SOD1 or Zn-SOD1 initiates the formation of cross-β-amyloid 
fibrils creating a "nucleus." The "nucleus" fragments to produce "seeds" that 
convert soluble SOD1 into insoluble β-rich structures, elongating the cross-β-
amyloid fibrils.  
 
Cancer. The rapid proliferation of cancer cells requires increased rates of protein 
synthesis and folding, and increased expression of folding chaperones, including 
members of the PDI family, is characteristic of ovarian, breast, prostate, lung and 
other cancers6, 93. Decreased PDIA1 levels in patients with breast cancer or 
glioblastoma has been associated with higher survival rates94-96, and increased 
PDIA1 levels are associated with chemo-resistance97. These results together 
suggest that increased disulfide-bond formation and isomerization capability is 
essential to the survival of cancer cells. In addition to PDIA1, PDIA4 and PDIA6 
levels are increased 11.2-fold and 7.75-fold, respectively, in cisplatin-resistant lung 
adenocarcinoma. Knockdown of PDIA4 and PDIA6 reinstated cisplatin sensitivity 
via a mitochondrial apoptosis or non-canonical cell-death pathway98.  
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Global methods to identify structural disulfide bonds. 
 Several methods exist to identify structural disulfide bonds in proteins 
through conformational changes in the protein following reduction. These 
methods include NMR, CD, and X-ray crystallography, and while extremely 
useful for identifying structural changes in a purified homogenous protein, they 
are not applicable for the global identification of structural disulfides within a 
proteome. A mass spectrometry (MS)-based method was recently developed to 
map native disulfide bonds on a global scale99. In this method, proteins are 
precipitated with trichloacetic acid (TCA) to maintain the integrity of disulfide 
linkages, and the precipitated proteins are dissolved in a denaturing buffer and 
free thiols capped with N-ethylmaleimide (NEM). Proteins were then digested 
with a combination of proteases such as Lys-C, trypsin, Glu-C, and/or Asp-N and 
analyzed by LC-MS/MS. Data analysis was performed using an adapted form of 
the p-Link software, pLink-SS, for identifying cross-linked peptides100. Analysis of 
the secreted proteome of human umbilical vein endothelial cells (HUVECs), 
identified more than 550 disulfide bonds. 
 
Redox-active Disulfides 
 Redox-active disulfide bonds are reversible and responsive to changes in 
the redox potential of the surrounding environment, and the formation or 
reduction of these disulfide bonds serve to regulate protein activity and cellular 
localization. These disulfides can be intramolecular (oxidoreductases, allosteric 
disulfides, etc.) or mixed disulfides between a cysteine residue and a small-
molecule thiol resulting in glutathionylated and cysteinylated adducts. 
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Dysregulation of redox-active disulfide formation contributes to various diseases 
including Parkinson’s and HIV infection.  
 
Reactive oxygen species and disulfide-bond formation.  
 Endogenous reactive oxygen species (ROS), such as superoxide (O2-), the 
hydroxyl radical (.OH) and hydrogen peroxide (H2O2), are produced during 
cellular respiration in the electron transport chain of the mitochondria, 
peroxisomal activity and oxidase activity as seen during the reoxidation of 
PDIA1101-103. Additionally, exogenous factors such as smoke, xenobiotics, radiation 
and other sources may generate ROS that diffuse into the cell or induce 
endogenous ROS production104-106. ROS are a common byproduct during cellular 
processes and play roles in cell signaling and homeostasis, however, high and 
persistent levels of ROS can cause oxidative damage and lead to a variety of 
disease states107. Exposure of a cysteine thiol to ROS results in the formation of a 
sulfenic acid (-RSOH), which could react with GSH (glutathionylation) or a nearby 
cysteine to form an –inter or –intra molecular disulfide bond108-109. Additionally, 
higher cellular GSSG levels resulting from increased ROS exposure can trigger 
disulfide-bond formation through thiol-disulfide exchange. ROS-induced 
reversible disulfide-bond formation contributes to the regulation of cellular 
antioxidant defense, chaperone systems and metabolism107, 110 111-113. For example, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) catalyzes the conversion of 
glyceraldehyde 3-phophate (G3P) to 1,3-bisphosphoglycerate (1,3-BPG) in 
glycolysis114. Under oxidative stress, the active-site cysteine of GAPDH is 
sulfenylated and subsequently forms a disulfide with a nearby cysteine115, which 
limits flux through glycolysis and reroutes metabolic intermediates to the pentose 
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phosphate pathway to generate NADPH116. NADPH is essential for the reduction 
and reactivation of thioredoxin (Trx) and glutaredoxin (Grx)117, which are 
antioxidants that act to reduce cellular levels of redox-active disulfides.   
  
Redox-active disulfides with small-molecule thiols. 
Glutathionylation. Glutathionylation refers to the formation of a mixed disulfide 
between a protein thiol and GSSG via thiol-disulfide exchange10, 118, or reaction of 
S-nitrosated or sulfenylated proteins with GSH119. Removal of glutathione adducts 
can occur spontaneously by thiol-disulfide exchange with GSH, and enzymatically 
by Grx, Trx or sulfiredoxin120-122. Various cellular pathways are regulated by 
glutathionylation, including the NF-𝜅β pathway that triggers inflammation123. 
Glutathionylation of Cys62 in the p50 subunit of NF-𝜅β inhibits DNA binding and 
downstream transcriptional activity124. In addition to affecting the function of 
transcription factors, glutathionylation can act to either inhibit or activate a variety 
of enzymes. Glutathionylation of protein tyrosine phosphatases (PTPs), 
specifically the active-site cysteine of PTP1B, inhibits phosphatase activity125 126. In 
contrast, glutathionylation of Cys346 in cystathionine β-synthase (CBS) enhances 
the homocysteine to cysteine enzymatic conversion127.  
 
Cysteinylation.  Cysteinylation involves the formation of a mixed disulfide between 
a protein cysteine thiol and the thiol group of free cysteine. Intracellular cysteine 
concentrations have been found to be around 100 µM, approximately a magnitude 
lower than glutathione concentrations128. Cysteinylation is analogous to 
glutathionylation; although, it remains poorly characterized in eukaryotic 
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systems129. Cysteinylation has been observed in human serum albumin130 and a 
recent study showed an increase in cysteinylation of plasma protein thiols with 
age131. Additionally, SOD1, which  catalyzes the dismutation of superoxide anions 
into molecular oxygen and hydrogen peroxide132, was found to be cysteinylated in 
human neuronal tissue133. In vitro studies showed that cysteinylated SOD1 is 
protected from oxidative damage133. The small number of characterized human 
cysteinylated proteins is likely due to the scarcity of methods to study this 
modification, and as technologies for enrichment and identification improve, the 
targets of cysteinylation may prove to be more prevalent. 
 
Redox-active disulfides on oxidoreductases.  
Thioredoxin (Trx). The Trx family is composed of two Trx systems, Trx1 (12 kDa) 
and Trx2 (18 kDa), that catalyze thiol-disulfide exchange117, 134-135. Each Trx is 
composed of a thioredoxin-fold (four α-helices and five β-sheets) and a CGPC 
(CXXC) active-site motif134. Trx1 is found extracellularly136 and intracellularly in 
the cytoplasm and nucleus while Trx2 is localized to the mitochondria9. Trx1 is 
responsible for activation of extracellular proteins, regulation of the intracellular 
redox environment, and modulation of transcription factors and gene expression 
in the nucleus137-138. Trx2 regulates the mitochondrial redox environment and 
protects cells from oxidant-induced apoptosis139. The redox potentials of the CXXC 
motifs of the Trx proteins are around -270 mV rendering them some of the most 
reducing of the oxidoreductases140. Similar to PDIA1, the N-terminal cysteine in 
the active site has a low pKa, ~ 6.3141, and acts as the nucleophile for thiol-disulfide 
exchange reactions. The mixed disulfide is resolved by the C-terminal active-site 
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cysteine yielding oxidized Trx and a reduced substrate142. Oxidized Trx is reduced 
by the dimeric flavoenzyme, thioredoxin reductase (TrxR)143, which utilizes 
NADPH as the electron donor (Figure 1-5)143. Trx activity is regulated by Trx-
interacting protein (Txnip), which binds to the active site and inhibits Trx1 
reductase activity144. Overexpression of Txnip has been shown to slow cell 
growth145 and stimulate apoptosis146. Trx activity is also regulated by 
glutathionylation of Cys73, a non-active-site cysteine147. Interestingly, nitrosation 
of Cys73  results in Trx gaining trans-nitrosation activity, whereby the NO moiety 
is transferred to the active-site cysteine of caspase-3148. Members of the thioredoxin 
system (Trx, NADPH, TrxR, and Txnip) are implicated in various aspects of 
(patho)physiology, including embryonic development, neurodegenerative 
diseases, viral infections, cardiovascular diseases, cancer and aging9, 149.   
 
 
Figure 1-5. The Trx-TrxR mediated disulfide reduction pathway. Trx reduces 
disulfide bonds in substrate proteins. TrxR reoxidizes Trx by transferring 
oxidizing equivalents from FAD to Trx.  
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Glutaredoxin (Grx). Grx proteins constitute a family of relatively small 
oxidoreductases (~9-15 kDa)150, primarily localized in the cytosol, nucleus and 
mitochondria151 (human Grx1 is also known to be secreted152). Grx proteins contain 
a Trx-like fold and either dithiol (CXXC) or monothiol (CXXS), active-site motifs 
for reducing protein disulfides or glutathionylation adducts151, 153-154. The 
mechanism for protein-disulfide reduction by dithiol Grx proteins is analogous to 
that described for PDIA1 and Trx. The resulting oxidized dithiol Grx is re-reduced 
after each catalytic cycle by GSH to form reduced Grx and GSSG151. For monothiol 
Grx proteins that act on glutathionylated substrates, the resulting Grx-glutathione 
mixed disulfide is resolved by a second molecule of GSH to form GSSG and 
reduced monothiol Grx154 155. The cellular GSSG:GSH ratio is restored by 
glutathione reductase and NADPH117, whereby electrons are transferred from 
NADPH to GSSG via a redox-active disulfide on glutathione reductase to 
regenerate GSH (Figure 1-6)117. Due to the high specificity displayed by Grx 
proteins for reducing glutathionylated proteins, this family of proteins are 
important players in cellular pathways regulated by protein glutathionylation118. 
Additionally, Grx proteins can reduce intra- and inter-protein disulfide bonds on 
ribonucleotide reductase156, peroxiredoxin157, and collapsing response mediator 
protein 2 (CRMP2)158, thereby affecting proliferation, detoxification and 
developmental pathways, respectively. For example, CRMP2 was shown to be 
reduced by Grx2, and silencing of Grx2 in zebrafish resulted in increased levels of 
oxidized CRMP2 and subsequent neuronal loss by apoptotic cell death158. Lastly, 
dysregulated Grx activity is implicated in various diseases, including Parkinson’s 
disease and HIV infection159. 
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Figure 1-6. Grx-GR mediated disulfide reduction pathway. Similar to Trx, Grx 
reduces disulfide bonds in substrate proteins. Grx is reoxidized by GSSG, yielding 
two equivalents of GSH and oxidized Grx. GSSG levels are restored by GR via the 
transfer of oxidizing equivalents from NADP+ to GSH. 
 
Allosteric redox-active disulfides. 
 Allosteric redox-active disulfide bonds are typically distal to functional loci 
within the protein, but induce a functional change in the protein upon reduction 
by oxidoreductases or thiol-disulfide exchange160-161 12. Functional changes elicited 
by allosteric disulfides include changes in ligand binding, substrate hydrolysis, 
proteolysis, and oligomerization12. Allosteric disulfides are not defined by a 
common sequence motif, but do share similarities in the disulfide-bond geometry. 
Disulfide bonds are classified by the five chi (𝜒) angles of the six atoms that make 
up the bond, Cα-Cβ-Sɣ-Sɣ’-Cβ’-Cα’, whereby each 𝜒 angle can be positive or 
negative, rendering twenty possible disulfide geometries. Three of the twenty 
configurations, -right-hand staple (-RHstaple), -left-handed hook (-LHhook) and -
/+RHhook (-/+RHhook), are enriched in allosteric disulfide bonds. Of these, –
RHstaples are enriched six-fold, and LHhooks and -/+RHhooks are enriched 
threefold in allosteric disulfides relative to all disulfides161-162. –RHstaples and -
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/+RHhooks were found through computational studies to be more stressed than 
other geometries, due to stretching of the S-S bond and bending of the neighboring 
bond angles163. In contrast, -LHhooks show similar bond stress when compared to 
the other 17 disulfide configurations and it remains unknown as to why this 
configuration is enriched in allosteric disulfides. Interestingly, –RHstaples are 
often cross-strand disulfides that link adjacent strands in a β-sheet, and the 
proximity of the strands generate a highly strained disulfide bond7, 161. Cleavage of 
this strained disulfide bond can therefore induce large conformational changes. 
For example, reduction of the intramolecular –RHstaple between Cys130-Cys159 
in CD4 results in domain swapping and the formation of an intermolecular 
disulfide-linked homodimer164-166.  
Allosteric disulfide-bond reduction by oxidoreductases is governed by 
several factors. Importantly, steric factors, including the accessibility of the 
disulfide and accommodation of the disulfide in the oxidoreductase active site, 
contribute significantly to disulfide-bond recognition and reduction by 
oxidoreductases. Furthermore, the environmental context, in terms of which 
oxidoreductases are present in the local vicinity, is also important in determining 
which disulfides are reduced by which oxidoreductases11. Additionally, disulfide-
bond reduction occurs via SN2 nucleophilic substitution, whereby the three sulfurs 
involved in disulfide bond reduction must be oriented in a 180o angle167. Stretching 
and twisting of proteins may change the orientation of the three sulfurs making it 
easier or more difficult for disulfide cleavage to occur168. Lastly, allosteric 
disulfide-bond reduction by oxidoreductases is also dictated by the redox 
potentials of the disulfide and the oxidoreductase active-site redox couple. The 
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redox potential for allosteric disulfides range from -184 mV to -255 mV12, and lie 
within the redox potential range for oxidoreductases (-120 mV to -270 mV)169. Most 
allosteric-disulfide redox potentials are more negative than PDIA1, thereby 
necessitating a stronger reductase such as thioredoxin. However, allosteric 
disulfide cleavage has been performed by PDIA1, PDIA6, and potentially 
PDIA3170-173. The number of characterized allosteric disulfide bonds remains 
relatively small, amounting to ~30 across mammals, bacteria, plants, and 
viruses162, and are implicated in the pathogenesis of various diseases and viral 
infection162, 170. Ongoing efforts to structurally define characteristic features of 
allosteric disulfides are likely to expand the identification and underlying 
functions of these motifs12. For a comprehensive review on allosteric disulfides 
refer to references:11-12, 137, 162.  
 
Contributions of redox-active disulfide bonds to disease. 
 Oxidative stress is the result of an imbalance between ROS and antioxidant 
defenses leading to a deviation from the resting redox state of the cell, and is 
implicated in a variety of diseases including neurodegenerative diseases 
(Parkinson’s Disease and ALS)8, cardiovascular disease174 and cancer175. High 
GSSG/GSH ratios and increased disulfide-bond formation are often characteristic 
of these diseases176-177. For example, a recent study showed that a cysteinylated 
cysteine in human serum albumin (HSA), Cys34, may be used as a marker for 
oxidative stress-related diseases using blood samples of patients with chronic liver 
disease, chronic kidney disease, or diabetes mellitus178. Redox-active disulfides 
that are directly linked to disease pathology are described below. Future 
identification of similar inter- or intra-molecular disulfides could yield a wider 
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range of biomarkers for diagnosis and therapeutic targets for treatment of diseases 
characterized by oxidative stress.  
 
Glutathionylation of DJ-1 in Parkinson’s disease. Parkinson’s disease (PD) is a 
progressive neurodegenerative disease that affects the central nervous system and 
is characterized by the formation of Lewy bodies and the death of dopaminergic 
neurons in the substantia nigra179. Oxidative stress is implicated in the pathology of 
PD and mutations in DJ-1, an antioxidant protein, correlate with early onset PD in 
humans8, 180. Oxidizing conditions result in sulfenic acid formation or 
glutathionylation of Cys106 in DJ-1181, 182, and mutations to this residue increase 
sensitivity to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+). Interestingly, 
Grx1 knockdown is associated with a decrease in DJ-1 protein levels, suggesting 
that deglutathionylation of DJ-1 by Grx1 protects DJ-1 from degradation183. The 
protective function of Grx1 is further supported by the observation that Grx1 
levels are significantly decreased in the dopaminergic neurons of PD patients184. 
Additionally, overexpression of DJ-1 in a C. elegans model of PD containing a 
GLRX-10 (Grx1 homolog) knockdown provided dopaminergic neuronal 
protection182, confirming that glutathionylation of DJ-1 and potentially other 
proteins may contribute to the pathogenesis of PD.   
 
Allosteric redox-active disulfide bonds in HIV-1 gp120 and CD4. Human 
immunodeficiency virus-1 (HIV-1) is a lentivirus that ultimately causes acquired 
immunodeficiency syndrome (AIDS). Viral entry of HIV-1 into host cells requires 
interactions between the HIV viral envelope protein, gp160, and host cell surface 
co-receptors, CD4 and chemokine receptor, CXCR4 or CCR5185. The gp160 
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envelope protein is proteolytically cleaved into two subunits: gp120, a disulfide 
rich surface glycoprotein, and gp41, a transmembrane protein, which non-
covalently interact to form a trimer of gp120-gp41 heterodimers. Upon binding to 
CD4 and CXCR4, gp120 and gp41 dissociate and initiate fusion of the viral and 
host membranes186.  
Of relevance is the fact that both gp120 and CD4 contain allosteric redox-
active disulfide bonds, which require reduction prior to viral entry 12. Reduction 
of disulfide bonds on gp120 unmasks the fusion peptide in gp41 for membrane 
insertion (Figure 1-7)170. PDIA1 is responsible for gp120 reduction and inhibition 
of PDIA1 prevents membrane fusion170, 187. Moreover, six of the nine disulfide 
bonds in gp120 have been shown to be reduced by PDIA1170, Trx188-189 and/or 
Grx159. Recently, MS analysis using a Trx kinetic trapping mutant identified a 
disulfide bond in the V3 domain of gp120, Cys296-Cys331, as a target of Trx189. 
Importantly, this disulfide bond is in the –RHStaple configuration, which is a 
hallmark of many allosteric redox-active disulfides. Furthermore, binding of CD4 
to gp120 enhances the reduction of Cys296-Cys331, postulated to be due to 
conformational changes in the V1/V2 and V3 loops of gp120 that increases 
interactions with oxidoreductases190. Lastly, reduction of the Cys296-Cys331 
disulfide induces conformational changes in the V3 loop that ultimately activate 





Figure 1-7. Reduction of a disulfide bond in gp120 by PDI or Trx promotes HIV 
virus-cell fusion.  
 
Similarly to gp120, CD4 contains a disulfide bond in its second domain, 
Cys130-Cys159, which is categorized as a –RHStaple configuration with high 
strain energy, thereby fulfilling the criteria of an allosteric redox-active disulfide12, 
164.  In vitro reduction of this metastable disulfide was shown to induce a structural 
collapse in the second domain and increase thermal stability in the first two 
domains of CD4191. This disulfide is reduced by Trx secreted by CD4+ T cells164, and 
promotes the formation of CD4 disulfide-linked dimers. CD4 dimerization 
enhances binding to the major histocompatibility complex class II (MHCII) and 
triggers the immune response166. Importantly, preventing dimer formation 
through cysteine mutation increases HIV entry192 193, alluding that the monomeric 
form of CD4 is preferential for efficient HIV entry (Figure 1-8). Recombinant 2-
domain CD4 (2dCD4) bound to gp120 was unable to undergo Trx-mediated 
dimerization in vitro suggesting that gp120 may inhibit CD4 dimerization and 




Figure 1-8. The role of a redox disulfide in CD4 in HIV entry. Reduction of CD4 
results in the formation of CD4 homodimers linked by disulfide bonds. Dimeric 
CD4 results in increased binding to MHC Class II. The reduced monomer of CD4 
is preferred for HIV entry. 
 
In addition to inducing structural changes, changes to the redox state of 
CD4 also regulates CD4 membrane localization195. CD4 may move laterally on the 
cell surface into different membrane microdomains including detergent-resistant 
membrane (DRM)/”lipid rafts” or detergent-soluble membrane (DSM)/”non-
rafts”196-197. CD4 is recruited to lipid rafts near MHCII-T-Cell receptor complexes 
upon antigen presentation198. Additionally, translocation of CD4 to lipid rafts has 
been proposed to play a role in HIV infection, however, discrepancies exist in the 
findings of different studies. Studies have shown that CD4 localization to DRM is 
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necessary for HIV infection199-200 while others have shown that CD4 localized in 
DSM supports HIV entry197, 201. While contradictory, this information supports the 
notion that movement of CD4 across various microdomains on the cell surface is 
important for HIV entry and immunoregulation. Inhibition of Trx-1 by DTNB, a 
membrane-impermeable sulfhydryl-blocker, or an inhibitory Trx-1 antibody 
resulted in translocation of CD4 into DRM microdomains and reduced HIV-
entry195.  These findings suggest that changes in redox activity at the cell surface 
and potential changes to the redox state of the allosteric disulfide in CD4 plays a 
role in the membrane microdomain localization of CD4 and translocation of CD4 
may affect HIV entry.  
 
Allosteric redox-active disulfides in hemostasis and thrombosis. Hemostasis is a process 
that involves the coagulation of blood at the site of damaged blood vessels. 
Hypercoagulation can lead to hemostatic disorders such as thrombosis, in which 
excessive blood clotting obstructs blood flow in the circulatory system. Allosteric 
disulfide bonds in blood proteins such as β2-glycoprotein I202, β3 integrin203 and 
von Willebrand factor (VWF)204 are implicated in hemostasis and thrombosis. VWF 
is a multimeric plasma glycoprotein that mediates platelet adhesion at the sites of 
injury205. Low levels of VWF lead to von Willebrand’s disease, which is 
characterized by excessive bleeding, and high levels of VWF can lead to 
thrombosis206-207. The shear forces of flowing blood induce conformational changes 
in VWF from coiled balls to elongated structures that self-associate into a 
meshwork that binds platelets (Figure 1-9)208. Mutagenesis and MS studies of VWF 
showed that thiol-disulfide exchange at two disulfide bonds in the C2 domain of 
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VWF results in self-association of VWF to form VWF oligomers204. The proposed 
mechanism involves oxidoreductase-mediated cleavage of the Cys2431-Cys2453 
disulfide, followed by intermolecular thiol-disulfide exchange to form a VWF 
dimer. Similarly, oxidoreductase-mediated cleavage of a second functional 
disulfide in the C2 domain, Cys2451-Cys2468, promotes trimer formation. This 
disulfide bond is categorized as a –RH staple, congruent with allosteric disulfides.  
 
 
Figure 1-9. The role of allosteric disulfide bonds in hemostasis. The shear force of 
flowing blood induces conformational changes in VWF from a coiled ball to an 
elongated structure. Intramolecular disulfides in elongated VWF may be reduced 
by an oxidoreductase, promoting intermolecular disulfide bond formation and the 




Global methods to identify redox disulfide bonds. 
Global methods to identify and quantify redox-sensitive disulfides are 
fundamental to fully illuminate the physiological roles of functional disulfides. 
This section will summarize recent developments in proteomic methods to 
identify redox-sensitive disulfides. Adaptation of standard two-dimensional 
electrophoresis (2DE)-based separation methods can provide facile visualization 
of all oxidized cysteines within a proteome. Differentiation of oxidized and 
reduced cysteines is achieved using the following sequence of steps; (1) cap 
reduced thiols with a thiol-reactive agent such as iodoacetamide (IAM) or N-
ethylmaleimide (NEM); (2) reduce oxidized cysteines with reducing agents such 
as dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP); (3) derivatize 
these newly reduced cysteine thiols with radiolabeled209 or fluorescent210-211 
derivatives of IAM or NEM; and (4) separate proteins by 2DE and visualize by 
autoradiography or fluorescence212. Whilst 2DE provides facile visualization of 
oxidized proteins within a sample, the poor reproducibility and necessity to 
individually process each gel spot for protein identification by MS, limit the 
applicability of this method. 
 Shotgun-proteomic strategies that utilize isotope-coded affinity tags (ICAT) 
have been adapted for redox proteomics. ICAT reagents are biotinylated-IAM 
derivatives containing isotopically light or heavy linkers213, which allow for 
cysteine tagging and quantitative monitoring of the relative abundance of 
cysteine-containing peptides using the light:heavy signal intensities. Initial 
applications of ICAT to redox proteomics used a similar workflow to the 2DE 
methods, where reduced cysteines were capped with IAM, and oxidized cysteines 
were reduced and capped with ICAT reagents for enrichment on streptavidin 
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beads and subsequent identification of oxidized cysteines using MS. Light and 
heavy ICAT reagents were used to compare oxidized cysteines in control (heavy 
ICAT) to hydrogen peroxide-treated (light ICAT) proteomes214-215. In a later 
iteration of this method, termed OxICAT, quantification of the extent of oxidation 
was performed by using the light and heavy ICAT reagents to cap reduced and 
oxidized cysteines within a single sample (Figure 1-10)216.   
 
Figure 1-10. OxICAT may be used to study cysteine oxidation including changes 
to the oxidation status of redox disulfides.   
 
Analogous to the ICAT methods, a cysteine-reactive iodoacetamide-alkyne 
(IA-alkyne) probe has been used to identify hundreds of reactive cysteines within 
a complex proteome 217. This method, termed isotopic tandem orthogonal 
proteolysis – activity-based protein profiling (isoTOP-ABPP), and derivatives 
thereof 218, have been applied to identify oxidized, nitrosated, and electrophile-
modified cysteines, based on the resulting loss in cysteine reactivity (Figure 1-
11A)219-221. Recently, a live-cell compatible cysteine-reactive probe, caged-
bromomethylketone (caged-BK), was developed to allow for temporal and 
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spatially controlled tagging of reduced cysteines (Figure 1-11B). This method was 
applied to identify protein oxidation events, including disulfide-bond formation, 
triggered by growth-factor stimulation and subsequent intracellular hydrogen-
peroxide release222. 
 
Figure 1-11. Proteomic methods to profile cysteine reactivity. A) isoTOP-ABPP 
utilizes a cysteine-reactive iodoacetamide-alkyne (IAA) probe to identify reactive 
cysteines within a proteome. B) Caged-bromomethylketone (Caged-BK) is used to 
spatially and temporally label reduced cysteines in live cells. UV irradiation of 
cells treated with caged-BK results in uncaging of the probe and subsequent 
labeling of reduced cysteines.  
 
Importantly, 2DE, ICAT and isoTOP-ABPP-based methods for redox 
proteomics are unable to differentiate between different forms of oxidation to 
selectively identify disulfide adducts. Although methods specific for inter- and 
intra-molecular protein disulfides are lacking, proteomic platforms are available 
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to selectively identify glutathionylated cysteines within a proteome (Figure 1-
12A). These include the use of biotinylated derivatives of glutathione, such as 
BioGSH, BioGSSG, or the cell permeable BioGEE223 224, which allow for enrichment 
of glutathionylated proteins on streptavidin, and subsequent release of 
glutathionylated peptides/proteins with reducing agents for MS identification 
(Figure 1-12B). The added bulk of the biotin group in these glutathione derivatives 
could affect the protein targets of glutathione modification, and furthermore, 
necessitates the addition of exogenous biotinylated glutathione, which does not 
allow for monitoring endogenous glutathionylation events. To overcome these 
limitations, a recent method developed a mutant of glutathione synthetase (GS), 
capable of coupling γGlu-Cys to azido-Ala to form azido-GSH (Figure 1-12B). The 
generation of a GSH-analog with a built-in bioorthogonal handle allows for 
enrichment and subsequent identification of glutathionylated proteins225-226. 
Lastly, a Grx-mediated reduction method was used in place of DTT or TCEP to 
selectively reduce glutathionylation adducts for gel and MS analysis, allowing for 
targeted identification of glutathionylated residues within proteomes (Figure 1-
12C)227. Further development of sensitive and selective methods for identifying the 
various types of redox-active disulfides is critical for further characterizing the role 
of disulfides in regulating catalytic activity and protein-protein interactions.  
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Figure 1-12. Proteomic methods to study glutathionylated proteins. (A) 
Glutathionylation results in the formation of a mixed disulfide between a protein 
and glutathione. (B) Biotinylated glutathione adducts used to study 
glutathionylation include BioGSH, BioGEE and N3GSH. (C) Glutathionylated 
proteins can be identified by capping reduced cysteines with NEM followed by 
Grx-mediated reduction of glutathionylated cysteines. The resulting newly-




Disulfide bonds are highly dynamic and are important contributors to both 
protein structure and function. Functional disulfides regulate protein folding and 
structural stabilization, sense and control changes in the redox environment, and 
regulate protein activity, localization and interactions via disulfide breakage or 
formation. This diverse array of functions illustrates the importance of disulfide 
bonds in biological systems. Dysregulation of all aspects of protein disulfide bonds 
can contribute to disease pathogenesis. As such, the protein levels and redox states 
of oxidoreductases, the undesired reduction of structural disulfides, oxidative 
stress-induced disulfide formation and thiol-disulfide exchange-mediated 
reduction of allosteric disulfides, all have substantial roles in various diseases. 
Methods for identifying and characterizing functional disulfides continue to 
improve and may lead to the discovery of new functions for disulfide bonds and 
reveal uncharacterized diseases regulated by disulfide-bond formation. 
Pharmacological targeting of oxidoreductases, and modulation of cellular redox 
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Introduction 
The endoplasmic reticulum (ER) is the largest intracellular organelle and 
contains cisternae that are contiguous with the nuclear membrane and extend 
toward the plasma membrane. The ER is separated into the smooth and rough ER, 
each of which performs distinct cellular functions. The smooth ER is absent of 
ribosomal proteins and responsible for lipid biogenesis, Ca2+ storage and signaling, 
and xenobiotic metabolism. The rough ER is characterized by a high density of 
ribosomes and predominantly mediates protein synthesis, folding, and export1-2 
(Figure 2-1).  
 
 
Figure 2-1. Overview of the various functions of the endoplasmic reticulum.  
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Proteins destined for the secretory pathway are co-translationally 
translocated into the ER lumen, where protein folding, glycosylation, and 
disulfide-bond formation occurs to generate the mature protein3. Properly folded 
proteins are transported to the Golgi via coated protein complex II (COPII)-
mediated anterograde transport for further processing. As an example, cysteines 
in plasma membrane targeted proteins may be s-palmitoylated to promote 
localization to the plasma membrane. Alternatively, ER-localized proteins that 
escape the ER and proteins that are to be retained within the ER-Golgi system are 
retrogradely transported back to the ER in COPI vesicles4. Following sorting in the 
Golgi, secreted and plasma membrane bound proteins are assembled into 
secretory granules for transport to the plasma membrane or extracellular 
environment3 (Figure 2-2).  
 
  
Figure 2-2. Overview of the secretory pathway.  
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Protein maturation within the ER involves several folding chaperones, 
including heat shock proteins (HSPs) and lectin-based chaperones. HSPs, such as 
HSPA5 (BiP), stabilize intermediate structures to promote folding and minimize 
aggregation5. The lectin-based chaperones, calreticulin (CALR) and calnexin 
(CALX), are sensitive to Ca2+ signaling and recognize N-linked glycan 
intermediates as a quality control mechanism to promote proper folding6 (Figure 
2-1 and 2-2). Dysregulation of protein folding in the ER leads to the accumulation 
of unfolded proteins and upregulation of the unfolded protein response (UPR). 
The UPR attenuates translation and upregulates expression of folding chaperones 
and endoplasmic reticulum associated degradation (ERAD) components7. ERAD 
degrades irreversibly misfolded proteins through ubiquitin-mediated 26S 
protease protein degradation upon translocation to the cytosol8 (Figure 2-1). 
Dysregulated protein folding in the ER is associated with several diseases, 
including diabetes, cancer, and neurodegeneration9-13.  
A critical component of ER-localized protein folding, is the proper 
formation of disulfide bonds to stabilize protein structure. The highly oxidizing 
extracellular environment can spontaneously introduce inter- and intramolecular 
disulfide bonds14, necessitating the controlled formation of disulfide bonds prior 
to extracellular export. As one of the most oxidizing organelles in the cell, the ER 
is the favored location for the installation of disulfide bonds on secretory 
proteins15-16. Disulfide-bond formation in the ER is mediated by the protein 
disulfide isomerase (PDI) family through thiol-disulfide exchange reactions 
(Figure 2-2)17. Dysregulated disulfide-bond formation can lead to the 
accumulation of misfolded proteins, and contribute to various diseases, including 
transmissible spongiform encephalopathies (TSEs) and amyotrophic lateral 
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sclerosis (ALS), where improper disulfide-bond formation leads to protein 
misfolding and aggregation11-13. 
Methods to identify functional cysteines and quantify cysteine oxidation in 
the ER can illuminate the (dys)regulation of disulfide-bond formation, and protein 
folding processes within the secretory pathway. Cysteine-reactivity profiling 
using isotopic tandem orthogonal proteolysis – activity-based protein profiling 
(isoTOP-ABPP) has enabled the interrogation of cysteine reactivity, modifications 
and inhibition18-20. Typical isoTOP-ABPP studies are performed in whole-cell 
lysates18, and afford poor coverage of the ER proteome; 42 ER-localized cysteine 
residues (from 35 proteins) out of 1096 total cysteine containing peptides (812 
proteins) are identified in a prototypical study18. Recently, an ER-localized 
fluorinated rhodol-containing chloroacetamide probe was generated to selectively 
target ER cysteines. However, due to preferential localization of this rhodol-based 
probe to the ER membrane, cysteine residues from only 19 ER proteins were 
identified21. Therefore, with currently available methods, the number of ER-
localized cysteine residues that can be identified remain minimal, necessitating 
platforms that combine ER enrichment with cysteine profiling. Potential strategies 
to enrich ER proteins, include the use of engineered ascorbate peroxidases 
(APEX)22-23, proximity-dependent biotin identification (BioID/TurboID)24, and 
subcellular fractionation by differential centrifugation25. Previously, 
mitochondrial isolation using differential centrifugation provided enhanced 
coverage of reactive mitochondrial cysteines26, without the need to engineer the 
cellular system, as required for APEX and BioID/TurboID. Furthermore, APEX is 
incompatible with many cysteine profiling studies, because APEX requires the 
addition of H2O2 which can lead to artificial oxidation and inactivation of 
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cysteines. Differential centrifugation methods to isolate the ER have previously 
identified ~469 ER-associated proteins from rat pancreas27. Combining these 
established ER fractionation methods with isoTOP-ABPP has the potential to 
significantly enhance coverage of ER-localized cysteines for reactivity profiling. 
Although cysteine-reactivity profiling can indirectly inform on cysteine 
oxidation states through an observed loss in cysteine reactivity across two 
samples, several proteomic methods exist to more directly monitor cysteine 
oxidation within a single biological sample28-30. One such method is OxICAT 
(isotopically coded affinity tags), which adapts thiol-trapping techniques with 
isotopically encoded alkylating reagents to interrogate cysteine oxidation state31. 
Briefly, all reduced cysteine residues are capped with an isotopically light 
alkylating reagent, followed by treatment with a reducing agent to expose 
previously oxidized cysteines for tagging with an isotopically heavy reagent. 
Light:heavy (L:H) ratios for identified cysteine-containing peptides directly reflect 
the percentage of oxidation for each cysteine residue. OxICAT methods have been 
performed in E. coli31, yeast32, and mammalian cells33, as well as in enriched 
mitochondria34. More recently, OxICAT was implemented to study the effects of 
ethanol consumption on redox homeostasis in the ER of murine pancreas tissue35. 
In this study, the oxidation states of ~ 500 secretory pathway localized cysteines 
were identified and evaluated for changes due to ethanol consumption.  
Here, we report the use of ER isolation by differential centrifugation 
coupled to isoTOP-ABPP and OxICAT analyses to monitor cysteine reactivity and 
oxidation, respectively. We observed a 4-fold enrichment for ER proteins 
following differential centrifugation and substantiate this method’s ability to 
significantly expand the coverage of secretory pathway cysteines. For cysteine-
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reactivity studies, we apply the isoTOP-ABPP platform to rank 923 ER-localized 
cysteine residues by reactivity, representing the first study to profile cysteine 
reactivity in the ER. Our studies revealed a subset of hyperreactive ER-localized 
cysteines that are functionally implicated in protein stabilization through disulfide 
bonds, and membrane localization through S-palmitoylation. To directly 
interrogate the oxidation state of cysteines in the ER, OxICAT analysis afforded 
the quantification of percent oxidation of 736 cysteines on secretory proteins. 
Together, these studies establish methodological guidelines for in-depth 
proteomic interrogation of cysteine function and oxidation within the ER. We 
demonstrate the utility of this platform by evaluating the effects of UPR 
upregulation on cysteine oxidation state of ER-localized proteins. 
 
Results and Discussion  
 
Isolation of the endoplasmic reticulum using differential centrifugation.  
The low abundance of ER proteins, relative to highly abundant cytosolic 
and nuclear proteins, results in poor coverage of ER-localized cysteines in typical 
isoTOP-ABPP analyses of whole-cell lsates18, 36 In addition to low protein 
abundance, obtaining substantial coverage of the ER is further challenged by the 
relatively small number of genes encoding for ER localizing proteins compared to 
the number of genes encoding for proteins localizing to the nucleus or cytosol37. 




Figure 2-3. Representation of subcellular genomic and proteomic composition. A) 
Percentage of genes in the genome that encode for proteins localizing to respective 
subcellular locations. Data obtained from the Human Protein Atlas37. B) 
Comparison of the relative number of proteins identified per subcellular location 
in a whole-cell in-solution trypsin digested MS sample. Protein localization 
determined by UniprotKB. 
 
To enrich for ER proteins prior to isoTOP-ABPP analysis, a differential 
centrifugation method developed for isolation of rat pancreas ER27 was adapted to 
mammalian cells (Figure 2-4). It was rationalized that the removal of organelles 
containing highly abundant proteins would increase the coverage of ER proteins 
and ER cysteine containing peptides. Briefly, SKOV-3 cells were gently 
homogenized to disrupt the cell membrane while preserving the integrity of 
organelles. Multiple differential centrifugation steps were used to pellet dense 
organelles, such as nuclei and mitochondria, after which a high speed 
centrifugation step (150,000g x 30 min.) afforded a microsomal fraction. This 
microsomal fraction was incubated in a “stripping buffer” to remove ribosomal 
proteins and further enhance coverage of ER proteins. A final centrifugation step 
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(48,000g x 30 min.) generated ER proteomes for isoTOP-ABPP and OxICAT-based 
proteomic studies. 
 
Figure 2-4. Isolation of ER by differential centrifugation to enrich for ER proteins. 
Schematic representation of the differential centrifugation steps used to isolate the 
ER proteome, and proteomic workflow to analyze ER-derived trypsin-digested 
peptides. 
 
ER enrichment was confirmed by western blot of each fraction, including 
whole-cell, nucleus, mitochondria, cytosol, ribosomes, and ER (Figure 2-5). Two 
ER markers, protein disulfide isomerase A4 (PDIA4) and CALR, a cytosolic 
marker, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a ribosomal 
marker, 40s ribosomal protein S6 (RPS6), a nuclear marker, histone H3 (H3FA), 
and a mitochondrial marker, ATPase inhibitor (ATPIF1), were used to confirm 
successful organelle fractionation. Notably, the whole-cell sample exhibited strong 
signals for cytosolic, ribosomal, nuclear, and mitochondrial proteins, but a poor 
signal for ER proteins, underscoring the necessity for ER isolation. As expected, 
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the isolated ER fraction demonstrates a strong enrichment for ER resident proteins, 
PDIA4 and CALR, and a significant decrease of proteins found in other subcellular 




Figure 2-5. Confirmation of ER enrichment by differential centrifugation. Western-
blot analysis of isolated organellar fractions against ER markers, PDIA4 and 
CALR, cytosolic marker, GAPDH, ribosomal marker, RPS6, nuclear marker, 
H3FA, and mitochondrial marker, ATPIF1. Subcellular fractions analyzed include: 
whole-cell lysate (WC), nucleus (Nuc.), mitochondria (Mito.), cytosol (Cyto.), 
ribosomes (Ribo.), and ER. 
 
Confirmation of ER enrichment using mass spectrometry.  
In addition to western-blot analysis, mass-spectrometry (MS) analyses were 
performed to determine the major protein constituents of the ER-enriched 
samples. To achieve this, whole-cell lysates and ER fractions were analyzed by 
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LC/LC-MS/MS after trypsin digestion (Figure 2-4). Filtering of MS data for 
proteins with ≥2 identified peptides, generated 1,582 and 1,844 proteins for whole-
cell and ER fractions, respectively (Table 2A-1). Gene ontology (GO) enrichment 
analysis38 (Table 2-1 and Table 2A-2 and Table 2A-3) demonstrated that the ER 
fraction was enriched for ER-associated biological processes, such as protein 
localization to the ER, vesicle cargo loading, N-linked glycosylation, and 
chaperone-mediated folding. None of these aforementioned biological processes 
were significantly enriched in the whole-cell sample.  
 
Table 2-1. GO enrichment analysis evaluating enrichment for ER biological 
processes. A list of the top 10 most overrepresented GO biological processes for 
proteins identified in whole-cell or ER fractions. ER-associated biological 
processes are highlighted in red while secretory pathway processes are 
highlighted in blue. 
Whole Cell Endoplasmic Reticulum 
viral latency COPII-coated vesicle cargo loading 
proteasomal ubiquitin-independent protein 
catabolic process 
formation of cytoplasmic translation initiation 
complex 
negative regulation of mRNA splicing, via 
spliceosome 
SRP-dependent cotranslational protein 
targeting to membrane 
negative regulation of mRNA processing cotranslational protein targeting to membrane 
interleukin-12-mediated signaling pathway establishment of protein localization to endoplasmic reticulum 
cellular response to interleukin-12 protein targeting to ER 
response to interleukin-12 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 
antigen processing and presentation of 
exogenous peptide antigen vesicle cargo loading 
negative regulation of mRNA metabolic 
process translational initiation 
intermediate filament cytoskeleton 




Subcellular localization of identified proteins was determined by mining 
the Uniprot database for cellular locations, including cell membrane, cytoskeleton, 
ER, Golgi, mitochondria, nucleus, and secreted. The number of spectral counts for 
peptides in each subcellular location was calculated, and plotted as a percentage 
of the total spectral counts (Figure 2-6A). In the whole-cell analysis, spectral counts 
from ER proteins represented only 4% of total spectral counts, with the majority 
(~40%) attributed to nuclear proteins. In contrast, the ER fraction displayed a ~4 
fold enrichment of ER spectral counts (15%), concurrent with a substantial 
reduction in nuclear spectral counts (17%). Furthermore, the ER fraction was 
enriched for cell membrane (10%) and cytoplasmic vesicles (3%) compared to 
whole-cell lysates, (3% and ~0%, respectively). In total, MS analysis of the ER 
fraction identified 1,926 ER peptides from 212 proteins, in contrast to the 488 ER 





Figure 2-6. Evaluation of ER enrichment in whole-cell and isolated ER in-solution 
trypsin digested MS samples. A) Subcellular localization of proteins identified by 
MS analysis, plotted as the percent of spectral counts. Organelles in the MS 
analysis include: cell membrane (CM), cytoskeleton (Cytoskel.), cytoplasmic 
vesicles (Cyto. Ves.), endosomes (Endo.), endoplasmic reticulum (ER), Golgi 
apparatus (Golgi), lysosomes (Lyso.), mitochondria (Mito.), nucleus (Nuc.), 
peroxisomes (Pero.), and secreted proteins (Sec.). Subcellular localization was 
determined by Uniprot. B) Number of Uniprot annotated ER proteins identified 
from MS analyses of trypsin digests from whole-cell and isolated ER fractions. 
	 81	
 C) Number of peptides derived from Uniprot annotated ER proteins identified 
from MS analyses of trypsin digests from whole-cell and isolated ER fractions. 
 
In addition to Uniprot, the Human Protein Atlas database37 contains 
annotation for proteins whose localization to the ER has been experimentally 
detected. Of all protein encoding genes, 443 genes have been experimentally 
shown to localize to the ER. Using this database as a measure of ER coverage, only 
~10% of all experimentally detected ER proteins are identified in whole-cell lysates 
compared to ~40% in the ER fraction, representing a substantial increase in 
coverage of ER proteins using differential centrifugation to enrich the ER prior to 
MS analysis (Figure 2-7 and Table 2A-4). 
 
 
Figure 2-7. Coverage of the Human Protein Atlas annotated ER proteome. Relative 
coverage of Human Protein Atlas annotated ER proteins was determined by 
plotting MS-identified ER annotated proteins as a percent of the total number of 
ER annotated proteins. 
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isoTOP-ABPP analysis uncovers reactive and functional cysteines in the ER.  
Reactive-cysteine profiling by isoTOP-ABPP18 enables the quantification of 
cysteine reactivity across two different samples. This platform relies on the use of 
a cysteine-reactive iodoacetamide-alkyne (IA) probe to modify highly nucleophilic 
cysteines within complex proteomes. Concentration-dependent analysis of 
cysteine labeling by the IA probe can be used to rank cysteines by reactivity. Here 
we applied isoTOP-ABPP to ER-enriched samples, in order to rank cysteines in the 
ER by reactivity. Profiling cysteine reactivity in isolated ER was predicted to 
provide insight into a subset of cysteines not identified in whole-cell samples. This 
includes a population of cysteines susceptible to oxidative PTMs (e.g. disulfide-
bond formation and s-palmitoylation of cell membrane proteins) during the 
maturation and folding process in the ER and secretory pathway. Isotopically 
encoded IA-alkyne (IA-light and IA-heavy) probes, containing an iodoacetamide 
electrophile, alkyne handle for biorthogonal conjugation to cleavable affinity tags, 
and an isotopically encoded benzyl group, were utilized for this analysis (Figure 
2-8)33. ER proteomes were treated with either 10 µM IA-heavy or 100 µM IA-light 
prior to copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) of a photo-
cleavable biotin azide tag (Figure 2-8 and 2-9). Following CuAAC, light and heavy 
samples were combined, labeled cysteines were enriched on streptavidin beads, 
and subjected to on-bead trypsin digestion and UV exposure to release IA-tagged 
peptides for MS analysis (Figure 2-9).  
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Figure 2-8. Isotopically encoded alkylating reagents and photo-cleavable biotin-
containing tag for evaluating cysteine reactivity and cysteine oxidation states. 
 
 
Figure 2-9. Schematic representation of the isoTOP-ABPP platform used to rank 
cysteine residues by reactivity. 
 
LC/LC-MS/MS analysis generated parent ion (MS1) spectra for peptide 
quantitation, and fragmentation (MS2) spectra for peptide identification. For each 
identified peptide, the light to heavy ratio (L:H) reports on the reactivity of the 
referenced cysteine residues. A highly reactive cysteine is expected to saturate 
labeling at low IA concentrations to generate low L:H values of ~1, while less 
reactive cysteines will show increased labeling in the 100 uM (IA-light) sample 
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resulting in L:H ratios >>1. Across two replicates, isoTOP-ABPP analysis of ER-
enriched samples determined L:H ratios for 923 cysteine-containing peptides 
annotated to derive from ER and secretory pathway proteins (Figure 2-10 and 
Table 2A-5). Due to their temporary residency in the ER and the interesting 
cysteine chemistries that occur during protein folding and secretion, secretory 
pathway proteins were also included in data analysis.  Secretory pathway proteins 
comprised cell surface, extracellular, intracellular vesicle, and Golgi as annotated 
by either UniProt or GO annotation. 
 
 
Figure 2-10. L:H ratio plot ranking secretory pathway cysteines by reactivity. Inset 
1 is composed of cysteine residues with a ratio <2.5 (highly reactive cysteines) 
while inset 2 consists of cysteine residues with a ratio >7.5 (cysteines with low 
reactivity). Cysteines with no functional annotation are grey. Cysteine functional 
annotation was obtained from Uniprot and SwissPalm. Protein localization was 
determined using UniprotKB and GO databases.   
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Highly reactive cysteines (L:H <2.5) identified in the ER fraction were 
searched against a previous whole-cell analysis18 to evaluate whether subcellular 
fractionation reveals a novel subset of highly reactive cysteines. This comparative 
analysis revealed that ~85% (332 out of 388) of these highly reactive cysteines were 
unique to the ER. To further interrogate the relationship between cysteine 
reactivity and function in the ER, cysteines annotated as functional in Uniprot and 
SwissPalm databases were binned by isoTOP-ABPP ratio (L:H <2.5, 2.5-5.0, 5.0-
7.5, and >7.5) (Figure 2-11A and Table 2A-5). This analysis revealed that ~30% of 
all highly reactive secretory pathway cysteines were functionally annotated, 
which is comparable to the percentage of highly reactive cysteines identified as 
functional in the whole-cell proteome (Figure 2-11B).  
 
 
Figure 2-11. Comparison of cysteine reactivity and function between (A) isolated 
ER, and (B) previously published whole-cell lysate data, Weerapana et al.18 
Cysteine function annotation was determined by UniprotKB. Cysteines are 
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grouped by function: any function, disulfide-bonding, S-palmitoylated, active site, 
and other functions. These residues are further binned by levels of reactivity (most 
to least): <2.5, 2.5-5.0, 5.0-7.5, and >7.5.  
 
Cysteine function and reactivity level were plotted as a percent of all 
identified cysteines (annotated and unannotated). Interestingly, the functions 
attributed to reactive cysteines in the ER differed significantly from total cellular 
proteins. Specifically, highly reactive cysteines (L:H <2.5) in the ER were enriched 
for structural disulfides and S-palmitoylated residues, compared to unreactive 
cysteines (L:H >7.5) (Figure 2-10 Insets 1 and 2). For example, the disulfide-
annotated cysteine, Cys185, from the disulfide-rich protein, integrin alpha-V 
(ITGAV) was identified as highly reactive in the ER, containing ratio of 1.42.  
Meanwhile, a ratio of 1.30 was observed for a S-palmitoylated residue, Cys100, in 
cytoskeleton-associated protein 4 (CKAP4). These cysteines are likely from 
partially matured proteins in the ER where disulfide bonds and S-palmitoyl units 
have yet to be installed. S-palmitoylation in particular is often catalyzed by 
palmitoyl acyl transferases such as zinc finger DHHC domain-containing protein 
3 (ZDHHC3) that localize in the Gogli39 (Figure 2-12).  
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Figure 2-12. S-palmitoylation of cysteine. Palmitoyl acyl transferase catalyzes the 
covalent attachment of a palmitoyl group from  palmitoyl coenzyme A to cysteine. 
The removal of S-palmitoyl groups is catalyzed by palmitoyl thioesterases in the 
cytosol. 
In contrast, structural disulfide bonds and palmitoylated cysteines were 
significantly underrepresented in whole-cell datasets, likely because these 
cysteines are fully oxidized or S-palmitoylated, rendering them unreactive. 
Furthermore, any highly reactive disulfide annotated cysteines identified in 
whole-cell datasets, such as Cys35 in thioredoxin (TXN) or Cys26 in glutaredoxin 
(GLRX), were often annotated as redox-active and not structural. Compared to 
whole-cell datasets, the number of active-site cysteines identified in isolated ER 
was relatively poor. Only two highly reactive active-site cysteines were identified 
in isolated ER, Cys47 in peroxiredoxin-6 (PRDX6) and Cys152 in GAPDH, ~10% of 
the amount identified in whole-cell studies. Differences in the number of active 
sites identified between the two datasets may be attributed to the removal of 
cytosolic enzymes during ER isolation. Intriguingly, our data show that cysteines 
destined for structural disulfide-bond formation or S-palmitoylation display 
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significantly elevated reactivity relative to other non-functional cysteines within 
the ER proteome. In addition to disulfide and S-palmitoylated residues, cysteines 
located within nucleotide-binding regions of proteins were identified in the ER but 
not whole-cell fractions, including cysteines in the highly conserved G-domain of 
several secretory pathway localized Ras superfamily members (Figure 2-13). The 
majority of these G-domain cysteines belong to a G4 motif containing a conserved 
GNKxD motif that interacts with guanidine40, and is known to be sensitive to 
oxidation41-42. 
 
Figure 2-13. A) Highly reactive cysteines positioned in nucleotide binding pockets 
of the Ras superfamily. B) Crystal structure of NRAS (PDB: 5UHV)43. One of four 
GTP binding domains is highlighted in orange and the reactive cysteine in red. 5'-
guanylyl imidodiphosphate (GNP) is shown in green. 
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Adaptation of the OxICAT platform to interrogate cysteine oxidation in the ER.  
The significant presence of reactive cysteines annotated to be sites of 
disulfide-bond formation triggered our interest in more directly interrogating the 
oxidation states of cysteines, and thereby differentiating fully oxidized ER 
cysteines from those that are fully or partially reduced. To achieve this, we 
implemented a proteomic platform combining ER enrichment with an adapted 
OxICAT method34. For this analysis, ER fractions were isolated from SKOV-3 cells, 
and these microsomal fractions were immediately lysed in a denaturing buffer 
containing 10 mM IA-light to prevent artificial oxidation. Reversibly oxidized 
cysteines were then reduced with tris(2-carboxyethyl)phosphine (TCEP) and 
alkylated with 10 mM IA-heavy. A photocleavable biotin-azide tag was appended 
to labeled cysteines via CuAAC, followed by streptavidin enrichment, trypsin 
digestion, photocleavage, and LC/LC-MS/MS analysis (Figure 2-8 and Figure 2-
14). Cysteine oxidation was determined by converting L:H and H:L ratios into a 
calculated value of percent oxidation, 1 − & ':)
':)*+
,  or ):'
):'*+
 , for each individual 
cysteine. 
 
Figure 2-14. Schematic representation of the OxICAT platform designed to 
quantify oxidation states of cysteines from the ER fraction. 
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Across two replicates, oxidation states were determined for 734 cysteines 
on secretory proteins (Figure 2-15 and Table 2A-6). Of these cysteines, the majority 
(499, 68%) were highly reduced (<25% oxidation), and ~16% (116 peptides) were 
highly oxidized (>75% oxidized). Of these 116 highly oxidized cysteines, 70 
cysteines (60%) were functionally annotated as structural disulfides. The 
remaining 46 cysteines have no functional annotation, however, it’s likely that 
many of these residues participate in structural disulfides. As an example, Cys192 
and Cys208 (95.24% and 95.23% oxidized) in the CD151 antigen are part of a large 
extracellular loop (EC2) conserved in the tetraspanin superfamily. These residues 
are predicted to form intramolecular disulfides based on structural similarities 
with other tetraspanins44-45. Additionally, some of these unannotated oxidized 
cysteines belong to proteins that are highly disulfide rich, including six cysteine 
residues (Cys531, Cys1042, Cys1270, Cys1282, Cys1461, and Cys1476) in cation-
independent mannose-6-phosphate receptor (IGF2R) and Cys615 (93.06% 
oxidized) in plexin-B2 (PLXNB2). Cysteines annotated as metal binding, S-
nitrosated, or within nucleotide-binding domains were mostly reduced. Notably, 
S-palmitoylated cysteines were also generally highly reduced (91 residues) (Figure 
2-15 and Table 2A-6), agreeing with the reported observation that plasma 
membrane proteins primarily undergo S-palmitoylation in the Golgi prior to 
trafficking to the membrane46, and are therefore found in the reduced and 
unmodified state within the ER.  
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Figure 2-15. OxICAT analysis to determine cysteine oxidation states in the ER. Plot 
of cysteine oxidation states in ER and secretory pathway proteins. Uniprot 
annotated cysteine residues that partake in disulfide bonds are colored blue. 
SwissPalm annotated sites of S-palmitoylation are colored red. Oxidation states 
are presented as an average percent oxidized, calculated directly from light:heavy 
and heavy:light ratios of cysteine residues, n = 2. Protein localization was 
determined using UniprotKB and GO databases. 
 
The ability of the OxICAT platform to provide residue-specific oxidation 
information is underscored by several proteins where multiple cysteines with 
disparate oxidation states were detected. For example, the oxidation states for 3 
out of 4 cysteines in CALR were quantified (Figure 2-16), where two of these 
cysteines (Cys105 and Cys137) form a disulfide bond and were highly oxidized 
(86.17% and 92.65% oxidized, respectively), while the third cysteine (Cys163) was 
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mostly reduced (27.57% oxidized) and is proposed to participate in a disulfide-
bridged homodimer under physiological stress47. Three cysteine oxidation states 
were also quantified in ERp44 (Figure 2-16); disulfide annotated Cys301 and 
Cys318 were highly oxidized (84.76% and 95.24% oxidized, respectively) and 
Cys92 was mostly reduced (18.38% oxidized).  
 
 
Figure 2-16. Extracted ion chromatograms from OxICAT analysis for cysteine 
residues in CALR and ERp44. Uniprot annotated disulfide bonds are represented 
by a bridge. Displayed chromatograms are representative of a single replicate. 
 
Upregulation of the UPR has minimal effects on cysteine oxidation state.  
Having developed a proteomic platform to determine cysteine oxidation 
states in the secretory pathway, we applied the OxICAT analysis to interrogate 
changes in cysteine oxidation upon induction of the unfolded protein response 
(UPR). The accumulation of unfolded proteins in the ER activates the UPR by 
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triggering three different signaling pathways: activating transcription factor-6α 
(ATF6), inositol-requiring 1α (IRE1α), and PKR-like ER kinase (PERK) (Figure 2-
17)7, 48-49.  
 
Figure 2-17. Overview of the three arms of the UPR. IRE1α dimerization results in 
the splicing of an active transcription factor XBP1s. XBP1s controls the 
transcription of genes encoding for folding chaperones, proteins involved in lipid 
synthesis, and components of ERAD. Dimerization of PERK results in the 
phosphorylation of eIF2α and attenuation of general protein translation. As well, 
phosphorylated eIF2α promotes translation of a transcription factor, ATF4, that 
controls transcription of autophagy and apoptosis related genes. Finally, ATF6 is 
transported to the Golgi where it undergoes proteolytic cleavage, yielding the 
fragment, ATF6f. ATF6f controls the transcription of genes encoding for ERAD 
components48, 49.  
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Several small molecules, including thapsigargin (Tg) and tunicamycin (Tn), 
target different homeostatic mechanisms in the ER to activate the UPR. Tg is a 
sesquiterpene lactone that non-competitively inhibits the sarco/endoplasmic 
reticulum Ca2+-ATPase (SERCA) (Figure 2-18). Inhibiting SERCA-mediated Ca2+ 
import decreases the activity of Ca2+ binding chaperones such as CALR, CALX, 
and BiP50-51, leading to an accumulation of unfolded proteins. Tn is a nucleoside 
antibiotic that inhibits GlcNAc phosphotransferase (GPT), preventing the 
formation of preassembled oligosaccharides required for N-linked glycosylation 
in the ER (Figure 2-18). Inhibition of N-glycosylation hinders proper protein 
folding, and additionally prevents lectin chaperones52 from recognizing misfolded 
proteins, leading to activation of the UPR. Although none of these chemical UPR 
modulators directly target disulfide-bond forming pathways in the ER, we were 
interested to study the effects on cysteine oxidation since dysregulation of protein 
homeostasis could potentially indirectly alter disulfide-bond formation in the ER. 
  
Figure 2-18. Structures and illustrations depicting mechanisms of action for UPR 
activating agents, Tg and Tn.  
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UPR activation upon administration of Tg and Tn was confirmed using 
quantitative polymerase chain reaction (qPCR). Briefly, SKOV-3 cells were treated 
with DMSO, Tg (5 µM), or Tn (3 µM) for 5 hours, and isolated RNA was subjected 
to qPCR analysis for mRNA encoding known downstream targets from each arm 
of the UPR, including GRP94 (ATF6-regulated), ERDJ4 (IRE1α-regulated), and 
CHOP (PERK-regulated). As expected, all three arms of the UPR were activated 
following Tg and Tn treatments (Figure 2-19). 
 
 
Figure 2-19. Activation of UPR target genes was evaluated by qRT-PCR following 
treatments with DMSO, Tg (5 µM), or Tn (3 µM). Data was plotted as a fold change 
in mRNA expression, Tg or Tn relative to DMSO, and represents the mean ± s.d. 
of two replicates. * P value <0.05, *** P value <0.001, unpaired t test. 
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Prior to examining cysteine-oxidation changes upon Tg and Tn treatments, 
unenriched proteomic analyses were performed to determine changes in protein 
abundance in ER fractions from UPR-upregulated cells. Quantitative proteomic 
analyses were performed upon isotopic tagging of peptides using reductive 
dimethylation (ReDiMe) of primary amines53. Briefly, SKOV-3 cells were treated 
with DMSO, Tg (5 µM), or Tun (3 µM) for 5 hours, harvested, and ER was isolated 
to enrich for secretory pathway proteins. Following isolation, ER lysates were TCA 
precipitated, reduced, alkylated, and in-solution trypsin digested. Peptides 
resulting from the DMSO-treated sample were dimethylated with light ReDiMe 
reagents while Tg or Tn samples were dimethylated with heavy ReDiMe reagents 
for LC/LC-MS/MS analysis (Figure 2-20).  
 
 
Figure 2-20. Schematic representation of a quantitative MS platform to quantify 
changes to protein abundance following treatment with DMSO, Tg (5 µM) , or Tn 
(3 µM).  
 
Across two replicates, we quantified 656 and 632 ER secretory pathway 
proteins in Tg:DMSO (Figure 2-21A and Table 2A-7) and Tn:DMSO samples 
(Figure 2-21B and Table 2A-8), respectively. While we were able to confirm 
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activation of the UPR at the transcriptomic level for both treatments, only Tg 
treatments led to increased expression of proteins known to be associated with 
UPR activation. PDIs (e.g. PDIA3, PDIA4 and PDIA6), HSPs (e.g. HSPA5, HSPA13, 
and HYOU1), and N-linked glycosylation and lectin-assisted folding chaperones 
(e.g. STT3A and CALR) showed a greater than two-fold expression following Tg 
treatment (Figure 2-21A). Performing a GO analysis38 of the top 100 most abundant 
proteins following Tg treatment revealed an enrichment for several biological 
processes associated with the UPR, including, IRE1α-mediated UPR, cellular 
response to topologically incorrect protein, and the ERAD pathway (Table 2-2 and 
Table 2A-9). Furthermore, the protein abundance changes following Tg treatment 
were similar to those reported in a previous proteomic study after independent 
activation of the IRE1α and ATF6 arms of the UPR54. Surprisingly, very few 
changes in protein expression were observed for Tn-treated samples (Figure 2-21B 
and Table 2A-8), where folding chaperones were relatively unchanged with ratios 
close to 1. This general expression profile was similar to a recent study using stable 
isotope labeling with amino acids in cell culture (SILAC) to profile changes in 
protein expression following Tn treatments21. Additionally, the differences 
between Tn-treated transcriptomic and proteomic data could be attributed to 
known discrepancies between mRNA expression and protein expression or a 
temporal delay between transcriptional and translational machineries or both55-56. 
Longer treatments with Tn and Tg will likely result in more dramatic restructuring 
of the ER proteome. 
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Figure 2-21. ReDiMe MS analyses of unenriched ER fractions upon Tg and Tn 
treatment. Proteins above (>1) or below (<-1) dotted lines are more than 2-fold 
upregulated or downregulated, respectively. A) Log2 ratio plot (Tg:DMSO) of 
identified ER and secretory pathway proteins. B) Log2 ratio plot (Tn:DMSO) of 
identified ER and secretory pathway proteins. Protein localization was 




Table 2-2. Top 10 most enriched biological processes in the 100 most abundant 
proteins following Tg treatment.  
Biological Process Fold Enrichment 
protein folding in endoplasmic reticulum 63.7 
4-hydroxyproline metabolic process 54.36 
protein hydroxylation 39.2 
protein N-linked glycosylation via asparagine 30.89 
peptidyl-asparagine modification 29.98 
IRE1-mediated unfolded protein response 29.65 
peptidyl-proline modification 24.6 
endoplasmic reticulum unfolded protein response 24.46 
cellular response to topologically incorrect protein 21.38 
cell redox homeostasis 21.18 
 
To explore perturbations to disulfide-bond formation upon UPR activation, 
the OxICAT platform was implemented in Tg and Tn treated cells. As before, 
SKOV-3 cells were treated with DMSO, Tg (5 µM), or Tn (3 µM) for 5 hours and 
subjected to the OxICAT analysis (Figure 2-14). Three replicates were performed 
for each treatment and an average percent oxidized value was calculated for each 
cysteine. In order to accurately compare cysteine oxidation states between 
treatments, ratios were required to be present in at least 2 out of 3 samples per 
treatment. Differences in cysteine oxidation were determined by subtracting Tg or 
Tn percent oxidation values from DMSO percent oxidation values. 1,166 and 978 
differences in oxidation states for secretory pathway cysteines were calculated in 
Tg versus DMSO and Tn versus DMSO datasets, respectively. Calculated 
differences were then statistically analyzed by multiple t-tests to obtain a final 
dataset of cysteines whose oxidation states were significantly and reproducibly 
sensitive to Tg or Tn treatments. Of these calculated differences, 499 (42.8%) 
cysteine oxidation states were significantly changed following Tg treatment 
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(Figure 2-22A and Table 2A-10), while 341 (34.9%) cysteine oxidation states were 
significantly changed following Tn treatment (Figure 2-22B and Table 2A-11).   
 
 
Figure 2-22. Statistical analyses of changes to cysteine oxidation following 
activation of the UPR with Tg or Tn treatment. A) Volcano plot displaying 
difference in average % oxidized (DMSO - Tg) for 1,166 secretory pathway cysteine 
containing peptides against -log(P-value), unpaired t-tests, n=3. B) Volcano plot 
displaying difference in average % oxidized (DMSO - Tg) for 978 secretory 
pathway cysteine containing peptides against -log(P-value), unpaired t-tests, n=3. 
(A,B) Cysteine residues with statistically significant (P-value <0.05) changes in 
oxidation states are located above the horizontal dotted line. Cysteine residues 
with a difference (DMSO - Tg or DMSO - Tun) greater than 10% (sensitive cysteine 
residues) are located to the left and right of the vertical dotted lines. Protein 
localization was determined using UniprotKB and GO databases.  
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  Percent oxidation for each cysteine upon Tn and Tg treatment was 
compared to the DMSO control (Figure 2-23A and B). The majority of identified 
cysteine residues showed minimal changes in oxidation state upon Tg and Tn 
treatment  (grey circles, <10% change in oxidation state).  However, 105 cysteines 
(21.0%) and 68 cysteines (19.9%) in Tg and Tn treated samples, respectively, 
exhibited a change larger than 10% (black circles).  
 
 
Figure 2-23. Quantification of changes to ER cysteine oxidation states following 
induction of the unfolded protein response (UPR). A) Plot comparing secretory 
pathway cysteine oxidation states in DMSO and Tg treated samples. B) Plot 
comparing secretory pathway cysteine oxidation states in DMSO and Tn treated 
samples. Colored regions indicate cysteine residues that show >10% change in 
cysteine oxidation state. Protein localization was determined using UniprotKB 




Cys163 in CALR become >10% more oxidized following Tg treatments. This 
observation is supported by a previous study that found that Tg-mediated ER Ca2+ 
depletion resulted in the formation of a CALR disulfide bound homodimer at 
Cys163 57. A large change in cysteine oxidation (~76%) was observed for Cys312 in 
neural cell adhesion molecule L1 precursor (L1CAM). Cys312 is annotated as a 
structural disulfide, suggesting that Tg treatment resulted in at least partial 
misfolding L1CAM. It has been shown that L1CAM expression is Ca2+ dependent, 
whereby Tg treatment leads to increased expression58. This Tg-induced increase in 
L1CAM expression may overwhelm folding chaperones producing a misfolded 
population. Following Tn treatment, Cys545 in ribophorin I (RPN1) was 25% more 
oxidized. Interestingly, RPN1 is a subunit of the oligosaccharyltransferase (OST) 
complex which catalyzes N-linked glycosylation downstream of Tn inhibition59. 
Additionally, RPN1 complexes with malectin to recognize misfolded 
glycoproteins and prevent their secretion60. While no correlations between RPN1 
cysteine oxidation and Tn treatment have been reported, it’s feasible that the 
disappearance of glycoproteins leads to changes in RPN1 protein structure or 
complex formation thereby altering the oxidation state of Cys545.  
 
Conclusion 
In conclusion, we have developed a proteomic platform to quantify cysteine 
reactivity and oxidation in secretory pathway proteins localized in the ER. 
Previous studies on ER cysteines relied on isoTOP-ABPP analysis of whole-cell 
lysates18 or the use of fluorinated-rhodol tagged alkylating reagents (ERMs)21, but 
both strategies were plagued by low ER cysteine coverage. Using subcellular 
fractionation by differential centrifugation prior to proteomic analysis, we enrich 
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for ~40% of the Human Protein Atlas annotated ER proteome, a 4-fold enrichment 
compared to whole-cell lysates. Combining ER enrichment with isoTOP-ABPP, we 
ranked 923 cysteine residues from 523 secretory pathway proteins by reactivity, 
representing a significant increase in identified cysteine residues relative to 
previous studies18, 21. Highly reactive cysteines were annotated as destined for S-
palmitoylation or disulfide-bond formation, highlighting a subset of cysteine 
functionality typically not identified in whole-cell cysteine reactivity studies. To 
investigate cysteine oxidation in the ER, we combined ER isolation with OxICAT 
to quantify the percentage oxidation for 734 secretory pathway cysteine residues. 
Highly oxidized cysteines were frequently annotated as structural disulfide bonds 
while S-palmitoylated residues were predominantly present in the reduced state. 
These results were expected, given the spatiotemporal introduction of each 
cysteine modification within the cell, whereby disulfide-bond formation occurs in 
the ER, resulting in annotated disulfides identified as primarily oxidized, whereas 
S-palmitoylation occurs primarily in the Golgi, and thereby S-palmitoylated 
cysteines in the ER would be expected to be in the reduced, unmodified state. The 
OxICAT platform was applied to evaluate changes in cysteine oxidation following 
chemical induction of the UPR with Tg or Tn. In general, these treatments resulted 
in minimal changes to cysteine oxidation, with a few proteins, such as L1CAM, 
displaying dysregulated disulfide-bond formation.  
Together, these studies demonstrate the advantages of combining organelle 
isolation with MS-proteomic platforms such as isoTOP-ABPP and OxICAT to 
improve coverage of low-abundant proteins in organelles such as the ER. These 
chemoproteomic platforms can be applied to investigate proteomic changes 
induced by direct perturbation of ER disulfide-bond forming chaperones, and in 
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misfolding diseases, such as prion-related disorders and ALS, where changes in 
disulfide-bond formation are proposed to induce protein aggregation61. Further 
improvements in fractionation methodology, at the organelle, protein and/or 
peptide level, together with improved sensitivity of new MS instrumentation, can 





All chemicals and biological reagents were purchased from Fisher Scientific 
or Millipore Sigma unless specified. SKOV-3 cells were obtained from ATCC 
(HTB-77). RPMI 1640, Trypsin-EDTA, and Antibiotic-Antimycotic (Anti-Anti) 
were purchased from Fisher Scientific. Fetal bovine serum (FBS) was acquired 
from Atlanta Biologicals. Protein concentrations were determined using the DC 
Protein Assay kit from Bio-Rad. IA-light and IA-heavy were synthesized in-house 
according to Abo, M. et al.33. PC biotin azide was purchased from Click Chemistry 
Tools. Anti-GAPDH (cat. 14C10), anti-CALR (cat. D3E6), ant-PDIA4 (cat. D70D12), 
anti-Histone H3 (D1H2), anti-RPS6 (5G10), anti-ATPIF1 (D6P1Q), and rabbit anti-
IgG secondary antibody (cat. 7074S) were purchased from Cell Signaling 
Technologies. Applied Biosystems High-capacity cDNA reverse transcription kit 
and Applied Biosystems PowerUP SYBR green master mix were purchased from 





Cell culture and preparation of SKOV-3 whole-cell lysates.  
SKOV-3 cells were cultured at 37 °C under an atmosphere of 5% CO2 in 
RPMI 1640 medium (Corning) supplemented with 10% FBS (Atlanta Biologicals) 
and 1% Anti-Anti (25 µg/mL Amphotecerin B, 10,000 units/mL penicillin, 10,000 
µg/mL streptomycin, Gibco). Cells were harvested by scraping and pelleted at 
1,000g. Cells were washed with DPBS and then resuspended in appropriate 
volumes of DPBS. Cell suspensions were sonicated using an ultrasonic tip 
sonicator (Cole Parmer). Lysates were centrifuged at 45,000 rpm for 45 minutes at 
4°C to separate soluble and insoluble lysate fractions. The insoluble fraction was 
discarded and the soluble fraction’s protein concentration was determined using 
the DC Protein Assay kit (Bio-Rad).  
 
Isolation of ER.  
SKOV-3 pellets were washed 3x with homogenization buffer (0.3 M sucrose, 
10 mM HEPES, 1 mM EGTA, and 25 µg/mL spermidine, pH 7.0). ER isolation was 
adapted from Chen, X. et al.27. Briefly, SKOV-3 pellets were resuspended in 5x 
volume of homogenization buffer and homogenized by a motor driven glass 
Teflon homogenizer (Wheaton) at 1000 rpm with 50 strokes over the course of 25 
min. After every 10 strokes, the homogenate was allowed to briefly incubate on 
ice. The homogenate was centrifuged twice at 1000g for 10 min at 4°C with the 
supernatant being collected and pellet discarded after each spin. The supernatant 
was then spun twice at 12,000g for 10 min at 4°C with the supernatant being 
collected and pellet discarded after each spin. Next, the supernatant was spun at 
150,000g for 30 min at 4°C and the pellet was collected and supernatant discarded. 
The pellet was resuspended in 2 mL of “ribosomal stripping buffer” (0.3 M sucrose, 
	 106	
1.0 M KCl, and 1 mM puromycin dihydrochloride (Santa Cruz Biotechnology)) 
and incubated at 25 °C for 1 hour and 4°C for 30 min. The solution was spun at 
48,000g for 30 min at 4°C and the pellet was collected and supernatant discarded. 
The supernatant was resuspended in 2 mL of DPBS and centrifuged at 48,000g for 
30 min at 4°C. The supernatant was removed and the pellet was collected, 
affording an isolated ER pellet at this point. For all experiments except cysteine 
oxidation studies (OxICAT), the isolated ER pellet was resuspend in DPBS and 
sonicated using an ultrasonic tip sonicator (Cole Parmer). Isolated ER lysate 
protein concentrations were determined using the DC Protein Assay kit (Bio-Rad).  
 
Western blot detection of GAPDH, CALR, PDIA4, Histone H3, RPS6, and 
ATPIF1.  
25 µg of whole-cell or ER lysates were separated on a 12.5% SDS-PAGE gel 
and transferred to nitrocellulose membrane (GE Healthcare) at 75V for 90 min. 
Membranes were blotted with TBST and 5% milk for 1 hour. Membranes were 
washed once with TBST for 5 min. Blocked membranes were then incubated with 
rabbit anti-GAPDH (1:1000, TBST and 5% bovine serum albumin (BSA)), rabbit 
anti-CALR (1:1000, TBST and 5% milk), rabbit anti-PDIA4 (1:1000, TBST and 5% 
BSA), rabbit anti-Histone H3 (1:2000, TBST and 5% milk), rabbit anti-RPS6 (1:1000, 
TBST and 5% BSA), or rabbit anti-ATPIF1 (1:1000, TBST and 5% BSA) overnight at 
4°C. Membranes were washed 3x with TBST for 5 min and incubated with anti-
rabbit IgG HRP conjugated secondary 1:300 in TBST for 2 hours at 25°C. 
Membranes were washed 3x with TBST and imaged by the addition of ECL 
western blotting substrates.  
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Quantitative RT-PCR (qPCR).  
RNA extraction. SKOV-3 cells were grown in 100 mm dishes to ~90% confluency 
and treated with DMSO, Thapsigargin (Tg, 5 µM) (Cayman Chemical), or 
Tunicamcyin (Tn, 3 µM) (MilliporeSigma) for 5 hours. Cells were lysed using 1 mL 
of TRIzol reagent (Life Technologies) and incubated at 25°C for 5 min. TRIzol 
solution was transferred to an Eppendorf tube and 200 µL of chloroform was 
added. Samples were shaken and centrifuged at 12,000g for 12 min. at 4°C. The 
upper aqueous phase was transferred to a new Eppendorf tube and 400 µL of 
isopropanol was added. Samples were vortexed and incubated for 10 min. at 25°C. 
Samples were centrifuged at 12,000g for 10 min. at 4°C, and supernatants were 
discarded. RNA pellets were washed with 400 µL 75% ethanol in DEPC-treated 
water. Samples were vortexed and centrifuged at 12,000g for 5 min. at 4°C. 
Samples were allowed to air dry and resuspended in ~ 50 µL of DEPC-treated 
water. RNA concentrations were determined using a Nanodrop 2000 (Thermo 
Fisher). 
cDNA Formation. 1 µg of total RNA was used for cDNA reverse transcription with 
the Applied Biosystems High-Capacity cDNA Reverse Transcription kit. cDNA 
was reverse transcribed as according to the manufacturer’s instructions. Following 
cDNA formation, cDNA was diluted with 3 volumes of water.  
qPCR. Applied Biosystems Powerup SYBR Green Master Mix, primers (see table 
below), and cDNA were used for mRNA amplification in an Applied Biosystems 
7500 PCR system. In addition to amplification, a melt curve was used to ensure 
homogenous PCR products from primers. 2 replicates were performed with each 
replicate containing triplicate reactions. mRNA transcripts were normalized to a 
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housekeeping gene, RPL2, and data was analyzed using the ΔΔCt method. Final 
data was presented as a mean fold change (Tg or Tn relative to DMSO treatment). 
Fold changes were statistically analyzed by unpaired t tests.  
 
Table 2-3. Primers used for qPCR. 
Transcript Forward Reverse 
RPLP CCATTCAGCTCACTGATAACCTTG CGTCGCCTCCTACCTGCT 
CHOP GGAGCTGGAAGCCTGGTATG GCCAGAGAAGCAGGGTCAAG 
ERDJ4 CTGTATGCTGATTGGTAGAGTCAA AGTAGACAAAGGCATCATTTCCAA 
GRP94 GGCCAGTTTGGTGTCGGTTT CGTTCCCCGTCCTAGAGTGTT 
 
MS Sample Preparation: In-solution trypsin digestion of whole-cell and 
isolated ER lysates.  
50 µg of SKOV-3 whole-cell or isolated ER lysate was precipitated in 10% 
trichloroacetic acid (TCA) in DPBS and frozen at -80°C for 1 hour. Samples were 
allowed to thaw and centrifuged at 15,000 RPM for 10 min. Supernatants were 
discarded and protein pellets were washed with 500 µL of ice cold acetone, 
resuspended in acetone, and centrifuged at 5,000 RPM for 10 min. Supernatants 
were discarded and the washed pellet was allowed to air dry. Pellets were 
resuspended in 30 µL of 8 M Urea in DPBS and underwent sonication to 
resolubilize. 70 µL of 100 mM ammonium bicarbonate was added to bring sample 
volumes to 100 µL. 1.5 µL of 1 M DTT was added and samples were incubated at 
65°C for 15 min. 2.5 µL of 500 mM iodoacetamide was added and samples were 
incubated at 25°C for 30 min. 120 µL of PBS was added and samples were vortexed. 
2 µL of sequencing-grade trypsin (0.5 µg/ µL, Promega) (1:50 enzyme:substrate) 
and 2.5 µL of 100 mM CaCl2 was added and samples were incubated at 37°C 
overnight under agitation. 10 µL of MS-grade formic acid was added, and samples 
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were centrifuged at 15,000 RPM for 20 min. The supernatant was collected and 
stored at -20°C until MS analysis.  
 
MS Sample Preparation: Reductive dimethylation (ReDiMe) of peptides for 
protein abundance quantification.  
ReDiMe methods were modified from the in-solution trypsin digestion 
methods described above to make sample preparation compatible with ReDiMe. 
SKOV-3 cells were grown to 90% confluency and treated with DMSO, Tg (5 µM), 
or Tn (3 µM) for 5 hours. Cells were washed with DPBS 3x, harvested, and isolated 
ER lysates were obtained as described above. 100 µg of lysate was precipitated in 
10% trichloroacetic acid (TCA) in DPBS and frozen at -80°C for 1 hour. Samples 
were allowed to thaw and centrifuged at 15,000 RPM for 10 min. Supernatants 
were discarded and protein pellets were washed with 500 µL of ice cold acetone, 
resuspended in acetone, and centrifuged at 5,000 RPM for 10 min. Supernatants 
were discarded and washed pellets were allowed to air dry. Pellets were 
resuspended in 30 µL of 8 M Urea in DPBS and underwent sonication to 
resolubilize. 70 µL of 100 mM triethylammonium bicarbonate (TEAB) was added 
to bring sample volumes to 100 µL. 1.5 µL of 1 M DTT was added and samples 
were incubated at 65°C for 15 min. 2.5 µL of 500 mM iodoacetamide was added 
and samples were incubated at 25°C for 30 min. 120 µL of PBS was added and 
samples were vortexed. 4 µL of sequencing-grade trypsin (0.5 µg/ µL resuspended 
in TEAB) (1:50 enzyme:substrate) and 2.5 µL of 100 mM CaCl2 was added and 
samples were incubated at 37°C overnight under agitation.  
4 µL of 20% formaldehyde or 20% formaldehyde - 13C, D2 was added to 
DMSO or Tg/Tn treated samples, respectively. 20 µL of 0.6 M sodium 
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cyanoborohydride was added to each sample and incubated at 25°C for 2 hours. 
Samples were placed on ice, and 4 µL of 20% ammonium hydroxide was added to 
quench reactions. 8 µL of MS-grade formic acid was added and samples were 
combined (DMSO and Tg or DMSO and Tn). Samples were desalted using Sep Pak 
C18 cartridges (Waters), eluted with 0.75 mL of 40% MS-grade acetonitrile (ACN) 
and 0.5% acetic acid and 0.75 mL of 80% MS-grade ACN and 0.5% acetic acid. 
Samples were dried in a SpeedVac (ThermoFisher), resuspended in 100 µL 95% 
MS-grade water, 5% MS-grade ACN, and 0.1% MS-grade formic acid, and stored 
at -20°C until MS analysis. 
 
MS Sample Preparation: isoTOP-ABPP to study isolated ER cysteine reactivity.  
Methods for studying cysteine reactivity were adapted from Weerapana, E. 
et al.18 and Abo, M. et al.33 200 µg of isolated ER lysates (500 µL, 0.4 mg/mL) were 
labeled with either 100 µM IA-light, 10 µM IA-light, or 10 µM IA-heavy for 1 hour 
at 25°C. A photo-cleavable PC biotin-azide tag was appended to samples by 
CuAAC. 100 µM PC biotin azide (Click Chemistry Tools), 1 mM TCEP, 100 µM of 
TBTA (17x stock in t-BuOH:DMSO 4:1), and 1 mM copper (II) sulfate was added 
and the reaction was incubated for 1 hour at 25°C. 100 µM IA-light and 10 µM IA-
heavy treated samples were combined (1:1). As a control, 10 µM IA-light and 10 
µM IA-heavy were combined (1:1). Proteins were pelleted at 6,500g for 4 min. 500 
µL of cold methanol was added, proteins were resuspended by tip sonication and 
centrifuged at 6,500g for 4 min. After a second methanol wash and centrifugation, 
pelleted proteins were solubilized in 1.2% SDS/DPBS solution by tip sonication 
and incubated for 5 min. at 80°C. SDS concentrations were diluted to 0.2% SDS 
with 5 mL DPBS and 100 µL of streptavidin agarose beads were added. Samples 
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were incubated at 4°C overnight and then at 25°C for 2 hours. Samples bound to 
beads were washed with 5 mL of 0.2% SDS/DPBS, 3x with 5 mL of DPBS, and 3x 
with 5 mL of water. Following each wash, beads were pelleted by centrifugation 
at 1400g for 3 min. Beads were resuspended in 500 µL of 6 M urea/DPBS with 10 
mM DTT and incubated at 65°C for 20 min. Next, 20 mM iodoacetamide was 
added to beads and incubated for 30 min. at 25°C. Beads were centrifuged at 1,400g 
for 3 min. and resuspended in 200 µL of 2 M urea/DPBS, 1 mM CaCl2, and 2 µg of 
sequencing grade trypsin. On-bead trypsin digestion was performed overnight at 
37°C under agitation.  
Beads were pelleted at 1,400g for 3 min and the supernatant was discarded. 
Beads were washed 3x with 500 µL DPBS and 3x with 500 µL water. Washed beads 
were resuspended in 200 µL of DPBS and incubated under UV light (365nm, 80W, 
B-100SP High Intensity UV Lamp (UVP)) for 3 hours at 25°C. Samples were spun 
down and supernatant was collected. Finally, beads were washed 2x with 75 µL of 
water and each wash was collected and combined with previous collections of 
supernatant. 17.5 µL of MS-grade formic acid was added and samples were stored 
at -20°C until MS analysis. 
 
MS Sample Preparation: Evaluating cysteine oxidation with OxICAT.  
Methods for using OxICAT to study cysteine oxidation in isolated ER were 
adapted from Topf, U. et al.34 and Abo, M. et al.33. ER isolated from SKOV-3 cells 
were resuspended in 500 µL of denaturing alkylation buffer (DAB) (6 M urea, 200 
mM Tris-HCl, 10 mM EDTA, 0.5% SDS, pH 8.5) and 10 mM IA-light and lysed 
using an ultrasonic tip sonicator. Following lysis, cysteines were labelled for 2 
hours at 37°C under agitation. Samples were centrifuged at 16,000g for 1 min. at 
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4°C to pellet insoluble debris. Supernatants were diluted 3-fold with water, and 
then proteins were precipitated by incubating with 5 volumes of ice-cold acetone 
for 2 hours at -20°C. Precipitated proteins were pelleted by centrifugation for 30 
min. at 4,500g and 4°C. Pellets were washed with ice-cold acetone, centrifuged for 
10 min. at 4,500g and 4°C, and allowed to air dry. Pellets were resolubilized in 
DAB and protein concentrations were determined using the DC Assay Kit. 200 µg 
of protein was brought to a final volume of 80 µL with DAB. Samples were treated 
with 2.5 mM TCEP and incubated for 5 min. at 37°C. Reduced samples were then 
diluted with 120 µL of DAB and 10 mM IA-heavy and briefly sonicated. Following 
sonication, samples were labelled for 2 hours at 37°C under agitation. Samples 
were diluted 3-fold with water and proteins were precipitated with 5 volumes of 
ice-cold acetone and incubated overnight at -20°C. Precipitated proteins were 
pelleted by centrifugation for 30 min. at 4,500g and 4°C. Pellets were washed with 
ice-cold acetone, centrifuged for 10 min. at 4,500g and 4°C, and allowed to air dry. 
Samples were resolubilized in 500 µL DPBS by sonicating with an ultrasonic tip 
sonicator.  
A photo-cleavable PC biotin-azide tag was appended to samples by 
CuAAC. 500 µM PC biotin-azide, 5 mM TCEP, 500 µM of TBTA (17x stock in t-
BuOH:DMSO 4:1), and 5 mM copper (II) sulfate was added and the reaction was 
incubated for 1 hour at 25°C. Proteins were pelleted at 6,500g for 4 min. 500 µL of 
ice-cold methanol was added, proteins were resuspended by tip sonication, and 
centrifuged at 6,500g for 4 min. After a second methanol wash and centrifugation, 
pelleted proteins were solubilized in 1.2% SDS/DPBS solution by tip sonication 
and incubated for 5 min. at 80°C. SDS concentrations were diluted to 0.2% SDS 
with 5 mL DPBS and 100 µL of streptavidin agarose beads were added. Samples 
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were incubated at 4°C overnight and then at 25°C for 2 hours. Samples bound to 
beads were washed with 5 mL of 0.2% SDS/DPBS, 3x with 5 mL of DPBS, and 3x 
with 5 mL of water. Following each wash, beads were pelleted by centrifugation 
at 1,400g for 3 min. Beads were then resuspended in 500 µL of 6 M urea/DPBS and 
incubated for 30 min. at 25°C. Beads were centrifuged at 1,400g for 3 min. and 
resuspended in 200 µL of 2 M urea/DPBS, 1 mM CaCl2, and 2 µg of sequencing-
grade trypsin. On-bead trypsin digestion was performed overnight at 37°C under 
agitation.  
Beads were pelleted at 1,400g for 3 min and the supernatant was discarded. 
Beads were washed 3x with 500 µL DPBS and 3x with 500 µL water. Washed beads 
were resuspended in 200 µL of DPBS and incubated under UV light (365nm, 80W, 
B-100SP High Intensity UV Lamp (UVP)) for 3 hours at 25°C. Samples were spun 
down and supernatant was collected. Finally, beads were washed 2x with 75 µL of 
water and each wash was collected and combined with previous collections of 
supernatant. 17.5 µL of MS-grade formic acid was added and samples were stored 
at -20°C until MS analysis. 
For monitoring changes in cysteine oxidation following treatment with 
DMSO, Tn, and Tg, SKOV-3 cells were first treated with DMSO, Tg (5 µM) 
(Cayman Chemical), or Tn (3 µM) for 5 hours. Cells were washed with DPBS 3x 
and harvested. ER was isolated as previously detailed and subjected to the 
OxICAT prep describe above.  
 
LC/LC-MS/MS.  
Mass spectrometry data was obtained using a Thermo Fisher LTQ Orbitrap 
Discovery mass spectrometer coupled to an Agilent 1200 series HPLC. In solution 
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trypsin digested or azide tagged peptides were pressure loaded onto a 250 µm 
fused silica desalting column (Agilent) packed with 4 cm of Aqua C18 reverse 
phase resin (Phenomenex) using a high pressure injection cell (Next Advance). 
Peptides were eluted onto a 100 µm fused silica biphasic column with a 5 µm tip, 
packed with 10 cm of C18 resin and 4 cm of Partisphere strong cation exchange 
resin (SCX, Whatman) using a gradient from 0% to 100% Buffer B in Buffer A 
(Buffer A: 95% water, 5% ACN, 0.1% formic acid; Buffer B: 20% water, 80% ACN, 
0.1% formic acid). Peptides were eluted from SCX to C18 using 4 separate salt 
pushes (In-solution trypsin digested samples: 25%, 50%, 80%, 100%; azide tagged 
samples: 50%, 80%, 100%, 100%) followed by a gradient of Buffer B in Buffer A as 
according to Weerapana, E. et al.62. The flow rate of buffer through the column was 
set to 0.25 µL/min and the spray voltage was set to 2.75 kV. For in-solution trypsin 
digested samples, one full MS scan (FTMS) was followed by 7 data dependent 
scans (ITMS) of the nth most intense ions. For azide-tagged samples, one full MS 
scan (FTMS) was followed by 8 data dependent scans (ITMS) of the nth most 
intense ions. Dynamic exclusion was enabled for each run.  
 
LC/LC-MS/MS data analysis.  
MS data from all samples were searched using the SEQUEST algorithm63 
against a concatenated target/decoy non-redundant variant of the human UniProt 
database. A static modification of +57.02146 on cysteine was included to account 
for alkylation by iodoacetamide.  
Whole-cell and isolated ER in-solution trypsin digested samples. SEQUEST output files 
were filtered using DTASelect2.064 with the -trypstat option and a maximum false 
discovery rate of 5% applied. Additionally, at least two peptides were required 
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per locus. Subcellular localization of proteins for in-solution trypsin digested 
whole-cell and isolated ER samples was determined using a previously described 
in-house Python program that uses biopython functionalities to search the Uniprot 
Protein Knowledgebase (UniProtKB) and totals subcellular annotation counts for 
proteins, peptides, and spectral counts26.  
In-solution trypsin digested ReDiMe samples. In addition to a static modification on 
cysteine, static modifications of +28.0313 (light) or +34.06312 (heavy) on the N-
terminus of the peptide and on lysine were included to account for dimethylation 
of primary amines. SEQUEST output files were filtered using DTASelect 2.0 with 
the -trypstat option and a maximum false discovery rate of 5% applied. 
Furthermore, at least two peptides were required per locus. H:L ratios (Tg:DMSO 
or Tn:DMSO) were calculated using the previously described cimage 
quantification package18. From two replicates, data was filtered for proteins whose 
ratio was quantified in both samples and Uniprot or GO annotated as localizing to 
part of the secretory pathway (described below). Ratios were converted to log2 and 
averaged. Standard deviations were calculated as well as the coefficient of 
variation (standard deviation/average). Ratios >1 (log2) or -1> (log2) whose 
absolute coefficient of variation was >0.5 were removed, resulting in the final 
datasets. 
isoTOP-ABPP. In addition to a static modification on cysteine, differential 
modifications of +228.13749 (light) or +234.15762 (heavy) on cysteine were 
included to account for labeling of IA-light or IA-heavy appended to a cleaved PC 
biotin-azide tag. SEQUEST output files were filtered using DTASelect 2.0 with -
trypstat and -modstat options and a maximum false discovery rate of 5% applied. 
Additionally, peptides were required to be fully tryptic (-y 2), have a found 
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modification (-m 0), a delta-CN score greater than 0.06 (-d 0.06), and only a single 
peptide was required per locus (-p 1). L:H ratios were quantified using the cimage 
quantification package. Functional annotation of cysteines within the dataset is 
described below. Two replicates of 10 µM IA-light:10 µM IA-heavy and two 
replicates of 100 µM IA-light:10 µM IA-heavy were analyzed. Data was filtered for 
peptides whose ratio was calculated in both 100 µM IA-light:10 µM IA-heavy 
samples. The median ratio was calculated for each control sample (10µM IA-
light:10 µM IA-heavy) and ratios from 100 µM IA-light:10 µM IA-heavy data were 
corrected (100 µM IA-light:10 µM IA-heavy / Median (10µM IA-light:10 µM IA-
heavy)). Averages for corrected ratios (100 µM IA-light:10 µM IA-heavy) were 
calculated as well as the standard deviation and coefficient of variation. Peptides 
with a coefficient of variation >0.7 were removed from the data. Finally, data was 
filtered for only peptides belonging to proteins that are either Uniprot or GO 
annotated to localize in the secretory pathway.  
OxICAT. In addition to a static modification on cysteine, differential modifications 
of +228.13749 (light) and +234.15762 (heavy) on cysteine were included to account 
for labeling of IA-light or IA-heavy appended to a cleaved PC biotin-azide tag. 
SEQUEST output files were filtered using DTASelect 2.0 with -trypstat and -
modstat options and a maximum false discovery rate of 5% applied. Additionally, 
peptides were required to be fully tryptic (-y 2), have a found modification (-m 0), 
a delta-CN score greater than 0.06 (-d 0.06), and only a single peptide was required 
per locus (-p 1). L:H and H:L ratios from two replicates were quantified using the 
cimage quantification package. Data was filtered for secretory pathway annotated 
peptides whose ratios appeared in both samples. L:H and H:L ratios were 
converted to % oxidized using the equations: 1-(L:H/(L:H+1)) or H:L/(H:L+1). 
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Averages and standard deviations for % oxidized values for each peptide were 
calculated, and peptides with a standard deviation >20% were removed.  
 DMSO, Tg, and Tn treated samples were each performed in triplicate. When 
analyzing DMSO versus Tg or DMSO versus Tn, data was filtered for secretory 
pathway annotated peptides with ratios appearing in at least 2/3 replicates in each 
treatment (4/6 total replicates). Ratios were converted to % oxidized (as described 
above), averaged, and a standard deviation was calculated. Differences in % 
oxidation of cysteines (DMSO – Tg or DMSO – Tn) was statistically analyzed using 
unpaired t tests and peptides with statistically insignificant differences (p>0.05) 
were removed (Table 2A-10 and 2A-11).  
 
Statistical analysis of overrepresented GO biological processes using 
PANTHER.  
Panther overrepresentation tests (http://pantherdb.org)38 were performed 
on whole-cell and isolated ER in-solution trypsin digested samples and Tg treated 
ReDiMe samples. For whole-cell and isolated ER data, only proteins with ≥ 2 
spectral counts were included in the analysis. PANTHER determines an “expected” 
value for the number of protein IDs that are predicted to be found in an input 
dataset for each functional category (GO biological process complete) based on the 
percentage of protein IDs for each category within the complete human genome. 
Overrepresentation is presented as a ratio (observed:expected) for each biological 
process. A Fisher’s exact test with a Bonferroni correction was used to determine 
statistical significance of overrepresentation for each biological process with a P 
value cutoff of 0.05.  
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Subcellular localization analysis.  
Outside of in-solution trypsin digested whole-cell and isolated ER samples, 
subcellular localization was assessed using an in-house python program. 
Specifically, web scraping was performed to extract localization terminology from 
Uniport annotation and GO – cellular component tabs on 
https://www.uniprot.org for identified proteins and corresponding peptides. 
Subcellular localization for proteins was outputted as three separate columns 
(Uniprot localization, GO localization, and combined localization) and the 
combined localization column was used for filtering. Proteins were considered ER 
or secretory pathway proteins if they contained at least one of the following 
localization terms: “endoplasmic reticulum”, “golgi”, “plasma membrane”, 
“lysosome”, “peroxisome”, “vesicle”, “endosome”, “secreted” or “extracellular”, 
or “cell junction”. 
 To evaluate coverage of the ER proteome, the Human Protein Atlas: The 
Cell Atlas (https://www.proteinatlas.org/humanproteome/cell)37 was used to 
determine the number of identified ER proteins in isolated ER relative to the total 
number of ER proteins that have been experimentally shown to localize to the ER. 
The Cell Atlas mapped protein localization by combining transcriptomics and 
antibody-based immunofluorescence confocal microscopy against a panel of 64 
cell lines. 
 
Cysteine functional annotation.  
Cysteines with annotated functions were identified using a previously 
described Python program26. To summarize, labeled cysteines identified in 
isoTOP-ABPP and OxICAT datasets were compared against the UniProtKB for 
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residue specific information including the keywords 'CA_BIND', 'ZN_FING', 
'DNA_BIND', 'NP_BIND', 'ACT_SITE', 'METAL', 'BINDING', 'SITE', 'NON_STD', 
'MOD_RES', 'LIPID', 'CARBOHYD', 'DISULFID', 'CROSSLINK', 'VARIANT', 
'MUTAGEN', 'UNSURE', 'CONFLICT', and 'REGION'. 
 S-palmitoylated cysteines were identified using the Python program 
described above as well as the SwissPalm database65 (https://swisspalm.org). 
Proteins with cysteines labeled in isoTOP-ABPP and OxICAT experiments were 
searched in the SwissPalm database for annotated sites of S-palmitoylation. These 
sites were then cross-referenced with cysteines identified in datasets. SwissPalm 
annotated sites of S-palmitoylation require either experimental validation of S-
palmitoylation, or the appearance of the site in at least 1 palmitoyl proteome study.    
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 Nascent proteins destined for the secretory pathway and plasma membrane 
are translocated into the highly oxidizing environment of the endoplasmic 
reticulum (ER) where controlled folding and oxidative post-translational 
modifications including disulfide-bond formation are facilitated by folding 
chaperones such as heat shock proteins (HSPs), N-linked glycosylation and lectin-
assisted folding chaperones (i.e. calreticulin and calnexin), and protein disulfide 
isomerases (PDIs)1-4. PDIs, specifically, are responsible for catalyzing the 
oxidation, reduction, and isomerization of disulfide bonds in actively folding 
substrates (Figure 3-1). Disulfide-bond formation and rearrangement are 
accelerated by thiol-disulfide exchange reactions between a CXXC active-site 
motif, conserved in many PDIs, and cysteines on a substrate4-5. PDI reductase and 
isomerase activity requires a reduced dithiol-containing active site, while oxidase 
activity is dependent on an oxidized disulfide-containing active-site6. 
Additionally, PDIs may function as classical chaperones independent of their 
oxidoreductase active-sites4.  
	 130	
 
Figure 3-1. Functional roles of PDI a-domain active sites. A) The oxidase activity 
of PDI results in the formation of a disulfide on a substrate and the reduction of 
PDI’s redox-active disulfide bond. B) The reductase activity of PDI results in the 
reduction of a disulfide on a substrate and the oxidation of PDI’s active-site 
cysteines. C) The isomerase activity of PDI catalyzes the rearrangement of 
incorrectly formed disulfide bonds in substrates to yield a properly folded protein. 
In the net reaction, the oxidation state of PDI’s active-site cysteines remains 
unchanged.  
	 131	
The PDI family consists of 21 family members with each member 
containing at least one thioredoxin-like domain7 (Table 3-1). These domains are 
differentiated into two categories, the catalytic a-domain characterized by the 
conserved CXXC active-site motifs4, and the noncatalytic b-domain that’s 
proposed to play roles in substrate recognition or chaperone complex formation8-
9. The PDI family is structurally diverse with some members containing several a- 
and b-domains (i.e. PDIA1, PDIA3, and PDIA4), while others are limited in their 
complexity, containing only b-domains (i.e. PDIA8 and PDIA9). Sequence 
homology amongst PDIs ranges from as low as 29% similarity between PDIA1 and 
PDIA18 and as high as 60% similarity between PDIA3 and PDIA47. As a result, it 
is believed that some members have functional overlap with one another, while 
others may have a more selective and unique set of substrates9-10.  
 
Table 3-1. The PDI family consists of 21 members with varying structures.  
Name Length Domain composition 
# a-type 
domains Active-site sequence 
PDIA1 (PDI) 508 a-b-b’-a’ 2 CGHC, CGHC 
PDIA2 (PDIp) 525 a-b-b’-a’ 2 CGHC, CTHC 
PDIA3 (ERp57) 505 a-b-b’-a’ 2 CGHC, CGHC 
PDIA4 (ERp72) 645 ao-a-b-b’-a’ 3 CGHC, CGHC, CGHC 
PDIA5 (PDIr) 519 b-ao-a-a’ 3 CSMC, CGHC, CPHC 
PDIA6 (P5) 440 ao-a-b 2 CGHC, CGHC 
PDIA7 (PDILT) 584 a-b-b’-a’ 2 SKQS, SKKC 
PDIA8 (ERp27) 273 b-b’ 0 N/A 
PDIA9 (ERp28) 261 b-D 0 N/A 
PDIA10 (ERp44) 406 a-b-b’ 1 CRFS 
PDIA11 (TMX1) 280 a 1 CPAC 
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PDIA12 (TMX2) 296 a 1 SNDC 
PDIA13 (TMX3) 454 a-b-b’ 1 CGHC 
PDIA14 (TMX4) 349 a 1 CPSC 
PDIA15 (ERp46) 432 ao-a-a’ 3 CGHC, CGHC, CGHC 
PDIA16 (ERp18) 172 a 1 CGAC 
PDIA17 (HAG-2) 175 a 1 CPHS 
PDIA18 (HAG-3) 165 a 1 CQYS 
PDIA19 (ERdj5) 793 J-a’’-b-ao-a-a’ 4 CSHC, CPPC, CHPC, CGPC 
PDIB1 (CASQ1) 396 Unknown N/A N/A 
PDIB2 (CASQ2) 399 Unknown N/A N/A 
 
The most abundant and well-studied PDI, PDIA1, is a 57 kDa 
oxidoreductase comprising up to 0.8% of all cellular protein. Structurally, PDIA1 
is composed of four thioredoxin-like domains, a, b, b’, and a’ (Figure 3-2A), 
arranged in a horseshoe conformation with the a-domain active sites facing one 
another. Additionally, PDIA1 contains a C-terminal extension and a KDEL ER 
retention motif9. The oxidation state of cysteines in the a and a’ active site influence 
conformational changes in PDIA1’s structure. In the reduced, dithiol form, PDIA1 
adopts a narrow conformation (~15 Å) while in the oxidized, disulfide form, 
PDIA1 shifts to a more open conformation (~30 Å)11 (Figure 3-2B). Also, substrate 
recognition was found to be dependent on a hydrophobic pocket in the b’ 
domain12. PDIA1 is reported to have broad substrate specificity, folding various 
protein classes13. Beyond its function as an oxidoreductase, PDIA1 is also a subunit 
of prolyl 4-hydroxylase (P4H), participating in the synthesis and maturation of 




Figure 3-2. Domain composition and structural conformation of PDIA1. A) 
Organization of the thioredoxin-like domains in PDIA1. B) Crystal structures of 
reduced (PDB: 4EKZ) and oxidized (PDB: 4EL1) PDIA1 thioredoxin-like domains 
demonstrating changes to protein conformation.  
 
In comparison to PDIA1, PDIA4, is a 72 kDa oxidoreductase that contains 
an extra catalytic a-domain with the following domain arrangement from N-
terminus to C-terminus: ao, a, b, b’, and a’ (Figure 3-3)7. Similar in structure to 
PDIA1, the active sites in the a-domains are oriented to face one another; however, 
a hydrophobic substrate recognition motif is missing from the b’ domain. Instead, 
it’s been proposed that hydrophobic patches near the active sites play a role in 
substrate recognition15. Additionally, a set of highly acidic residues in the N-
terminus were found to play a role in Ca2+ binding, although, the role that this 
binding interaction plays is currently unclear. While less abundant than PDIA1, 
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PDIA4 is still considered a highly expressed member in the PDI family7. 
Annotation for specific substrates of PDIA4 is extremely poor, but, PDIA4 was 
found to have functional overlap with PDIA3, a PDI responsible for folding 
glycoproteins. Upon depletion of PDIA3 in murine fibroblasts, PDIA4 colocalized 
with PDIA3 glycoprotein substrates16.  
 
 
Figure 3-3. Domain composition of PDIA4. 
 
Dysregulation of PDIs, including PDIA1 and PDIA4 is associated with 
various cancers and misfolding diseases17-18. An increase in protein synthesis is 
associated with rapidly proliferating cancer cells, requiring a larger folding 
capacity within the ER and increased expression of the PDI family. Overexpression 
of PDIA1 has been associated with several cancers including lymphoma19, 
ovarian20, and prostate21. Furthermore, upregulation of PDIA1 is correlated with 
poor cancer prognosis. The survival rates of breast22 and glioblastoma23 cancer 
patients are lower when PDIA1 expression levels are high. Recently, PDIA4 was 
found to be a negative regulator of Lewis lung carcinoma cellular apoptosis due 
to interactions between procaspases 3 or 7 and PDIA4’s active sites24. Additionally, 
increased expression of PDIA4 and PDIA6 in non-small lung cancer cells mediated 
cisplatin resistance, preventing cell death in lung cancer. Knockdown of PDIA4 
and PDIA6 increased sensitivity to cisplatin treatment and induced apoptosis25. 
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Neurodegenerative diseases such as transmissible spongiform encephalopathies 
(TSEs) and Parkinson’s disease are associated with the aggregation of misfolded 
proteins3, 18. A consequence of protein misfolding in these diseases is the 
upregulation of the unfolded protein response (UPR) and increased expression of 
folding chaperones as a protective effort to reduce protein aggregation and ER 
stress. As a result, increased expression of PDIs in these diseases are considered 
neuroprotective18. In Parkinson’s disease, PDIA1 was found to prevent the 
aggregation of two disease-related proteins, synphilin-1 and α-synuclein26-27. 
Meanwhile, PDIA3 is upregulated in Creutzfeldt-Jakob Disease (CJD), protecting 
cells from toxic misfolded PrP28-29. Although PDIs contain ER retention signals, 
members have been found to localize beyond the ER. Secreted PDIs have been 
implicated in diseases such as thrombosis30 and HIV viral entry31. In regards to 
HIV infection, the reduction of an allosteric disulfide bond on gp120 by PDIA1 
induces a large conformational change that unmasks a fusion peptide in gp41, 
promoting HIV-cell fusion31.  
While the general oxidoreductase activity of family members and 
expression profiles in disease are modestly characterized, the identification of PDI 
substrates and functional overlap between members remains sparse. Due to the 
complex nature of protein folding, including the vast number of PDIs and quality 
control mechanisms such as the UPR and ER associated degradation (ERAD) of 
misfolded proteins, studying these interactions is challenging. In an effort to 
identify substrates, several techniques have been recently implemented. 
Rutkevich et al. used immunoblotting to identify disulfide-rich secreted substrates 
of various PDIs and radiolabeling to determine the folding kinetics of these 
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proteins by the PDI family32. For a more global evaluation of PDI substrates, two 
different PDI-substrate trapping techniques have been implemented. Jessop et al. 
developed Cys to Ala mutants in the active sites of various PDIs to trap PDI-
substrate intermediates. PDI-substrate complexes were separated by 2D gel 
electrophoresis and gel bands were evaluated by mass spectrometry10. Although 
substrates were identified for various PDIs, no mixed disulfides were observed 
between PDIA1 or PDIA4 and substrates, highlighting a limitation to these 
studies. In an alternative approach, Stopa et al. developed a kinetic based trapping 
method whereby mutation of histidine in the CGHC motif of PDIA1 resulted in 
the formation of stable oxidative traps33. It was hypothesized that mutation of 
histidine altered the pKa of the nucleophilic N-terminal cysteine in the active site, 
slowing the transition between reduced and oxidized states of the active site. 
Similar to Jessop et al. gel bands were analyzed by mass spectrometry. A challenge 
to identifying these complexes is that only highly abundant PDI-substrate 
complexes will be visually resolvable in a gel. While useful for the identification 
and confirmation of substrates, these platforms are limited in scope to the 
immunoblotting of already predicted substrates or the identification of only the 
most abundant PDI-substrate interactions.  
Here, we report biological and chemoproteomic techniques for the (1) 
global profiling of PDIA1- and PDIA4-mediated disulfide-bond formation, (2) 
functional overlap in the PDI family, and (3) ER-stress induced compensatory 
folding mechanisms following CRISPR-cas9 mediated knockout of PDIA1 or 
PDIA4 in ovarian cystadenocarcinoma, SKOV-3 cells. Furthermore, we isolated ER 
by differential centrifugation to enhance coverage of the folding proteome and 
narrow in on the subcellular location of the cell most directly affected by PDI 
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perturbation. Isotopic tagging of peptides by reductive dimethylation of primary 
amines (ReDiMe) in isolated ER revealed changes to protein abundance for 547 
and 463 proteins in PDIA1KO and PDIA4KO cells, respectively. Our studies 
revealed increased abundance of several PDIs and folding chaperones for 
PDIA1KO cells, while more selective changes to PDI and chaperone abundance 
were observed in PDIA4KO cells. In an effort to identify novel substrates of PDIA1 
and PDIA4, changes to cysteine oxidation in the ER and secretory pathway, such 
as loss or gain of disulfide bonds were directly interrogated by combining ER 
isolation with OxICAT analysis. While a majority of cysteines showed no changes 
in oxidation upon knockout of PDIA1 or PDIA4, 56 and 52 cysteines displayed 
changes of >10% in PDIA1KO and PDIA4KO cells, respectively. Together, these 
studies demonstrate the applicability of global proteomic methods towards 
profiling substrate specificity and functional overlap within the PDI family and 
help reveal the complex compensatory mechanisms that exist within not just the 
PDI family, but the entire folding machinery of the ER.  
 
Results and Discussion 
 
CRISPR-Cas9 mediated knockout of PDIA1 and PDIA4.  
In order to characterize the roles of PDIA1 and PDIA4 in oxidative folding 
and how perturbation to each protein’s function affects ER homeostasis, PDIA1 
and PDIA4 were separately knocked out in SKOV-3 cells using CRISPR-Cas9 
technology. SKOV-3, an ovarian cancer cell line, was specifically chosen as an ideal 
model for investigating PDIA1 and PDIA4 function, due to the aforementioned 
roles of PDIs in cancer. It was expected that SKOV-3 cells would exhibit higher 
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levels of sensitivity to PDI knockouts compared to healthy, noncancerous cell 
lines.  
Single guide RNA (sgRNA) were designed to selectively target the coding 
regions of PDIA1 or PDIA4. Specifically, a 21 nucleotide sgRNA targeting exon 7 
of PDIA1 was predicted to produce a Cas9 cleavage-site at a base coding for Ser331 
in the substrate binding b’ domain14, while a 20 nucleotide sgRNA targeting exon 
8 of PDIA4 was predicted produce a Cas 9 cleavage-site at a base coding for Tyr409 
in the b’ domain34 (Figure 3-4).  
 
 
Figure 3-4. sgRNA designed against exon 7 of PDIA1 and exon 8 of PDIA4. The 
sgRNA is highlighted in red and the protospacer adjacent motif (PAM) is 
highlighted in blue. 
 
Importantly, each sgRNA was not predicted to promote off-target activity. sgRNA 
were cloned into LentiCRISPR v2 constructs permitting lentiviral delivery of Cas9, 
sgRNA, and puromycin resistance as a selectable marker35. 293T cells were 
transfected to generate lentivirus that was then harvested for the infection of 
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SKOV-3 cells. Successfully infected SKOV-3 cells conferring puromycin resistance 
as well as Cas9 and sgRNA expression were selected from uninfected cells with 
puromycin (Figure 3-5). 
 
 
Figure 3-5. Schematic representation of lentiviral transfections used to obtain 
PDIA1 and PDIA4 knockout cell lines.  
  
Following selection, the general population of infected cells were evaluated 
for PDIA1 or PDIA4 gene editing by the identification of indels with the Surveyor 
nuclease mismatch cleavage assay36. The Surveyor nuclease cleaves base pair 
mismatches created by nucleotide deletions or insertions following Cas9-mediated 
gene editing. Briefly, regions surrounding PDIA1 or PDIA4 gene editing were 
amplified by PCR (polymerase chain reaction). Double stranded DNA from each 
population was denatured and rehybridized to allow non-edited WT and edited 
mutant strands to anneal to one another, forming a heteroduplex. Treatment with 
Surveyor nuclease resulted in the cleavage of heteroduplexes. Analysis on a 2% 
agarose gel revealed the formation of cleavage products representative of indel 
formation. Gel band integration estimated ~28% and ~48% indel occurrence in 
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PDIA1 and PDIA4 gene edited SKOV-3 cells, respectively (Figure 3-6), indicating 
successful editing of PDIA1 and PDIA4 by Cas9. 
 
 
Figure 3-6. Surveyor assay was performed to confirm gene editing in the general 
population of knockout cells. Arrowheads indicate fragments of DNA cleaved by 
the Surveyor nuclease due to the presence of indels.  
 
Monoclonal populations of PDIA1 or PDIA4 edited SKOV-3 cells were 
obtained by performing single cell dilutions to isolate individual clones. Select 
monoclonal cell lines that survived single cell dilutions were analyzed by ICE 
(inference of CRISPR edits)37 and western blotting to validate the generation of 
PDIA1KO or PDIA4KO cell lines (PDIA1KO or PDIA4KO). ICE compares Sanger 
sequencing data from PCR products encompassing the region around the 
cleavage-sites of an edited gene to the Sanger sequencing data of an unedited wild 
type gene. This comparison enables the estimation of indel sizes and percentage 
of indel occurrence and provides a knockout score for a given cellular 
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population37. Significant editing of PDIA1 or PDIA4 genes was observed in a 
monoclonal population of PDIA1KO or PDIA4KO SKOV-3 cells, with both cell 
lines receiving a knockout score of 94 out of 100. Specifically, the PDIA1KO cell 
line contained frameshift mutations from -4, -5, and -14 base pair deletions. A 
fourth deletion of -30 bases was observed and predicted to be large enough to 
impair protein function and subject the protein to degradation37 (Figure 3-7A). 
Meanwhile, the PDIA4KO cell line contained frameshift mutations from -11 and -
13 base pair deletions (Figure 3-7B).  
 
Figure 3-7. ICE analysis of PDIA1 and PDIA4 SKOV-3 knockouts following 
isolation of clonal populations. Primers were designed to produce genomic PCR 
products that encompass both sides of the edited site. PCR products were purified 
and submitted for sequencing. Sequencing results were then analyzed by ICE and 
compared to a WT control. A) Cas9-mediated PDIA1KO predominantly produced 
indel sizes of -4, -5, -14, and -30. Furthermore, a knockout score of 94 was 
predicted. B) Cas9-mediated PDIA4KO predominantly produced indel sizes of -
11 and -13. A knockout score of 94 was predicted. 
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Having confirmed significant editing at the genomic level, western blots 
were performed to confirm knockouts at the protein level. Western blotting 
against PDIA1, PDIA4, and a GAPDH control confirmed that CRISPR-Cas9 gene 
editing successfully fully reduced PDIA1 and PDIA4 protein abundance in 
respective knockout cell lines (Figure 3-8). As well, protein abundance for PDIA1 
in PDIA4KO and PDIA4 in PDIA1KO cell lines remained relatively unchanged. 
 
 
Figure 3-8. Western blot analysis of PDIA1 or PDIA4 protein abundance in SKOV-
3 WT, PDIA1KO or PDIA4KO cell lines. Cell lines were derived from a single 
clonal population. GAPDH was monitored as a control. 
 
In addition to confirming knockouts by biological techniques, PDIA1KO 
cells were validated by chemically probing for cysteine reactivity in PDIA1’s active 
sites. We recently reported the development of a highly selective PDIA1 a-domain 
(Cys53) covalent inhibitor, KSC-3438. KSC-34 was developed around a triazine 
scaffold containing a chloroacetamide electrophile, alkyne handle, and a (4-
phenylbutyl)methylamine diversity element for selective non-covalent 
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interactions with a hydrophobic pocket near PDIA1’s a domain active-site 
cysteine. Pertinent to this study, there have been no covalent inhibitors reported 
to selectively target PDIA4 nor it’s individual active sites, limiting the scope of this 
particular analysis to PDIA1. WT, PDIA1KO, and PDIA4KO SKOV-3 ER lysates 
were treated with 5 µM KSC-34 for 1 hour and then appended to a rhodamine 
azide fluorophore by copper(I)-catalyzed azide alkyne cycloaddition (CuAAC). 
Samples were then analyzed by SDS-PAGE and in-gel fluorescence (Figure 3-9). 
As evident by in-gel fluorescence, labeling of PDIA1 by KSC-34 in PDIA1KO cells 
was completely abolished. In comparison, similar levels of PDIA1 labeling were 
observed between WT and PDIA4KO samples. Taken together, these results 
amply confirm the generation of stable PDIA1KO or PDIA4KO SKOV-3 cell lines.  
 
 
Figure 3-9. KSC-34, a highly selective PDIA1 inhibitor, was used to confirm a loss 
in PDIA1 activity due to PDIA1 depletion in PDIA1KO cells.  
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Effects of PDIA1 or PDIA4 knockouts on SKOV-3 proliferation and survival.  
Previous studies have reported mixed conclusions on cell viability 
following the depletion of PDI family members. In murine models, PDIA1 
knockouts are embryonic lethal39, and in yeast, 10-20% of maximal Pdi1p (yeast 
PDIA1 homologue) activity was required to prevent cell death4. In mammalian 
cells, Park et al. found prolonged expression of PDIA1 siRNA to result in Hela cell 
death40, while Hashida et al. found the cytotoxicity of PDIA1 knockdowns to be 
entirely cell line dependent41. Due to the discrepancies listed above and the 
importance of PDIs in cancer cell pathogenesis, PDIA1KO and PDIA4KO SKOV-3 
cell proliferation and survival were assessed.  
Cellular proliferation studies were executed in serum-containing media to 
promote the propagation of cells, while survival was performed in serum-free 
media to inhibit cellular growth. The addition of WST-1 to cells enables the direct 
readout of cellular proliferation and survival through the reduction of WST-1 to 
formazan by a reduction dependent on the glycolytic production of NAD(P)H in 
viable cells42 (Figure 3-10). 
 
 
Figure 3-10. The WST-1 salt is reduced to formazan by mitochondrial 
dehydrogenases in viable cells resulting in increased absorbance at 450 nm.  
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Changes to proliferation and survival of PDIA1KO and PDIA4KO cells 
were evaluated at 0 hour, 24 hour, 48 hour, and 72 hour time points and compared 
to a SKOV-3 WT control. Cellular proliferation was significantly reduced in 
PDIA1KO and PDIA4KO cells with relative cell viability as low as ~45% and ~60% 
in PDIA1KO and PDIA4KO cells, respectively (Figure 3-11A). Meanwhile, only 
PDIA1KO cells exhibited significant reductions in cell survival, ~50% cell viability 
compared to the SKOV-3 WT control (Figure 3-11B). After the first 24 hours of the 
survival assay, PDIA4KO cells recovered and demonstrated no changes to cell 
viability in serum-free media. Taken together, these results suggest that depletion 
of PDIA1 disrupts cellular homeostasis and sensitizes cells to environmental 




Figure 3-11. Evaluating cellular viability in PDIA1 and PDIA4 knockout SKOV-3 
cells. A) Cellular proliferation following PDIA1KO or PDIA4KO was 
characterized. Cells were compared to a WT control. Data is presented as a mean 
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+/- SEM, n = 5. B) Cellular serum-free survival in PDIA1KO and PDIA4KO cells 
was evaluated and compared to a WT control. Data is presented as a mean +/- 
SEM, n = 5. * P value <0.05. 
 
Knocking out PDIA1 or PDIA4 in SKOV-3 cells modestly upregulates the 
unfolded protein response.  
The unfolded protein response (UPR) is sensitive to the accumulation of 
misfolded proteins in the ER and serves as a quality control mechanism to 
maintain ER protein-folding homeostasis43. Because of PDIA1’s and PDIA4’s roles 
in the introduction and rearrangement of disulfide bonds on nascent proteins 
within the ER, knocking out PDIA1 and PDIA4 in SKOV-3 cells was expected to 
result in an accumulation of misfolded proteins and thereby upregulate the UPR. 
Upon sensing an increased presence of misfolded proteins, the UPR is activated 
by the triggering of three different signaling pathways: activating transcription 
factor-6α (ATF6), inositol-requiring 1α (IRE1α), and PKR-like ER kinase (PERK)43-
45. Acute activation of the UPR typically leads to the inhibition of general 
translation and concurrent increased expression of proteins associated with the ER 
folding and ERAD machineries to increase folding capacity and reduce protein 
aggregation. Prolonged stimulation of the UPR may result in the reprogramming 
of the cell for apoptosis. The effects of PDIA1 and PDIA4 knockouts on each arm 
of the UPR were assessed by quantitative real-time polymerase chain reactions 
(qPCR).  
 In order to perform qPCR analysis, RNA was isolated from WT, PDIA1KO, 
and PDIA4KO SKOV-3 cells, reverse transcribed, and amplified by qPCR to 
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evaluate mRNA levels encoding for known upregulated downstream targets of 
the three UPR arms. Specifically, primers were designed to amplify GRP94 (ATF6-
regulated), ERDJ4 (IRE1α-regulated), and CHOP (PERK-regulated). Interestingly 
PDIA1KO led to modest but general activation of the UPR across all three arms 
with larger increases in GRP94 (~2-fold) and CHOP (~3-fold) mRNA levels, and a 
smaller but significant increase in ERDJ4 mRNA levels (~1.5-fold) (Figure 3-12). In 
comparison, PDIA4KO did not activate the ATF6 and PERK arms of the UPR, 
however, a slight activation of the IRE1α arm as evident by the reproducibly small 
increase in ERDJ4 mRNA levels (~1.5) was observed (Figure 3-12). Inhibition of 
PDIA1 by the a domain selective inhibitor, KSC-34, also stimulated the IRE1α arm 
of the UPR, but not ATF6 or PERK38, suggesting that the loss of function in both 
active sites, a and a’, of PDIA1 by Cas9 is required to induce a more global 
upregulation of the UPR. Additionally, activation of the UPR following 
knockdown of PDIA1 levels appears to be cell line specific. In previous studies, 
siRNA mediated PDIA1 knockdowns in HepG2 cells did not induce the UPR32, 
while shRNA mediated PDIA1 knockdowns in glioblastoma multiforme cell lines, 
U87 and D54, led to UPR activation46. These differing results highlight the varying 
degrees of resiliency that cells have towards perturbation of protein folding. 
Finally, upregulation of the UPR within PDIA1KO and PDIA4KO SKOV-3 cells is 
most likely attributed to incorrect disulfide-bond formation in substrates, thereby 






Figure 3-12. Activation of UPR target genes was evaluated by qRT-PCR in WT, 
PDIA1KO, and PDIA4KO cells. Transcripts were normalized to a housekeeping 
gene, RPLP2, and relative mRNA expression levels were calculated. Data 
represents the mean ± s.d. of two replicates. * P value <0.05. 
 
Enriching for protein folding interactions by isolation of the ER.  
Because PDIs are ER resident proteins, changes to the ER folding machinery 
and disulfide-bond formation were expected to be most prominent within the ER. 
Furthermore, misfolded substrates of the PDI family are typically degraded by 
ERAD before export can ever occur47. As a result, assessing changes to the ER 
folding machinery and cysteine oxidation states following PDIA1KO or PDIA4KO 
would be difficult to resolve within whole-cell experiments due to the 
overwhelming number of cytosolic and nuclear proteins found within whole-cell 
proteomic data. In Chapter 2, we reported the combination of an adapted ER 
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organelle isolation technique48 with isoTOP-ABPP and OxICAT methods to profile 
cysteine reactivity and oxidation states within the ER. A similar strategy may be 
applied to study changes to oxidative folding in the ER of PDIA1KO and 
PDIA4KO SKOV-3 cells.  
 In order to enrich for ER proteins, a differential centrifugation method was 
applied. Briefly, WT, PDIA1KO, or PDIA4KO SKOV-3 cells were gently 
homogenized to disrupt the cell membrane while preserving the integrity of 
organelles. Several differential centrifugation steps were used to pellet more dense 
organelles, such as nuclei and mitochondria, after which a high-speed 
centrifugation step (150,000g x 30 min.) yielded a microsomal fraction. This 
microsomal fraction was stripped of ribosomal proteins, and a final centrifugation 
step (48,000g x 30 min.) generated ER proteomes for assessing cysteine reactivity 
profiles and other downstream proteomic studies.  
 
Proteomic analysis uncovers changes to folding chaperone abundance and 
prospective PDIA1 or PDIA4 substrates in PDIA1KO and PDIA4KO cells.  
In order to globally profile upregulation of the UPR and compensatory 
folding mechanisms that occur in the ER following depletion of PDIA1 or PDIA4, 
quantitative proteomic methods were implemented to assess changes to protein 
abundance in the isolated ER of WT, PDIA1KO, and PDIA4KO cell lines. In 
addition to evaluating expression profiles of other chaperones, quantitative 
proteomics may reveal potential substrates for PDIA1 or PDIA4. Proteins that 
require PDIA1 or PDIA4 for disulfide-bond formation and folding will be 
misfolded in cells and either aggregate within the ER or become degraded by 
ERAD. Therefore, proteins that show substantial increases or decreases in 
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abundance could be potential PDIA1 or PDIA4 substrates. To prepare samples for 
quantitative MS analysis, ER lysates were first obtained from WT, PDIA1KO, and 
PDIA4KO cells and, proteins were precipitated with trichloroacetic acid (TCA). 
Precipitated proteins were resolubilized, reduced with dithiothreitol (DTT), and 
newly reduced cysteines were capped with iodoacetamide. Samples underwent 
in-solution trypsin digestion to generate tryptic peptides. For quantitative 
analyses, peptides were isotopically tagged by reductive dimethylation (ReDiMe)  
of primary amines49 (Figure 3-13A). Briefly, peptides resulting from WT ER were 
dimethylated with light ReDiMe reagents while peptides resulting from PDIA1KO 
or PDIA4KO ER were dimethylated with heavy ReDiMe reagents. WT and 
PDIA1KO or PDIA4KO samples were combined and analyzed by LC/LC-
MS/MS. Across two replicates, we quantified 547 and 463 secretory pathway 
proteins in PDIA1KO:WT (Figure 3-13B and Table 3A-1) and PDIA4KO:WT 














Figure 3-13. Quantifying changes in secretory pathway protein abundance 
following PDIA1 and PDIA4 knockout in SKOV-3 cells. A) Schematic 
representation of a ReDiMe MS platform design to quantify changes to protein 
abundance in the isolated ER of PDIA1KO an PDIA4KO cells.  
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B) ReDiMe MS analysis was performed to evaluate changes in protein abundance 
following knockout of PDIA1. Changes to protein abundance are shown as a log2 
ratio plot (PDIA1KO:WT) of identified ER and secretory pathway Uniprot/Go 
annotated proteins. C) ReDiMe MS analysis was performed to evaluate changes in 
protein abundance following knockout of PDIA4. Changes to protein abundance 
are shown as a log2 ratio plot (PDIA4KO:WT) of identified ER and secretory 
pathway Uniprot/Go annotated proteins. 
 
A plethora of folding chaperones including PDIs, heat shock proteins, and 
chaperones known to play a role in N-linked glycosylation and lectin-assisted 
folding were upregulated in PDIA1KO ER, while many were unchanged in 
PDIA4KO ER. In particular, Binding-immunoglobulin protein (BiP or HSPA5) 
(2.3-fold), the primary signaling protein for activation of the UPR, and its co-
chaperone, DnaJ homolog subfamily C member 3 (DNAJC3) (2.5-fold), were the 
two most overexpressed chaperones in PDIA1KO ER. In comparison, Bip was only 
increased 1.4-fold in PDIA4KO ER. Expression profiles of the PDI family were 
unique between the isolated ER of PDIA1KO and PDIA4KO cell lines. Several PDI 
family members were significantly upregulated in PDIA1KO ER including, ER 
resident protein 29 (ERp29 or PDIA9, 1.8-fold), thioredoxin-related 
transmembrane protein 4 (TMX4 or PDIA14, 1.7-fold), and ER resident protein 57 
(ERp57 or PDIA3, 1.6-fold), suggesting broad functional overlap and 
compensation by the PDI family to fold PDIA1 substrates. In comparison, 
PDIA4KO resulted in a large increased abundance of thioredoxin-related 
transmembrane protein 3 (TMX3 or PDIA13, 1.9-fold) with the second most 
upregulated being ERp57 at 1.4-fold. Finally, endoplasmin (HSP90B1, 1.9-fold) 
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and calnexin (CALX, 1.8-fold), chaperones known to form complexes with PDIs 
also exhibited increased protein abundance in PDIA1KO ER but not PDIA4KO ER. 
Performing a GO analysis50 for enriched biological processes in the top 100 most 
abundant proteins (~1.5-fold and greater) in PDIA1KO ER revealed a significantly 
large enrichment for processes associated with the UPR including: protein folding 
in the ER, IRE1α-mediated UPR, and the ERAD pathway (Tables 3-2 and 3A-3), 
mostly in agreement with the presented qPCR data. Furthermore, upregulation of 
the IRE1α arm in the UPR coincides with similar results observed for KSC-34 
mediated inhibition of PDIA138. A GO analysis for PDIA4KO ER did not reveal an 
enrichment for UPR-associated biological processes. These results demonstrate 
that PDIA1KO compared to PDIA4KO induces a greater response to 
compensatory mechanisms by upregulation of various folding chaperones and 
components of the UPR and ERAD. This may be the result of a broader range of 
substrates for PDIA1 than PDIA4 and therefore a greater need to correct disulfide-
bond formation and return the ER to folding homeostasis within PDIA1KO ER.  
Table 3-2. Top 10 most enriched biological processes in the 100 most abundant 
proteins following knockout of PDIA1. 
Biological Process Fold Enrichment 
protein folding in endoplasmic reticulum 81.17 
IRE1-mediated unfolded protein response 31.48 
endoplasmic reticulum unfolded protein response 22.89 
cellular response to unfolded protein 18.9 
response to unfolded protein 18.71 
cellular response to topologically incorrect protein 17.67 
response to topologically incorrect protein 17.55 
response to endoplasmic reticulum stress 16.32 
regulation of response to endoplasmic reticulum stress 15.28 
ERAD pathway 14.59 
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In addition to evaluating functional overlap and compensatory 
mechanisms of the ER folding machinery, we were also interested in identifying 
potential substrates or interactors of PDIA1 and PDIA4. These candidates would 
demonstrate either large increases in abundance due to protease resistant 
aggregation51, or they would display large decreases in abundance due to ERAD-
mediated degradation47. Surprisingly, prolyl 4-hydroxylase subunits alpha-1 and 
alpha-2 (P4HA1 and P4HA2) displayed nearly the same decreases in protein 
abundance as PDIA1 in PDIA1KO ER, 2.64-fold and 2.76-fold decreases, 
respectively (Table 3-3). PDIA1, otherwise known as prolyl 4-hydroxylase subunit 
beta (P4HB), is a subunit of the prolyl 4-hydroxylase complex (P4H) and plays a 
role in the maturation of collagen52. A previous study found the presence of PDIA1 
required for stabilizing P4HA1 and P4HA2 and preventing protein aggregation. 
Furthermore, P4HA1 and P4HA2 aggregates associated with Bip, a chaperone 
known to escort misfolded aggregates to ERAD53. As a result, it is likely that upon 
knockout of PDIA1, P4HA1 and P4HA2 become misfolded and targeted by ERAD 
for degradation. Due to changes in P4H abundance, changes to collagen levels 
would also be expected. While collagen IDs were limited within the dataset, 
collagen alpha-1 (XVIII) chain (COL18A1) was the most overexpressed protein in 
the PDIA1KO dataset (5.2-fold increase) (Table 3-3). This change in protein 
abundance may be a result of collagen not maturing to its proper fold, resulting in 
the formation of misfolded protease resistant COL18A1 aggregates. The observed 
increase in COL18A abundance was further supported by a study in which 
depletion of P4H in zebrafish led to a 2.1-fold increase in COL18A1 mRNA levels54. 
Interestingly, a cleavage product of COL18A1, endostatin, is known to have anti-
proliferative properties55 and may contribute to the results observed in the 
	 155	
proliferation assay. There were no large changes to abundance for any collagen 
types in PDIA4KO ER demonstrating the unique interactions between PDIA1 in 
the P4H complex and collagen. 
Several proteins associated with plasma membrane and actin filament 
tethering and cytoskeleton reorganization were significantly upregulated or 
downregulated in PDIA1KO samples and to a lesser extent in PDIA4KO samples 
(Tables 3-3, 3A-1, and 3A-2). These observations suggest that PDIA1 and PDIA4 
may fold some of these proteins, or that cellular stress from PDIA1KO or 
PDIA4KO has implications beyond the ER and throughout the entire secretory 
pathway. Previous studies have found that PDIA1 interacts with beta-actin to 
regulate cytoskeleton reorganization; however, no substantial changes to beta 
actin were observed within our ReDiMe datasets56. Furthermore, the cytoskeleton 
plays a role in ER dynamics and network remodeling,57 and the dimerization of 
PERK, while UPR-independent, was found to facilitate ER and plasma membrane 
contact through the binding of Filamin A and downstream f-actin remodeling58. 
PERK also dimerizes upon activation of the UPR. Protein abundance for the entire 
ERM (ezrin, radixin, and moesin) family decreased in PDIA1KO cells (2.8-fold to 
3.4-fold) and were mostly unchanged in PDIA4KO cells. ERM family members 
contain a c-terminal region that binds to actin, while a conserved FERM (4.1 
protein, ezrin, radixin, and moesin) domain binds to the plasma membrane, 
forming a crosslink between the plasma membrane and cytoskeleton59. Within the 
FERM domain are two highly conserved, yet poorly characterized cysteines. 
Along with the ERM family, another FERM domain containing protein myosin-10 
(MYH10)59 showed reduced levels in PDIA1KO ER (3-fold) but not PDIA4KO ER. 
Additionally, a study on ER stress and its role in epithelial-to-mesenchymal 
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transition found that activation of the UPR with tunicamycin led to increased 
vimentin mRNA levels and changes in actin from cortical structures to stress 
fibers60. In PDIA1KO ER and PDIA4KO ER, vimentin was increased 1.8-fold and 
3.1-fold, respectively, suggesting that perturbation to protein folding by PDIA1KO 
or PDIA4KO affects cytoskeleton structure. Several other proteins with functional 
relevance to the cytoskeleton, actin filaments, and plasma membrane were also 
highly increased or decreased in PDIA1KO ER (increased: annexin A4 and integrin 
beta-3; decreased: fibronectin and filamin-B) and PDIA4KO ER (increased: desmin 
and dystonin; decreased: alpha actinin-1 and 4 and annexin A5) (Table 3-3).  
Receptor tyrosine-protein kinase erbB-2 (ERBB2 or HER2), exhibited 
diametric changes in protein expression in PDIA1KO and PDIA4KO ER. In 
PDIA1KO ER, ERBB2 was overexpressed 2.2-fold, while in PDIA4KO ER ERBB2 
was underexpressed 2.9-fold. Interactions between PDIs and the ERBB family are 
poorly characterized at best. Interestingly, overexpression of PDIA4 and ERBB2 
are each correlated with cisplatin resistance in cancer25, 61. Because ERBB2 levels 
were reduced following PDIA4KO, it is possible that ERBB2 is a substrate of 
PDIA4 and that ERBB2 misfolding resulted in its degradation. Overexpression in 
PDIA1KO cells may be linked to ERBB2’s role in regulating apoptosis62. ERBB2 
signaling suppresses apoptosis; therefore, it is possible that under sustained ER-
stress, ERBB2 expression is increased to protect PDIA1KO cells from apoptosis.  
Finally, many other secretory pathway proteins displayed substantial 
changes to abundance in PDIA1KO ER, including aminopeptidase N (ANPEP, 2.5-
fold decrease) and the cysteine-rich manganese-transporting ATPase 13A1 
(ATP13A1, 2.3-fold increase). In PDIA4KO ER, changes in transmembrane 9 
superfamily member 3 (TM9S3, 2-fold decrease) or lysophosphatidylserine lipase 
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ABHD12 (ABHD12, 1.9-fold increase) abundance were observed. However, many 
of these proteins have no reported interactions with PDIs, highlighting the 
identification of a novel field of proteins that are at a minimum affected by 
perturbation to protein folding and could be potential substrates for PDIA1 or 
PDIA4.   
Table 3-3. Top 10 most abundant and least abundant proteins in the isolated ER of 
PDIA1 and PDIA4 knockout cells. 
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PDIA1KO and PDIA4KO have minimal effects on secretory pathway cysteine 
oxidation states.  
ReDiMe-based proteomic analysis revealed general ER adaptation to 
protein misfolding and potential PDI substrates by evaluating changes to protein 
abundance following PDIA1KO and PDIA4KO. However, ReDiMe-based studies 
alone are incapable of directly detecting changes to disulfide-bond formation after 
PDIA1KO and PDIA4KO. It was anticipated that depletion of PDIA1 or PDIA4, 
chaperones responsible for the introduction and rearrangement of disulfide 
bonds, would induce changes to cysteine oxidation states in substrates. In order to 
explore perturbations to disulfide-bond formation and general changes to cysteine 
oxidation states following PDIA1KO or PDIA4KO, ER enrichment was combined 
with an adapted OxICAT platform63. For OxICAT analysis, previously reported 
isotopically encoded IA-alkyne (IA-light and IA-heavy) probes were used (Figure 
3-14)64. Briefly, WT, PDIA1KO, or PDIA4KO SKOV-3 cells were harvested and ER 
was isolated using the previously described differential centrifugation methods. 
Microsomal fractions were immediately lysed in denaturing buffer containing 10 
mM IA-light. Reversibly oxidized cysteines, including disulfide bonds, were 
reduced with tris(2-carboxyethyl)phosphine (TCEP) and then alkylated with 10 
mM IA-heavy. Labelled cysteines were appended to a photocleavable biotin azide 
via CuAAC, followed by streptavidin enrichment, on-bead trypsin digestion, 







Figure 3-14. Schematic representation of an OxICAT MS platform designed to 
capture and quantify cysteine oxidation states in isolated ER. 
 
 Cysteine oxidation was determined by converting L:H and H:L ratios into 
a calculated value (Experimental Procedures) representing percent oxidation for 
each individual cysteine. Three replicates were performed for each cell line, and 
cysteines that had ratios quantified in at least 2 out of 3 replicates were used for 
comparing changes to cysteine oxidation. Differences in cysteine oxidation were 
determined by subtracting percent oxidation in PDIA1KO or PDIA4KO samples 
from percent oxidation in the WT sample. This resulted in 930 and 944 calculated 
differences in oxidation for secretory pathway cysteines in WT versus PDIA1KO 
and WT versus PDIA4KO datasets, respectively. Calculated differences in cysteine 
oxidation were then subjected to statistical analysis by multiple t-tests to obtain a 
final set of cysteines that displayed significant and reproducible oxidative changes 
in PDIA1KO or PDIA4KO samples relative to the WT sample. 257 (28%) cysteine 
oxidation states were significantly changed following knockout of PDIA1 (Figure 
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3-15A and Table 3A-4), while 289 (31%) cysteine oxidation states were significantly 
changed upon knockout of PDIA4 (Figure 3-15B and Table 3A-5).  
 
 
Figure 3-15. Statistical analyses of changes to cysteine oxidation following genetic 
depletion of PDIA1 or PDIA4. ER was isolated from WT, PDIA1KO, and PDIA4KO 
SKOV-3 cell lines and subjected to OxICAT MS methods. A) Volcano plot 
displaying differences in average percent oxidized (WT-PDIA1KO) for 930 ER and 
secretory pathway annotated cysteines against -log(P-value). B) Volcano plot 
displaying difference in average percent oxidized (WT-PDIA4KO) for 944 ER and 
secretory pathway annotated cysteines against -log(P-value). (A,B) Differences in 
average percent oxidized (WT- PDIA1KO or WT - PDIA4KO) were assessed for 
statistical significance using unpaired t tests, n = 3. A P-value of 0.05 was set for 
statistical significance (horizontal dotted line). Cysteine residues with a difference 
(WT - PDIA1KO or WT - PDIA4KO) greater than 10% (sensitive cysteine residues) 
are plotted to the left and right of the vertical dotted lines. 
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 After identifying cysteines with statistically significant changes to cysteine 
oxidation, we wanted to evaluate the degree of change for these cysteine oxidation 
states between PDIA1KO or PDIA4KO and WT cells. Percent oxidation for 
cysteines in PDIA1KO or PDIA4KO samples was compared to the WT control for 
cysteines demonstrating statistically significant changes in oxidation (Figure 3-
16A and 3-16B).  
 
 
Figure 3-16. Evaluating changes to secretory pathway cysteine oxidation states 
following depletion of PDIA1 or PDIA4 in SKOV-3 cells. A) Plot comparing 
secretory pathway cysteine oxidation states in the isolated ER of WT and 
PDIA1KO cells. B) Plot comparing secretory pathway cysteine oxidation states in 
the isolated ER of WT and PDIA4KO cells. 
 
The majority of identified cysteines contained minimal changes to their oxidation 
state in PDIA1KO and PDIA4KO samples (grey circles <10% change in oxidation 
state). However, 56 cysteines (22%) in PDIA1KO samples and 52 cysteines (18%) 
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in PDIA4KO samples displayed ≥10% change in oxidation state (black circles). 
Many of these changes were selective to either PDIA1KO or PDIA4KO, while 10 
cysteines demonstrated large (≥10%) changes in both knockout samples (Figure 3-
17A). Differences in cysteine oxidation for PDIA1KO samples were generally less 
dramatic than the differences observed for some cysteines in PDIA4KO 
(differences in cysteine oxidation up to 65%). For example, a cysteine in 
translocation protein SEC63, Cys296, was ~18% more oxidized in PDIA1KO ER 
than WT ER (Figure 3-17B). SEC63 forms a complex with other SEC proteins and 
is known to interact with chaperones such as Bip during the translocation of 
peptides into the ER65. Small changes such as those in SEC63 may be attributed to 
the large number of chaperones upregulated in the PDIA1KO ReDiMe dataset, 
indicating that other PDIs and chaperones can efficiently compensate for 
PDIA1KO. In agreement, a previous study on PDI-mediated oxidative folding 
kinetics found that while disulfide-bond formation was delayed in PDI 
knockdowns, the correctly folded parent protein was eventually formed32. In 
PDIA4KO samples, a large change was observed for Cys342 in ERBB2, becoming 
65% more reduced following knockout of PDIA4 (Figure 3-17C). Furthermore, the 
Uniprot knowledgebase (UniprotKB) annotates Cys342 as a disulfide bond. 
Additionally, a second, non-annotated cysteine, Cys1133, was also reduced, 
although mildly (~10% reduced). While other ERBB2 disulfide-containing 
cysteines were relatively unchanged in PDIA4KO samples, these results combined 
with protein abundance data suggest that at least partial misfolding of ERBB2 
occurs in PDIA4KO cells. Finally, small changes to the oxidation states of Cys576 
and Cys645 in HSP90B1 were observed in both PDIA1KO and PDIA4KO samples. 
Cys576 became ~11.5% more reduced in both datasets (data not shown) while 
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C645 became 13% and 15% more reduced in PDIA1KO and PDIA4KO samples, 
respectively (Figure 3-17D). HSP90B1 interacts with substrates near the c-terminus 
of the protein, the same region that Cys576 and Cys645 occupy. It has been shown 
that HSP90B1 dimerizes at the c-terminus and adopts different conformations, 
open or closed66. Furthermore, it has been suggested that interdimer disulfides at 
Cys576 and Cys645 may aid in homodimer formation67. While both of these 
cysteines were mostly reduced in all three datasets, it appears that PDIA1KO and 
PDIA4KO may induce changes to HSP90B1 conformation and dimerization.  
 
 
Figure 3-17. Cysteine oxidation state sensitivity is predominantly unique to 
PDIA1KO or PDIA4KO. A) Venn Diagram illustrating unique and overlapping 
changes in cysteine oxidation states following genetic depletion of PDIA1 or 
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PDIA4. B) Extracted ion chromatogram from OxICAT analysis for Cys296 in 
SEC63, a residue found to be sensitive to PDIA1 knockout. C) Extracted ion 
chromatogram from OxICAT analysis for Cys342 in ERBB2, a residue found to be 
sensitive to PDIA4 knockout. D) Extracted ion chromatogram from OxICAT 
analysis for Cys645 in HSP90B1, a residue found to be sensitive to both, PDIA1 
and PDIA4 knockouts. 
 
Conclusion 
 In this study, we engineered and characterized CRISPR-Cas9 mediated 
PDIA1KO and PDIA4KO SKOV-3 cell lines and used proteomic techniques to 
evaluate global changes to protein abundance and oxidative folding in an effort to 
illuminate functional overlap amongst the PDI family and unique substrates of 
PDIA1 and PDIA4. SKOV-3 cellular proliferation was reduced in both PDIA1KO 
and PDIA4KO, while only knockout of PDIA1 affected cell survival, ~50%, 
demonstrating that while viable, depletion of protein disulfide isomerases affects 
cancer cell growth and survival. Furthermore, this reduction to cellular viability is 
likely attributed to protein misfolding and ER stress. Indeed, qPCR analysis 
revealed that PDA1KO led to upregulation of all three UPR arms, while PDIA4KO 
only led to modest upregulation of the IRE1α arm.  
 Combining ER isolation with ReDiMe labeling techniques, we were able to 
evaluate global changes to protein abundance for 547 and 463 secretory pathway 
proteins in PDIA1KO and PDIA4KO cells, respectively. Several folding 
chaperones including PDI family members were upregulated following PDIA1KO 
while only a few showed increased expression in PDIA4KO cells, suggesting that 
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PDIA1 has a broader substrate range than PDIA4 and that PDIA1’s depletion 
elicits stronger upregulation of various UPR-associated proteins. PDIA1KO was 
also correlated with decreased protein abundance of other P4H subunits and as a 
result altered collagen abundance. Additionally, several cytoskeleton proteins 
known to interact with the plasma membrane and actin filaments exhibited large 
changes to protein abundance, likely leading to cytoskeleton reorganization. 
Finally, ERBB2 (Her2) showed polar changes to protein abundance in PDIA1KO 
and PDIA4KO, being increased in PDIA1KO cells and decreased in PDIA4KO 
cells.  
 In addition to evaluating changes to protein abundance, changes to cysteine 
oxidation were directly quantified for secretory pathway proteins in PDIA1KO 
and PDIA4KO ER. In general, knockout of PDIA1 or PDIA4 resulted in minimal 
changes to cysteine oxidation. 56 cysteines in PDIA1KO cells and 52 cysteines in 
PDIA4KO cells displayed changes ≥10% relative to WT cysteine oxidation states. 
Changes to cysteine oxidation were bidirectional with increased and decreased 
oxidation observed. The fact that there were relatively few changes to cysteine 
oxidation compared to protein abundance changes in PDIA1KO and PDIA4KO 
cells may be attributed to the ER’s ability to efficiently degrade misfolded proteins 
through ERAD. 
Taken together, the results from this study demonstrate that while genetic 
ablation of PDIA1 or PDIA4 induces cellular stress at the protein folding level, the 
folding machinery is highly complex and capable of compensating for the 
misfolding of most PDIA1 and PDIA4 substrates. Additionally, the quantitative 
proteomic (ReDiMe) and chemoproteomic (OxICAT) platforms described within 
enable facile global evaluation of changes to ER stress responses and protein 
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misfolding following PDI knockout. These techniques allow for greater coverage 
of PDI interactions compared to previous studies characterizing PDI functions or 
cellular consequences to PDI knockdown. Prior studies were often limited to select 
PDI-substrate interactions through co-immunoprecipitation, or thiol trapping 
techniques that resolve more highly abundant interactions and were dependent 
on a labile mixed disulfide10, 16, 32-33. Finally, improvements to the temporal control 
of PDI function through inducible knockouts or the discovery and application of 
highly selective PDI family inhibitors may yield more dramatic and unique 
changes to protein folding and cysteine oxidation by permitting the opportunity 
to study changes in between the perturbation of PDIs and the upregulation of the 





All chemicals and biological reagents were purchased from Fisher Scientific 
or Millipore Sigma unless specified. 293T and SKOV-3 cells were obtained from 
ATCC (CRL-3216 and HTB-77, respectively). Dulbecco’s modified eagle media 
(DMEM), RPMI 1640, Trypsin-EDTA, and Antibiotic-Antimycotic (Anti-Anti) 
were purchased from Fisher Scientific. Fetal bovine serum (FBS) was acquired 
from Atlanta Biologicals. LentiCRISPR v2 constructs containing sgRNA were 
purchased by GenScript. psPAX2 and pMD2.G were gifts from Didier Trono 
(Addgene #12260 and #12259, respectively). Puromycin dihydrochloride was 
purchased from Santa Cruz Biotechnology. Protein concentrations were 
determined using the DC Protein Assay kit from Bio-Rad. IA-light and IA-heavy 
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were synthesized in-house according to Abo, M. et al.64. PC biotin azide and 
rhodamine-azide was purchased from Click Chemistry Tools. Anti-GAPDH 
(14C10, cat. 2118), anti-PDIA1 (C81H6, cat. 5051S), anti-PDIA4 (D70D12, cat. 5033), 
and rabbit anti-IgG secondary antibody (cat. 7074S) were purchased from Cell 
Signaling Technologies. QuickExtract DNA extraction solution, Phusion High 
Fidelity DNA polymerase, GeneAmp 10X PCR Buffer I, Applied Biosystems 
GeneAmp 10x PCR buffer, IDTNA Surveyor mutation detection kit, Applied 
Biosystems High-capacity cDNA reverse transcription kit, and Applied 
Biosystems PowerUP SYBR green master mix were purchased from Fisher 
Scientific. QIAquick PCR purification kit and QIAquick gel extraction kit were 
purchased from Qiagen. Primers for ICE analysis and qPCR were purchased from 
Eurofins Genomics.  
 
General cell culture and preparation of SKOV-3 whole-cell lysates.  
SKOV-3 cells were cultured at 37 °C under an atmosphere of 5% CO2 in 
RPMI 1640 medium (Corning) supplemented with 10% FBS (Atlanta Biologicals) 
and 1% Anti-Anti (25 µg/mL Amphotecerin B, 10,000 units/mL penicillin, 10,000 
µg/mL streptomycin, Gibco). 293T cells were cultured at 37 °C under an 
atmosphere of 5% CO2 in DMEM medium (GE Healthcare Life Sciences) 
supplemented with 10% FBS (Atlanta Biologicals). SKOV-3 cells were harvested 
by scraping and pelleted at 1,000g. Cells were washed with DPBS and then 
resuspended in appropriate volumes of DPBS. Cell suspensions were sonicated 
using an ultrasonic tip sonicator (Cole Parmer). Lysates were centrifuged at 45,000 
rpm for 45 minutes at 4°C to separate soluble and insoluble lysate fractions. The 
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insoluble fraction was discarded, and the soluble fraction’s protein concentration 
was determined using the DC Protein Assay kit (Bio-Rad).  
 
Generation of PDIA1 and PDIA4 knockouts.  
The design of sgRNA targeting the coding regions of PDIA1 and PDIA4 
was performed with the assistance of the Broad Institute’s genetic perturbation 
platform sgRNA designer68 and CHOPCHOP69 to ensure the selection of sgRNA 
that were predicted to be highly efficient and selective. Ultimately sgRNAs 
targeting exon 7, 5’-GCAAGTACAAGCCCGAATCGG-3’, of PDIA1 and exon 8, 
5’-GACGATGCTAAGCGCTACACC-3’ of PDIA4 were selected. LentiCRISPR v2 
plasmids containing the sgRNAs were obtained by GenScript. 293T cells were 
grown to 70-80% confluency and transfected in DMEM medium containing heat 
inactivated serum (DMEM-HIS). In an Eppendorf tube, 24 µL of Lipofectamine 
2000 (Invitrogen) was added to 600 µL of serum free DMEM. In a separate 
Eppendorf tube, 2 µg psPAX2 (Addgene), 2 µg pMD2.6 (Addgene), and 2 µg of 
LentiCRISPR v2 constructs (containing sgRNA) were added to 600 µL of serum 
free DMEM. Solutions were incubated for 5 min. and combined. Following 
combination, solutions were incubated for 30 min. to allow complex formation. 
Solutions containing DNA and Lipofectamine 2000 complexes were added 
dropwise to 293T cells in 100 mm dishes and incubated overnight at 37 ℃. On the 
second day, media was removed and replaced with 5 mL of fresh DMEM-HIS and 
incubated overnight. On the third day, virus-containing media was harvested, 
filtered with a 10 mL syringe and 0.45 µm Millex filter (MilliporeSigma), and 
added to 5 mL of RPMI 1640-HIS and 10 µL of 10 mg/mL hexadimethrine bromide 
(MilliporeSigma). The solution was then fed to SKOV-3 cells (~20% confluent) in 
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a 100 mm dish. As a negative control, 5 mL of DMEM-HIS, 5 mL of RPMI 1640-
HIS, and 10 µL of 10 mg/mL hexadimethrine bromide was added to a 100 mm 
dish. One day after infection, virus containing media was removed and replaced 
with 10 mL of RPMI 1640 containing 10% FBS and 1% Anti-Anti. Additionally, 
puromycin dihydrochloride (Santa Cruz Biotechnology) was added at a final 
concentration of 1 µg/mL to positively select for infected SKOV-3 cells. Once all 
SKOV-3 cells in the negative control (no virus added) died, SKOV-3 cells stably 
expressing Cas9 and PDIA1 or PDIA4 were serially diluted to single cell 
populations and plated in 96 well plates in order to isolate clonal populations that 
will contain homogenous edits. Cells that survived single cell dilution were grown 
to ~80% confluency and passaged into 24 well plates for downstream analysis.  
 
Confirmation of CRISPR-Cas9 mediated gene editing in the general population 
of PDIA1 and PDI4 knockout SKOV-3 cells by the Surveyor nuclease assay.  
Protocols for the Surveyor nuclease assay were adapted from Ran et al.70.  
Extraction of genomic DNA: 50 µL of QuickExtract DNA extraction solution was 
combined to ~ 1/10th of WT, PDIA1KO, or PDIA4KO SKOV-3 cells (general 
population) harvested from a 100 mm dish in a PCR tube and vortexed. Tubes 
were inserted into a thermocycler and the following cycle was performed: 65℃/15 
min.; 68℃/15 min.; 98℃/10 min.; 4℃ final.  
Surveyor PCR: DNA concentrations were normalized to 150 ng/µL and then the 
following reactions were prepared for Surveyor PCR: 10 µL of 5x Phusion HF 
buffer, 1 µL 10 mM dNTPs, 2.5 µL 10 µM forward primer, 2.5 µL 10 µM reverse 
primer, 1 µL of 150 ng/µL template (WT, PDIA1KO, or PDIA4KO genomic DNA), 
32.5 µL water (to bring volume to 45.5 µL), and 0.5 µL Phusion polymerase. PCR 
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was performed under the following conditions: 98℃ for 2 min.; 30 cycles: 95℃/20 
sec, 60℃/20 sec, 72℃/30 sec; 72℃/10 min., 4℃ final. PCR products were 
purified using a QIAQuick PCR purification kit and DNA was normalized to 20 
ng/µL.  
 
Table 3-4. Primers used for Surveyor Assay. 
Gene Forward – Surveyor Primer Reverse - Surveyor Primer 
PDIA1 TGACTATGACGGCAAACTGAG ACAAGAGGGCTCCTACAGGTC 
PDIA4 TCCAGTCGTTGTGAAGTGTG TGAATCTAAGCTCCCATCCTG 
 
Heteroduplex formation: For heteroduplex formation, the following reaction was 
prepared: 2 µL of 10X GeneAmp PCR Buffer I was combined with 18 µL of 20 
ng/µL PCR product and then the following conditions were performed with 
temperature gradients for several steps: 95℃/10 min; 95-85℃/-2℃ s-1; 85℃/1 
min.; 85-75℃/-0.3℃ s-1; 75℃/1 min.; 75-65℃/-0.3℃ s-1; 65℃/1 min.; 65-55℃/-
0.3℃ s-1; 55℃/1 min.; 55-45℃/-0.3℃ s-1; 45℃/1 min.; 45-35℃/-0.3℃ s-1; 35℃/1 
min.; 35-25℃/-0.3℃ s-1; 25℃/1 min.; 25-4℃/-0.3℃ s-1; 4℃ final.  
Surveyor nuclease S digestion: A nuclease digestion was then performed on any 
heteroduplexes that were formed in the previous step.  The following reaction was 
prepared: 20 µL annealed heteroduplex, 2.5 µL 0.15 M MgCl2, 0.5 µL water, 1 µL 
Surveyor nuclease S, and 1 µL enhancer S. The reaction was vortexed and 
incubated at 42℃ for 1 hr.  
Visualization and quantification of indel formation following Surveyor nuclease digestion: 
Surveyor nuclease digestion products were then visualized on 2% agarose gel with 
ethidium bromide. Gels were imaged and gel band intensities were integrated 
using ImageJ. The fraction of PCR product cleaved by the surveyor nuclease was 
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calculated as according to Ran et al.70. Finally the percent of indel occurrence was 
calculated using the following formula: 𝑖𝑛𝑑𝑒𝑙	% = 100	𝑥	(1 −
81 − 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛	𝑜𝑓	𝑃𝐶𝑅	𝑝𝑟𝑜𝑑𝑢𝑐𝑡	𝑐𝑙𝑒𝑎𝑣𝑒𝑑).  
 
Confirmation of CRISPR-Cas9 mediated gene editing in a monoclonal 
population of PDIA1 or PDIA4 knockout SKOV-3 cells by ICE analysis.  
Extraction of genomic DNA: 50 µL of QuickExtract DNA extraction solution 
(Lucigen) was added to WT SKOV-3 cells or a monoclonal population of PDIA1KO 
or PDIA4KO SKOV-3 cells harvested from a 24 well plate in a PCR tube and 
vortexed. Tubes were inserted into a thermocycler and the following cycle was 
performed: 65℃/15 min.; 68℃/15 min.; 98℃/10 min.; 4℃ final.  
ICE PCR: DNA concentrations were normalized to 150 ng/µL and the following 
50 µL PCR reactions were prepared: 10 µL of 5x Phusion HF buffer, 1 µL 10 mM 
dNTPs, 2.5 µL 10 µM forward primer, 2.5 µL 10 µM reverse primer, 1 µL of 150 
ng/µL template (WT, PDIA1KO, or PDIA4KO genomic DNA), 32.5 µL water (to 
bring volume to 45.5 µL), and 0.5 µL Phusion polymerase. PCR was performed 
under the following conditions: 98℃ for 30 sec.; 30 cycles: 98℃/10 sec, 63℃/30 
sec, 72℃/30 sec; 72℃/10 min., 4℃ final.  
 
Table 3-5. Primers used for ICE analysis.  
Gene Forward – ICE Primer Reverse - ICE Primer 
PDIA1 TGACTATGACGGCAAACTGAG ACAAGAGGGCTCCTACAGGTC 




ICE analysis: PCR products were visualized on a 2% agarose gel with ethidium 
bromide. Gel bands were extracted from the gel and purified using a QIAquick gel 
extraction kit (Qiagen). Purified PCR products were submitted for sequencing 
(Genewiz) and trace files submitted for ICE analysis (ice.synthego.com)37. Briefly, 
ICE compared trace files between WT and PDIA1KO or PDIA4KO samples to 
predict the location and size of indels formed as well as provide a predicted 
knockout score.  
 
Western blot analysis of PDIA1 and PDIA4 knockouts in SKOV-3 cells.  
25 µg of WT, PDIA1KO, or PDIA4KO whole-cell lysates were separated on 
a 10% SDS-PAGE gel and transferred to nitrocellulose membrane (GE Healthcare) 
at 75V for 90 min. Membranes were blotted with TBST and 5% milk for 1 hour. 
Membranes were washed once with TBST for 5 min. Blocked membranes were 
then incubated in TBST and 5% BSA with rabbit anti-GAPDH (1:1000), rabbit anti-
PDIA1 (1:1000), or rabbit anti-PDIA4 (1:1000) overnight at 4°C. Membranes were 
washed 3x with TBST for 5 min and incubated with anti-rabbit IgG HRP 
conjugated secondary 1:300 in TBST for 2 hours at 25°C. Membranes were washed 
3x with TBST and imaged by the addition of ECL western blotting substrates.  
 
Confirmation of PDIA1KO by labeling with KSC-34.  
KSC-34 was synthesized as according to Cole et al.38. WT, PDIA1KO, and 
PDIA4KO SKOV-3 cells were harvested and lysates were generated as described 
above. 50 µL of WT, PDIA1KO, and PDIA4KO SKOV-3 cell lysates (1 mg/mL) in 
DPBS were incubated with 5 µM KSC-34 (2 µL from 40x stock in DMSO) for 1 hour. 
Rhodamine-azide (Click Chemistry Tools) was appended to KSC-34 labeled 
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proteins by CuAAC. Briefly, 25 µM rhodamine-azide, 1 mM tris(2-
carboxyethyl)phosphine (TCEP), 100 µM TBTA, and 1 mM copper (II) sulfate were 
added to treated cell lysates. The CuAAC reaction was incubated for 1 hour at 
25℃. 50 µL of 2X Laemmli buffer was added to each reaction and 28 µL of the 
diluted reaction was separated on a 10% SDS-PAGE gel. Gels were imaged for 
rhodamine fluorescence on a ChemiDOC MP imaging system (BioRad). Following 
imaging, gels were stained with Coomassie Brilliant Blue for 1 hour and destained 
overnight according to standard procedures. Coomassie stained gels were then 
imaged on ChemiDoc imager described above.  
 
Survival and proliferation assay.  
 WT, PDIA1KO, and PDIA4KO SKOV-3 cells were grown in 100 mm dishes 
to ~90% confluency. Media was removed from cells and refed with serum free 
RPMI 1640 (RPMI 1640-SF). Cells were incubated and serum starved for ~ 2 hours. 
Following serum starvation, cells were washed with DPBS, trypsinized, and 
resuspended in 10 volumes of RPMI 1640-SF. Cells were pelleted by spinning at 
300g for 5 min. and the supernatant was removed. Cells were then resuspended in 
appropriate volumes for cell counting with a TC20 automated cell counter 
(BioRad).  
Survival assay: WT, PDIA1KO, and PDIA4KO cell stocks were diluted in RPMI 
1640-SF to a concentration of 133,333 cells/mL. 150 µL of cellular stocks were 
added to 5 wells in 4 clear 96-well plates (20 wells total) yielding 20,000 cells per 
well. Additionally, 5 wells for each plate received 150 µL of RPMI 1640-SF without 
any cells to serve as a blank.  
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Proliferation assay: WT, PDIA1KO, and PDIA4KO cell stocks were diluted in RPMI 
1640 containing serum to a concentration of 66,666 cells/mL. 150 µL of cellular 
stocks were added to 5 wells in 4 clear 96-well plates (20 wells total) yielding 10,000 
cells per well. Additionally, 5 wells for each plate received 150 µL of RPMI 1640 
with serum without any cells to serve as a blank. 
For each assay, plates were designated as 0 hours, 24 hours, 48 hours, and 
72 hours. At each time point, 10 µL of WST-1 was added to wells and incubated 
for 30 min. at 37℃. Absorbances were read at 450 nm. Changes to cell viability in 
PDIA1KO or PDIA4KO cells relative to WT cells was quantified and analyzed for 
statistical significance by a Student’s t-Test.  
 
Quantitative RT-PCR (qPCR).  
RNA extraction. WT, PDIA1KO, and PDIA4KO SKOV-3 cells were grown in 100 
mm dishes to ~90% confluency, and washed 2 times with DPBS. Cells were lysed 
using 1 mL of TRIzol reagent (Life Technologies) and incubated at 25°C for 5 min. 
TRIzol solution was transferred to an Eppendorf tube and 200 µL of chloroform 
was added. Samples were shaken and centrifuged at 12,000g for 12 min. at 4°C. 
The upper aqueous phase was transferred to a new Eppendorf tube and 400 µL of 
isopropanol was added. Samples were vortexed and incubated for 10 min. at 25°C. 
Samples were centrifuged at 12,000g for 10 min. at 4°C, and supernatants were 
discarded. RNA pellets were washed with 400 µL 75% ethanol in DEPC-treated 
water. Samples were vortexed and centrifuged at 12,000g for 5 min. at 4°C. 
Samples were allowed to air dry and resuspended in ~50 µL of DEPC-treated 
water. RNA concentrations were determined using a Nanodrop 2000 (Thermo 
Fisher). 
	 175	
cDNA Formation. 1 µg of total RNA was used for cDNA reverse transcription with 
the Applied Biosystems High-Capacity cDNA Reverse Transcription kit. cDNA 
was reverse transcribed as according to the manufacturer’s instructions. Following 
cDNA formation, cDNA was diluted with 3 volumes of water.  
qPCR. Applied Biosystems Powerup SYBR Green Master Mix, primers (see table 
below), and cDNA were used for mRNA amplification in an Applied Biosystems 
7500 PCR system. In addition to amplification, a melt curve was used to ensure 
homogenous PCR products from primers. 2 biological replicates were performed 
with each replicate containing triplicate reactions. mRNA transcripts were 
normalized to a housekeeping gene, RPL2, and data was analyzed using the ΔΔCt 
method. Final data was presented as a mean fold change (PDIA1KO or PDIA4KO 
relative to WT cells). Fold changes were statistically analyzed by unpaired t tests.  
 
Table 3-6. Primers used for qPCR. 
Transcript Forward Reverse 
RPLP CCATTCAGCTCACTGATAACCTTG CGTCGCCTCCTACCTGCT 
CHOP GGAGCTGGAAGCCTGGTATG GCCAGAGAAGCAGGGTCAAG 
ERDJ4 CTGTATGCTGATTGGTAGAGTCAA AGTAGACAAAGGCATCATTTCCAA 
GRP94 GGCCAGTTTGGTGTCGGTTT CGTTCCCCGTCCTAGAGTGTT 
 
Isolation of ER.  
WT, PDIA1KO, and PDIA4KO SKOV-3 pellets were washed 3x with 
homogenization buffer (0.3 M sucrose, 10 mM HEPES, 1 mM EGTA, and 25 µg/mL 
spermidine, pH 7.0). ER isolation was adapted from Chen, X. et al.48. Briefly, WT, 
PDIA1KO, and PDIA4KO SKOV-3 pellets were resuspended in 5x volume of 
homogenization buffer and homogenized by a motor driven glass Teflon 
homogenizer (Wheaton) at 1000 rpm with 50 strokes over the course of 25 min. 
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After every 10 strokes, homogenates were allowed to briefly incubate on ice. 
Homogenates were centrifuged twice at 1000g for 10 min at 4°C with the 
supernatant being collected and pellets discarded after each spin. The supernatant 
were then spun twice at 12,000g for 10 min at 4°C with the supernatant being 
collected and pellets discarded after each spin. Next, the supernatant were spun at 
150,000g for 30 min at 4°C and pellets were collected and supernatant discarded. 
Pellets were resuspended in 2 mL of “ribosomal stripping buffer” (0.3 M sucrose, 
1.0 M KCl, and 1 mM puromycin dihydrochloride (Santa Cruz Biotechnology)) 
and incubated at 25 °C for 1 hour and 4°C for 30 min. Solutions were spun at 
48,000g for 30 min at 4°C and pellets were collected and supernatant discarded. 
The supernatant were resuspended in 2 mL of DPBS and centrifuged at 48,000g 
for 30 min at 4°C. The supernatant were removed, and pellets were collected, 
affording isolated ER pellets at this point. For ReDiMe experiments, the isolated 
ER pellets were resuspend in DPBS and sonicated using an ultrasonic tip sonicator 
(Cole Parmer). Isolated ER lysate protein concentrations were determined using 
the DC Protein Assay kit (Bio-Rad). Isolated ER pellet lysis was different for 
OxICAT studies as described below.  
 
MS Sample Preparation: Reductive dimethylation (ReDiMe) of peptides for 
protein abundance quantification. 
WT, PDIA1KO, and PDIA4KO SKOV-3 cells were grown to 90% confluency, 
washed with DPBS 3x, harvested, and isolated ER lysates were obtained as 
described above. 100 µg of lysate was precipitated in 10% trichloroacetic acid 
(TCA) in DPBS and frozen at -80°C for 1 hour. Samples were allowed to thaw and 
centrifuged at 15,000 RPM for 10 min. Supernatants were discarded and protein 
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pellets were washed with 500 µL of ice-cold acetone, resuspended in acetone, and 
centrifuged at 5,000 RPM for 10 min. Supernatants were discarded and washed 
pellets were allowed to air dry. Pellets were resuspended in 30 µL of 8 M Urea in 
DPBS and underwent sonication to resolubilize. 70 µL of 100 mM 
triethylammonium bicarbonate (TEAB) was added to bring sample volumes to 100 
µL. 1.5 µL of 1 M DTT was added and samples were incubated at 65°C for 15 min. 
2.5 µL of 500 mM iodoacetamide was added and samples were incubated at 25°C 
for 30 min. 120 µL of PBS was added and samples were vortexed. 4 µL of 
sequencing-grade trypsin (0.5 µg/ µL resuspended in TEAB) (1:50 
enzyme:substrate) and 2.5 µL of 100 mM CaCl2 was added and samples were 
incubated at 37°C overnight under agitation.  
4 µL of 20% formaldehyde or 20% formaldehyde - 13C, D2 was added to WT 
or PDIA1KO/PDIA4KO samples, respectively. 20 µL of 0.6 M sodium 
cyanoborohydride was added to each sample and incubated at 25°C for 2 hours. 
Samples were placed on ice, and 4 µL of 20% ammonium hydroxide was added to 
quench reactions. 8 µL of MS-grade formic acid was added and samples were 
combined (WT and PDIA1KO or WT and PDIA4KO). Samples were desalted using 
Sep Pak C18 cartridges (Waters), eluted with 0.75 mL of 40% MS-grade acetonitrile 
(ACN) and 0.5% acetic acid and 0.75 mL of 80% MS-grade ACN and 0.5% acetic 
acid. Samples were dried in a SpeedVac (ThermoFisher), resuspended in 100 µL 
95% MS-grade water, 5% MS-grade ACN, and 0.1% MS-grade formic acid, and 





MS Sample Preparation: Evaluating cysteine oxidation with OxICAT.  
Methods for using OxICAT to study cysteine oxidation in isolated ER were 
adapted from Topf, U. et al.63 and Abo, M. et al.64. ER isolated from WT, PDIA1KO, 
and PDIA4KO SKOV-3 cells were resuspended in 500 µL of denaturing alkylation 
buffer (DAB) (6 M urea, 200 mM Tris-HCl, 10 mM EDTA, 0.5% SDS, pH 8.5) and 
10 mM IA-light and lysed using an ultrasonic tip sonicator. Following lysis, 
cysteines were labelled for 2 hours at 37°C under agitation. Samples were 
centrifuged at 16,000g for 1 min. at 4°C to pellet insoluble debris. Supernatants 
were diluted 3-fold with water, and then proteins were precipitated by incubating 
with 5 volumes of ice-cold acetone for 2 hours at -20°C. Precipitated proteins were 
pelleted by centrifugation for 30 min. at 4,500g and 4°C. Pellets were washed with 
ice-cold acetone, centrifuged for 10 min. at 4,500g and 4°C, and allowed to air dry. 
Pellets were resolubilized in DAB and protein concentrations were determined 
using the DC Assay Kit. 200 µg of protein was brought to a final volume of 80 µL 
with DAB. Samples were treated with 2.5 mM TCEP and incubated for 5 min. at 
37°C. Reduced samples were then diluted with 120 µL of DAB and 10 mM IA-
heavy and briefly sonicated. Following sonication, samples were labelled for 2 
hours at 37°C under agitation. Samples were diluted 3-fold with water and 
proteins were precipitated with 5 volumes of ice-cold acetone and incubated 
overnight at -20°C. Precipitated proteins were pelleted by centrifugation for 30 
min. at 4,500g and 4°C. Pellets were washed with ice-cold acetone, centrifuged for 
10 min. at 4,500g and 4°C, and allowed to air dry. Samples were resolubilized in 
500 µL DPBS by sonicating with an ultrasonic tip sonicator.  
A photo-cleavable PC biotin-azide tag was appended to samples by 
CuAAC. 500 µM PC biotin-azide, 5 mM TCEP, 500 µM of TBTA (17x stock in t-
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BuOH:DMSO 4:1), and 5 mM copper (II) sulfate was added and the reaction was 
incubated for 1 hour at 25°C. Proteins were pelleted at 6,500g for 4 min. 500 µL of 
ice-cold methanol was added, proteins were resuspended by tip sonication, and 
centrifuged at 6,500g for 4 min. After a second methanol wash and centrifugation, 
pelleted proteins were solubilized in 1.2% SDS/DPBS solution by tip sonication 
and incubated for 5 min. at 80°C. SDS concentrations were diluted to 0.2% SDS 
with 5 mL DPBS and 100 µL of streptavidin agarose beads were added. Samples 
were incubated at 4°C overnight and then at 25°C for 2 hours. Samples bound to 
beads were washed with 5 mL of 0.2% SDS/DPBS, 3x with 5 mL of DPBS, and 3x 
with 5 mL of water. Following each wash, beads were pelleted by centrifugation 
at 1,400g for 3 min. Beads were then resuspended in 500 µL of 6 M urea/DPBS and 
incubated for 30 min. at 25°C. Beads were centrifuged at 1,400g for 3 min. and 
resuspended in 200 µL of 2 M urea/DPBS, 1 mM CaCl2, and 2 µg of sequencing-
grade trypsin. On-bead trypsin digestion was performed overnight at 37°C under 
agitation.  
Beads were pelleted at 1,400g for 3 min and the supernatant was discarded. 
Beads were washed 3x with 500 µL DPBS and 3x with 500 µL water. Washed beads 
were resuspended in 200 µL of DPBS and incubated under UV light (365nm, 80W, 
B-100SP High Intensity UV Lamp (UVP)) for 3 hours at 25°C. Samples were spun 
down and supernatant was collected. Finally, beads were washed 2x with 75 µL of 
water and each wash was collected and combined with previous collections of 
supernatant. 17.5 µL of MS-grade formic acid was added and samples were stored 





Mass spectrometry data was obtained using a Thermo Fisher LTQ Orbitrap 
Discovery mass spectrometer coupled to an Agilent 1200 series HPLC. In solution 
trypsin digested or azide tagged peptides were pressure loaded onto a 250 µm 
fused silica desalting column (Agilent) packed with 4 cm of Aqua C18 reverse 
phase resin (Phenomenex) using a high pressure injection cell (Next Advance). 
Peptides were eluted onto a 100 µm fused silica biphasic column with a 5 µm tip, 
packed with 10 cm of C18 resin and 4 cm of Partisphere strong cation exchange 
resin (SCX, Whatman) using a gradient from 0% to 100% Buffer B in Buffer A 
(Buffer A: 95% water, 5% ACN, 0.1% formic acid; Buffer B: 20% water, 80% ACN, 
0.1% formic acid). Peptides were eluted from SCX to C18 using 4 separate salt 
pushes (in-solution trypsin digested ReDiMe samples: 25%, 50%, 80%, 100%; azide 
tagged samples: 50%, 80%, 100%, 100%) followed by a gradient of Buffer B in 
Buffer A as according to Weerapana, E. et al.71. The flow rate of buffer through the 
column was set to 0.25 µL/min and the spray voltage was set to 2.75 kV. For in-
solution trypsin digested samples, one full MS scan (FTMS) was followed by 7 data 
dependent scans (ITMS) of the nth most intense ions. For azide-tagged OxICAT 
samples, one full MS scan (FTMS) was followed by 8 data dependent scans (ITMS) 
of the nth most intense ions. Dynamic exclusion was enabled for each run.  
 
LC/LC-MS/MS data analysis.  
MS data from all samples were searched using the SEQUEST algorithm72 
against a concatenated target/decoy non-redundant variant of the human UniProt 
database. A static modification of +57.02146 on cysteine was included to account 
for alkylation by iodoacetamide.  
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In-solution trypsin digested ReDiMe samples. In addition to a static modification on 
cysteine, static modifications of +28.0313 (light) or +34.06312 (heavy) on the N-
terminus of the peptide and on lysine were included to account for dimethylation 
of primary amines. SEQUEST output files were filtered using DTASelect 2.0 with 
the -trypstat and -u (unique peptides only) options and a maximum false 
discovery rate of 5% applied. Furthermore, at least two peptides were required per 
locus. H:L ratios (PDIA1KO:WT or PDIA4KO:WT) were calculated using the 
previously described cimage quantification package73. From two replicates, data 
was filtered for proteins whose ratio was quantified in both samples and Uniprot 
or GO annotated as localizing to part of the secretory pathway (described below). 
Ratios were converted to log2 and averaged. Standard deviations were calculated 
as well as the coefficient of variation (standard deviation/average). Ratios >1 
(log2) or -1> (log2) whose absolute coefficient of variation was >0.5 were removed, 
resulting in the final datasets. 
OxICAT. In addition to a static modification on cysteine, differential modifications 
of +228.13749 (light) and +234.15762 (heavy) on cysteine were included to account 
for labeling of IA-light or IA-heavy appended to a cleaved PC biotin-azide tag. 
SEQUEST output files were filtered using DTASelect 2.0 with -trypstat and -
modstat options and a maximum false discovery rate of 5% applied. Additionally, 
peptides were required to be fully tryptic (-y 2), have a found modification (-m 0), 
a delta-CN score greater than 0.06 (-d 0.06), and only a single peptide was required 
per locus (-p 1). L:H and H:L ratios from three replicates per cell line (WT, 
PDIA1KO, and PDIA4KO) were quantified using the cimage quantification 
package. Data was filtered for secretory pathway annotated peptides whose ratios 
appeared in at least 2/3 replicates per cell line for each comparison (WT vs 
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PDIA1KO or WT vs PDIA4KO, 4/6 total replicates). L:H and H:L ratios were 
converted to % oxidized using the equations: 1-(L:H/(L:H+1)) or H:L/(H:L+1). 
Averages and standard deviations for % oxidized values for each peptide were 
calculated. Differences in % oxidation of cysteines (WT – PDIA1KO or WT – 
PDIA4KO) were statistically analyzed using unpaired t tests and peptides with 
statistically insignificant differences (p>0.05) were removed (Tables 3A-4 and 3A-
5).  
 
Statistical analysis of overrepresented GO biological processes using 
PANTHER.  
A Panther overrepresentation test (http://pantherdb.org)50 was performed 
for the top 100 most abundant proteins in PDIA1KO ER. PANTHER determines 
an “expected” value for the number of protein IDs that are predicted to be found 
in an input dataset for each functional category (GO biological process complete) 
based on the percentage of protein IDs for each category within the complete 
human genome. Overrepresentation is presented as a ratio (observed:expected) 
for each biological process. A Fisher’s exact test with a Bonferroni correction was 
used to determine statistical significance of overrepresentation for each biological 
process with a P value cutoff of 0.05.  
 
Subcellular localization analysis.  
Subcellular localization was assessed using an in-house python program. 
Specifically, web scraping was performed to extract localization terminology from 
Uniport annotation and GO – cellular component tabs on 
https://www.uniprot.org for identified proteins and corresponding peptides. 
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Subcellular localization for proteins was outputted as three separate columns 
(Uniprot localization, GO localization, and combined localization) and the 
combined localization column was used for filtering. Proteins were considered ER 
or secretory pathway proteins if they contained at least one of the following 
localization terms: “endoplasmic reticulum”, “Golgi”, “plasma membrane”, 
“lysosome”, “peroxisome”, “vesicle”, “endosome”, “secreted” or “extracellular”, 
or “cell junction”. 
 
Cysteine functional annotation.  
Cysteines with annotated functions were identified using a previously 
described Python program74. To summarize, labeled cysteines identified in 
isoTOP-ABPP and OxICAT datasets were compared against the UniProtKB for 
residue specific information including the keywords 'CA_BIND', 'ZN_FING', 
'DNA_BIND', 'NP_BIND', 'ACT_SITE', 'METAL', 'BINDING', 'SITE', 'NON_STD', 
'MOD_RES', 'LIPID', 'CARBOHYD', 'DISULFID', 'CROSSLINK', 'VARIANT', 
'MUTAGEN', 'UNSURE', 'CONFLICT', and 'REGION'. 
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Introduction 
 As described in Chapter 3, the PDI family is responsible for the introduction 
and rearrangement of disulfide bonds in nascent substrates. Furthermore, the 
identity of these substrates remains poorly characterized for most of the PDI 
family. Beyond the substandard knowledge pertaining to PDI substrates, other 
properties of various family members are either unknown or understudied, 
including: 1) the functional contributions made by individual active sites within 
multi-domain containing PDIs 2) the identification of small molecule inhibitors 
that are selective for PDI family members.  
 
Efforts made towards characterizing the functional roles of PDI active sites. 
 While it’s generally accepted that PDIs containing CXXC active-site motifs 
in their a-domains exhibit oxidase, isomerase, and reductase activity, the 
functional contributions made by each active site in PDIs, such as PDIA3 or PDIA4, 
remain crudely defined. Studies pertaining to individual active-site functionality 
primarily focus on the a and a’ domains of PDIA1. PDIA1’s a-domains only share 
~ 36.8% sequence identity, suggesting that these domains may be functionally 
distinct from one another. Enzyme kinetic studies on PDIA1’s a and a’ domain 
revealed that the two active sites functionally complement one another. In this 
study, the oxidase activity of each active site was evaluated1, and it was found that 
the a site primarily contributed to catalysis (higher kcat) in the PDIA1-substrate 
complex, while the a’ site enhanced PDIA1-substrate interactions (lower Km). More 
recently, a former member of the Weerapana lab characterized the importance of 
each active-site cysteine for PDIA1’s oxidase activity2. A ribonuclease (RNase) 
oxidation activity assay was performed on single cysteine to alanine active-site 
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mutants (C53A, C56A, C397A, and C400A) to evaluate the contribution of each 
cysteine to PDIA1’s oxidase activity. It was found that C53A and C397A PDIA1 
mutants each resulted in a 50% reduction to PDIA1’s oxidase activity. Meanwhile, 
C56A and C400A minimally affected oxidase activity (Table 4-1).  
 
Table 4-1. Kinetic values for PDIA1 WT and active-site mutant oxidase activity2. 
Isoform Vmax (µM/min) Km (µM) kcat (min-1) kcat/Km (M-1 min-1) 
WT 0.505 4.595 0.356 7.74 x 104 
C53A 0.296 2.687 0.208 7.75 x 104 
C56A 0.438 4.659 0.308 6.62 x 104 
C397A 0.243 1.827 0.171 9.35 x 104 
C400A 0.341 2.759 0.240 8.70 x 104 
 
In comparison to PDIA1, PDIA4 has three active-site containing a-domains, 
ao, a, and a’, adding further complexity to studying functional contributions made 
by each active site. Sequence identity varies amongst the three active sites with ao 
and a sharing 60.82% identity, ao and a’ sharing 41.12% identity, and a and a’ 
sharing 44.74% identity suggesting potentially distinct functions amongst these 
active sites. A previous study evaluated the role of each a-domain in PDIA4’s 
reductase activity3 by creating double cysteine to serine mutants within each active 
site. A well-characterized insulin reduction assay4 was used to measure WT, ao 
mutant, a mutant, or a’ mutant PDIA4’s ability to reduce disulfide bonds in 
insulin. These studies revealed that the ao and a domains are important for 
catalysis while the a’ domain primarily contributes to PDIA4-substrate binding3. 
Finally, Rupp et al. reported the general oxidase activity of a rat analog of PDIA4, 
calcium-binding protein 2 (CaBP2), by evaluating CaBP2’s ability to re-oxidize 
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reduced RNase A5. While the role for each active site in PDIA4’s reductase activity 
has been characterized, each active site’s capacity for oxidase and isomerase 
activity has yet to be characterized. Herein, we report efforts towards 
characterizing PDIA4’s oxidase activity and future directions for determining the 
contributions of each active site towards this function.  
 
Development of inhibitors for PDIs.  
In addition to characterizing the contributions of each active site to PDI 
function, the development of highly selective small-molecule inhibitors for PDIs 
is significantly understudied. Given the relevancy of various PDIs in cancers and 
folding diseases, inhibitors targeting individual family members could serve 
therapeutic purposes and help elucidate the role of PDIs in these disease states. 
Currently, potent and selective inhibitors have been primarily developed for 
PDIA1. The first reported inhibitor of PDIA1 was an antibiotic, bacitracin, in 19816. 
Bacitracin was found to suppress reductase activity of PDIA1, however, it required 
high micromolar concentrations to do so. Furthermore, bacitracin was membrane 
impermeable and non-selective making it a poor inhibitor7. Since the development 
of bacitracin, several inhibitors have been reported for PDIA1 with varying 
degrees of potency, selectivity, and reversibility. A select number of these are 
described below.  
Non-covalent inhibitors of PDIA1. Due to the desirable pharmacological modes of 
action for reversible small-molecules, many efforts have been made towards 
developing non-covalent inhibitors of PDIA1. Juniferdin, a sesquiterpenoid, was 
identified as a PDIA1 inhibitor through a high-throughput screen of a natural 
product library8 (Figure 4-1). Interestingly, juniferdin was found to inhibit PDIA1 
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reductase activity but not oxidase activity. In particular, juniferdin inhibition 
prevented the reduction of HIV-1 envelope glycoprotein gp120 by PDIA1, thereby 
blocking HIV-1 entry into host cells8.  
A screening of a commercial compound library led to the discovery of two 
potent inhibitors of PDIA1, JP04-042 and a derivative resulting from structure-
activity relationship (SAR) studies, PS-899 (Figure 4-1). Proteomic studies for each 
compound confirmed interactions with PDIA1, however, they were also found to 
bind to PDIA3 and PDIA4. Both compounds were able to sensitize cancer cells to 
treatment of etoposide at subtoxic concentrations9, exemplifying a therapeutic 
strategy for overcoming chemoresistant cancers through PDI inhibition.  
Covlaent inhibitors of PDIA1. Irreversible inhibitors that covalently bind to active-
site cysteines in PDIs may selectively target a single a-domain such as a or a’ in 
PDIA1, or modulate both active sites equally. As a result, covalent inhibitors of 
PDIs have not only therapeutic potential, but also may be used as tools to 
characterize individual active-site function in PDIs. 16F16 was identified as an 
irreversible inhibitor of PDIA1 following a high-throughput screen of 68,887 
compounds by Hoffstrom et al.10 (Figure 4-1). A chloroacetamide electrophile 
covalently labels cysteines in the active sites of PDIA1. At the time of its discovery, 
active-site selectivity was unknown. More recently, we found 16F16 to be mostly 
non-selective, exhibiting 2-fold selectivity for the a domain11. The addition of an 
alkyne handle to 16F16 enabled copper (I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) for downstream proteomics, revealing 16F16’s targets to be PDIA1 and 
PDIA310. Additionally, at concentrations above 12 µM, 16F16 displayed 
cytotoxicity. At doses lower than 12 µM, 16F16 was found to rescue cells from 
apoptosis in a model of Huntington’s disease10.  
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Previous members in the Weerapana lab identified selective covalent 
inhibitors of PDIA1 including RB-11-ca12, KSC-3411, and SMC-913 (Figure 4-1). RB-
11-ca was developed as part of a 1,3,5-trisubstituted triazine library containing 
three elements: 1) an alkyne handle for CuAAC-mediated conjugation of reporter 
tags for in-gel fluorescence and proteomic experiments, 2) an electrophilic 
chloroacetamide for covalent modification of cysteines, and 3) a diversity element 
for binding specificity12. The implementation of an octylamine as RB-11-ca’s 
diversity element promoted selective binding to PDIA1. Site-directed mutagenesis 
studies found RB-11-ca to be 21-fold selective for the a domain of PDIA1, 
representing the development of the first a domain selective PDIA1 inhibitor. 
Additionally, RB-11-ca inhibited PDIA1 reductase activity at levels comparable to 
16F16 and impeded HeLa cell proliferation at 23.9 µM13.  
Recently KSC-34 was reported as an optimized PDIA1 inhibitor developed 
around the same 1,3,5-trisubsituted triazine scaffold11. Covalent docking studies 
revealed that RB-11-ca, the previous lead compound, demonstrated a domain 
selectivity due to interactions between the octylamine diversity element and a 
hydrophobic pocket near the a domain. As a result, a second generation triazine-
based library was developed around diversity elements containing hydrophobic 
functional groups. KSC-34 contains a (4-phenylbutyl)methylamine diversity 
element and was found to be 30-fold selective for the a domain, demonstrating 
improved selectivity. Furthermore, PDIA1 is ~ 8-fold more potent than RB-11-ca. 
Proteomic studies found KSC-34 to be highly selective for PDIA1, participating in 
minimal off-target engagement. Inhibition of PDIA1 by KSC-34 was found to 
decrease the secretion of a destabilized, amyloidogenic antibody light chain 
illustrating a potential therapeutic use for KSC-34 in treating amyloidosis11.  
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SMC-9 was developed as part of a conformationally flexible 4-
aminopiperidine scaffold-based library containing similar elements to the triazine 
scaffold (alkyne handle, cysteine-reactive electrophile, and diversity element)13. In 
whole-cell labeling experiments and subsequent proteomic studies, SMC-9 was 
found to be highly selective for PDIA1. SMC-9 contains a D-tyrosine methyl ester 
directing group and, through site-directed mutagenesis, was determined to be 
mostly non-selective between the two a-domains, ~ 2-fold selective for the a 
domain. 
 
Figure 4-1. Small molecule inhibitors of PDIA1. Non-covalent inhibitors are 




Currently, there is only one reported inhibitor of PDIA4, 1,2-
dihydroxytrideca-5,7,9,11-tetrayne (DHTT) (Figure 4-2)14. DHTT was identified as 
a PDIA4 inhibitor through molecular docking based screening and an insulin 
reductase assay. Inhibition of PDIA4 was found to reduce tumor development in 
tumor-specific antigen (TSA) presenting mice14. However, the general selectivity 
of DHTT has yet to be characterized. With only one known inhibitor of PDIA4, 
there is a scientific need to identify and characterize more PDIA4 inhibitors. We 
screened our triazine-based and 4-aminopiperidine-based libraries against 
recombinant PDIA4 and whole-cell lysates to identify potential PDIA4 inhibitors. 
The identification of covalent PDIA4 inhibitors may help reveal PDIA4’s role in 
cancer pathogenesis and be used as a probe for profiling PDIA4 function.  
 
 
Figure 4-2. Structure of 1,2-dihydroxytrideca-5,7,9,11-tetrayne (DHTT) a small 
molecule inhibitor of PDIA4.  
 
Results and Discussion 
 
Characterizing PDIA4 oxidase activity.  
 PDI mediated disulfide-bond formation in the ER is critical to preserving 
the structural integrity of secreted proteins. Through the controlled formation of 
structural disulfide bonds, to-be secreted proteins are protected from spontaneous 
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oxidation and subsequent inactivation when exposed to the highly oxidizing 
extracellular environment. To demonstrate PDIA4’s oxidase activity and establish 
a platform for characterizing the roles of each active site in oxidative folding, we 
recombinantly expressed and purified PDIA4 for use in a previously reported 
RNase oxidation activity assay1, 15. Properly folded and active RNase A catalyzes 
the hydrolysis of phosphodiester bonds in single-stranded RNA at the 3’ end of 
cytidine or uridine. Furthermore, RNase A contains four disulfide-bonds that 
when reduced eliminates enzymatic activity. The RNase oxidation activity assay 
uses PDIA4 to catalyze the renaturation of reduced and inactive RNase A to its 
active oxidized form. Following reactivation, RNase A catalyzes the hydrolysis of 
2’,3’-cyclic cytidine monophosphate (cCMP), resulting in an observable increase 
in absorbance at 296 nm (Figure 4-3). As a result, PDIA4’s oxidase activity is 
related to the rate of cCMP hydrolysis. 
 
 
Figure 4-3. RNase A oxidation activity assay to measure PDI family oxidase 
activity. The refolding of reduced RNase A by PDIs is coupled to the hydrolysis of 
cCMP by RNase A.  
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WT PDIA4 oxidase activity was initially evaluated in parallel with WT 
PDIA1 to determine relative oxidase activity. PDIA1 and PDIA4 were cloned into 
a bacterial expression vector (pET-23a(+)) containing a C-terminal His-tag for 
purification by a Ni-NTA column. WT PDIA1 and WT PDIA4 were expressed, 
purified, and then subjected to the RNase oxidation activity assay (Figure 4-4A). 
Interestingly, the Km for PDIA4 was 60% less than PDIA1 suggesting that PDIA4 
has a stronger affinity for RNaseA than PDIA1 (Figure 4-4B and Table 4-2). 
However, PDIA4 was 37% less catalytically efficient (kcat/Km) than PDIA1 in 
oxidatively refolding RNaseA. Taken together, these results indicate that although 
PDIA4-RNase A interactions are more substantial, PDIA1 exhibits more robust 
oxidase activity when refolding RNase A. One caveat to this comparison is that 
because RNase A is a general substrate, PDIA1 and PDIA4 may exhibit different 
and enhanced oxidase activities in vivo for substrates unique to PDIA1 or PDIA4.   
 
Figure 4-4. Evaluation of PDIA1 and PDIA4 oxidase activity. A) Recombinant 
PDIA1 and PDIA4 were expressed and purified. B) Purified PDIA1 and PDIA4 
were subjected to an RNase A oxidative activity assay, demonstrating each PDIs 
relative oxidase activity.  
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Table 4-2. Enzyme kinetics for PDIA1 and PDIA4 oxidase activity. 
PDI Vmax (µM/min) Km (µM) kcat (min-1) kcat/Km (M-1 min-1) 
PDIA1 0.597 10.43 0.426 4.08 x 104 
PDIA4 0.250 6.933 0.179 2.58 x 104 
 
 Future directions for characterizing PDIA4 oxidase activity includes 
generating active-site mutants so that only one third of the active sites remain 
functional (Figure 4-5). Developing these mutants and applying them to the RNase 
oxidative activity assay will help illuminate the independent contributions made 
by each active site towards PDIA4’s oxidase activity. 
 
 
Figure 4-5. Schematic representation of cysteine to alanine PDIA4 active-site 
mutants used to independently study the role of each active site in PDIA4’s 
oxidase activity.  
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In addition to characterizing each active site’s role in PDIA4’s oxidase 
activity, the contributions made by each a-domain towards PDIA4’s isomerase 
activity have also not been investigated. Isomerase activity may be studied using 
an activity assay in which RNase A’s disulfide bonds are reduced and then 
oxidized under air to promote random disulfide-bond formation16. PDIA4 can 
then be added to scrambled RNase A resulting in the rearrangement of disulfides 
and restoration of RNase A’s function. Similar to the oxidase activity assay, the 
hydrolysis of cCMP by reactivated RNase A is correlated to PDIA4’s isomerase 
activity. These studies will help reveal the importance of each active site for 
PDIA4’s oxidase and isomerase activity and may be applied to other PDI family 
members in the future.  
 
Efforts towards identifying novel inhibitors of PDIA4.  
In order to identify small molecule probes and potential inhibitors of 
PDIA4, we employed a gel-based fluorescence screening platform. Purified 
recombinant PDIA4 was screened against the previously described triazine and 4-
aminopiperidine libraries to identify small molecules that potently label PDIA4. 
Briefly, PDIA4 (0.2 mg/mL) was incubated with various library members (10 µM) 
for 1 hour. Following incubation, covalent modification of PDIA4 was evaluated 
through CuAAC mediated appendage of a rhodamine azide fluorophore and 
subsequent analysis by in-gel fluorescence. Small molecules from each library that 
displayed the most robust labeling of PDIA4 (Figure 4-6A) were then compared in 
a single in-gel fluorescence experiment to determine the top three library members 
to carry forward for further analysis (Figure 4-6B).  
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Figure 4-6. Screening of triazine and 4-aminopiperidine small molecule libraries 
against purified recombinant PDIA4. A) Library members that demonstrated the 
most potent covalent modification of PDIA4. B) 0.2 mg/mL purified recombinant 
PDIA4 was incubated with various library members (10 µM) for 1 hour and 
analyzed by in-gel fluorescence.  
SMC-19, SMC-20, and RB-9-ca were determined to be the most potent 
library members and were subjected to further analysis. In order to evaluate 
selectivity, SMC-19, SMC-20, and RB-9-ca (10 µM) were screened against SKOV-3 
lysate (2 mg/mL) with or without PDIA4 (0.2 mg/mL) spiked in to determine 
whether each library member is selective for PDIA4 (Figure 4-7). All three library 
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members covalently modified additional proteins. Furthermore, labeling of PDIA4 
was only observed when recombinant purified PDIA4 was added to the sample, 
indicating that these library members covalently modify other proteins more 
potently. While none of these library members demonstrated selectivity for 
PDIA4, SMC-20 treatments still resulted in strong labeling of recombinant PDIA4. 
Therefore, SMC-20 could still serve as a chemical tool to perturb PDIA4. As well, 
docking studies may reveal how SMC-20 interacts with PDIA4 allowing for the 
optimization and development of a PDIA4-selective chemical probe. Additional 
experiments in the future may use site-directed mutagenesis of PDIA4 active-site 
cysteines to determine which specific cysteines within PDIA4 are covalently 
modified by SMC-20.  
 
Figure 4-7. Screening of SMC-19, SMC-20, and RB-9-ca (10 µM) against SKOV-3 
lysates (2 mg/mL), recombinant purified PDIA4 (0.2 mg/mL), or SKOV-3 lysates 
(2 mg/mL) spiked with recombinant purified PDIA4 (0.2 mg/mL). Reactions were 
incubated for one hour and then analyzed by in-gel fluorescence.  
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Conclusion 
 In conclusion, we used recombinantly purified PDIA4 to assess PDIA4’s 
oxidase activity and screened in-house triazine and 4-aminopiperidine small 
molecule libraries against PDIA4 to identify potential inhibitors of PDIA4. In an 
activity assay, recombinant purified PDIA4’s oxidase activity was required to 
oxidatively refold RNase resulting in the hydrolysis of cCMP. PDIA4 was 37% less 
catalytically efficient than PDIA1. Interestingly, PDIA4 demonstrated a lower Km 
than PDIA1 suggesting that PDIA4 may have a higher affinity for RNase A. Future 
work will focus on generating active-site mutants to determine how each active-
site cysteine supports PDIA4’s overall oxidase activity. Upon evaluating general 
contributions to oxidase activity, an isomerase activity assay will then be 
implemented to better understand PDIA4’s ability to isomerize disulfide bonds in 
substrates.  
 Along with evaluating PDIA4’s oxidase activity, recombinant purified 
PDIA4 was screened against in-house synthesized triazine and 4-aminopiperidine 
small molecule libraries to identify potential inhibitors of PDIA4. After an initial 
screening of ~ 30 small molecules, three members, SMC-19, SMC-20, and RB-9-ca 
were screened in SKOV-3 lysate supplemented with recombinant PDIA4 to 
determine whether or not these small molecules were selective for PDIA4. 
Ultimately, none of these small molecules demonstrated selectivity for PDIA4, 
however, SMC-20 retained strong labeling of recombinant PDIA4. Therefore, 
future plans involve using site-directed mutagenesis to determine which active-
site cysteines SMC-20 covalently modifies. Additionally, SMC-20 may be used as 
a chemical tool to perturb PDIA4 function in-vitro when studying general PDIA4 
activity. Finally, future screening of PDIA4 against large commercially available 
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 Chemical and biological reagents were purchased from Thermo Fisher or 
MilliporeSigma unless otherwise noted. SKOV-3 cells were obtained from ATCC 
(HTB-77). RPMI 1640, Trypsin-EDTA, and Antibiotic-Antimycotic (Anti-Anti) 
were purchased from Fisher Scientific. Fetal bovine serum (FBS) was acquired 
from Atlanta Biologicals. Protein concentrations were determined using the DC 
Protein Assay kit from Bio-Rad. BL21 competent E. Coli cells were purchased from 
New England BioLabs. Small molecule probes were synthesized in-house by Kyle 
S. Cole and Shalise M. Couvertier. PDIA1 subcloned in pET-23a(+) was obtained 
from Nick Pace.  
 
Cell culture and preparation of SKOV-3 whole-cell lysates.  
SKOV-3 cells were cultured at 37 °C under an atmosphere of 5% CO2 in 
RPMI 1640 medium (Corning) supplemented with 10% FBS (Atlanta Biologicals) 
and 1% Anti-Anti (25 µg/mL Amphotecerin B, 10,000 units/mL penicillin, 10,000 
µg/mL streptomycin, Gibco). Cells were harvested by scraping and pelleted at 
1,000g. Cells were washed and resuspended with DPBS. Cell suspensions were 
sonicated using an ultrasonic tip sonicator (Cole Parmer). Lysates were 
centrifuged at 45,000 rpm for 45 minutes at 4°C to separate soluble and insoluble 
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lysate fractions. The insoluble fraction was discarded and the soluble fraction’s 
protein concentration was determined using the DC Protein Assay kit (Bio-Rad). 
 
Cloning of PDIA4 WT into a pET-23a(+) bacterial expression vector. 
 A WT PDIA4 construct was subcloned into pET-23a(+) using BamHI and 
XhoI restriction sites. The first 60 bases were removed and replaced with an ATG 
sequence to account for the loss of a 20 amino acid signaling sequence that is 
cleaved during the processing of PDIA4 to its mature form.  
 
PDIA1 and PDIA4 expression BL21 E. coli. 
 10 mL of LB broth containing 1 µg/mL ampicillin was inoculated with a 
BL21 E. Coli colony containing WT PDIA4 or WT PDIA1 in pet-23a(+) and grown 
overnight at 37℃. Overnight starter cultures were added to 1 L of LB broth 
containing 1 µg/mL ampicillin and grown to an OD600 of ~0.8. Cultures were 
induced with the addition of 0.6 mM IPTG (isopropyl-β-D-thiogalactoside) and 
shaken at 37℃ for 5 hours. Cells were divided into four aliquots, harvested by 
centrifugation (10 mins, 4500g) and pellets were frozen at -80℃ until needed. 
 
Purification of PDIA1 and PDIA4. 
 E. coli pellets were thawed and resuspended in a volume of PBS equal to 
the volume of the pellet. Bacterial suspensions were sonicated to lyse cells. Soluble 
lysates were separated from insoluble membrane by spinning at 45,000 rpm at 4℃ 
for 45 mins. The supernatant was collected and loaded onto a Ni-NTA column that 
has been equilibrated with DPBS. After loading samples, the column was washed 
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with 7 mL of 25 mM imidazole. Purified PDIA1 or PDIA4 was eluted with 4 mL of 
500 mM imidazole. Collected fractions were analyzed on a 10% SDS-PAGE gel and 
stained with Coomassie Brilliant Blue. Fractions representing pure PDIA1 or 
PDIA4 underwent buffer exchange with PD-10 size exclusion column (GE Life 
Sciences) to remove imidazole. Protein concentrations were determined using the 
DC Protein Assay Kit. Purified PDIA1 and PDIA4 were stored on ice in DPBS. 
 
PDIA1 and PDIA4 oxidase activity assay. 
Preparation of RNase substrate. 10 mg/mL RNase A, 6 M guanidine HCl, and 1.4 
mM DTT were combined and incubated overnight at 37℃ to produce denatured 
and reduced RNase A (rRNase A). Prior to use, rRNase A was buffer exchanged 
with a Nap-5 size exclusion column (GE Life Sciences) to remove guanidine HCl 
and DTT.  
Preparation of activity assay. The following activity assay stock solution was 
prepared: 1 mM GSH, 0.2 mM GSSG, 4.5 mM 2’,3’-cCMP, 100 mM Tris-acetic acid, 
2 mM EDTA, (pH 8.0). 1 µM recombinant PDIA1 or PDIA4 was added to activity 
assay stock solution and 86.4 µL was aliquoted to wells in a UV-capable 96-well 
plate (Greiner). 13.6 µL of rRNase solution (1, 5, 10, 25, 50 µM final concentration) 
was added to each well.  
Collection of data and analysis. The absorbance at 296 nm was recorded every 30 
seconds for 15 mins. The derivative of absorbance (A) vs. time (s) yielded a dA vs. 
time (s) which was then converted to [aRNase] vs time (769 A = 1 µM active RNase 
A (aRNase A)). Finally, a linear regression was performed for each concentration 
of rRNase to produce a plot of [aRNase A}/Time vs [rRNase]. 
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In-gel fluorescence analysis.  
 For analysis of labeled recombinant purified PDIA4, 50 µL of 0.2 mg/mL 
PDIA4 was incubated with 10 µM probe (triazine or 4-aminopiperidine library 
members) for one hour. For analysis of SKOV-3 lysates spiked with recombinant 
purified PDIA4, 50 µL of 2 mg/mL SKOV-3 lysates containing 0.2 mg/mL PDIA4 
was incubated with 10 µM probe for one hour. 25 µM rhodamine-azide (Click 
Chem Tools), 1 mM tris(2-carboxyethyl)phosphine (TCEP), 100 µM TBTA (17x 
stock in t-BuOH:DMSO 4:1), and 1 mM copper (II) sulfate were added to samples. 
Samples were incubated for one hour at room temperature. An equal volume of 
2X Laemmli buffer was added to samples, and 28 µL of this solution was analyzed 
on 10% SDS-PAGE gel. Fluorescent images were captured using a ChemiDoc MP 
imaging system (BioRad). Gels were then stained with Coomassie Brilliant Blue 
using a standard procedure and photographed on the same imager.  
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Table 2A-1. List of proteins identified from trypsin digested whole-cell and ER 
fractions containing at least 10 spectral counts in isolated ER. 















P08670 VIM Vimentin 129 1732 86 637 
P60709 ACTB Actin, cytoplasmic 1 21 44 60 512 
P27797 CALR Calreticulin 23 66 44 302 
Q09666 AHNAK Neuroblast differentiation-associated protein AHNAK 520 2304 204 286 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 7 13 49 271 
Q15149 PLEC Plectin 55 84 162 251 
P14625 HSP90B1 Endoplasmin 7 8 62 215 
P07237 P4HB Protein disulfide-isomerase 56 257 52 203 
P11021 HSPA5 78 kDa glucose-regulated protein 9 18 47 195 
P21333 FLNA Filamin-A 111 279 94 185 
P09651 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 12 24 36 172 
P22626 HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1 22 49 47 163 
P07437 TUBB Tubulin beta chain 9 17 41 163 
P35579 MYH9 Myosin-9 119 497 96 161 
Q00610 CLTC Clathrin heavy chain 1 2 2 89 160 
Q92616 GCN1L1 Translational activator GCN1 0 0 94 154 
Q14697 GANAB Neutral alpha-glucosidase AB 2 2 64 151 
P27816 MAP4 Microtubule-associated protein 4 95 323 64 147 
P68133 ACTA1 Actin, alpha skeletal muscle 10 14 22 144 
P00338 LDHA L-lactate dehydrogenase A chain 13 20 31 142 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 0 0 37 139 
Q71U36 TUBA1A Tubulin alpha-1A chain 4 10 32 139 
P15311 EZR Ezrin 12 27 43 136 
P07355 ANXA2 Annexin A2 17 24 46 133 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 0 0 102 129 
P68104 EEF1A1 Elongation factor 1-alpha 1 9 24 37 126 
P68371 TUBB4B Tubulin beta-4B chain 8 16 34 124 
P68366 TUBA4A Tubulin alpha-4A chain 3 7 26 121 
P30101 PDIA3 Protein disulfide-isomerase A3 9 12 57 119 
Q9NZM1 MYOF Myoferlin 0 0 75 110 
Q08211 DHX9 ATP-dependent RNA helicase A 2 2 50 108 
Q9BVA1 TUBB2B Tubulin beta-2B chain 0 0 27 108 
P78527 PRKDC DNA-dependent protein kinase catalytic subunit 3 0 85 107 
Q14764 MVP Major vault protein 0 0 52 106 
Q9NQC3 RTN4 Reticulon-4 3 10 19 104 
Q9Y490 TLN1 Talin-1 36 45 69 102 
P39023 RPL3 60S ribosomal protein L3 0 0 24 99 
P27824 CANX Calnexin 3 4 35 94 
Q13283 G3BP1 Ras GTPase-activating protein-binding protein 1 3 13 26 93 
P05388 RPLP0 60S acidic ribosomal protein P0 0 0 23 92 
P46821 MAP1B Microtubule-associated protein 1B 58 150 53 86 
P08195 SLC3A2 4F2 cell-surface antigen heavy chain 10 11 42 86 
P36578 RPL4 60S ribosomal protein L4 0 0 52 83 
O00571 DDX3X ATP-dependent RNA helicase DDX3X 0 0 38 83 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 0 0 35 79 
P50454 SERPINH1 Serpin H1 0 0 36 78 
P27635 RPL10 60S ribosomal protein L10 0 0 17 78 
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P11216 PYGB Glycogen phosphorylase, brain form 0 0 42 76 
P26038 MSN Moesin 12 19 33 76 
Q14152 EIF3A Eukaryotic translation initiation factor 3 subunit A 8 11 45 75 
P06733 ENO1 Alpha-enolase 8 19 28 75 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 0 0 45 73 
P14618 PKM Pyruvate kinase isozymes M1/M2 12 18 36 73 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 2 2 18 72 
Q15436 SEC23A Protein transport protein Sec23A 0 0 34 70 
O43707 ACTN4 Alpha-actinin-4 19 27 48 68 
P49257 LMAN1 Protein ERGIC-53 0 0 34 68 
Q6P2E9 EDC4 Enhancer of mRNA-decapping protein 4 9 13 43 66 
Q9NY65 TUBA8 Tubulin alpha-8 chain 0 0 19 66 
O75369 FLNB Filamin-B 61 93 52 65 
Q86UP2 KTN1 Kinectin 51 95 48 65 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit alpha-2 0 0 16 65 
O15523 DDX3Y ATP-dependent RNA helicase DDX3Y 0 0 27 64 
Q13813 SPTAN1 Spectrin alpha chain, non-erythrocytic 1 120 208 53 63 
P15880 RPS2 40S ribosomal protein S2 0 0 13 63 
Q00341 HDLBP Vigilin 0 0 41 61 
P29401 TKT Transketolase 47 262 31 60 
P05556 ITGB1 Integrin beta-1 9 17 21 60 
P12814 ACTN1 Alpha-actinin-1 13 21 35 59 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit alpha 0 0 11 59 
P49327 FASN Fatty acid synthase 0 0 37 57 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 0 0 13 57 
P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic 0 0 31 56 
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M 8 11 34 55 
P08238 HSP90AB1 Heat shock protein HSP 90-beta 9 15 26 54 
P04792 HSPB1 Heat shock protein beta-1 63 254 23 54 
P26006 ITGA3 Integrin alpha-3 5 9 20 54 
O43852 CALU Calumenin 32 65 29 52 
P61224 RAP1B Ras-related protein Rap-1b 0 0 11 52 
Q01082 SPTBN1 Spectrin beta chain, non-erythrocytic 1 43 71 43 51 
O60716 CTNND1 Catenin delta-1 2 2 35 51 
Q14157 UBAP2L Ubiquitin-associated protein 2-like 17 34 29 51 
Q15233 NONO Non-POU domain-containing octamer-binding protein 12 15 24 48 
Q92900 UPF1 Regulator of nonsense transcripts 1 0 0 32 47 
Q92499 DDX1 ATP-dependent RNA helicase DDX1 0 0 27 47 
Q05639 EEF1A2 Elongation factor 1-alpha 2 0 0 13 47 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor 2 3 34 46 
P02751 FN1 Fibronectin 11 11 33 46 
P04844 RPN2 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 0 0 30 46 
P07900 HSP90AA1 Heat shock protein HSP 90-alpha 7 11 26 46 
Q9BUF5 TUBB6 Tubulin beta-6 chain 0 0 15 46 
Q13509 TUBB3 Tubulin beta-3 chain 0 0 21 45 
P62829 RPL23 60S ribosomal protein L23 0 0 10 44 
P43243 MATR3 Matrin-3 9 10 29 43 
P51114 FXR1 Fragile X mental retardation syndrome-related protein 1 0 0 28 43 
Q9Y4L1 HYOU1 Hypoxia up-regulated protein 1 6 11 26 42 
Q14444 CAPRIN1 Caprin-1 26 59 22 42 
Q04637 EIF4G1 Eukaryotic translation initiation factor 4 gamma 1 8 10 32 41 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2 4 5 31 41 
Q9Y3I0 C22orf28 tRNA-splicing ligase RtcB homolog 0 0 22 41 
P0CW22 RPS17L 40S ribosomal protein S17-like 2 2 18 41 
P62847 RPS24 40S ribosomal protein S24 0 0 7 41 
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Q15019 SEPT2 Septin-2 0 0 25 40 
P53992 SEC24C Protein transport protein Sec24C 3 4 24 40 
Q16647 PTGIS Prostacyclin synthase 0 0 21 40 
Q6DD88 ATL3 Atlastin-3 0 0 24 39 
P78344 EIF4G2 Eukaryotic translation initiation factor 4 gamma 2 0 0 24 39 
O15371 EIF3D Eukaryotic translation initiation factor 3 subunit D 0 0 23 39 
P46940 IQGAP1 Ras GTPase-activating-like protein IQGAP1 2 2 31 38 
Q06830 PRDX1 Peroxiredoxin-1 19 30 19 38 
P00387 CYB5R3 NADH-cytochrome b5 reductase 3 0 0 15 38 
P07814 EPRS Bifunctional glutamate/proline--tRNA ligase 0 0 28 37 
A5YKK6 CNOT1 CCR4-NOT transcription complex subunit 1 0 0 27 37 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 22 74 20 37 
Q15293 RCN1 Reticulocalbin-1 33 65 20 37 
B5ME19 EIF3CL Eukaryotic translation initiation factor 3 subunit C 3 6 25 36 
P00533 EGFR Epidermal growth factor receptor 3 3 25 36 
P16435 POR NADPH--cytochrome P450 reductase 0 0 24 36 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 0 0 24 36 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha-1 3 4 21 36 
Q15437 SEC23B Protein transport protein Sec23B 0 0 21 36 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 0 0 20 36 
A6NE09 RPSAP58 Protein RPSAP58 0 0 18 36 
P46783 RPS10 40S ribosomal protein S10 0 0 8 36 
Q9H4M9 EHD1 EH domain-containing protein 1 0 0 26 35 
Q01813 PFKP 6-phosphofructokinase type C 0 0 21 35 
P23246 SFPQ Splicing factor, proline- and glutamine-rich 12 17 20 35 
P04083 ANXA1 Annexin A1 10 17 19 35 
P07099 EPHX1 Epoxide hydrolase 1 0 0 19 35 
Q13740 ALCAM CD166 antigen 11 25 18 35 
P18621 RPL17 60S ribosomal protein L17 0 0 15 35 
J3QL51 RPL17-C18ORF32 Protein RPL17-C18ORF32 0 0 15 35 
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B 0 0 14 35 
P46778 RPL21 60S ribosomal protein L21 0 0 10 35 
P62081 RPS7 40S ribosomal protein S7 0 0 10 35 
Q9NZN4 EHD2 EH domain-containing protein 2 2 2 24 34 
Q00839 HNRNPU Heterogeneous nuclear ribonucleoprotein U 8 9 19 34 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 4 6 18 34 
Q13200 PSMD2 26S proteasome non-ATPase regulatory subunit 2 0 0 16 34 
O75643 SNRNP200 U5 small nuclear ribonucleoprotein 200 kDa helicase 0 0 27 33 
P11142 HSPA8 Heat shock cognate 71 kDa protein 9 12 24 33 
Q13310 PABPC4 Polyadenylate-binding protein 4 6 22 20 33 
Q12907 LMAN2 Vesicular integral-membrane protein VIP36 0 0 14 33 
Q6P2Q9 PRPF8 Pre-mRNA-processing-splicing factor 8 0 0 29 32 
P13667 PDIA4 Protein disulfide-isomerase A4 2 2 25 32 
O43795 MYO1B Unconventional myosin-Ib 0 0 24 32 
P35221 CTNNA1 Catenin alpha-1 3 3 23 32 
P11940 PABPC1 Polyadenylate-binding protein 1 7 26 18 32 
P06756 ITGAV Integrin alpha-V 6 8 16 32 
P32969 RPL9P9 60S ribosomal protein L9 0 0 12 32 
Q9Y520 PRRC2C Protein PRRC2C 41 61 19 31 
Q9P2E9 RRBP1 Ribosome-binding protein 1 29 57 17 31 
P51991 HNRNPA3 Heterogeneous nuclear ribonucleoprotein A3 7 12 14 31 
O00303 EIF3F Eukaryotic translation initiation factor 3 subunit F 0 0 14 31 
P61160 ACTR2 Actin-related protein 2 0 0 12 31 
P15924 DSP Desmoplakin 0 0 27 30 
Q92841 DDX17 Probable ATP-dependent RNA helicase DDX17 2 2 22 30 
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P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 0 0 20 30 
Q15084 PDIA6 Protein disulfide-isomerase A6 0 0 17 30 
Q9H223 EHD4 EH domain-containing protein 4 0 0 17 30 
P18124 RPL7 60S ribosomal protein L7 0 0 15 30 
P43686 PSMC4 26S protease regulatory subunit 6B 0 0 14 30 
P09382 LGALS1 Galectin-1 20 448 9 30 
P14314 PRKCSH Glucosidase 2 subunit beta 43 74 24 29 
Q14258 TRIM25 E3 ubiquitin/ISG15 ligase TRIM25 0 0 20 29 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 13 21 19 29 
Q13162 PRDX4 Peroxiredoxin-4 19 40 17 29 
P35241 RDX Radixin 5 6 16 29 
Q9P0L0 VAPA Vesicle-associated membrane protein-associated protein A 0 0 15 29 
Q9NYU2 UGGT1 UDP-glucose:glycoprotein glucosyltransferase 1 0 0 24 28 
O43491 EPB41L2 Band 4.1-like protein 2 17 30 20 28 
P40227 CCT6A T-complex protein 1 subunit zeta 0 0 20 28 
P26599 PTBP1 Polypyrimidine tract-binding protein 1 4 7 19 28 
Q9UN86 G3BP2 Ras GTPase-activating protein-binding protein 2 0 0 17 28 
Q16181 SEPT7 Septin-7 0 0 16 28 
O75531 BANF1 Barrier-to-autointegration factor 9 13 11 28 
O00159 MYO1C Unconventional myosin-Ic 0 0 22 27 
O00116 AGPS Alkyldihydroxyacetonephosphate synthase, peroxisomal 0 0 19 27 
P61221 ABCE1 ATP-binding cassette sub-family E member 1 0 0 17 27 
P62263 RPS14 40S ribosomal protein S14 0 0 15 27 
P04075 ALDOA Fructose-bisphosphate aldolase A 5 11 14 27 
Q02878 RPL6 60S ribosomal protein L6 0 0 14 27 
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 0 0 14 27 
P46781 RPS9 40S ribosomal protein S9 0 0 9 27 
O95487 SEC24B Protein transport protein Sec24B 0 0 21 26 
P80303 NUCB2 Nucleobindin-2 24 38 18 26 
P51659 HSD17B4 Peroxisomal multifunctional enzyme type 2 3 4 14 26 
P49755 TMED10 Transmembrane emp24 domain-containing protein 10 0 0 12 26 
P39656 DDOST Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 0 0 12 26 
P23528 CFL1 Cofilin-1 27 182 11 26 
P62841 RPS15 40S ribosomal protein S15 2 3 9 26 
Q29940 HLA-B HLA class I histocompatibility antigen, B-59 alpha chain 0 0 6 26 
Q9H0U4 RAB1B Ras-related protein Rab-1B 0 0 6 26 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 0 0 19 25 
P53675 CLTCL1 Clathrin heavy chain 2 0 0 18 25 
Q9Y262 EIF3L Eukaryotic translation initiation factor 3 subunit L 0 0 18 25 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 0 0 17 25 
P09486 SPARC SPARC 15 21 16 25 
P13807 GYS1 Glycogen 0 0 16 25 
Q9Y285 FARSA Phenylalanine--tRNA ligase alpha subunit 0 0 14 25 
P30685 HLA-B HLA class I histocompatibility antigen, B-35 alpha chain 0 0 6 25 
P13639 EEF2 Elongation factor 2 4 4 20 24 
P35222 CTNNB1 Catenin beta-1 6 9 17 24 
P13010 XRCC5 X-ray repair cross-complementing protein 5 2 3 15 24 
P50570 DNM2 Dynamin-2 0 0 15 24 
P62269 RPS18 40S ribosomal protein S18 0 0 15 24 
Q6NZI2 PTRF Polymerase I and transcript release factor 8 9 14 24 
P62249 RPS16 40S ribosomal protein S16 0 0 13 24 
P60903 S100A10 Protein S100-A10 5 6 10 24 
Q07020 RPL18 60S ribosomal protein L18 0 0 10 24 
O95881 TXNDC12 Thioredoxin domain-containing protein 12 3 11 6 24 
P35580 MYH10 Myosin-10 26 40 23 23 
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Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protein 1 0 0 19 23 
Q6PKG0 LARP1 La-related protein 1 4 6 18 23 
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 3 3 18 23 
Q13724 MOGS Mannosyl-oligosaccharide glucosidase 0 0 18 23 
Q9Y2A7 NCKAP1 Nck-associated protein 1 0 0 18 23 
Q07065 CKAP4 Cytoskeleton-associated protein 4 5 6 15 23 
P31943 HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 3 3 10 23 
P30512 HLA-A HLA class I histocompatibility antigen, A-29 alpha chain 0 0 6 23 
P01891 HLA-A HLA class I histocompatibility antigen, A-68 alpha chain 0 0 6 23 
P31949 S100A11 Protein S100-A11 6 159 5 23 
Q07000 HLA-C HLA class I histocompatibility antigen, Cw-15 alpha chain 0 0 5 23 
Q8IVF2 AHNAK2 Protein AHNAK2 74 110 21 22 
O75165 DNAJC13 DnaJ homolog subfamily C member 13 0 0 21 22 
P63010 AP2B1 AP-2 complex subunit beta 0 0 18 22 
O15173 PGRMC2 Membrane-associated progesterone receptor component 2 2 2 17 22 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 0 0 17 22 
P23258 TUBG1 Tubulin gamma-1 chain 0 0 16 22 
O94979 SEC31A Protein transport protein Sec31A 0 0 16 22 
P60228 EIF3E Eukaryotic translation initiation factor 3 subunit E 0 0 11 22 
Q562R1 ACTBL2 Beta-actin-like protein 2 0 0 10 22 
O15372 EIF3H Eukaryotic translation initiation factor 3 subunit H 0 0 10 22 
P30443 HLA-A HLA class I histocompatibility antigen, A-1 alpha chain 0 0 7 22 
P16070 CD44 CD44 antigen 5 9 5 22 
P30504 HLA-C HLA class I histocompatibility antigen, Cw-4 alpha chain 0 0 5 22 
P30453 HLA-A HLA class I histocompatibility antigen, A-34 alpha chain 0 0 5 22 
O00429 DNM1L Dynamin-1-like protein 0 0 17 21 
O94874 UFL1 E3 UFM1-protein ligase 1 0 0 16 21 
P63104 YWHAZ 14-3-3 protein zeta/delta 7 13 15 21 
P02786 TFRC Transferrin receptor protein 1 3 3 15 21 
Q5JPE7 NOMO2 Nodal modulator 2 0 0 15 21 
Q9ULV4 CORO1C Coronin-1C 3 3 13 21 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 6 11 12 21 
Q96I24 FUBP3 Far upstream element-binding protein 3 2 3 12 21 
P62158 CALM3 Calmodulin 25 167 11 21 
P30040 ERP29 Endoplasmic reticulum resident protein 29 6 10 11 21 
P51149 RAB7A Ras-related protein Rab-7a 0 0 11 21 
Q9P035 PTPLAD1 3-hydroxyacyl-CoA dehydratase 3 0 0 8 21 
P62820 RAB1A Ras-related protein Rab-1A 0 0 5 21 
Q96TA1 FAM129B Niban-like protein 1 0 0 19 20 
Q03135 CAV1 Caveolin-1 3 4 16 20 
O15031 PLXNB2 Plexin-B2 2 2 16 20 
P29317 EPHA2 Ephrin type-A receptor 2 0 0 16 20 
P12956 XRCC6 X-ray repair cross-complementing protein 6 2 2 15 20 
P55209 NAP1L1 Nucleosome assembly protein 1-like 1 5 8 14 20 
P30519 HMOX2 Heme oxygenase 2 0 0 14 20 
P07947 YES1 Tyrosine-protein kinase Yes 0 0 13 20 
P62258 YWHAE 14-3-3 protein epsilon 3 5 12 20 
Q9NTJ3 SMC4 Structural maintenance of chromosomes protein 4 0 0 12 20 
Q7L576 CYFIP1 Cytoplasmic FMR1-interacting protein 1 0 0 11 20 
P46777 RPL5 60S ribosomal protein L5 0 0 9 20 
P01892 HLA-A HLA class I histocompatibility antigen, A-2 alpha chain 0 0 5 20 
P10586 PTPRF Receptor-type tyrosine-protein phosphatase F 0 0 18 19 
Q14573 ITPR3 Inositol 1,4,5-trisphosphate receptor type 3 0 0 18 19 
A0FGR8 ESYT2 Extended synaptotagmin-2 0 0 17 19 
Q9UBG0 MRC2 C-type mannose receptor 2 0 0 16 19 
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P15144 ANPEP Aminopeptidase N 0 0 16 19 
P00558 PGK1 Phosphoglycerate kinase 1 7 9 14 19 
P31946 YWHAB 14-3-3 protein beta/alpha 4 5 12 19 
P55884 EIF3B Eukaryotic translation initiation factor 3 subunit B 0 0 16 18 
P27708 CAD CAD protein 0 0 16 18 
P04040 CAT Catalase 0 0 15 18 
P56192 MARS Methionine--tRNA ligase, cytoplasmic 0 0 15 18 
P47897 QARS Glutamine--tRNA ligase 0 0 15 18 
Q9Y5S2 CDC42BPB Serine/threonine-protein kinase MRCK beta 0 0 15 18 
Q14203 DCTN1 Dynactin subunit 1 0 0 15 18 
Q7Z478 DHX29 ATP-dependent RNA helicase DHX29 0 0 15 18 
Q5VYK3 ECM29 Proteasome-associated protein ECM29 homolog 0 0 14 18 
Q9HCE1 MOV10 Putative helicase MOV-10 0 0 13 18 
P48643 CCT5 T-complex protein 1 subunit epsilon 0 0 12 18 
P61981 YWHAG 14-3-3 protein gamma 3 6 11 18 
P06493 CDK1 Cyclin-dependent kinase 1 0 0 11 18 
P62280 RPS11 40S ribosomal protein S11 0 0 10 18 
P50914 RPL14 60S ribosomal protein L14 0 0 6 18 
Q96Q15 SMG1 Serine/threonine-protein kinase SMG1 0 0 17 17 
Q6YHK3 CD109 CD109 antigen 5 5 16 17 
Q9UGR2 ZC3H7B Zinc finger CCCH domain-containing protein 7B 0 0 16 17 
Q96AC1 FERMT2 Fermitin family homolog 2 0 0 15 17 
Q02818 NUCB1 Nucleobindin-1 35 55 14 17 
Q63HN8 RNF213 E3 ubiquitin-protein ligase RNF213 0 0 14 17 
P61158 ACTR3 Actin-related protein 3 0 0 14 17 
P06737 PYGL Glycogen phosphorylase, liver form 0 0 14 17 
Q32P28 LEPRE1 Prolyl 3-hydroxylase 1 0 0 13 17 
Q9BTV4 TMEM43 Transmembrane protein 43 0 0 13 17 
P62195 PSMC5 26S protease regulatory subunit 8 0 0 13 17 
Q1KMD3 HNRNPUL2 Heterogeneous nuclear ribonucleoprotein U-like protein 2 0 0 12 17 
Q12797 ASPH Aspartyl/asparaginyl beta-hydroxylase 0 0 12 17 
P62424 RPL7A 60S ribosomal protein L7a 0 0 12 17 
Q9HAV0 GNB4 Guanine nucleotide-binding protein subunit beta-4 0 0 12 17 
P61106 RAB14 Ras-related protein Rab-14 2 2 11 17 
Q9NPI6 DCP1A mRNA-decapping enzyme 1A 0 0 11 17 
O14950 MYL12B Myosin regulatory light chain 12B 15 40 10 17 
P26885 FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2 0 0 8 17 
P61586 RHOA Transforming protein RhoA 0 0 7 17 
Q9NP72 RAB18 Ras-related protein Rab-18 0 0 7 17 
O43169 CYB5B Cytochrome b5 type B 0 0 5 17 
P46939 UTRN Utrophin 0 0 16 16 
P53621 COPA Coatomer subunit alpha 0 0 14 16 
O75533 SF3B1 Splicing factor 3B subunit 1 9 12 13 16 
P55072 VCP Transitional endoplasmic reticulum ATPase 2 3 13 16 
P49368 CCT3 T-complex protein 1 subunit gamma 0 0 12 16 
Q8NCA5 FAM98A Protein FAM98A 0 0 12 16 
Q9BRK5 SDF4 45 kDa calcium-binding protein 9 13 11 16 
Q8WVM8 SCFD1 Sec1 family domain-containing protein 1 0 0 11 16 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit I 0 0 10 16 
Q15363 TMED2 Transmembrane emp24 domain-containing protein 2 0 0 8 16 
P62906 RPL10A 60S ribosomal protein L10a 0 0 8 16 
P60953 CDC42 Cell division control protein 42 homolog 2 2 6 16 
Q03001 DST Dystonin 27 32 14 15 
Q92896 GLG1 Golgi apparatus protein 1 0 0 14 15 
Q5T6F2 UBAP2 Ubiquitin-associated protein 2 14 25 13 15 
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Q96QK1 VPS35 Vacuolar protein sorting-associated protein 35 0 0 13 15 
Q9NZN8 CNOT2 CCR4-NOT transcription complex subunit 2 0 0 13 15 
Q7L2E3 DHX30 Putative ATP-dependent RNA helicase DHX30 0 0 13 15 
P35613 BSG Basigin 2 3 12 15 
Q9UII4 HERC5 E3 ISG15--protein ligase HERC5 0 0 12 15 
P29323 EPHB2 Ephrin type-B receptor 2 0 0 12 15 
Q14694 USP10 Ubiquitin carboxyl-terminal hydrolase 10 2 3 11 15 
A1L0T0 ILVBL Acetolactate synthase-like protein 0 0 11 15 
Q8IYS2 KIAA2013 Uncharacterized protein KIAA2013 0 0 11 15 
Q9UHD8 SEPT9 Septin-9 6 6 10 15 
Q9BZF1 OSBPL8 Oxysterol-binding protein-related protein 8 0 0 10 15 
Q9NZ01 TECR Trans-2,3-enoyl-CoA reductase 0 0 10 15 
O75083 WDR1 WD repeat-containing protein 1 0 0 10 15 
Q9BVK6 TMED9 Transmembrane emp24 domain-containing protein 9 0 0 9 15 
P62191 PSMC1 26S protease regulatory subunit 4 0 0 9 15 
P06703 S100A6 Protein S100-A6 15 38 8 15 
Q9UHG3 PCYOX1 Prenylcysteine oxidase 1 0 0 7 15 
H3BN98 Uncharacterized protein 0 0 6 15 
P55795 HNRNPH2 Heterogeneous nuclear ribonucleoprotein H2 0 0 5 15 
Q9H3N1 TMX1 Thioredoxin-related transmembrane protein 1 0 0 5 15 
P39060 COL18A1 Collagen alpha-1(XVIII) chain 2 2 13 14 
Q5T4S7 UBR4 E3 ubiquitin-protein ligase UBR4 0 0 13 14 
Q10567 AP1B1 AP-1 complex subunit beta-1 0 0 13 14 
Q13308 PTK7 Inactive tyrosine-protein kinase 7 3 3 12 14 
Q6Y7W6 GIGYF2 PERQ amino acid-rich with GYF domain-containing protein 2 3 3 12 14 
O94855 SEC24D Protein transport protein Sec24D 0 0 12 14 
P55265 ADAR Double-stranded RNA-specific adenosine deaminase 0 0 12 14 
P18669 PGAM1 Phosphoglycerate mutase 1 9 9 11 14 
Q9Y224 C14orf166 UPF0568 protein C14orf166 3 4 11 14 
Q9BXF6 RAB11FIP5 Rab11 family-interacting protein 5 4 4 11 14 
P46459 NSF Vesicle-fusing ATPase 0 0 11 14 
P53396 ACLY ATP-citrate synthase 0 0 11 14 
P07602 PSAP Proactivator polypeptide 15 41 10 14 
Q8N766 EMC1 ER membrane protein complex subunit 1 0 0 10 14 
O75844 ZMPSTE24 CAAX prenyl protease 1 homolog 0 0 10 14 
Q99832 CCT7 T-complex protein 1 subunit eta 0 0 10 14 
Q5JWF2 GNAS Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas 0 0 10 14 
P63092 GNAS Guanine nucleotide-binding protein G(s) subunit alpha isoforms short 0 0 10 14 
P05386 RPLP1 60S acidic ribosomal protein P1 10 26 9 14 
P29692 EEF1D Elongation factor 1-delta 8 11 9 14 
Q12904 AIMP1 Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 2 2 9 14 
Q96A33 CCDC47 Coiled-coil domain-containing protein 47 0 0 9 14 
P35998 PSMC2 26S protease regulatory subunit 7 0 0 9 14 
P60660 MYL6 Myosin light polypeptide 6 24 195 8 14 
P20908 COL5A1 Collagen alpha-1(V) chain 12 16 8 14 
O00264 PGRMC1 Membrane-associated progesterone receptor component 1 2 4 8 14 
P14923 JUP Junction plakoglobin 0 0 8 14 
P46782 RPS5 40S ribosomal protein S5 0 0 8 14 
Q13151 HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 0 0 7 14 
Q9Y281 CFL2 Cofilin-2 0 0 4 14 
Q14671 PUM1 Pumilio homolog 1 3 3 13 13 
Q96RT1 ERBB2IP Protein LAP2 2 2 13 13 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 0 0 13 13 
Q9NZJ4 SACS Sacsin 0 0 13 13 
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P32004 L1CAM Neural cell adhesion molecule L1 7 15 12 13 
P18206 VCL Vinculin 9 14 12 13 
O00231 PSMD11 26S proteasome non-ATPase regulatory subunit 11 0 0 12 13 
P54136 RARS Arginine--tRNA ligase, cytoplasmic 0 0 12 13 
O14828 SCAMP3 Secretory carrier-associated membrane protein 3 0 0 11 13 
Q86TB9 PATL1 Protein PAT1 homolog 1 0 0 11 13 
P29144 TPP2 Tripeptidyl-peptidase 2 0 0 11 13 
Q14126 DSG2 Desmoglein-2 5 6 10 13 
Q00796 SORD Sorbitol dehydrogenase 0 0 10 13 
Q96HE7 ERO1L ERO1-like protein alpha 0 0 10 13 
Q7L2H7 EIF3M Eukaryotic translation initiation factor 3 subunit M 0 0 10 13 
Q14160 SCRIB Protein scribble homolog 0 0 10 13 
Q96PK6 RBM14 RNA-binding protein 14 3 5 9 13 
Q15029 EFTUD2 116 kDa U5 small nuclear ribonucleoprotein component 0 0 9 13 
O15270 SPTLC2 Serine palmitoyltransferase 2 0 0 9 13 
P21964 COMT Catechol O-methyltransferase 0 0 9 13 
P62491 RAB11A Ras-related protein Rab-11A 0 0 9 13 
P67809 YBX1 Nuclease-sensitive element-binding protein 1 22 247 8 13 
P61769 B2M Beta-2-microglobulin 3 8 8 13 
O95758 PTBP3 Polypyrimidine tract-binding protein 3 0 0 8 13 
Q9Y2B0 CNPY2 Protein canopy homolog 2 10 22 7 13 
Q9BQE5 APOL2 Apolipoprotein L2 0 0 7 13 
P61019 RAB2A Ras-related protein Rab-2A 0 0 6 13 
P11234 RALB Ras-related protein Ral-B 0 0 6 13 
Q6UW68 TMEM205 Transmembrane protein 205 0 0 2 13 
reverse_Q8WZ42 TTN Titin 0 0 0 13 
Q9UPN3 MACF1 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 13 15 12 12 
Q14789 GOLGB1 Golgin subfamily B member 1 24 29 11 12 
P08758 ANXA5 Annexin A5 3 5 11 12 
O75976 CPD Carboxypeptidase D 2 2 11 12 
Q15021 NCAPD2 Condensin complex subunit 1 0 0 11 12 
Q6PGP7 TTC37 Tetratricopeptide repeat protein 37 0 0 11 12 
Q9BZF9 UACA Uveal autoantigen with coiled-coil domains and ankyrin repeats 0 0 10 12 
Q9P2J5 LARS Leucine--tRNA ligase, cytoplasmic 0 0 10 12 
P30530 AXL Tyrosine-protein kinase receptor UFO 0 0 10 12 
P06744 GPI Glucose-6-phosphate isomerase 2 4 9 12 
O75175 CNOT3 CCR4-NOT transcription complex subunit 3 3 3 9 12 
Q9NZN3 EHD3 EH domain-containing protein 3 0 0 9 12 
P08581 MET Hepatocyte growth factor receptor 0 0 9 12 
Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3 0 0 9 12 
Q12959 DLG1 Disks large homolog 1 0 0 9 12 
O15269 SPTLC1 Serine palmitoyltransferase 1 0 0 9 12 
Q9UQB8 BAIAP2 Brain-specific angiogenesis inhibitor 1-associated protein 2 0 0 9 12 
P62277 RPS13 40S ribosomal protein S13 0 0 9 12 
O14979 HNRPDL Heterogeneous nuclear ribonucleoprotein D-like 17 67 8 12 
P53618 COPB1 Coatomer subunit beta 0 0 8 12 
P50395 GDI2 Rab GDP dissociation inhibitor beta 0 0 8 12 
P29992 GNA11 Guanine nucleotide-binding protein subunit alpha-11 0 0 8 12 
Q9UHX1 PUF60 Poly(U)-binding-splicing factor PUF60 0 0 7 12 
O15400 STX7 Syntaxin-7 0 0 7 12 
B0V043 VARS Valyl-tRNA synthetase 0 0 7 12 
P18463 HLA-B HLA class I histocompatibility antigen, B-37 alpha chain 2 2 6 12 
Q13155 AIMP2 Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 0 0 6 12 
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Q96F07 CYFIP2 Cytoplasmic FMR1-interacting protein 2 0 0 5 12 
Q5BJH7 YIF1B Protein YIF1B 0 0 4 12 
Q13435 SF3B2 Splicing factor 3B subunit 2 23 34 11 11 
Q5JSZ5 PRRC2B Protein PRRC2B 9 11 11 11 
O43815 STRN Striatin 0 0 11 11 
P41252 IARS Isoleucine--tRNA ligase, cytoplasmic 0 0 11 11 
Q6WKZ4 RAB11FIP1 Rab11 family-interacting protein 1 8 9 10 11 
Q07666 KHDRBS1 KH domain-containing, RNA-binding, signal transduction-associated protein 1 3 5 10 11 
P27348 YWHAQ 14-3-3 protein theta 4 5 10 11 
P09525 ANXA4 Annexin A4 3 4 10 11 
Q15067 ACOX1 Peroxisomal acyl-coenzyme A oxidase 1 3 3 10 11 
Q9BUJ2 HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like protein 1 3 3 10 11 
P33176 KIF5B Kinesin-1 heavy chain 3 3 10 11 
Q7Z7H5 TMED4 Transmembrane emp24 domain-containing protein 4 0 0 10 11 
Q8IVL5 LEPREL1 Prolyl 3-hydroxylase 2 0 0 10 11 
Q6P3W7 SCYL2 SCY1-like protein 2 0 0 10 11 
Q7Z2W4 ZC3HAV1 Zinc finger CCCH-type antiviral protein 1 0 0 10 11 
Q7Z6Z7 HUWE1 E3 ubiquitin-protein ligase HUWE1 0 0 10 11 
P78371 CCT2 T-complex protein 1 subunit beta 0 0 10 11 
P17858 PFKL 6-phosphofructokinase, liver type 0 0 10 11 
Q6PIU2 NCEH1 Neutral cholesterol ester hydrolase 1 0 0 9 11 
Q93050 ATP6V0A1 V-type proton ATPase 116 kDa subunit a isoform 1 0 0 9 11 
P38606 ATP6V1A V-type proton ATPase catalytic subunit A 0 0 9 11 
P53582 METAP1 Methionine aminopeptidase 1 0 0 9 11 
P30153 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 0 0 9 11 
Q02543 RPL18A 60S ribosomal protein L18a 0 0 9 11 
Q13586 STIM1 Stromal interaction molecule 1 3 4 8 11 
P31689 DNAJA1 DnaJ homolog subfamily A member 1 0 0 8 11 
Q15738 NSDHL Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating 0 0 8 11 
P62333 PSMC6 26S protease regulatory subunit 10B 0 0 8 11 
Q12906 ILF3 Interleukin enhancer-binding factor 3 0 0 7 11 
Q15003 NCAPH Condensin complex subunit 2 0 0 7 11 
Q9HDC9 APMAP Adipocyte plasma membrane-associated protein 0 0 7 11 
P27487 DPP4 Dipeptidyl peptidase 4 0 0 7 11 
P46779 RPL28 60S ribosomal protein L28 0 0 7 11 
O00487 PSMD14 26S proteasome non-ATPase regulatory subunit 14 0 0 6 11 
Q9NTJ5 SACM1L Phosphatidylinositide phosphatase SAC1 0 0 5 11 
P08134 RHOC Rho-related GTP-binding protein RhoC 0 0 4 11 
P61313 RPL15 60S ribosomal protein L15 0 0 3 11 
Q641Q2 FAM21A WASH complex subunit FAM21A 20 27 10 10 
P07942 LAMB1 Laminin subunit beta-1 5 6 10 10 
Q15154 PCM1 Pericentriolar material 1 protein 4 4 10 10 
Q9P0K7 RAI14 Ankycorbin 3 3 10 10 
Q8IWR0 ZC3H7A Zinc finger CCCH domain-containing protein 7A 0 0 10 10 
Q9UHI6 DDX20 Probable ATP-dependent RNA helicase DDX20 0 0 10 10 
Q9UG63 ABCF2 ATP-binding cassette sub-family F member 2 0 0 10 10 
P11047 LAMC1 Laminin subunit gamma-1 8 8 9 10 
Q9H6S3 EPS8L2 Epidermal growth factor receptor kinase substrate 8-like protein 2 5 6 9 10 
Q06787 FMR1 Fragile X mental retardation protein 1 0 0 9 10 
Q8N3C0 ASCC3 Activating signal cointegrator 1 complex subunit 3 0 0 9 10 
Q15477 SKIV2L Helicase SKI2W 0 0 9 10 
Q6P9B6 KIAA1609 TLD domain-containing protein KIAA1609 0 0 9 10 
Q14974 KPNB1 Importin subunit beta-1 0 0 9 10 
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Q15042 RAB3GAP1 Rab3 GTPase-activating protein catalytic subunit 0 0 9 10 
P40429 RPL13A 60S ribosomal protein L13a 0 0 9 10 
Q96CS3 FAF2 FAS-associated factor 2 0 0 9 10 
P17980 PSMC3 26S protease regulatory subunit 6A 0 0 9 10 
P37802 TAGLN2 Transgelin-2 23 100 8 10 
P30533 LRPAP1 Alpha-2-macroglobulin receptor-associated protein 10 18 8 10 
Q15459 SF3A1 Splicing factor 3A subunit 1 5 12 8 10 
P19022 CDH2 Cadherin-2 8 12 8 10 
P06576 ATP5B ATP synthase subunit beta, mitochondrial 6 9 8 10 
P80723 BASP1 Brain acid soluble protein 1 5 6 8 10 
Q01518 CAP1 Adenylyl cyclase-associated protein 1 2 5 8 10 
Q9UMS4 PRPF19 Pre-mRNA-processing factor 19 0 0 8 10 
P54886 ALDH18A1 Delta-1-pyrroline-5-carboxylate synthase 0 0 8 10 
P51572 BCAP31 B-cell receptor-associated protein 31 0 0 8 10 
Q969V3 NCLN Nicalin 0 0 8 10 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1 0 0 8 10 
Q9NSD9 FARSB Phenylalanine--tRNA ligase beta subunit 0 0 8 10 
P62917 RPL8 60S ribosomal protein L8 0 0 8 10 
Q9P0V9 SEPT10 Septin-10 0 0 8 10 
Q13561 DCTN2 Dynactin subunit 2 18 44 7 10 
P28288 ABCD3 ATP-binding cassette sub-family D member 3 0 0 7 10 
P52597 HNRNPF Heterogeneous nuclear ribonucleoprotein F 0 0 7 10 
Q96JJ7 TMX3 Protein disulfide-isomerase TMX3 0 0 7 10 
P11166 SLC2A1 Solute carrier family 2, facilitated glucose transporter member 1 0 0 7 10 
Q99653 CHP1 Calcineurin B homologous protein 1 3 3 6 10 
P30466 HLA-B HLA class I histocompatibility antigen, B-18 alpha chain 0 0 6 10 
Q16630 CPSF6 Cleavage and polyadenylation specificity factor subunit 6 6 10 5 10 
Q8WWM7 ATXN2L Ataxin-2-like protein 5 8 5 10 
Q15006 EMC2 ER membrane protein complex subunit 2 0 0 5 10 
O60762 DPM1 Dolichol-phosphate mannosyltransferase 0 0 5 10 
Q13190 STX5 Syntaxin-5 0 0 5 10 
Q03518 TAP1 Antigen peptide transporter 1 0 0 5 10 
 
Table 2A-2. PANTHER GO Biological Processes enrichment analysis for proteins 
identified in whole-cell lysates. Data filtered for processes enriched >3-fold. 
Analysis Type: 
PANTHER Overrepresentation Test (Released 
20181113) 
Annotation Version and Release Date: GO Ontology database  Released 2019-01-01 
Reference List: Homo sapiens (all genes in database)  
Test Type: FISHER     
Correction: BONFERRONI          
 Protein Number   








P - value 
viral latency  (GO:0019042) 12 8 0.68 11.79 4.06E-02 
proteasomal ubiquitin-independent protein catabolic process  (GO:0010499) 25 14 1.41 9.91 5.47E-05 
negative regulation of mRNA splicing, via spliceosome  (GO:0048025) 21 10 1.19 8.42 2.56E-02 
negative regulation of mRNA processing  (GO:0050686) 30 14 1.7 8.25 3.24E-04 
interleukin-12-mediated signaling pathway  (GO:0035722) 46 19 2.6 7.31 6.16E-06 
cellular response to interleukin-12  (GO:0071349) 48 19 2.71 7 1.09E-05 
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response to interleukin-12  (GO:0070671) 49 19 2.77 6.86 1.44E-05 
negative regulation of mRNA metabolic process  (GO:1903312) 81 27 4.58 5.9 9.75E-08 
intermediate filament cytoskeleton organization  (GO:0045104) 46 15 2.6 5.77 4.67E-03 
antigen processing and presentation of exogenous peptide antigen via MHC 
class I, TAP-dependent  (GO:0002479) 75 24 4.24 5.66 2.69E-06 
intermediate filament-based process  (GO:0045103) 47 15 2.66 5.65 5.85E-03 
positive regulation of viral transcription  (GO:0050434) 41 13 2.32 5.61 3.43E-02 
spliceosomal complex assembly  (GO:0000245) 55 17 3.11 5.47 1.56E-03 
antigen processing and presentation of exogenous peptide antigen via MHC 
class I  (GO:0042590) 79 24 4.47 5.37 6.45E-06 
regulation of RNA stability  (GO:0043487) 181 53 10.23 5.18 1.45E-15 
RNA splicing, via transesterification reactions  (GO:0000375) 294 86 16.62 5.17 5.61E-27 
RNA stabilization  (GO:0043489) 48 14 2.71 5.16 3.32E-02 
regulation of mRNA stability  (GO:0043488) 175 51 9.89 5.15 8.37E-15 
regulation of cellular amino acid metabolic process  (GO:0006521) 62 18 3.51 5.14 1.50E-03 
mRNA splicing, via spliceosome  (GO:0000398) 291 84 16.45 5.11 6.13E-26 
RNA splicing, via transesterification reactions with bulged adenosine as 
nucleophile  (GO:0000377) 291 84 16.45 5.11 6.13E-26 
regulation of hematopoietic stem cell differentiation  (GO:1902036) 70 20 3.96 5.05 3.92E-04 
regulation of mRNA processing  (GO:0050684) 137 39 7.75 5.04 1.95E-10 
regulation of mRNA splicing, via spliceosome  (GO:0048024) 99 28 5.6 5 1.01E-06 
mRNA 3'-end processing  (GO:0031124) 82 23 4.64 4.96 5.22E-05 
antigen processing and presentation of peptide antigen via MHC class I  
(GO:0002474) 94 26 5.31 4.89 6.94E-06 
regulation of transcription from RNA polymerase II promoter in response to 
hypoxia  (GO:0061418) 76 21 4.3 4.89 2.95E-04 
negative regulation of protein dephosphorylation  (GO:0035308) 66 18 3.73 4.82 3.28E-03 
negative regulation of RNA catabolic process  (GO:1902369) 59 16 3.34 4.8 1.54E-02 
regulation of mRNA catabolic process  (GO:0061013) 197 53 11.14 4.76 3.29E-14 
regulation of hematopoietic progenitor cell differentiation  (GO:1901532) 82 22 4.64 4.75 2.19E-04 
RNA splicing  (GO:0008380) 391 104 22.11 4.7 2.63E-30 
regulation of cellular response to heat  (GO:1900034) 79 21 4.47 4.7 5.17E-04 
regulation of mRNA metabolic process  (GO:1903311) 322 85 18.2 4.67 5.50E-24 
negative regulation of phosphoprotein phosphatase activity  (GO:0032515) 61 16 3.45 4.64 2.22E-02 
cell redox homeostasis  (GO:0045454) 77 20 4.35 4.59 1.46E-03 
RNA export from nucleus  (GO:0006405) 131 34 7.41 4.59 7.90E-08 
mRNA export from nucleus  (GO:0006406) 109 28 6.16 4.54 6.50E-06 
mRNA-containing ribonucleoprotein complex export from nucleus  
(GO:0071427) 109 28 6.16 4.54 6.50E-06 
regulation of oxidative stress-induced cell death  (GO:1903201) 63 16 3.56 4.49 3.17E-02 
NIK/NF-kappaB signaling  (GO:0038061) 80 20 4.52 4.42 2.47E-03 
regulation of RNA splicing  (GO:0043484) 136 34 7.69 4.42 1.89E-07 
ribonucleoprotein complex export from nucleus  (GO:0071426) 128 32 7.24 4.42 7.30E-07 
positive regulation of viral process  (GO:0048524) 104 26 5.88 4.42 4.23E-05 
ribonucleoprotein complex localization  (GO:0071166) 129 32 7.29 4.39 8.66E-07 
nuclear export  (GO:0051168) 160 39 9.05 4.31 1.25E-08 
regulation of cellular amine metabolic process  (GO:0033238) 83 20 4.69 4.26 4.08E-03 
mRNA processing  (GO:0006397) 471 113 26.63 4.24 9.76E-30 
negative regulation of G2/M transition of mitotic cell cycle  (GO:0010972) 88 21 4.98 4.22 2.44E-03 
protein export from nucleus  (GO:0006611) 151 36 8.54 4.22 1.56E-07 
mRNA transport  (GO:0051028) 157 36 8.88 4.06 4.01E-07 
ribonucleoprotein complex subunit organization  (GO:0071826) 241 54 13.62 3.96 1.32E-11 
RNA transport  (GO:0050658) 197 44 11.14 3.95 6.16E-09 
nucleic acid transport  (GO:0050657) 197 44 11.14 3.95 6.16E-09 
regulation of stem cell differentiation  (GO:2000736) 112 25 6.33 3.95 5.65E-04 
anaphase-promoting complex-dependent catabolic process  (GO:0031145) 81 18 4.58 3.93 4.05E-02 
SCF-dependent proteasomal ubiquitin-dependent protein catabolic process  
(GO:0031146) 90 20 5.09 3.93 1.22E-02 
establishment of RNA localization  (GO:0051236) 199 44 11.25 3.91 8.29E-09 
ribonucleoprotein complex assembly  (GO:0022618) 227 50 12.83 3.9 2.64E-10 
negative regulation of cell cycle G2/M phase transition  (GO:1902750) 100 22 5.65 3.89 4.25E-03 
Wnt signaling pathway, planar cell polarity pathway  (GO:0060071) 96 21 5.43 3.87 8.33E-03 
nuclear transport  (GO:0051169) 252 54 14.25 3.79 6.56E-11 
tumor necrosis factor-mediated signaling pathway  (GO:0033209) 117 25 6.61 3.78 1.17E-03 
negative regulation of dephosphorylation  (GO:0035305) 113 24 6.39 3.76 2.28E-03 
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regulation of nucleocytoplasmic transport  (GO:0046822) 104 22 5.88 3.74 7.54E-03 
non-canonical Wnt signaling pathway  (GO:0035567) 133 28 7.52 3.72 2.77E-04 
RNA localization  (GO:0006403) 219 46 12.38 3.72 1.20E-08 
protein folding  (GO:0006457) 226 47 12.78 3.68 9.35E-09 
negative regulation of translation  (GO:0017148) 130 27 7.35 3.67 6.18E-04 
maintenance of location in cell  (GO:0051651) 97 20 5.48 3.65 3.29E-02 
positive regulation of canonical Wnt signaling pathway  (GO:0090263) 141 29 7.97 3.64 2.46E-04 
stimulatory C-type lectin receptor signaling pathway  (GO:0002223) 112 23 6.33 3.63 6.71E-03 
regulation of G2/M transition of mitotic cell cycle  (GO:0010389) 195 40 11.02 3.63 6.50E-07 
nucleocytoplasmic transport  (GO:0006913) 249 51 14.08 3.62 1.69E-09 
regulation of transcription from RNA polymerase II promoter in response to 
stress  (GO:0043618) 118 24 6.67 3.6 4.52E-03 
positive regulation of protein localization to membrane  (GO:1905477) 123 25 6.95 3.6 2.66E-03 
mRNA metabolic process  (GO:0016071) 683 138 38.61 3.57 3.27E-30 
regulation of DNA-templated transcription in response to stress  (GO:0043620) 124 25 7.01 3.57 3.04E-03 
antigen processing and presentation of exogenous peptide antigen  
(GO:0002478) 175 35 9.89 3.54 1.76E-05 
innate immune response activating cell surface receptor signaling pathway  
(GO:0002220) 115 23 6.5 3.54 9.98E-03 
regulation of cell cycle G2/M phase transition  (GO:1902749) 212 42 11.99 3.5 5.66E-07 
negative regulation of phosphatase activity  (GO:0010923) 106 21 5.99 3.5 3.28E-02 
DNA packaging  (GO:0006323) 174 34 9.84 3.46 4.99E-05 
RNA 3'-end processing  (GO:0031123) 134 26 7.58 3.43 3.40E-03 
posttranscriptional regulation of gene expression  (GO:0010608) 512 99 28.95 3.42 1.96E-19 
antigen processing and presentation of exogenous antigen  (GO:0019884) 182 35 10.29 3.4 4.28E-05 
regulation of gene silencing  (GO:0060968) 126 24 7.12 3.37 1.26E-02 
nucleosome assembly  (GO:0006334) 116 22 6.56 3.35 3.61E-02 
chromatin assembly  (GO:0031497) 132 25 7.46 3.35 8.36E-03 
antigen processing and presentation of peptide antigen  (GO:0048002) 185 35 10.46 3.35 6.18E-05 
negative regulation of cellular amide metabolic process  (GO:0034249) 148 28 8.37 3.35 1.94E-03 
platelet degranulation  (GO:0002576) 128 24 7.24 3.32 1.60E-02 
neutrophil degranulation  (GO:0043312) 483 90 27.31 3.3 1.86E-16 
positive regulation of Wnt signaling pathway  (GO:0030177) 173 32 9.78 3.27 4.29E-04 
neutrophil activation involved in immune response  (GO:0002283) 487 90 27.53 3.27 2.99E-16 
nucleosome organization  (GO:0034728) 153 28 8.65 3.24 3.51E-03 
viral process  (GO:0016032) 690 126 39.01 3.23 1.24E-23 
nucleobase-containing compound transport  (GO:0015931) 241 44 13.62 3.23 1.99E-06 
neutrophil mediated immunity  (GO:0002446) 494 90 27.93 3.22 6.79E-16 
leukocyte degranulation  (GO:0043299) 505 92 28.55 3.22 2.59E-16 
neutrophil activation  (GO:0042119) 496 90 28.04 3.21 8.56E-16 
symbiont process  (GO:0044403) 767 138 43.36 3.18 1.13E-25 
viral gene expression  (GO:0019080) 128 23 7.24 3.18 4.86E-02 
granulocyte activation  (GO:0036230) 501 90 28.32 3.18 1.52E-15 
myeloid leukocyte mediated immunity  (GO:0002444) 515 92 29.12 3.16 8.14E-16 
myeloid cell activation involved in immune response  (GO:0002275) 518 92 29.28 3.14 1.14E-15 
chromatin assembly or disassembly  (GO:0006333) 153 27 8.65 3.12 1.04E-02 
regulation of protein dephosphorylation  (GO:0035304) 137 24 7.75 3.1 4.49E-02 
DNA conformation change  (GO:0071103) 270 47 15.26 3.08 1.98E-06 
regulation of protein localization to membrane  (GO:1905475) 184 32 10.4 3.08 1.48E-03 
regulation of gene expression, epigenetic  (GO:0040029) 232 40 13.12 3.05 5.48E-05 
regulation of microtubule cytoskeleton organization  (GO:0070507) 186 32 10.52 3.04 1.84E-03 
translational initiation  (GO:0006413) 146 25 8.25 3.03 4.11E-02 
interspecies interaction between organisms  (GO:0044419) 810 138 45.79 3.01 1.34E-23 
positive regulation of multi-organism process  (GO:0043902) 182 31 10.29 3.01 3.44E-03 
response to unfolded protein  (GO:0006986) 159 27 8.99 3 1.99E-02 
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COPII-coated vesicle cargo loading  (GO:0090110) 13 11 1.13 9.76 6.68E-03 
formation of cytoplasmic translation initiation complex  (GO:0001732) 14 11 1.21 9.06 1.11E-02 
SRP-dependent cotranslational protein targeting to membrane  (GO:0006614) 97 67 8.41 7.96 3.37E-27 
cotranslational protein targeting to membrane  (GO:0006613) 102 68 8.85 7.69 5.69E-27 
establishment of protein localization to endoplasmic reticulum  (GO:0072599) 113 73 9.8 7.45 1.65E-28 
protein targeting to ER  (GO:0045047) 109 70 9.45 7.4 4.13E-27 
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay  
(GO:0000184) 120 77 10.41 7.4 4.47E-30 
vesicle cargo loading  (GO:0035459) 25 15 2.17 6.92 1.66E-03 
translational initiation  (GO:0006413) 146 87 12.66 6.87 1.56E-32 
protein localization to endoplasmic reticulum  (GO:0070972) 137 81 11.88 6.82 6.47E-30 
viral transcription  (GO:0019083) 114 67 9.89 6.78 3.66E-24 
viral gene expression  (GO:0019080) 128 75 11.1 6.76 2.64E-27 
protein exit from endoplasmic reticulum  (GO:0032527) 23 13 1.99 6.52 1.80E-02 
low-density lipoprotein particle clearance  (GO:0034383) 24 13 2.08 6.25 2.57E-02 
regulation of defense response to virus by virus  (GO:0050690) 30 16 2.6 6.15 2.19E-03 
cytoplasmic translation  (GO:0002181) 70 37 6.07 6.09 4.29E-11 
nuclear-transcribed mRNA catabolic process  (GO:0000956) 195 99 16.91 5.85 6.18E-33 
protein targeting to membrane  (GO:0006612) 160 79 13.88 5.69 4.38E-25 
antigen processing and presentation of peptide antigen via MHC class I  
(GO:0002474) 94 46 8.15 5.64 2.09E-13 
positive regulation of telomere maintenance via telomere lengthening  
(GO:1904358) 37 18 3.21 5.61 1.14E-03 
mRNA catabolic process  (GO:0006402) 211 101 18.3 5.52 5.61E-32 
positive regulation of telomere maintenance via telomerase  (GO:0032212) 34 16 2.95 5.43 7.99E-03 
vesicle budding from membrane  (GO:0006900) 96 45 8.33 5.4 1.62E-12 
protein N-linked glycosylation via asparagine  (GO:0018279) 32 15 2.78 5.4 1.81E-02 
antigen processing and presentation of exogenous peptide antigen via MHC 
class I, TAP-dependent  (GO:0002479) 75 35 6.5 5.38 3.93E-09 
antigen processing and presentation of exogenous peptide antigen via MHC 
class I  (GO:0042590) 79 36 6.85 5.25 3.18E-09 
peptidyl-asparagine modification  (GO:0018196) 33 15 2.86 5.24 2.44E-02 
Golgi vesicle budding  (GO:0048194) 77 35 6.68 5.24 7.14E-09 
COPII-coated vesicle budding  (GO:0090114) 69 31 5.98 5.18 1.81E-07 
vesicle coating  (GO:0006901) 67 30 5.81 5.16 4.05E-07 
positive regulation of telomere maintenance  (GO:0032206) 50 22 4.34 5.07 1.95E-04 
vesicle docking  (GO:0048278) 66 29 5.72 5.07 1.21E-06 
vesicle targeting  (GO:0006903) 89 39 7.72 5.05 8.96E-10 
RNA catabolic process  (GO:0006401) 242 106 20.99 5.05 4.72E-31 
regulation of cellular amino acid metabolic process  (GO:0006521) 62 27 5.38 5.02 6.06E-06 
vesicle fusion  (GO:0006906) 69 30 5.98 5.01 7.15E-07 
interleukin-12-mediated signaling pathway  (GO:0035722) 46 20 3.99 5.01 9.85E-04 
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COPII vesicle coating  (GO:0048208) 63 27 5.46 4.94 8.00E-06 
vesicle targeting, rough ER to cis-Golgi  (GO:0048207) 63 27 5.46 4.94 8.00E-06 
vesicle targeting, to, from or within Golgi  (GO:0048199) 70 30 6.07 4.94 9.44E-07 
positive regulation of substrate adhesion-dependent cell spreading  
(GO:1900026) 35 15 3.04 4.94 4.32E-02 
cortical actin cytoskeleton organization  (GO:0030866) 40 17 3.47 4.9 1.12E-02 
negative regulation of translation  (GO:0017148) 130 55 11.28 4.88 2.80E-14 
positive regulation of mRNA catabolic process  (GO:0061014) 45 19 3.9 4.87 2.92E-03 
cellular response to interleukin-12  (GO:0071349) 48 20 4.16 4.8 1.70E-03 
cell-substrate junction assembly  (GO:0007044) 41 17 3.56 4.78 1.47E-02 
endoplasmic reticulum organization  (GO:0007029) 51 21 4.42 4.75 9.95E-04 
response to interleukin-12  (GO:0070671) 49 20 4.25 4.71 2.22E-03 
regulation of mRNA stability  (GO:0043488) 175 71 15.18 4.68 2.36E-18 
establishment or maintenance of apical/basal cell polarity  (GO:0035088) 47 19 4.08 4.66 4.96E-03 
establishment or maintenance of bipolar cell polarity  (GO:0061245) 47 19 4.08 4.66 4.96E-03 
regulation of mRNA catabolic process  (GO:0061013) 197 79 17.09 4.62 1.82E-20 
organelle membrane fusion  (GO:0090174) 75 30 6.5 4.61 3.56E-06 
antigen processing and presentation of exogenous peptide antigen  
(GO:0002478) 175 70 15.18 4.61 8.80E-18 
regulation of telomere maintenance via telomerase  (GO:0032210) 55 22 4.77 4.61 7.51E-04 
IRE1-mediated unfolded protein response  (GO:0036498) 55 22 4.77 4.61 7.51E-04 
cortical cytoskeleton organization  (GO:0030865) 45 18 3.9 4.61 1.11E-02 
regulation of telomere maintenance via telomere lengthening  (GO:1904356) 63 25 5.46 4.58 1.14E-04 
ribosome assembly  (GO:0042255) 66 26 5.72 4.54 6.65E-05 
regulation of RNA stability  (GO:0043487) 181 71 15.7 4.52 1.09E-17 
tRNA aminoacylation for protein translation  (GO:0006418) 46 18 3.99 4.51 1.42E-02 
antigen processing and presentation of exogenous antigen  (GO:0019884) 182 71 15.79 4.5 1.40E-17 
antigen processing and presentation of peptide antigen  (GO:0048002) 185 72 16.05 4.49 8.12E-18 
establishment of protein localization to membrane  (GO:0090150) 261 101 22.64 4.46 6.10E-26 
vesicle docking involved in exocytosis  (GO:0006904) 44 17 3.82 4.45 3.17E-02 
establishment or maintenance of epithelial cell apical/basal polarity  
(GO:0045197) 44 17 3.82 4.45 3.17E-02 
regulation of hematopoietic stem cell differentiation  (GO:1902036) 70 27 6.07 4.45 4.95E-05 
negative regulation of cellular amide metabolic process  (GO:0034249) 148 57 12.84 4.44 2.12E-13 
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum  
(GO:0006890) 84 32 7.29 4.39 2.54E-06 
ubiquitin-dependent ERAD pathway  (GO:0030433) 66 25 5.72 4.37 2.40E-04 
regulation of telomere maintenance  (GO:0032204) 82 31 7.11 4.36 5.58E-06 
gene silencing by miRNA  (GO:0035195) 48 18 4.16 4.32 2.32E-02 
ribosomal large subunit biogenesis  (GO:0042273) 72 27 6.24 4.32 8.03E-05 
ribonucleoprotein complex assembly  (GO:0022618) 227 85 19.69 4.32 1.31E-20 
endoplasmic reticulum to Golgi vesicle-mediated transport  (GO:0006888) 206 77 17.87 4.31 2.23E-18 
posttranscriptional gene silencing  (GO:0016441) 59 22 5.12 4.3 2.01E-03 
ribonucleoprotein complex subunit organization  (GO:0071826) 241 89 20.9 4.26 2.28E-21 
ERAD pathway  (GO:0036503) 84 31 7.29 4.26 8.96E-06 
positive regulation of DNA biosynthetic process  (GO:2000573) 68 25 5.9 4.24 3.86E-04 
tRNA aminoacylation  (GO:0043039) 49 18 4.25 4.24 2.94E-02 
positive regulation of viral life cycle  (GO:1903902) 60 22 5.2 4.23 2.54E-03 
antigen processing and presentation  (GO:0019882) 213 78 18.47 4.22 3.29E-18 
regulation of hematopoietic progenitor cell differentiation  (GO:1901532) 82 30 7.11 4.22 1.96E-05 
posttranscriptional gene silencing by RNA  (GO:0035194) 58 21 5.03 4.17 5.57E-03 
chaperone-mediated protein folding  (GO:0061077) 58 21 5.03 4.17 5.57E-03 
gene silencing by RNA  (GO:0031047) 86 31 7.46 4.16 1.42E-05 
amino acid activation  (GO:0043038) 50 18 4.34 4.15 3.70E-02 
cell junction assembly  (GO:0034329) 164 59 14.22 4.15 7.48E-13 
organelle fusion  (GO:0048284) 92 33 7.98 4.14 4.73E-06 
nuclear envelope organization  (GO:0006998) 53 19 4.6 4.13 2.12E-02 
post-Golgi vesicle-mediated transport  (GO:0006892) 101 36 8.76 4.11 9.09E-07 
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regulation of transcription from RNA polymerase II promoter in response to 
hypoxia  (GO:0061418) 76 27 6.59 4.1 2.02E-04 
Wnt signaling pathway, planar cell polarity pathway  (GO:0060071) 96 34 8.33 4.08 3.42E-06 
regulation of mRNA metabolic process  (GO:1903311) 322 114 27.93 4.08 7.39E-27 
endosome to lysosome transport  (GO:0008333) 57 20 4.94 4.05 1.52E-02 
regulation of cellular amine metabolic process  (GO:0033238) 83 29 7.2 4.03 8.37E-05 
protein targeting  (GO:0006605) 351 122 30.44 4.01 2.42E-28 
antigen processing and presentation of exogenous peptide antigen via MHC 
class II  (GO:0019886) 98 34 8.5 4 5.31E-06 
positive regulation of mRNA metabolic process  (GO:1903313) 75 26 6.5 4 5.46E-04 
anaphase-promoting complex-dependent catabolic process  (GO:0031145) 81 28 7.03 3.99 1.81E-04 
antigen processing and presentation of peptide antigen via MHC class II  
(GO:0002495) 99 34 8.59 3.96 6.59E-06 
vascular endothelial growth factor receptor signaling pathway  (GO:0048010) 67 23 5.81 3.96 3.58E-03 
exocytic process  (GO:0140029) 70 24 6.07 3.95 2.05E-03 
neutrophil degranulation  (GO:0043312) 483 165 41.89 3.94 8.87E-39 
membrane docking  (GO:0022406) 177 60 15.35 3.91 3.86E-12 
neutrophil activation involved in immune response  (GO:0002283) 487 165 42.24 3.91 2.10E-38 
neutrophil mediated immunity  (GO:0002446) 494 167 42.85 3.9 8.14E-39 
viral process  (GO:0016032) 690 233 59.84 3.89 5.89E-56 
antigen processing and presentation of peptide or polysaccharide antigen via 
MHC class II  (GO:0002504) 101 34 8.76 3.88 1.01E-05 
vesicle organization  (GO:0016050) 295 99 25.59 3.87 1.73E-21 
Golgi vesicle transport  (GO:0048193) 365 122 31.66 3.85 4.88E-27 
neutrophil activation  (GO:0042119) 496 165 43.02 3.84 1.42E-37 
granulocyte activation  (GO:0036230) 501 166 43.45 3.82 1.21E-37 
leukocyte degranulation  (GO:0043299) 505 167 43.8 3.81 8.32E-38 
positive regulation of translation  (GO:0045727) 124 41 10.75 3.81 3.21E-07 
endoplasmic reticulum unfolded protein response  (GO:0030968) 100 33 8.67 3.8 2.65E-05 
vesicle-mediated transport to the plasma membrane  (GO:0098876) 88 29 7.63 3.8 2.42E-04 
cell junction organization  (GO:0034330) 210 69 18.21 3.79 9.17E-14 
myeloid leukocyte mediated immunity  (GO:0002444) 515 169 44.67 3.78 5.97E-38 
posttranscriptional regulation of gene expression  (GO:0010608) 512 168 44.41 3.78 1.07E-37 
nucleobase-containing compound catabolic process  (GO:0034655) 406 133 35.21 3.78 4.89E-29 
organelle localization by membrane tethering  (GO:0140056) 168 55 14.57 3.77 2.13E-10 
lysosomal transport  (GO:0007041) 98 32 8.5 3.76 5.65E-05 
ephrin receptor signaling pathway  (GO:0048013) 86 28 7.46 3.75 5.15E-04 
establishment of protein localization to organelle  (GO:0072594) 412 134 35.73 3.75 5.10E-29 
symbiont process  (GO:0044403) 767 249 66.52 3.74 1.70E-57 
regulation of translation  (GO:0006417) 342 111 29.66 3.74 1.94E-23 
positive regulation of protein localization to nucleus  (GO:1900182) 71 23 6.16 3.74 8.22E-03 
non-canonical Wnt signaling pathway  (GO:0035567) 133 43 11.54 3.73 1.96E-07 
protein folding  (GO:0006457) 226 73 19.6 3.72 2.23E-14 
myeloid cell activation involved in immune response  (GO:0002275) 518 167 44.93 3.72 1.20E-36 
negative regulation of mRNA metabolic process  (GO:1903312) 81 26 7.03 3.7 1.90E-03 
Golgi organization  (GO:0007030) 134 43 11.62 3.7 2.39E-07 
response to unfolded protein  (GO:0006986) 159 51 13.79 3.7 3.54E-09 
response to endoplasmic reticulum stress  (GO:0034976) 241 77 20.9 3.68 4.40E-15 
translation  (GO:0006412) 395 126 34.26 3.68 1.98E-26 
negative regulation of G2/M transition of mitotic cell cycle  (GO:0010972) 88 28 7.63 3.67 7.67E-04 
regulation of establishment of planar polarity  (GO:0090175) 110 35 9.54 3.67 1.96E-05 
positive regulation of cellular amide metabolic process  (GO:0034250) 145 46 12.58 3.66 6.78E-08 
response to topologically incorrect protein  (GO:0035966) 182 57 15.79 3.61 3.43E-10 
regulation of translational initiation  (GO:0006446) 77 24 6.68 3.59 8.51E-03 
mRNA metabolic process  (GO:0016071) 683 212 59.24 3.58 1.62E-45 
interspecies interaction between organisms  (GO:0044419) 810 249 70.25 3.54 9.15E-54 
entry into other organism involved in symbiotic interaction  (GO:0051828) 102 31 8.85 3.5 3.81E-04 
entry into cell of other organism involved in symbiotic interaction  
(GO:0051806) 102 31 8.85 3.5 3.81E-04 
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entry into host  (GO:0044409) 102 31 8.85 3.5 3.81E-04 
entry into host cell  (GO:0030260) 102 31 8.85 3.5 3.81E-04 
regulation of cellular amide metabolic process  (GO:0034248) 408 124 35.39 3.5 2.38E-24 
interaction with host  (GO:0051701) 158 48 13.7 3.5 8.54E-08 
regulation of stem cell differentiation  (GO:2000736) 112 34 9.71 3.5 8.83E-05 
exocytosis  (GO:0006887) 781 237 67.74 3.5 4.70E-50 
cellular response to unfolded protein  (GO:0034620) 122 37 10.58 3.5 2.05E-05 
protein localization to membrane  (GO:0072657) 479 145 41.54 3.49 7.16E-29 
membrane fusion  (GO:0061025) 129 39 11.19 3.49 8.22E-06 
peptide biosynthetic process  (GO:0043043) 418 126 36.25 3.48 1.62E-24 
cellular response to topologically incorrect protein  (GO:0035967) 143 43 12.4 3.47 1.33E-06 
NIK/NF-kappaB signaling  (GO:0038061) 80 24 6.94 3.46 1.49E-02 
regulation of mRNA processing  (GO:0050684) 137 41 11.88 3.45 3.96E-06 
endosome organization  (GO:0007032) 77 23 6.68 3.44 2.59E-02 
cell-cell junction assembly  (GO:0007043) 104 31 9.02 3.44 5.50E-04 
regulated exocytosis  (GO:0045055) 693 206 60.1 3.43 1.11E-41 
myeloid leukocyte activation  (GO:0002274) 573 170 49.7 3.42 1.46E-33 
cellular nitrogen compound catabolic process  (GO:0044270) 456 135 39.55 3.41 7.53E-26 
viral life cycle  (GO:0019058) 196 58 17 3.41 1.53E-09 
mRNA splicing, via spliceosome  (GO:0000398) 291 86 25.24 3.41 2.25E-15 
RNA splicing, via transesterification reactions with bulged adenosine as 
nucleophile  (GO:0000377) 291 86 25.24 3.41 2.25E-15 
heterocycle catabolic process  (GO:0046700) 455 134 39.46 3.4 1.90E-25 
aromatic compound catabolic process  (GO:0019439) 470 138 40.76 3.39 3.41E-26 
regulation of DNA biosynthetic process  (GO:2000278) 109 32 9.45 3.38 4.55E-04 
regulation of viral genome replication  (GO:0045069) 92 27 7.98 3.38 4.93E-03 
regulation of mRNA splicing, via spliceosome  (GO:0048024) 99 29 8.59 3.38 1.97E-03 
intracellular protein transport  (GO:0006886) 981 287 85.08 3.37 4.01E-59 
RNA splicing, via transesterification reactions  (GO:0000375) 294 86 25.5 3.37 3.85E-15 
regulation of cellular response to heat  (GO:1900034) 79 23 6.85 3.36 3.71E-02 
cell activation involved in immune response  (GO:0002263) 617 179 53.51 3.34 1.76E-34 
negative regulation of cell cycle G2/M phase transition  (GO:1902750) 100 29 8.67 3.34 2.35E-03 
endomembrane system organization  (GO:0010256) 397 115 34.43 3.34 6.73E-21 
leukocyte activation involved in immune response  (GO:0002366) 613 176 53.17 3.31 2.38E-33 
stimulatory C-type lectin receptor signaling pathway  (GO:0002223) 112 32 9.71 3.29 7.69E-04 
ribonucleoprotein complex biogenesis  (GO:0022613) 442 126 38.34 3.29 1.17E-22 
interleukin-1-mediated signaling pathway  (GO:0070498) 95 27 8.24 3.28 8.31E-03 
establishment of vesicle localization  (GO:0051650) 226 64 19.6 3.27 4.67E-10 
positive regulation of cell morphogenesis involved in differentiation  
(GO:0010770) 150 42 13.01 3.23 1.31E-05 
vesicle localization  (GO:0051648) 236 66 20.47 3.22 3.08E-10 
positive regulation of actin filament polymerization  (GO:0030838) 93 26 8.07 3.22 1.70E-02 
positive regulation of viral process  (GO:0048524) 104 29 9.02 3.22 4.65E-03 
innate immune response activating cell surface receptor signaling pathway  
(GO:0002220) 115 32 9.97 3.21 1.28E-03 
SCF-dependent proteasomal ubiquitin-dependent protein catabolic process  
(GO:0031146) 90 25 7.81 3.2 2.92E-02 
protein stabilization  (GO:0050821) 177 49 15.35 3.19 8.09E-07 
positive regulation of canonical Wnt signaling pathway  (GO:0090263) 141 39 12.23 3.19 6.64E-05 
viral entry into host cell  (GO:0046718) 94 26 8.15 3.19 2.00E-02 
positive regulation of protein localization to membrane  (GO:1905477) 123 34 10.67 3.19 6.02E-04 
vacuolar transport  (GO:0007034) 135 37 11.71 3.16 1.95E-04 
RNA localization  (GO:0006403) 219 60 18.99 3.16 9.33E-09 
protein localization to organelle  (GO:0033365) 705 193 61.15 3.16 1.52E-34 
RNA splicing  (GO:0008380) 391 107 33.91 3.16 1.18E-17 
modification of morphology or physiology of other organism involved in 
symbiotic interaction  (GO:0051817) 106 29 9.19 3.15 6.46E-03 
establishment or maintenance of cell polarity  (GO:0007163) 187 51 16.22 3.14 5.28E-07 
organic cyclic compound catabolic process  (GO:1901361) 503 137 43.63 3.14 2.78E-23 
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cell-cell junction organization  (GO:0045216) 136 37 11.8 3.14 2.29E-04 
regulation of RNA splicing  (GO:0043484) 136 37 11.8 3.14 2.29E-04 
peptide metabolic process  (GO:0006518) 558 151 48.4 3.12 9.54E-26 
amide biosynthetic process  (GO:0043604) 534 144 46.31 3.11 2.88E-24 
secretion by cell  (GO:0032940) 986 265 85.52 3.1 4.80E-48 
protein localization to plasma membrane  (GO:0072659) 179 48 15.52 3.09 3.10E-06 
regulation of G2/M transition of mitotic cell cycle  (GO:0010389) 195 52 16.91 3.07 6.84E-07 
establishment of organelle localization  (GO:0051656) 402 107 34.87 3.07 6.85E-17 
regulation of protein localization to cell periphery  (GO:1904375) 113 30 9.8 3.06 7.13E-03 
RNA transport  (GO:0050658) 197 52 17.09 3.04 9.34E-07 
nucleic acid transport  (GO:0050657) 197 52 17.09 3.04 9.34E-07 
ribonucleoprotein complex localization  (GO:0071166) 129 34 11.19 3.04 1.57E-03 
protein transport  (GO:0015031) 1480 390 128.36 3.04 1.26E-72 
intracellular transport  (GO:0046907) 1537 405 133.31 3.04 6.98E-76 
cytosolic transport  (GO:0016482) 141 37 12.23 3.03 5.03E-04 
establishment of RNA localization  (GO:0051236) 199 52 17.26 3.01 1.27E-06 
mRNA transport  (GO:0051028) 157 41 13.62 3.01 1.11E-04 
regulation of protein localization to membrane  (GO:1905475) 184 48 15.96 3.01 6.72E-06 
regulation of viral life cycle  (GO:1903900) 142 37 12.32 3 5.86E-04 
positive regulation of protein polymerization  (GO:0032273) 127 33 11.01 3 3.11E-03 
 
Table 2A-4. Human Protein Atlas1 ER annotated proteins and spectral counts 
identified in whole-cell and isolated ER samples.  
Uniprot ID Protein Description Whole Cell 
Isolated 
ER 
P14625 HSP90B1 Endoplasmin 8 215 
P07237 P4HB Protein disulfide-isomerase 257 203 
Q14697 GANAB Neutral alpha-glucosidase AB 2 151 
P30101 PDIA3 Protein disulfide-isomerase A3 12 119 
Q9NQC3 RTN4 Reticulon-4 10 104 
P27824 CANX Calnexin 4 94 
P05388 RPLP0 60S acidic ribosomal protein P0 0 92 
P36578 RPL4 60S ribosomal protein L4 0 83 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 0 79 
P27635 RPL10 60S ribosomal protein L10 0 78 
P50454 SERPINH1 Serpin H1 0 78 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 0 73 
Q86UP2 KTN1 Kinectin 95 65 
P15880 RPS2 40S ribosomal protein S2 0 63 
P05556 ITGB1 Integrin beta-1 17 60 
O43852 CALU Calumenin 65 52 
P04844 RPN2 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 0 46 
P62829 RPL23 60S ribosomal protein L23 0 44 
P0CW22 RPS17L 40S ribosomal protein S17-like 2 41 
P62847 RPS24 40S ribosomal protein S24 0 41 
Q16647 PTGIS Prostacyclin synthase 0 40 
Q6DD88 ATL3 Atlastin-3 0 39 
P00387 CYB5R3 NADH-cytochrome b5 reductase 3 0 38 
Q15293 RCN1 Reticulocalbin-1 65 37 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 0 36 
P18621 RPL17 60S ribosomal protein L17 0 35 
J3QL51 RPL17-C18ORF32 Protein RPL17-C18ORF32 0 35 
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P62081 RPS7 40S ribosomal protein S7 0 35 
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B 0 35 
P46778 RPL21 60S ribosomal protein L21 0 35 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 6 34 
P13667 PDIA4 Protein disulfide-isomerase A4 2 32 
Q9P2E9 RRBP1 Ribosome-binding protein 1 57 31 
P18124 RPL7 60S ribosomal protein L7 0 30 
Q15084 PDIA6 Protein disulfide-isomerase A6 0 30 
P14314 PRKCSH Glucosidase 2 subunit beta 74 29 
Q13162 PRDX4 Peroxiredoxin-4 40 29 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 21 29 
Q9P0L0 VAPA Vesicle-associated membrane protein-associated protein A 0 29 
P62263 RPS14 40S ribosomal protein S14 0 27 
P62841 RPS15 40S ribosomal protein S15 3 26 
Q9H0U4 RAB1B Ras-related protein Rab-1B 0 26 
P39656 DDOST Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 0 26 
P62249 RPS16 40S ribosomal protein S16 0 24 
Q07020 RPL18 60S ribosomal protein L18 0 24 
Q6PKG0 LARP1 La-related protein 1 6 23 
Q13724 MOGS Mannosyl-oligosaccharide glucosidase 0 23 
O94874 UFL1 E3 UFM1-protein ligase 1 0 21 
P62820 RAB1A Ras-related protein Rab-1A 0 21 
Q9P035 PTPLAD1 3-hydroxyacyl-CoA dehydratase 3 0 21 
P46777 RPL5 60S ribosomal protein L5 0 20 
P62280 RPS11 40S ribosomal protein S11 0 18 
P50914 RPL14 60S ribosomal protein L14 0 18 
O43169 CYB5B Cytochrome b5 type B 0 17 
Q12797 ASPH Aspartyl/asparaginyl beta-hydroxylase 0 17 
P62906 RPL10A 60S ribosomal protein L10a 0 16 
Q9NZ01 TECR Trans-2,3-enoyl-CoA reductase 0 15 
Q9H3N1 TMX1 Thioredoxin-related transmembrane protein 1 0 15 
P05386 RPLP1 60S acidic ribosomal protein P1 26 14 
O00264 PGRMC1 Membrane-associated progesterone receptor component 1 4 14 
P46782 RPS5 40S ribosomal protein S5 0 14 
Q96A33 CCDC47 Coiled-coil domain-containing protein 47 0 14 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 0 13 
P21964 COMT Catechol O-methyltransferase 0 13 
Q6UW68 TMEM205 Transmembrane protein 205 0 13 
Q96F07 CYFIP2 Cytoplasmic FMR1-interacting protein 2 0 12 
P62277 RPS13 40S ribosomal protein S13 0 12 
O15269 SPTLC1 Serine palmitoyltransferase 1 0 12 
Q13586 STIM1 Stromal interaction molecule 1 4 11 
Q15738 NSDHL Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating 0 11 
Q6PIU2 NCEH1 Neutral cholesterol ester hydrolase 1 0 11 
P46779 RPL28 60S ribosomal protein L28 0 11 
P30533 LRPAP1 Alpha-2-macroglobulin receptor-associated protein 18 10 
P11047 LAMC1 Laminin subunit gamma-1 8 10 
P51572 BCAP31 B-cell receptor-associated protein 31 0 10 
Q03518 TAP1 Antigen peptide transporter 1 0 10 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1 0 10 
P62917 RPL8 60S ribosomal protein L8 0 10 
Q96CS3 FAF2 FAS-associated factor 2 0 10 
Q9NYP7 ELOVL5 Elongation of very long chain fatty acids protein 5 0 9 
Q9UGP8 SEC63 Translocation protein SEC63 homolog 0 9 
O94905 ERLIN2 Erlin-2 0 9 
	 234	
Q9UKV5 AMFR E3 ubiquitin-protein ligase AMFR 0 9 
O75915 ARL6IP5 PRA1 family protein 3 0 9 
P23396 RPS3 40S ribosomal protein S3 0 9 
Q96HY6 DDRGK1 DDRGK domain-containing protein 1 0 9 
Q14318 FKBP8 Peptidyl-prolyl cis-trans isomerase FKBP8 0 9 
P26373 RPL13 60S ribosomal protein L13 0 9 
O95470 SGPL1 Sphingosine-1-phosphate lyase 1 0 9 
Q53EU6 AGPAT9 Glycerol-3-phosphate acyltransferase 3 0 9 
Q14257 RCN2 Reticulocalbin-2 14 8 
P50402 EMD Emerin 0 8 
P35610 SOAT1 Sterol O-acyltransferase 1 0 8 
Q96G23 CERS2 Ceramide synthase 2 0 8 
P83731 RPL24 60S ribosomal protein L24 0 8 
O15460 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 0 8 
Q96GC9 VMP1 Vacuole membrane protein 1 0 8 
P55145 MANF Mesencephalic astrocyte-derived neurotrophic factor 26 7 
P61247 RPS3A 40S ribosomal protein S3a 2 7 
P62979 RPS27A Ubiquitin-40S ribosomal protein S27a 0 7 
Q8NFQ8 TOR1AIP2 Torsin-1A-interacting protein 2 0 7 
P08123 COL1A2 Collagen alpha-2(I) chain 57 6 
Q9HCU5 PREB Prolactin regulatory element-binding protein 0 6 
Q14571 ITPR2 Inositol 1,4,5-trisphosphate receptor type 2 0 6 
Q6UWP7 LCLAT1 Lysocardiolipin acyltransferase 1 0 6 
P62266 RPS23 40S ribosomal protein S23 0 6 
Q8TCT9 HM13 Minor histocompatibility antigen H13 0 6 
P46776 RPL27A 60S ribosomal protein L27a 0 6 
Q03519 TAP2 Antigen peptide transporter 2 0 6 
Q70UQ0 IKBIP Inhibitor of nuclear factor kappa-B kinase-interacting protein 0 6 
Q8TCJ2 STT3B Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3B 0 6 
O15027 SEC16A Protein transport protein Sec16A 24 5 
P63220 RPS21 40S ribosomal protein S21 10 5 
Q9P265 DIP2B Disco-interacting protein 2 homolog B 0 5 
Q86XL3 ANKLE2 Ankyrin repeat and LEM domain-containing protein 2 0 5 
Q71UM5 RPS27L 40S ribosomal protein S27-like 0 5 
Q9Y2H6 FNDC3A Fibronectin type-III domain-containing protein 3A 0 5 
Q15043 SLC39A14 Zinc transporter ZIP14 0 5 
Q96S66 CLCC1 Chloride channel CLIC-like protein 1 0 5 
Q7L5N7 LPCAT2 Lysophosphatidylcholine acyltransferase 2 0 5 
P42677 RPS27 40S ribosomal protein S27 0 5 
P61254 RPL26 60S ribosomal protein L26 0 5 
Q86UE4 MTDH Protein LYRIC 0 5 
P28799 GRN Granulins 14 4 
P42330 AKR1C3 Aldo-keto reductase family 1 member C3 10 4 
P35030 PRSS3 Trypsin-3 6 4 
Q13443 ADAM9 Disintegrin and metalloproteinase domain-containing protein 9 0 4 
Q14BN4 SLMAP Sarcolemmal membrane-associated protein 0 4 
O95292 VAPB Vesicle-associated membrane protein-associated protein B/C 0 4 
P0CG08 GPR89B Golgi pH regulator B 0 4 
Q9UBS4 DNAJB11 DnaJ homolog subfamily B member 11 0 4 
Q9Y3U8 RPL36 60S ribosomal protein L36 0 4 
P43307 SSR1 Translocon-associated protein subunit alpha 0 4 
Q96D15 RCN3 Reticulocalbin-3 17 3 
P60866 RPS20 40S ribosomal protein S20 0 3 
Q13409 DYNC1I2 Cytoplasmic dynein 1 intermediate chain 2 0 3 
O43264 ZW10 Centromere/kinetochore protein zw10 homolog 0 3 
Q9UM00 TMCO1 Transmembrane and coiled-coil domain-containing protein 1 0 3 
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P61513 RPL37A 60S ribosomal protein L37a 0 3 
O75477 ERLIN1 Erlin-1 0 3 
O60831 PRAF2 PRA1 family protein 2 0 3 
Q8NHH9 ATL2 Atlastin-2 0 3 
P47755 CAPZA2 F-actin-capping protein subunit alpha-2 0 3 
P37268 FDFT1 Squalene synthase 0 3 
P63173 RPL38 60S ribosomal protein L38 0 3 
P62241 RPS8 40S ribosomal protein S8 0 3 
P61619 SEC61A1 Protein transport protein Sec61 subunit alpha isoform 1 0 3 
Q16850 CYP51A1 Lanosterol 14-alpha demethylase 0 3 
Q9BT22 ALG1 Chitobiosyldiphosphodolichol beta-mannosyltransferase 0 3 
Q96KA5 CLPTM1L Cleft lip and palate transmembrane protein 1-like protein 0 3 
P84098 RPL19 60S ribosomal protein L19 0 3 
Q92504 SLC39A7 Zinc transporter SLC39A7 0 3 
P62910 RPL32 60S ribosomal protein L32 0 3 
O00748 CES2 Cocaine esterase 0 3 
P29966 MARCKS Myristoylated alanine-rich C-kinase substrate 2 2 
Q99943 AGPAT1 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha 0 2 
Q27J81 INF2 Inverted formin-2 0 2 
Q6NUQ4 TMEM214 Transmembrane protein 214 0 2 
Q92575 UBXN4 UBX domain-containing protein 4 0 2 
reverse_P2328
4 PPIB Peptidyl-prolyl cis-trans isomerase B 0 2 
P62753 RPS6 40S ribosomal protein S6 0 2 
P54762 EPHB1 Ephrin type-B receptor 1 0 2 
Q16787 LAMA3 Laminin subunit alpha-3 0 2 
Q8N5K1 CISD2 CDGSH iron-sulfur domain-containing protein 2 0 2 
Q9NXW2 DNAJB12 DnaJ homolog subfamily B member 12 0 2 
Q9BUN8 DERL1 Derlin-1 0 2 
Q14696 MESDC2 LDLR chaperone MESD 0 2 
O95197 RTN3 Reticulon-3 0 2 
Q13438 OS9 Protein OS-9 0 2 
Q96KC8 DNAJC1 DnaJ homolog subfamily C member 1 0 2 
Q8NHP6 MOSPD2 Motile sperm domain-containing protein 2 0 2 
P20810 CAST Calpastatin 103 0 
P02768 ALB Serum albumin 16 0 
Q04828 AKR1C1 Aldo-keto reductase family 1 member C1 6 0 
O00193 SMAP Small acidic protein 4 0 









Table 2A-5. Filtered list of highly reactive (L:H <2.5) cysteine-containing peptides 
identified from secretory proteins using isoTOP-ABPP. The average light:heavy 
(L:H) ratio between two replicates treated with 100 µM (IA-light):10 µM (IA-
heavy) for ranking cysteine residues by reactivity is provided. Peptides were 
sorted by reactivity (low to high L:H ratio). Localization of parent proteins was 
determined using Uniprot and GO annotated tabs on UniprotKB. 
Uniprot 

















P17980 PSMC3 26S protease regulatory subunit 6A CTDDFNGAQCK 387 -- -- 0.62 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 LTTLPSDFCGLTHLVK 59 -- -- 0.73 
Q9NP72 RAB18 Ras-related protein Rab-18 TCDGVQCAFEELVEK 155 -- -- 0.84 
P61513 RPL37A 60S ribosomal protein L37a YTCSFCGK 39 -- -- 0.89 
E9PLN8 Uncharacterized protein ALCDVGTAISCSR 43 -- -- 0.91 
P46782 RPS5 40S ribosomal protein S5 AQCPIVER 66 -- YES 0.97 
P50914 RPL14 60S ribosomal protein L14 CMQLTDFILK 54 -- -- 0.97 
P60981 DSTN Destrin AVIFCLSADK 39 -- -- 0.99 
Q12974 PTP4A2 Protein tyrosine phosphatase type IVA 2 VCDATYDK 46 YES -- 1.01 
P30519 HMOX2 Heme oxygenase 2 GALEGSSCPFR 282 -- -- 1.01 
P09525 ANXA4 Annexin A4 GAGTDEGCLIEILASR 108 -- -- 1.02 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase IISNASCTTNCLAPLAK 152 -- YES 1.04 
P62280 RPS11 40S ribosomal protein S11 CPFTGNVSIR 60 -- YES 1.04 
O14950 MYL12B Myosin regulatory light chain 12B NAFACFDEEATGTIQEDYLR 109 -- -- 1.06 
Q8WUW
1 BRK1 Protein BRICK1 IADFLNSFDMSCR 43 -- -- 1.08 
Q9NRP0 OSTC Oligosaccharyltransferase complex subunit OSTC VPFLVLECPNLK 14 -- YES 1.09 
Q9NTJ5 SACM1L Phosphatidylinositide phosphatase SAC1 NAWADNANACAK 445 -- -- 1.09 
P62906 RPL10A 60S ribosomal protein L10a FSVCVLGDQQHCDEAK 66 -- YES 1.09 
P01111 NRAS GTPase NRas QVVIDGETCLLDILDTAGQEEYSAMR 51 -- -- 1.10 
Q96A33 CCDC47 Coiled-coil domain-containing protein 47 VCCEGMLIQLR 214 -- -- 1.11 
P30519 HMOX2 Heme oxygenase 2 CPFYAAEQDK 265 -- -- 1.13 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
SSWVMTCAYAPSGNYVACGGL
DNICSIYNLK 103 -- -- 1.13 
P61224 RAP1B Ras-related protein Rap-1b QWNNCAFLESSAK 141 -- -- 1.14 
P46776 RPL27A 60S ribosomal protein L27a NQSFCPTVNLDK 70 -- -- 1.15 
P18669 PGAM1 Phosphoglycerate mutase 1 YADLTEDQLPSCESLK 153 -- -- 1.16 
P50914 RPL14 60S ribosomal protein L14 ALVDGPCTQVR 42 -- -- 1.16 
P00338 LDHA L-lactate dehydrogenase A chain DDVFLSVPCILGQNGISDLVK 293 -- -- 1.18 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit LWDCETGK 81 -- -- 1.19 
P40925 MDH1 Malate dehydrogenase, cytoplasmic  AICDHVR 251 -- -- 1.21 
Q9H172 ABCG4 ATP-binding cassette sub-family G member 4 
MSCYIMQDDMLLPHLTVLEAM
MVSANLK 144 -- -- 1.21 
Q9Y490 TLN1 Talin-1 APGQLECETAIAALNSCLR 1661 -- -- 1.22 
O43795 MYO1B Unconventional myosin-Ib QAYEPCLER 641 -- -- 1.22 
Q00765 REEP5 Receptor expression-enhancing protein 5 NCMTDLLAK 18 -- -- 1.22 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K LFQECCPHSTDR 184 -- -- 1.23 
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O00592 PODXL Podocalyxin CGIR 395 -- -- 1.26 
P62330 ARF6 ADP-ribosylation factor 6 NWYVQPSCATSGDGLYEGLTWLTSNYK 155 -- -- 1.26 
P60709 ACTB Actin, cytoplasmic 1  CPEALFQPSFLGMESCGIHETTFNSIMK 257 -- -- 1.26 
Q6YHK3 CD109 CD109 antigen CFLEADPYIDIDQNVLHR 995 -- -- 1.26 
P13797 PLS3 Plastin-3 LGCR 349 -- -- 1.26 
O15144 ARPC2 Actin-related protein 2/3 complex subunit 2 NCFASVFEK 120 -- -- 1.27 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit 
ITSAVWGPLGECIIAGHESGELN
QYSAK 160 -- -- 1.27 
P62258 YWHAE 14-3-3 protein epsilon LICCDILDVLDK 97 -- YES 1.27 
Q9NQC3 RTN4 Reticulon-4 YSNSALGHVNCTIK 1101 -- YES 1.27 
P09486 SPARC SPARC LHLDYIGPCK 149 YES -- 1.28 
P39023 RPL3 60S ribosomal protein L3 TVFAEHISDECK 114 -- -- 1.29 
Q9NYP7 ELOVL5 Elongation of very long chain fatty acids protein YNFFCQGTR 96 -- -- 1.29 
P30041 PRDX6 Peroxiredoxin-6 DFTPVCTTELGR 47 -- -- 1.29 
Q07065 CKAP4 Cytoskeleton-associated protein 4 SSSSSSASAAAAAAAASSSASCSR 100 -- YES 1.30 
P15880 RPS2 40S ribosomal protein S2 GCTATLGNFAK 229 -- YES 1.34 
P50454 SERPINH1 Serpin H1 QHYNCEHSK 156 -- -- 1.34 
Q07020 RPL18 60S ribosomal protein L18 GCGTVLLSGPR 134 -- YES 1.35 
P18124 RPL7 60S ribosomal protein L7 YGIICMEDLIHEIYTVGK 186 -- -- 1.36 
Q9H223 EHD4 EH domain-containing protein 4 FMCSQLPNQVLK 141 -- -- 1.36 
Q15165 PON2 Serum paraoxonase/arylesterase 2 EVESVDLPHCHLIK 42 YES -- 1.36 
Q16647 PTGIS Prostacyclin synthase DHMCSVK 231 -- -- 1.37 
P30101 PDIA3 Protein disulfide-isomerase A3 FIQENIFGICPHMTEDNK 244 -- -- 1.38 
P62829 RPL23 60S ribosomal protein L23 ECADLWPR 125 -- YES 1.39 
O60493 SNX3 Sorting nexin-3 CLHMFLQDEIIDK 140 -- -- 1.40 
P16152 CBR1 Carbonyl reductase ILLNACCPGWVR 227 -- -- 1.40 
P42025 ACTR1B Beta-centractin YCFPNYVGR 34 -- -- 1.40 
P30519 HMOX2 Heme oxygenase 2 DMEYFFGENWEEQVQCPK 127 -- -- 1.41 
P08195 SLC3A2 4F2 cell-surface antigen heavy chain WCSWSLSQAR 431 -- YES 1.41 
P42677 RPS27 40S ribosomal protein S27 LTEGCSFR 77 -- YES 1.41 
P62280 RPS11 40S ribosomal protein S11 NMSVHLSPCFR 116 -- -- 1.42 
P06756 ITGAV Integrin alpha-V SQDIDADGQGFCQGGFSIDFTK 185 YES -- 1.42 
Q9UBG0 MRC2 C-type mannose receptor 2 CFQVQGQEPQSR 983 -- -- 1.43 
O95214 LEPROTL1 Leptin receptor overlapping transcript-like 1 LVDDTDAMSNACK 66 -- YES 1.43 
P0CW22 RPS17L 40S ribosomal protein S17-like VCEEIAIIPSK 35 -- YES 1.44 
P02462 COL4A1 Collagen alpha-1(IV) chain AHGQDLGTAGSCLR 1493 YES YES 1.46 
Q8NFQ8 TOR1AIP2 Torsin-1A-interacting protein 2 ISHLVLPVQPVSSIEEQGCLF 468 -- -- 1.47 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 ILYLDSSEICFPTVPGCPGAWDVDSENPQR 604 -- -- 1.47 
Q15286 RAB35 Ras-related protein Rab-35 WLHEINQNCDDVCR 110 -- -- 1.48 
P00338 LDHA L-lactate dehydrogenase A chain VIGSGCNLDSAR 163 -- YES 1.48 
P36578 RPL4 60S ribosomal protein L4 SGQGAFGNMCR 96 -- -- 1.49 
P50570 DNM2 Dynamin-2 LQDAFSSIGQSCHLDLPQIAVVGGQSAGK 27 -- -- 1.50 
P26006 ITGA3 Integrin alpha-3 TGAVYLCPLTAHK 94 YES -- 1.50 
P24752 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial  IHMGSCAENTAK 196 -- -- 1.51 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 VANILHDDCAFLSAFGDVSK 189 YES -- 1.51 




420 -- -- 1.52 
P23396 RPS3 40S ribosomal protein S3 GLCAIAQAESLR 97 -- YES 1.52 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 AVYSTNCPVWEEAFR 522 -- -- 1.52 
P32969 RPL9P9 60S ribosomal protein L9 PGVACSVSQAQK 134 -- -- 1.52 
P46777 RPL5 60S ribosomal protein L5 IYEGQVEVTGDEYNVESIDGQPGAFTCYLDAGLAR 144 -- -- 1.52 
Q9P2X0 DPM3 Dolichol-phosphate mannosyltransferase subunit 3 VATFHDCEDAAR 67 -- -- 1.52 
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P49721 PSMB2 Proteasome subunit beta type-2 NLADCLR 91 -- -- 1.52 
Q9H488 POFUT1 GDP-fucose protein O-fucosyltransferase 1 DGTAGSHFMASPQCVGYSR 267 YES -- 1.53 
Q92930 RAB8B Ras-related protein Rab-8B CDMNDK 123 -- -- 1.53 
P78344 EIF4G2 Eukaryotic translation initiation factor 4 gamma 2 
QEGIATSDNFMQAFLNVLDQC
PK 629 -- -- 1.53 
P20338 RAB4A Ras-related protein Rab-4A FAQENELMFLETSALTGENVEEAFVQCAR 170 -- -- 1.53 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 ATILDLSCNK 48 -- -- 1.53 
P29992 GNA11 Guanine nucleotide-binding protein subunit alpha-1 TLWEDPGIQECYDR 144 -- YES 1.54 
P08238 HSP90AB1 Heat shock protein HSP 90-beta LVSSPCCIVTSTYGWTANMER 589 -- -- 1.54 
P61224 RAP1B Ras-related protein Rap-1b QVEVDAQQCMLEILDTAGTEQFTAMR 51 -- -- 1.55 
P35221 CTNNA1 Catenin alpha-1 TIADHCPDSACK 767 -- -- 1.56 
P07099 EPHX1 Epoxide hydrolase 1 NHGLSDEHVFEVICPSIPGYGFSEASSK 182 -- -- 1.57 
P05141 SLC25A5 ADP/ATP translocase 2 GTDIMYTGTLDCWR 257 -- -- 1.58 
P22307 SCP2 Non-specific lipid-transfer protein ADCTITMADSDFLALMTGK 495 -- -- 1.58 
P50395 GDI2 Rab GDP dissociation inhibitor beta TDDYLDQPCYETINR 202 -- YES 1.60 
Q6UW02 CYP20A1 Cytochrome P450 20A1 YCQHVLCETVR 326 -- -- 1.60 
P61586 RHOA Transforming protein RhoA IGAFGYMECSAK 159 -- -- 1.61 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
QTFTGHESDINAICFFPNGNAF
ATGSDDATCR 233 -- -- 1.61 
P46782 RPS5 40S ribosomal protein S5 TIAECLADELINAAK 172 -- YES 1.61 
Q14697 GANAB Neutral alpha-glucosidase AB SSECMK 822 -- -- 1.62 
P39656 DDOST Dolichyl-diphosphooligosaccharide--protein glycosy ELGSECGIEFDEEK 145 -- -- 1.62 
P46777 RPL5 60S ribosomal protein L5 VGLTNYAAAYCTGLLLAR 100 -- YES 1.62 
P60866 RPS20 40S ribosomal protein S20 TPCGEGSK 70 -- YES 1.63 
P50990 CCT8 T-complex protein 1 subunit theta AHEILPNLVCCSAK 148 -- -- 1.63 
Q6P9B6 KIAA1609 TLD domain-containing protein KIAA1609 
SFCSQFLPEEQAEIDQLFDALSS
DK 13 -- -- 1.63 
Q13561 DCTN2 Dynactin subunit 2 C*DQDAQNPLSAGLQGAC*LMETVELLQAK 240 -- -- 1.64 
P61247 RPS3A 40S ribosomal protein S3a NCLTNFHGMDLTR 96 -- -- 1.64 
P35610 SOAT1 Sterol O-acyltransferase 1 SASLDNGGCALTTFSVLEGEK 92 -- -- 1.64 
P15144 ANPEP Aminopeptidase N SFPCFDEPAMK 223 -- -- 1.65 
P23258 TUBG1 Tubulin gamma-1 chain EADGSDSLEGFVLCHSIAGGTGSGLGSYLLER 138 -- -- 1.66 
O15533 TAPBP Tapasin WASGLTPAQNCPR 115 YES -- 1.67 
Q9NP72 RAB18 Ras-related protein Rab-18 LDNWLNELETYCTR 110 -- -- 1.67 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 SVNSLDGLASVLYPGCDTLDK 85 -- -- 1.68 
Q9NZN4 EHD2 EH domain-containing protein 2 VGPEPTTDCFVAVMHGDTEGTVPGNALVVDPDK 96 -- -- 1.68 
O15243 LEPROT Leptin receptor gene-related protein VTYDSDATSSACR 66 -- YES 1.68 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al 
SPLTICYPEYTGSNTYEEAAAYI
QCQFEDLNR 286 -- -- 1.68 
P54920 NAPA Alpha-soluble NSF attachment protein IEEACEIYAR 42 -- -- 1.68 
Q8TC12 RDH11 Retinol dehydrogenase 11 FYNAGLAYCHSK 203 -- -- 1.69 
Q7Z7H5 TMED4 Transmembrane emp24 domain-containing protein 4 CFIEEIPDETMVIGNYR 41 -- -- 1.70 
P60953 CDC42 Cell division control protein 42 homolog YVECSALTQK 157 -- YES 1.70 
P07099 EPHX1 Epoxide hydrolase 1 FTPPLEDSCFHYGFNSNYLK 80 -- -- 1.71 
P35268 RPL22 60S ribosomal protein L22 FTLDCTHPVEDGIMDAANFEQFLQER 25 -- -- 1.71 
P62829 RPL23 60S ribosomal protein L23 ISLGLPVGAVINCADNTGAK 28 -- YES 1.71 
P46459 NSF Vesicle-fusing ATPase SQLSCVVVDDIER 599 -- -- 1.72 
O96011 PEX11B Peroxisomal membrane protein 11B LLMEQESSACSR 153 -- -- 1.72 
P60604 UBE2G2 Ubiquitin-conjugating enzyme E2 G2 FTCEMFHPNIYPDGR 75 -- -- 1.72 
P05388 RPLP0 60S acidic ribosomal protein P0 AGAIAPCEVTVPAQNTGLGPEK 119 -- YES 1.73 
P07437 TUBB Tubulin beta chain VSDTVVEPYNATLSVHQLVENTDETYCIDNEALYDICFR 201 -- -- 1.73 
P62249 RPS16 40S ribosomal protein S16 TATAVAHCK 25 -- YES 1.73 
P08572 COL4A2 Collagen alpha-2(IV) chain AHNQDLGLAGSCLAR 1537 YES -- 1.74 
P61026 RAB10 Ras-related protein Rab-10 CDMDDK 124 -- -- 1.75 
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P36578 RPL4 60S ribosomal protein L4 GPCIIYNEDNGIIK 208 -- -- 1.76 
P17987 TCP1 T-complex protein 1 subunit alpha GANDFMCDEMER 385 -- -- 1.76 
P61106 RAB14 Ras-related protein Rab-14 FMADCPHTIGVEFGTR 40 -- -- 1.76 
P14868 DARS Aspartate--tRNA ligase, cytoplasmic  QFPCEPFK 334 -- -- 1.76 
P62333 PSMC6 26S protease regulatory subunit 10B AVASQLDCNFLK 193 -- -- 1.76 
P15880 RPS2 40S ribosomal protein S2 LLMMAGIDDCYTSAR 222 -- -- 1.76 
P61106 RAB14 Ras-related protein Rab-14 SCLLHQFTEK 26 -- -- 1.77 
Q969X5 ERGIC1 Endoplasmic reticulum-Golgi intermediate compartme IPLNNGAGCR 115 -- -- 1.77 
P36578 RPL4 60S ribosomal protein L4 YAICSALAASALPALVMSK 125 -- -- 1.78 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 VAGDCLDEK 131 -- -- 1.78 
P51153 RAB13 Ras-related protein Rab-13 CDMEAK 123 -- -- 1.78 
P62820 RAB1A Ras-related protein Rab-1A CDLTTK 126 -- -- 1.78 
P22626 HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1 LTDCVVMR 50 -- -- 1.79 
P48509 CD151 CD151 antigen VEGGCITK 208 -- -- 1.79 
P57721 PCBP3 Poly(rC)-binding protein 3 LVVPASQCGSLIGK 141 -- YES 1.79 
P05388 RPLP0 60S acidic ribosomal protein P0 CFIVGADNVGSK 27 -- -- 1.80 
P62280 RPS11 40S ribosomal protein S11 DVQIGDIVTVGECR 131 -- YES 1.80 
P40925 MDH1 Malate dehydrogenase, cytoplasmic  ENFSCLTR 154 -- -- 1.80 
Q99832 CCT7 T-complex protein 1 subunit eta QLCDNAGFDATNILNK 450 -- -- 1.81 
P51659 HSD17B4 Peroxisomal multifunctional enzyme type 2 FIYEGSSDFSCLPTFGVIIGQK 373 -- -- 1.81 
Q6YHK3 CD109 CD109 antigen FEVTLQTPLYCSMNSK 239 -- -- 1.82 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1 MYGAQEDGSVGEGDLSCILK 443 -- -- 1.82 
Q15286 RAB35 Ras-related protein Rab-35 ENVNVEEMFNCITELVLR 163 -- -- 1.82 
Q9UNH
7 SNX6 Sorting nexin-6 IGSSLYALGTQDSTDICK 264 -- -- 1.83 
P30041 PRDX6 Peroxiredoxin-6 DINAYNCEEPTEK 91 -- -- 1.83 
P36507 MAP2K2 Dual specificity mitogen-activated protein kinase LCDFGVSGQLIDSMANSFVGTR 211 -- -- 1.84 
P36578 RPL4 60S ribosomal protein L4 FCIWTESAFR 250 -- YES 1.84 
Q9NUP9 LIN7C Protein lin-7 homolog C VLQSEFCNAVR 47 -- -- 1.84 
P21281 ATP6V1B2 V-type proton ATPase subunit B, brain isoform  TSCEFTGDILR 112 -- -- 1.84 
P35998 PSMC2 26S protease regulatory subunit 7 PDVTYSDVGGCK 180 -- -- 1.84 
P35222 CTNNB1 Catenin beta-1 EDITEPAICALR 466 -- YES 1.84 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 PCTLSELE 528 -- -- 1.84 
Q96CW1 AP2M1 AP-2 complex subunit mu SYLSGMPECK 212 -- -- 1.85 
Q9P258 RCC2 Protein RCC2 AVQDLCGWR 428 -- YES 1.85 
P39060 COL18A1 Collagen alpha-1(XVIII) chain LTESYCETWR 1706 YES -- 1.85 
Q99536 VAT1 Synaptic vesicle membrane protein VAT-1 homolog ACGLNFADLMAR 86 -- -- 1.85 
O00299 CLIC1 Chloride intracellular channel protein 1 IGNCPFSQR 24 YES YES 1.87 
Q14697 GANAB Neutral alpha-glucosidase AB TCEESSFCK 41 YES -- 1.87 
P21796 VDAC1 Voltage-dependent anion-selective channel protein EHINLGCDMDFDIAGPSIR 127 -- -- 1.88 
A0FGR8 ESYT2 Extended synaptotagmin-2 DEQHQCSLGNLK 611 -- -- 1.88 
P61158 ACTR3 Actin-related protein 3 DYEEIGPSICR 408 -- -- 1.88 
Q9BW60 ELOVL1 Elongation of very long chain fatty acids protein CDPVDYSNSPEALR 93 -- -- 1.88 
Q8WVM
8 SCFD1 Sec1 family domain-containing protein 1 ALTDAGCNLNPLQYIK 485 -- -- 1.89 
P61769 B2M Beta-2-microglobulin SNFLNCYVSGFHPSDIEVDLLK 45 YES -- 1.90 
Q13308 PTK7 Inactive tyrosine-protein kinase 7 LPQPEGCPSK 1032 -- -- 1.91 
Q9UIQ6 LNPEP Leucyl-cystinyl aminopeptidase QSPDGACSVPSAR 103 -- YES 1.91 
Q6PIU2 NCEH1 Neutral cholesterol ester hydrolase 1 ICISGDSAGGNLAAALGQQFTQDASLK 186 -- -- 1.91 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) LLLAGYDDFNCNVWDALK 294 -- -- 1.92 
P62753 RPS6 40S ribosomal protein S6 LNISFPATGCQK 12 -- -- 1.92 
Q16181 SEPT7 Septin-7 QYPWGVAEVENGEHCDFTILR 280 -- -- 1.92 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 AGSDGESIGNCPFSQR 35 -- -- 1.92 
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Q96AC1 FERMT2 Fermitin family homolog 2 MQHLNPDPQLIPEQITTDITPECLVSPR 520 -- -- 1.92 
P07711 CTSL1 Cathepsin L1 NHCGIASAASYPTV 322 YES -- 1.92 
Q2M389 KIAA1033 WASH complex subunit 7 SGGLHCSSNAIR 936 -- -- 1.93 
P26885 FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2 GWDQGLLGMCEGEK 97 -- -- 1.93 
Q9NP72 RAB18 Ras-related protein Rab-18 TC*DGVQC*AFEELVEK 155 -- -- 1.93 
Q9Y3U8 RPL36 60S ribosomal protein L36 EVCGFAPYER 48 -- YES 1.93 
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 CLDDHK 141 -- -- 1.93 
P07355 ANXA2 Annexin A2 GDLENAFLNLVQCIQNK 262 -- -- 1.95 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) LLLAGYDDFNCNIWDAMK 294 -- -- 1.95 
P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  CTHWAEGGK 785 -- -- 1.95 
Q6JUT2 TIRAP3 TIR domain-containing adapter molecule 2 QCFYEDIAQGTK 0 -- -- 1.95 
P30086 PEBP1 Phosphatidylethanolamine-binding protein 1 APVAGTCYQAEWDDYVPK 168 -- -- 1.95 
O00429 DNM1L Dynamin-1-like protein CVELVHEEMQR 431 -- -- 1.96 
Q12907 LMAN2 Vesicular integral-membrane protein VIP36 WTELAGCTADFR 202 YES -- 1.96 
P61247 RPS3A 40S ribosomal protein S3a ACQSIYPLHDVFVR 201 -- YES 1.96 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta VEFLECSAK 246 -- -- 1.96 
P51149 RAB7A Ras-related protein Rab-7a AQAWCYSK 143 -- -- 1.96 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 GTINFLHADCDK 301 YES -- 1.96 
O75521 ECI2 Enoyl-CoA delta isomerase 2, mitochondrial  LHAVNAEECNVLQGR 368 -- -- 1.96 
Q15149 PLEC Plectin CDNFTSSWR 317 -- -- 1.97 
P61158 ACTR3 Actin-related protein 3 YSYVCPDLVK 235 -- -- 1.97 
P09486 SPARC SPARC FFETCDLDNDK 273 YES -- 1.98 
P40429 RPL13A 60S ribosomal protein L13a CEGINISGNFYR 38 -- -- 1.98 
Q6PIU2 NCEH1 Neutral cholesterol ester hydrolase 1 TYILTCEHDVLR 345 -- -- 1.98 
P61224 RAP1B Ras-related protein Rap-1b CDLEDER 118 -- -- 1.98 
Q8NEW
0 SLC30A7 Zinc transporter 7 TPPLLENSLPQCYQR 308 -- -- 1.98 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) ELPGHTGYLSCCR 148 -- -- 1.98 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit HVLTGSADNSCR 76 -- -- 1.99 
Q15149 PLEC Plectin YSCDR 888 -- -- 1.99 
O75521 ECI2 Enoyl-CoA delta isomerase 2, mitochondrial  WLSDECTNAVVNFLSR 380 -- -- 2.00 
P09651 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 SHFEQWGTLTDCVVMR 43 -- -- 2.00 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- YWLCAATGPSIK 249 -- -- 2.00 
P15121 AKR1B1 Aldose reductase VCALLSCTSHK 304 -- -- 2.00 
P04083 ANXA1 Annexin A1 MYGISLCQAILDETK 324 YES -- 2.00 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1 LPADTCLLEFAR 330 -- -- 2.01 
P27635 RPL10 60S ribosomal protein L10 VDEFPLCGHMVSDEYEQLSSEALEAAR 49 -- -- 2.01 
Q9NV70 EXOC1 Exocyst complex component 1 IFEQVLSELEPLCLAEQDFISK 526 -- -- 2.01 
Q4ZIN3 C19orf6 Membralin APVFLQFCDSGGR 129 -- -- 2.02 
O60716 CTNND1 Catenin delta-1 SNAAAYLQHLCYR 394 -- YES 2.02 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 HEASDFPCR 32 -- -- 2.02 
P10620 MGST1 Microsomal glutathione S-transferase 1 VFANPEDCVAFGK 50 -- -- 2.03 
P62917 RPL8 60S ribosomal protein L8 TELFIAAEGIHTGQFVYCGK 90 -- -- 2.03 
P14625 HSP90B1 Endoplasmin LTESPCALVASQYGWSGNMER 645 -- -- 2.03 
P21796 VDAC1 Voltage-dependent anion-selective channel protein YQIDPDACFSAK 232 -- -- 2.04 
Q96A33 CCDC47 Coiled-coil domain-containing protein 47 EMQDLSEFCSDK 283 -- -- 2.04 
Q8NBJ7 SUMF2 Sulfatase-modifying factor 2 CAADAGR 290 YES -- 2.04 
P04439 HLA-A HLA class I histocompatibility antigen, A-3 alpha  AYLDGTCVEWLR 188 YES -- 2.05 
Q02543 RPL18A 60S ribosomal protein L18a DLTTAGAVTQCYR 109 -- YES 2.05 
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Q9Y2A7 NCKAP1 Nck-associated protein 1 VAMNVYELSSAAGLPCEIDPALVVALSSQK 969 -- -- 2.05 
P30101 PDIA3 Protein disulfide-isomerase A3 VDCTANTNTCNK 85 YES -- 2.05 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
AEPPQCTSLAWSADGQTLFAG
YTDNLVR 286 -- -- 2.05 
Q9UKV5 AMFR E3 ubiquitin-protein ligase AMFR SWLEQDTSCPTCR 378 -- -- 2.06 
Q16181 SEPT7 Septin-7 EGGVQLLLTIVDTPGFGDAVDNSNCWQPVIDYIDSK 126 -- -- 2.07 
O43237 DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2 CNVWILDGDLYHK 104 -- -- 2.08 
P07900 HSP90AA1 Heat shock protein HSP 90-alpha LVTSPCCIVTSTYGWTANMER 597 -- -- 2.08 
P37268 FDFT1 Squalene synthase TQNLPNCQLISR 374 -- -- 2.08 
P83731 RPL24 60S ribosomal protein L24 VELCSFSGYK 6 -- -- 2.08 
P27635 RPL10 60S ribosomal protein L10 MLSCAGADR 105 -- -- 2.09 
P37802 TAGLN2 Transgelin-2 DGTVLCELINALYPEGQAPVK 63 -- -- 2.09 
Q01518 CAP1 Adenylyl cyclase-associated protein 1 ALLVTASQCQQPAENK 93 -- YES 2.09 
Q10567 AP1B1 AP-1 complex subunit beta-1 DCPLNAEAASSK 866 -- -- 2.09 
P04844 RPN2 Dolichyl-diphosphooligosaccharide--protein glycosy 
SNLDPSNVDSLFYAAQASQALS
GCEISISNETK 100 -- -- 2.09 
P30050 RPL12 60S ribosomal protein L12 CTGGEVGATSALAPK 17 -- -- 2.10 
Q15019 SEPT2 Septin-2 LTVVDTPGYGDAINCR 111 -- -- 2.10 
P14618 PKM Pyruvate kinase isozymes M1/M2 GIFPVLCK 474 -- YES 2.10 
Q6UX07 DHRS13 Dehydrogenase/reductase SDR family member 13 VVVVASAAHCR 174 -- -- 2.11 
P30040 ERP29 Endoplasmic reticulum resident protein 29 GQGVYLGMPGCLPVYDALAGEFIR 157 -- -- 2.11 
P60174 TPI1 Triosephosphate isomerase DCGATWVVLGHSER 124 -- YES 2.11 
P20645 M6PR Cation-dependent mannose-6-phosphate receptor AVVMISCNR 145 -- -- 2.11 
P68104 EEF1A1 Elongation factor 1-alpha 1 PMCVESFSDYPPLGR 411 -- YES 2.11 
P46776 RPL27A 60S ribosomal protein L27a SVGGACVLVA 144 -- YES 2.12 
Q53GQ0 HSD17B12 Estradiol 17-beta-dehydrogenase 12 TFVDFFSQCLHEEYR 215 -- -- 2.12 
P60903 S100A10 Protein S100-A10 DLDQCR 62 -- -- 2.13 
Q9UBI6 GNG12 Guanine nucleotide-binding protein G(I)/G(S)/G(O) ASADLMSYCEEHAR 43 -- -- 2.13 
Q9NX62 IMPAD1 Inositol monophosphatase 3 WDICAGNAILK 302 -- -- 2.13 
P16435 POR NADPH--cytochrome P450 reductase EQFWPAVCEHFGVEATGEESSIR 228 -- -- 2.14 
P08134 RHOC Rho-related GTP-binding protein RhoC LVIVGDGACGK 16 -- YES 2.14 
P23396 RPS3 40S ribosomal protein S3 GCEVVVSGK 134 -- YES 2.14 
O00560 SDCBP Syntenin-1 NGLLTEHNICEINGQNVIGLK 239 -- -- 2.15 
P37108 SRP14 Signal recognition particle 14 kDa protein CLLR 56 -- -- 2.15 
P07355 ANXA2 Annexin A2 GLGTDEDSLIEIICSR 133 -- YES 2.15 
P55735 SEC13 Protein SEC13 homolog FASGGCDNLIK 187 -- -- 2.16 
Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3 NLSGQPNFPCR 428 -- -- 2.16 
Q9Y6W5 WASF2 Wiskott-Aldrich syndrome protein family member 2 SELECVTNITLANVIR 27 -- -- 2.17 
Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3 YFSLPFCVGSK 66 -- -- 2.17 
P08123 COL1A2 Collagen alpha-2(I) chain LSHPEWSSGYYWIDPNQGCTMDAIK 1186 YES -- 2.17 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosy TEGSDLCDR 545 -- -- 2.17 
Q14764 MVP Major vault protein HYCTVANPVSR 59 -- -- 2.17 
Q9Y5X1 SNX9 Sorting nexin-9 IPIIVGDYGPMWVYPTSTFDCVVADPR 252 -- -- 2.17 
Q6JUT2 TIRAP3 TIR domain-containing adapter molecule 2 VSALTQMESACVSIHEALK 0 -- -- 2.18 
O15260 SURF4 Surfeit locus protein 4 LCLISTFLEDGIR 32 -- YES 2.19 
P27797 CALR Calreticulin HEQNIDCGGGYVK 105 YES -- 2.19 
Q9H1C4 UNC93B1 Protein unc-93 homolog B1 PCPYEQAQGGDGPEEQ 583 -- -- 2.20 
O60504 SORBS3 Vinexin LCDDGPQLPTSPR 521 -- -- 2.20 
P06733 ENO1 Alpha-enolase SGETEDTFIADLVVGLCTGQIK 389 -- YES 2.20 
P11216 PYGB Glycogen phosphorylase, brain form  TCAYTNHTVLPEALER 373 -- -- 2.21 
P08758 ANXA5 Annexin A5 ALLLLCGEDD 316 -- -- 2.21 
O95782 AP2A1 AP-2 complex subunit alpha-1 TVFEALQAPACHENMVK 492 -- -- 2.21 
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A0FGR8 ESYT2 Extended synaptotagmin-2 ACDLPAWVHFPDTER 181 -- -- 2.22 
P01116 KRAS GTPase KRas CDLPSR 118 -- -- 2.22 
P01111 NRAS GTPase NRas CDLPTR 118 -- -- 2.22 
P31949 S100A11 Protein S100-A11 CIESLIAVFQK 13 YES -- 2.22 
Q99832 CCT7 T-complex protein 1 subunit eta EGTDSSQGIPQLVSNISACQVIAEAVR 29 -- -- 2.22 
O60884 DNAJA2 DnaJ homolog subfamily A member 2 VIEPGCVR 308 -- -- 2.22 
Q7L7X3 TAOK1 Serine/threonine-protein kinase TAO1 NFVDSCLQK 261 -- -- 2.22 
P62888 RPL30 60S ribosomal protein L30 LVILANNCPALR 52 -- YES 2.23 
P11279 LAMP1 Lysosome-associated membrane glycoprotein 1 CNAEEHVR 338 YES -- 2.24 
Q15417 CNN3 Calponin-3 DGIILCELINK 59 -- -- 2.24 
P25398 RPS12 40S ribosomal protein S12 QAHLCVLASNCDEPMYVK 56 -- -- 2.24 
P32004 L1CAM Neural cell adhesion molecule L1 CLAENSLGSAR 312 YES -- 2.25 
Q9ULC3 RAB23 Ras-related protein Rab-23 IDLLDDSCIK 130 -- -- 2.25 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase VPTANVSVVDLTCR 247 -- YES 2.25 
Q99832 CCT7 T-complex protein 1 subunit eta DMFCAGR 310 -- -- 2.26 
Q99523 SORT1 Sortilin SAPGEDEECGR 86 YES -- 2.26 
P49207 RPL34 60S ribosomal protein L34 AYGGSMCAK 83 -- -- 2.27 
Q9Y230 RUVBL2 RuvB-like 2 FVQCPDGELQK 227 -- -- 2.27 
P46782 RPS5 40S ribosomal protein S5 VNQAIWLLCTGAR 155 -- -- 2.27 
P04075 ALDOA Fructose-bisphosphate aldolase A ALANSLACQGK 339 -- YES 2.28 
Q9UHG3 PCYOX1 Prenylcysteine oxidase 1 VNYGQSTDINAFVGAVSLSCSDSGLWAVEGGNK 242 -- -- 2.28 
P27797 CALR Calreticulin LFPNSLDQTDMHGDSEYNIMFGPDICGPGTK 137 YES -- 2.28 
P49257 LMAN1 Protein ERGIC-53 NNPAIVIIGNNGQIHYDHQNDGASQALASCQR 190 YES -- 2.28 
P60709 ACTB Actin, cytoplasmic 1  CDVDIR 285 -- YES 2.28 
Q9HAV0 GNB4 Guanine nucleotide-binding protein subunit beta-4 LLLAGYDDFNCNVWDTLK 294 -- -- 2.29 
P07099 EPHX1 Epoxide hydrolase 1 ESGYMHIQCTK 304 -- -- 2.29 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 GEGTGVLGSLSLPLSELLVADQLCLDR 890 -- -- 2.29 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 VTELQQQPLCTSVNTIYDNAVQGLR 277 -- -- 2.29 
Q9Y490 TLN1 Talin-1 TEDSGLQTQVIAAATQCALSTSQLVACTK 709 -- -- 2.30 
Q9HCN8 SDF2L1 Stromal cell-derived factor 2-like protein 1 GGSEGGCPR 92 -- -- 2.30 
Q9UQB8 BAIAP2 Brain-specific angiogenesis inhibitor 1-associated LPLWQQACADPSK 230 -- -- 2.30 
P29317 EPHA2 Ephrin type-A receptor 2 FTTEIHPSCVTR 612 -- -- 2.30 
O60716 CTNND1 Catenin delta-1 EVHLGACGALK 429 -- -- 2.31 
O14964 HGS Hepatocyte growth factor-regulated tyrosine kinase NCGQTVHDEVANK 75 -- -- 2.31 
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 TPEQCPSVVSLLSESYNPHVR 633 -- YES 2.31 
O15031 PLXNB2 Plexin-B2 LVECGSLFK 112 YES -- 2.31 
E7ENX8 Uncharacterized protein EALEQCR 362 -- -- 2.31 
P42025 ACTR1B Beta-centractin ACYLSINPQK 222 -- -- 2.31 
P57721 PCBP3 Poly(rC)-binding protein 3 INISEGNCPER 86 -- YES 2.32 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosy VACITEQVLTLVNK 477 -- YES 2.32 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 
IIPTLEEGLQLPSPTATSQLPLES
DAVECLNYQHYK 132 -- -- 2.33 
P14618 PKM Pyruvate kinase isozymes M1/M2 AEGSDVANAVLDGADCIMLSGETAK 358 -- -- 2.33 
P09525 ANXA4 Annexin A4 FLTVLCSR 198 -- -- 2.33 
O15372 EIF3H Eukaryotic translation initiation factor 3 subunit MDSLLIAGQINTYCQNIK 327 -- -- 2.33 
Q5VST6 FAM108B1 Abhydrolase domain-containing protein FAM108B1 INCNIFSYDYSGYGASSGK 120 -- -- 2.33 
P04075 ALDOA Fructose-bisphosphate aldolase A YASICQQNGIVPIVEPEILPDGDHDLK 178 -- YES 2.34 
P61158 ACTR3 Actin-related protein 3 TLTGTVIDSGDGVTHVIPVAEGYVIGSCIK 189 -- YES 2.34 
P46821 MAP1B Microtubule-associated protein 1B SWDTNLIECNLDQELK 73 -- -- 2.34 
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Q04941 PLP2 Proteolipid protein 2 LSAPGCWAACTNFSR 12 -- YES 2.35 
P09486 SPARC SPARC TFDSSCHFFATK 123 YES -- 2.35 
P11216 PYGB Glycogen phosphorylase, brain form  TCFETFPDK 326 -- -- 2.35 
Q16678 CYP1B1 Cytochrome P450 1B1 LGSCPIVVLNGER 92 -- -- 2.35 
Q9Y6I9 TEX264 Testis-expressed sequence 264 protein CAVGSILSEGEESPSPELIDLYQK 94 -- -- 2.35 
Q9H0V9 LMAN2L VIP36-like protein PTELGGCTAIVR 200 YES -- 2.35 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) LFVSGACDASAK 204 -- -- 2.35 
Q9UGP8 SEC63 Translocation protein SEC63 homolog NEPPLTCPYSLK 295 -- -- 2.35 
P40925 MDH1 Malate dehydrogenase, cytoplasmic  VIVVGNPANTNCLTASK 137 -- YES 2.36 
Q14697 GANAB Neutral alpha-glucosidase AB DGSDYEGWCWPGSAGYPDFTNPTMR 502 -- -- 2.36 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al 
QLFALSCTAEEQGVLPDDLSGV
IR 112 -- YES 2.36 
P13797 PLS3 Plastin-3 TISSSLAVVDLIDAIQPGCINYDLVK 566 -- -- 2.36 
Q9Y6E0 STK24 Serine/threonine-protein kinase 24 IIDLEEAEDEIEDIQQEITVLSQCDSPYVTK 89 -- -- 2.36 
P62424 RPL7A 60S ribosomal protein L7a TCTTVAFTQVNSEDK 199 -- YES 2.37 
Q9Y277 VDAC3 Voltage-dependent anion-selective channel protein VCNYGLTFTQK 65 -- -- 2.38 
Q96QK1 VPS35 Vacuolar protein sorting-associated protein 35 TQCALAASK 653 -- -- 2.38 
P60033 CD81 CD81 antigen TFHETLDCCGSSTLTALTTSVLK 156 YES YES 2.38 
Q9BXS5 AP1M1 AP-1 complex subunit mu-1 FHQCVR 241 -- -- 2.39 
P61158 ACTR3 Actin-related protein 3 LGYAGNTEPQFIIPSCIAIK 34 -- -- 2.39 
P21964 COMT Catechol O-methyltransferase YLPDTLLLEECGLLR 207 -- -- 2.39 
A1L0T0 ILVBL Acetolactate synthase-like protein AAVETLGVPCFLGGMAR 315 -- -- 2.39 
Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protei LLVDADNCLHR 53 -- -- 2.39 
P50570 DNM2 Dynamin-2 TEHAEFLHCK 86 -- -- 2.39 
P14923 JUP Junction plakoglobin VAAGVLCELAQDK 609 -- -- 2.39 
P25685 DNAJB1 DnaJ homolog subfamily B member 1 VSLEEIYSGCTK 179 -- -- 2.39 
Q8NBI6 XXYLT1 Xyloside xylosyltransferase 1 IYHGNCNTPIPED 386 YES -- 2.40 
P31689 DNAJA1 DnaJ homolog subfamily A member 1 GAVECCPNCR 149 -- -- 2.40 
Q13813 SPTAN1 Spectrin alpha chain, non-erythrocytic 1  CNSLEEIK 2120 -- -- 2.40 
P67870 CSNK2B Casein kinase II subunit beta YQQGDFGYCPR 109 -- -- 2.40 
O00232 PSMD12 26S proteasome non-ATPase regulatory subunit 12 AIYDTPCIQAESEK 255 -- -- 2.41 
P17987 TCP1 T-complex protein 1 subunit alpha VLCELADLQDK 76 -- -- 2.42 
P23526 AHCY Adenosylhomocysteinase FDNLYGCR 195 -- -- 2.42 
P62266 RPS23 40S ribosomal protein S23 ITAFVPNDGCLNFIEENDEVLVAGFGR 90 -- -- 2.42 
Q13200 PSMD2 26S proteasome non-ATPase regulatory subunit 2 GTLTLCPYHSDR 779 -- -- 2.42 
P07737 PFN1 Profilin-1 CYEMASHLR 128 -- YES 2.42 
P27635 RPL10 60S ribosomal protein L10 LIPDGCGVK 195 -- -- 2.43 
O00469 PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2  IFTENIVEQPCPDVFWFPIFSEK 562 -- -- 2.43 
Q9Y2B0 CNPY2 Protein canopy homolog 2 SQDLHCGACR 28 YES -- 2.43 
P67870 CSNK2B Casein kinase II subunit beta GNEFFCEVDEDYIQDK 23 -- -- 2.43 
O00571 DDX3X ATP-dependent RNA helicase DDX3X GADSLEDFLYHEGYACTSIHGDR 468 -- -- 2.44 
O14672 ADAM10 Disintegrin and metalloproteinase domain-containin 
DFDDGVLGLAWVGAPSGSSGG
ICEK 344 YES -- 2.44 
Q13162 PRDX4 Peroxiredoxin-4 EEECHFYAGGQVYPGEASR 51 -- -- 2.44 
P55735 SEC13 Protein SEC13 homolog LATCSSDR 31 -- -- 2.44 
Q9P0L0 VAPA Vesicle-associated membrane protein-associated pro CVFEMPNENDK 128 -- -- 2.44 
P08238 HSP90AB1 Heat shock protein HSP 90-beta VFIMDSCDELIPEYLNFIR 366 -- -- 2.45 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al DGGVQACFSR 139 -- -- 2.45 
Q9BYC5 FUT8 Alpha-(1,6)-fucosyltransferase  PVSETCTDR 266 YES -- 2.45 
Q9P0K7 RAI14 Ankycorbin CPAESVDSSGK 110 -- -- 2.46 
P29317 EPHA2 Ephrin type-A receptor 2 NILVNSNLVCK 753 -- -- 2.47 
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O60701 UGDH UDP-glucose 6-dehydrogenase ISSINSISALCEATGADVEEVATAIGMDQR 241 -- -- 2.47 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 VDCDQHSDIAQR 92 -- -- 2.48 
Q16563 SYPL1 Synaptophysin-like protein 1 IATGHNIIDELPPCK 193 -- -- 2.48 
P60468 SEC61B Protein transport protein Sec61 subunit beta NASCGTR 39 -- YES 2.48 
O43491 EPB41L2 Band 4.1-like protein 2 VTLLDGTEYSCDLEK 232 -- -- 2.49 
P08134 RHOC Rho-related GTP-binding protein RhoC ISAFGYLECSAK 159 -- -- 2.49 
P62851 RPS25 40S ribosomal protein S25 LCK 59 -- -- 2.49 
P09525 ANXA4 Annexin A4 VLLVLCGGDD 315 -- -- 2.50 
 
Table 2A-6. Filtered list of highly oxidized (>75%) and highly reduced (<25%) 
cysteine-containing peptides identified from secretory proteins using OxICAT. 
Reduced cysteines were tagged with IA-light and oxidized cysteines tagged with 
IA-heavy. Both L:H and H:L ratios were determined and used to calculate values 
for percent oxidation for cysteines identified in two replicates. Peptides were 
sorted by least oxidized to most oxidized. Localization of parent proteins was 
determined using Uniprot and GO annotated tabs on UniprotKB. 
Uniprot 
























O15400 STX7 Syntaxin-7  ITQCSVEIQR 28 -- -- 20.00 0.02 3.36% 
Q14764 MVP Major vault protein  LFSVPDFVGDACK 572 -- -- 20.00 0.03 3.84% 
P09525 ANXA4 Annexin A4  FLTVLCSR 198 -- -- 20.00 0.04 3.84% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al DGGVQACFSR 139 -- -- 20.00 0.04 4.07% 
Q15365 PCBP1 Poly(rC)-binding protein 1  AITIAGVPQSVTECVK 158 -- YES 20.00 0.03 4.15% 
P35221 CTNNA1 Catenin alpha-1  LIEVANLACSISNNEEGVK 438 -- -- 20.00 0.03 4.15% 
P63092 GNAS Guanine nucleotide-binding protein G(s) subunit al SNEYQLIDCAQYFLDK 174 -- -- 20.00 0.03 4.15% 
P53675 CLTCL1 Clathrin heavy chain 2  AHIAQLCEK 617 -- -- 20.00 0.04 4.15% 
P46777 RPL5 60S ribosomal protein L5  DIICQIAYAR 62 -- YES 20.00 0.04 4.30% 
Q00610 CLTC Clathrin heavy chain 1  LPVVIGGLLDVDCSEDVIK 824 -- -- 20.00 0.04 4.30% 
P35221 CTNNA1 Catenin alpha-1  IVAECNAVR 337 -- -- 20.00 0.04 4.30% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  
LLLAGYDDFNCNVWDA
LK 294 -- -- 20.00 0.04 4.30% 
Q15149 PLEC Plectin  CVEDPETGLR 3667 -- -- 20.00 0.04 4.46% 
Q15149 PLEC Plectin  LQLEACETR 1136 -- -- 19.69 0.05 4.48% 
Q9UHG3 PCYOX1 Prenylcysteine oxidase 1  LVCSGLLQASK 258 -- -- 20.00 0.05 4.53% 
Q9Y490 TLN1 Talin-1  TEDSGLQTQVIAAATQC*ALSTSQLVAC*TK 709 -- -- 20.00 0.05 4.53% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  
QTFTGHESDINAIC*FFP
NGNAFATGSDDATC*R 233 -- -- 19.94 0.05 4.54% 
Q9NZM1 MYOF Myoferlin  ELPDSVPQECTVR 1553 -- -- 19.91 0.05 4.54% 






TEGSDLCDR 545 -- -- 18.25 0.05 4.75% 
O14744 PRMT5 Protein arginine N-methyltransferase 5  DLNCVPEIADTLGAVAK 22 -- YES 20.00 -- 4.76% 
P54136 RARS Arginine--tRNA ligase, cytoplasmic  IVFVPGCSIPLTIVK 369 -- YES 20.00 -- 4.76% 
P60174 TPI1 Triosephosphate isomerase  VAHALAEGLGVIACIGEK 164 -- YES 20.00 -- 4.76% 
Q00610 CLTC Clathrin heavy chain 1  VIQCFAETGQVQK 491 -- YES 20.00 0.05 4.76% 
O43707 ACTN4 Alpha-actinin-4  CQLEINFNTLQTK 351 -- YES 20.00 -- 4.76% 
Q15149 PLEC Plectin  LPLLAVCDYK 950 -- -- 20.00 0.05 4.76% 
Q8NEW0 SLC30A7 Zinc transporter 7  TPPLLENSLPQCYQR 308 -- -- 20.00 0.05 4.76% 
P49588 AARS Alanine--tRNA ligase, cytoplasmic  AVYTQDCPLAAAK 671 -- -- 20.00 -- 4.76% 
Q8IZP0 ABI1 Abl interactor 1  NDDGWYEGVCNR 488 -- -- 20.00 -- 4.76% 
P12814 ACTN1 Alpha-actinin-1  ACLISLGYDIGNDPQGEAEFAR 774 -- -- 20.00 -- 4.76% 
P42025 ACTR1B Beta-centractin  ACYLSINPQK 222 -- -- 20.00 -- 4.76% 
P09525 ANXA4 Annexin A4  VLLVLCGGDD 315 -- -- 20.00 -- 4.76% 
O95782 AP2A1 AP-2 complex subunit alpha-1  AADLLYAMCDR 397 -- -- 20.00 -- 4.76% 
O95782 AP2A1 AP-2 complex subunit alpha-1  LVECLETVLNK 283 -- -- 20.00 -- 4.76% 
Q9Y6B7 AP4B1 AP-4 complex subunit beta-1  DQDPIVVVNCLR 179 -- -- 20.00 -- 4.76% 
P20020 ATP2B1 Plasma membrane calcium-transporting ATPase 1  IQESYGDVYGICTK 60 -- -- 20.00 -- 4.76% 
Q93050 ATP6V0A1 V-type proton ATPase 116 kDa subunit a isoform 1  AIYHTLNLCNIDVTQK 310 -- -- 20.00 -- 4.76% 
P61421 ATP6V0D1 V-type proton ATPase subunit d 1  NIVWIAECIAQR 335 -- -- 20.00 -- 4.76% 
P49368 CCT3 T-complex protein 1 subunit gamma  IPGGIIEDSCVLR 213 -- -- 20.00 -- 4.76% 
P49368 CCT3 T-complex protein 1 subunit gamma  WSSLACNIALDAVK 173 -- -- 20.00 -- 4.76% 
P12277 CKB Creatine kinase B-type  FCTGLTQIETLFK 254 -- -- 20.00 -- 4.76% 
P53675 CLTCL1 Clathrin heavy chain 2  LTDQLPLIIVCDR 778 -- -- 20.00 -- 4.76% 
P53618 COPB1 Coatomer subunit beta  CIYNLLQSSSPAVK 248 -- -- 20.00 -- 4.76% 
Q9Y678 COPG1 Coatomer subunit gamma-1  ELAPAVSVLQLFCSSPK 296 -- -- 20.00 -- 4.76% 
P55060 CSE1L Exportin-2  SQICDNAALYAQK 272 -- -- 20.00 -- 4.76% 
P35222 CTNNB1 Catenin beta-1  LVQNCLWTLR 381 -- -- 20.00 -- 4.76% 
Q15392 DHCR24 Delta(24)-sterol reductase  LGCQDAFPEVYDK 499 -- -- 20.00 -- 4.76% 
O75165 DNAJC13 DnaJ homolog subfamily C member 13  ADTVGLACEAINR 2110 -- -- 20.00 -- 4.76% 
O75165 DNAJC13 DnaJ homolog subfamily C member 13  VIHALSENELCVR 2082 -- -- 20.00 -- 4.76% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1  IQFVGACNPPTDPGR 2712 -- -- 20.00 -- 4.76% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1  ITNQVIYLNPPIEECR 978 -- -- 20.00 -- 4.76% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1  TSAPITCELLNK 1999 -- -- 20.00 -- 4.76% 
Q14156 EFR3A Protein EFR3 homolog A  EENPAVLAENCFR 237 -- -- 20.00 -- 4.76% 
P55884 EIF3B Eukaryotic translation initiation factor 3 subunit YWLEEAECR 302 -- -- 20.00 -- 4.76% 
P07099 EPHX1 Epoxide hydrolase 1  FTPPLEDSCFHYGFNSNYLK 80 -- -- 20.00 -- 4.76% 
P07814 EPRS Bifunctional glutamate/proline--tRNA ligase  INEAVECLLSLK 856 -- -- 20.00 -- 4.76% 
Q9H6S3 EPS8L2 Epidermal growth factor receptor kinase substrate  PPSEGEFIDCFQK 317 -- -- 20.00 -- 4.76% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1  GEGTGVLGSLSLPLSELLVADQLCLDR 890 -- -- 20.00 0.05 4.76% 
Q9NV70 EXOC1 Exocyst complex component 1  IFEQVLSELEPLCLAEQDFISK 526 -- -- 20.00 -- 4.76% 
Q96A65 EXOC4 Exocyst complex component 4  EIICEQAAIK 957 -- -- 20.00 -- 4.76% 
O75369 FLNB Filamin-B  SGCIVNNLAEFTVDPK 660 -- -- 20.00 -- 4.76% 
P63096 GNAI1 Guanine nucleotide-binding protein G(i) subunit al DSGVQACFNR 139 -- -- 20.00 -- 4.76% 
P01112 HRAS GTPase HRas  TGEGFLCVFAINNTK 80 -- -- 20.00 -- 4.76% 
P08238 HSP90AB1 Heat shock protein HSP 90-beta  CLELFSELAEDK 412 -- -- 20.00 -- 4.76% 
P46940 IQGAP1 Ras GTPase-activating-like protein IQGAP1  TCLDNLASK 1534 -- -- 20.00 0.05 4.76% 
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P35579 MYH9 Myosin-9  ADFCIIHYAGK 569 -- -- 20.00 -- 4.76% 
O43795 MYO1B Unconventional myosin-Ib  EICELTGIDQSVLER 310 -- -- 20.00 -- 4.76% 
Q9NZM1 MYOF Myoferlin  HSATTVFGANTPIVSCNFDR 1131 -- -- 20.00 -- 4.76% 
Q9NZM1 MYOF Myoferlin  MYELSCYLPQEK 1610 -- -- 20.00 -- 4.76% 
P54920 NAPA Alpha-soluble NSF attachment protein  ADPQEAINCLMR 103 -- -- 20.00 -- 4.76% 
A2RRP1 NBAS Neuroblastoma-amplified sequence  LLAAVQDQCVEIR 108 -- -- 20.00 -- 4.76% 
P01111 NRAS GTPase NRas  TGEGFLCVFAINNSK 80 -- -- 20.00 -- 4.76% 
P17858 PFKL 6-phosphofructokinase, liver type  VFANAPDSACVIGLK 708 -- -- 20.00 -- 4.76% 
Q15149 PLEC Plectin  TLLQGSGCLAGIYLEDTK 3493 -- -- 20.00 -- 4.76% 
P30153 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa reg ENVIMSQILPCIK 329 -- -- 20.00 -- 4.76% 
P31949 S100A11 Protein S100-A11  CIESLIAVFQK 13 YES -- 20.00 -- 4.76% 
Q9NTJ5 SACM1L Phosphatidylinositide phosphatase SAC1  
FYVEACDDGADDVLTID
R 23 -- -- 20.00 -- 4.76% 
Q8WVM8 SCFD1 Sec1 family domain-containing protein 1  ALTDAGCNLNPLQYIK 485 -- -- 20.00 -- 4.76% 
O94855 SEC24D Protein transport protein Sec24D  SCETDALINFFAK 780 -- -- 20.00 -- 4.76% 
O94979 SEC31A Protein transport protein Sec31A  
SDQLQQAVQSQGFINYC
QK 458 -- -- 20.00 -- 4.76% 
Q9UNH7 SNX6 Sorting nexin-6  GNLQLLQNCLAVLNGDT 398 -- -- 20.00 -- 4.76% 
O15269 SPTLC1 Serine palmitoyltransferase 1  LLQEIVDQCMNR 419 -- -- 20.00 -- 4.76% 
P52630 STAT2 Signal transducer and activator of transcription 2 DEAFGCYYQEK 676 -- -- 20.00 -- 4.76% 
Q86Y82 STX12 Syntaxin-12  DFSSIIQTCSGNIQR 29 -- -- 20.00 -- 4.76% 
P37837 TALDO1 Transaldolase  ALAGCDFLTISPK 250 -- -- 20.00 -- 4.76% 
Q9Y490 TLN1 Talin-1  ASVPTIQDQASAMQLSQCAK 1023 -- -- 20.00 -- 4.76% 
Q9Y490 TLN1 Talin-1  VVAPTISSPVCQEQLVEAGR 732 -- -- 20.00 -- 4.76% 
Q92973 TNPO1 Transportin-1  SECLNNIGDSSPLIR 103 -- -- 20.00 -- 4.76% 
O94874 UFL1 E3 UFM1-protein ligase 1  FINDCTELFR 372 -- -- 20.00 -- 4.76% 
O60701 UGDH UDP-glucose 6-dehydrogenase  DVLNLVYLCEALNLPEVAR 288 -- -- 20.00 -- 4.76% 
Q92900 UPF1 Regulator of nonsense transcripts 1  DFIILSCVR 852 -- -- 20.00 -- 4.76% 
Q92900 UPF1 Regulator of nonsense transcripts 1  
QGNGPVLVCAPSNIAV
DQLTEK 531 -- -- 20.00 -- 4.76% 
P46939 UTRN Utrophin  VPSGGQELTSELNVVLENYQLLCNR 1218 -- -- 20.00 -- 4.76% 
Q08AM6 VAC14 Protein VAC14 homolog  ELIEPVLTCFNDADSR 101 -- -- 20.00 -- 4.76% 
Q08AM6 VAC14 Protein VAC14 homolog  LQCVPNPELLQTEDSLK 719 -- -- 20.00 -- 4.76% 
P18206 VCL Vinculin  CDR 545 -- -- 20.00 -- 4.76% 
O94826 TOMM70A Mitochondrial import receptor subunit TOM70  ILLDQVEEAVADFDECIR 427 -- -- 20.00 -- 4.76% 
P04083 ANXA1 Annexin A1  CATSK 270 -- -- 19.42 0.05 4.83% 
Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3  NLSGQPNFPCR 428 -- -- 19.57 0.05 4.83% 
P26639 TARS Threonine--tRNA ligase, cytoplasmic  
TTPYQIACGISQGLADN
TVIAK 107 -- YES 19.68 -- 4.84% 
P56192 MARS Methionine--tRNA ligase, cytoplasmic  
LFVSDGVPGCLPVLAAA
GR 12 -- -- 19.52 0.05 4.84% 
P51636 CAV2 Caveolin-2  SVTDVIIAPLCTSVGR 145 -- YES 19.60 -- 4.86% 
P53992 SEC24C Protein transport protein Sec24C  NCETDTLINYMAK 842 -- -- 19.41 -- 4.90% 
P05141 SLC25A5 ADP/ATP translocase 2  GLGDCLVK 160 -- YES 18.99 0.05 4.92% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1  LCDEQLSSQSHYDFGLR 2076 -- -- 19.30 -- 4.93% 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta  NTPSFLIACNK 179 -- -- 18.33 0.05 4.98% 
P21796 VDAC1 Voltage-dependent anion-selective channel protein  YQIDPDACFSAK 232 -- -- 19.32 0.06 5.07% 
P51659 HSD17B4 Peroxisomal multifunctional enzyme type 2  ICDFENASK 277 -- -- 18.44 -- 5.18% 
Q15149 PLEC Plectin  FLEGTSCIAGVFVDATK 4071 -- -- 18.93 0.06 5.24% 
O43747 AP1G1 AP-1 complex subunit gamma-1  ADCASGIFLAAEK 400 -- -- 18.86 0.06 5.25% 
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P22626 HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1  LTDCVVMR 50 -- -- 17.68 0.06 5.29% 
Q00610 CLTC Clathrin heavy chain 1  GQC*DLELINVC*NENSLFK 926 -- -- 17.17 0.06 5.37% 
P35606 COPB2 Coatomer subunit beta  TFEVCDLPVR 56 -- -- 18.14 0.06 5.40% 
Q13200 PSMD2 26S proteasome non-ATPase regulatory subunit 2  SGALLACGIVNSGVR 448 -- -- 17.73 -- 5.41% 
P08758 ANXA5 Annexin A5  ALLLLCGEDD 316 -- -- 17.92 0.06 5.47% 
P50395 GDI2 Rab GDP dissociation inhibitor beta  TDDYLDQPCYETINR 202 -- YES 17.79 0.06 5.49% 
Q9Y2H6 FNDC3A Fibronectin type-III domain-containing protein 3A  YSSLQLNCEYR 1112 -- -- 17.51 -- 5.50% 
P46782 RPS5 40S ribosomal protein S5  TIAECLADELINAAK 172 -- YES 17.41 0.06 5.51% 
P63010 AP2B1 AP-2 complex subunit beta  CVSTLLDLIQTK 391 -- -- 17.43 0.06 5.55% 
Q9Y490 TLN1 Talin-1  AVEGCVSASQAATEDGQLLR 750 -- -- 18.81 0.07 5.56% 
P08195 SLC3A2 4F2 cell-surface antigen heavy chain  WCSWSLSQAR 431 -- YES 17.25 0.06 5.58% 
P13639 EEF2 Elongation factor 2  CLYASVLTAQPR 728 -- -- 17.17 0.06 5.59% 
P14625 HSP90B1 Endoplasmin  LTESPCALVASQYGWSGNMER 645 -- -- 17.28 -- 5.60% 
P61421 ATP6V0D1 V-type proton ATPase subunit d 1  
AGVLSQADYLNLVQCE
TLEDLK 39 -- -- 18.52 0.07 5.62% 
O14950 MYL12B Myosin regulatory light chain 12B  
NAFACFDEEATGTIQED
YLR 109 -- -- 18.47 0.07 5.63% 
P46940 IQGAP1 Ras GTPase-activating-like protein IQGAP1  
WMEACLGEDLPPTTELE
EGLR 57 -- -- 17.09 -- 5.63% 
P62195 PSMC5 26S protease regulatory subunit 8  NIDINDVTPNCR 112 -- -- 17.17 -- 5.64% 
P53992 SEC24C Protein transport protein Sec24C  LLPVYLNCVLK 910 -- -- 17.09 0.06 5.66% 
Q00610 CLTC Clathrin heavy chain 1  CYDEK 1205 -- -- 18.11 0.07 5.69% 
Q9NRP0 OSTC Oligosaccharyltransferase complex subunit OSTC  VPFLVLECPNLK 14 -- YES 16.83 0.06 5.70% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al LWADHGVQACFGR 140 -- -- 16.68 0.06 5.70% 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase  VPTANVSVVDLTCR 247 -- YES 16.33 0.06 5.72% 
P37802 TAGLN2 Transgelin-2  DGTVLCELINALYPEGQAPVK 63 -- -- 19.33 0.07 5.73% 
P35222 CTNNB1 Catenin beta-1  EDITEPAICALR 466 -- YES 17.42 0.07 5.82% 
P13639 EEF2 Elongation factor 2  TFCQLILDPIFK 290 -- YES 17.55 0.07 5.84% 
P14618 PKM Pyruvate kinase isozymes M1/M2  GIFPVLCK 474 -- YES 16.30 0.07 5.94% 
P49368 CCT3 T-complex protein 1 subunit gamma  TLIQNCGASTIR 455 -- YES 16.44 0.07 5.94% 
O60716 CTNND1 Catenin delta-1  TPAILEASAGAIQNLCAGR 692 -- -- 16.16 0.07 6.00% 
P21964 COMT Catechol O-methyltransferase  YLPDTLLLEECGLLR 207 -- -- 15.97 0.07 6.00% 
P14618 PKM Pyruvate kinase isozymes M1/M2  NTGIICTIGPASR 49 -- -- 15.93 0.07 6.02% 
H3BN98 Uncharacterized protein  FHEICSNLVK 109 -- -- 20.00 0.08 6.02% 
P29317 EPHA2 Ephrin type-A receptor 2  NILVNSNLVCK 753 -- -- 15.96 0.07 6.02% 
P39687 ANP32A Acidic leucine-rich nuclear phosphoprotein 32 fami SLDLFNCEVTNLNDYR 123 -- -- 16.33 -- 6.04% 
P53677 AP3M2 AP-3 complex subunit mu-2  SVCDYFFEAQER 29 -- -- 15.52 -- 6.06% 
P63104 YWHAZ 14-3-3 protein zeta/delta  DICNDVLSLLEK 94 -- YES 15.52 0.07 6.08% 
Q8NE01 CNNM3 Metal transporter CNNM3  DLAFVDPEDCTPLSTITR 376 -- -- 16.25 -- 6.08% 
O43707 ACTN4 Alpha-actinin-4  ACLISLGYDVENDR 793 -- YES 16.54 0.07 6.09% 





YGSVAFPNFEQGVACLR 404 -- -- 16.10 -- 6.17% 
Q99442 SEC62 Translocation protein SEC62  ESVVDYCNR 82 -- -- 14.97 0.07 6.21% 
P61160 ACTR2 Actin-related protein 2  LCYVGYNIEQEQK 221 -- -- 13.90 0.06 6.22% 
Q01813 PFKP 6-phosphofructokinase type C  FTTDDSICVLGISK 718 -- -- 15.31 0.07 6.29% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3  
SVNSLDGLASVLYPGCD
TLDK 85 -- -- 15.05 -- 6.31% 
P29992 GNA11 Guanine nucleotide-binding protein subunit alpha-1 TLWEDPGIQECYDR 144 -- YES 15.60 0.07 6.36% 
O95292 VAPB Vesicle-associated membrane protein-associated pro CVFELPAENDK 121 -- -- 15.57 0.07 6.36% 
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P07900 HSP90AA1 Heat shock protein HSP 90-alpha  CLELFTELAEDK 420 -- YES 16.51 0.08 6.38% 
Q6DD88 ATL3 Atlastin-3  ELYENFCK 429 -- -- 17.66 0.09 6.38% 
P04075 ALDOA Fructose-bisphosphate aldolase A  
YASICQQNGIVPIVEPEIL
PDGDHDLK 178 -- YES 15.59 0.07 6.39% 





VACITEQVLTLVNK 477 -- YES 16.05 0.08 6.44% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase  VGEATETALTCLVEK 447 -- -- 15.18 0.07 6.45% 
Q9P2X0 DPM3 Dolichol-phosphate mannosyltransferase subunit 3  VATFHDCEDAAR 67 -- -- 15.81 0.08 6.46% 
P61158 ACTR3 Actin-related protein 3  TLTGTVIDSGDGVTHVIPVAEGYVIGSCIK 189 -- YES 16.34 0.08 6.49% 
P35222 CTNNB1 Catenin beta-1  VAAGVLCELAQDK 619 -- -- 20.00 0.09 6.51% 
P60763 RAC3 Ras-related C3 botulinum toxin substrate 3  YLECSALTQR 157 -- YES 14.19 0.07 6.56% 
Q96N66 MBOAT7 Lysophospholipid acyltransferase 7  NIDC*YSTDFC*VR 304 -- -- 15.31 0.08 6.57% 
O60664 PLIN3 Perilipin-3  DIAQQLQATCTSLGSSIQGLPTNVK 341 -- -- 14.19 0.07 6.58% 
O60716 CTNND1 Catenin delta-1  SNAAAYLQHLCYR 394 -- YES 13.64 0.03 6.59% 
P04083 ANXA1 Annexin A1  ILVALCGGN 343 YES YES 15.77 0.08 6.68% 
P61019 RAB2A Ras-related protein Rab-2A  SCLLLQFTDK 21 -- -- 15.02 0.07 6.69% 
P60709 ACTB Actin, cytoplasmic 1  LCYVALDFEQEMATAASSSSLEK 217 -- YES 13.57 0.07 6.70% 
Q16658 FSCN1 Fascin  LSCFAQTVSPAEK 121 -- YES 14.21 -- 6.74% 
P61224 RAP1B Ras-related protein Rap-1b  QWNNCAFLESSAK 141 -- -- 14.16 0.08 6.79% 
Q15149 PLEC Plectin  EYGSCSHHYQQLLQSLEQGAQEESR 
Bad 
ID -- -- 15.06 -- 6.88% 
Q9Y490 TLN1 Talin-1  AGALQCSPSDAYTK 1939 -- -- 14.17 0.08 6.90% 
P14618 PKM Pyruvate kinase isozymes M1/M2  CDENILWLDYK 152 -- -- 13.80 0.08 6.90% 
P35221 CTNNA1 Catenin alpha-1  NVPILYTASQACLQHPDVAAYK 228 -- -- 15.69 0.09 6.91% 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1  SFLTAEDCFELGK 167 -- -- 13.56 0.08 6.93% 
Q13425 SNTB2 Beta-2-syntrophin  ILVQGCHAAAELIK 436 -- -- 13.59 0.08 6.95% 
P13797 PLS3 Plastin-3  TISSSLAVVDLIDAIQPGCINYDLVK 566 -- -- 15.17 0.09 7.05% 
P23258 TUBG1 Tubulin gamma-1 chain  LTQNADCVVVLDNTALNR 201 -- -- 15.66 0.09 7.13% 
P11216 PYGB Glycogen phosphorylase, brain form  TCAYTNHTVLPEALER 373 -- -- 15.47 0.09 7.13% 
P07355 ANXA2 Annexin A2  ALLYLCGGDD 335 -- YES 13.12 0.08 7.25% 
P07355 ANXA2 Annexin A2  GLGTDEDSLIEIICSR 133 -- YES 13.00 0.08 7.28% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1  AVYSTNCPVWEEAFR 522 -- -- 13.96 0.08 7.30% 
Q99832 CCT7 T-complex protein 1 subunit eta  INALTAASEAACLIVSVDETIK 511 -- -- 16.71 0.12 7.41% 
P07947 YES1 Tyrosine-protein kinase Yes  AANILVGENLVCK 410 -- -- 13.60 0.09 7.46% 
P61224 RAP1B Ras-related protein Rap-1b  QVEVDAQQCMLEILDTAGTEQFTAMR 51 -- -- 14.36 -- 7.53% 
P53396 ACLY ATP-citrate synthase  VDATADYICK 229 -- -- 15.19 0.10 7.55% 
P62241 RPS8 40S ribosomal protein S8  NCIVLIDSTPYR 100 -- YES 15.15 0.10 7.57% 
P23528 CFL1 Cofilin-1  AVLFCLSEDK 39 -- YES 11.89 0.08 7.58% 
P46782 RPS5 40S ribosomal protein S5  VNQAIWLLCTGAR 155 -- -- 16.27 0.12 7.62% 
P17987 TCP1 T-complex protein 1 subunit alpha  DCLINAAK 147 -- YES 14.60 0.10 7.70% 
Q9NZM1 MYOF Myoferlin  IYNCELENVAEFEGLTDFSDTFK 1483 -- -- 12.60 0.09 7.72% 
Q6P1M0 SLC27A4 Long-chain fatty acid transport protein 4  
AGMAAVASPTGNCDLE
R 560 -- -- 14.15 -- 7.76% 
P62820 RAB1A Ras-related protein Rab-1A  CDLTTK 126 -- -- 12.00 0.09 7.76% 
P35221 CTNNA1 Catenin alpha-1  AAAGEFADDPCSSVK 116 -- -- 14.30 0.11 7.86% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  
ACADATLSQITNNIDPV
GR 25 -- -- 11.54 0.09 7.91% 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha LIIVEGCQR 705 -- YES 11.50 0.09 7.92% 
Q5T4S7 UBR4 E3 ubiquitin-protein ligase UBR4  LENPDEACAVSQK 122 -- -- 14.00 -- 7.94% 
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Q9HAV0 GNB4 Guanine nucleotide-binding protein subunit beta-4  
ADQELLLYSHDNIICGIT
SVAFSK 271 -- -- 16.85 0.14 7.95% 
P50148 GNAQ Guanine nucleotide-binding protein G(q) subunit al SLWNDPGIQECYDR 144 -- YES 13.90 -- 8.06% 
P00338 LDHA L-lactate dehydrogenase A chain  
DDVFLSVPCILGQNGISD
LVK 293 -- -- 12.47 0.10 8.07% 
P84095 RHOG Rho-related GTP-binding protein RhoG  YLECSALQQDGVK 157 -- -- 14.71 0.11 8.09% 
O75521 ECI2 Enoyl-CoA delta isomerase 2, mitochondrial  LHAVNAEECNVLQGR 368 -- -- 12.17 -- 8.12% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5  GDGPICLVLAPTR 170 -- -- 12.71 0.10 8.12% 
P31946 YWHAB 14-3-3 protein beta/alpha  IEAELQDICNDVLELLDK 96 -- -- 13.81 -- 8.18% 
P30050 RPL12 60S ribosomal protein L12  CTGGEVGATSALAPK 17 -- -- 11.10 0.09 8.26% 
P49327 FASN Fatty acid synthase  LSIPTYGLQCTR 2273 -- -- 11.02 0.09 8.29% 
P49327 FASN Fatty acid synthase  AALQEELQLCK 1141 -- YES 14.36 0.11 8.32% 
P60953 CDC42 Cell division control protein 42 homolog  YVECSALTQK 157 -- YES 10.88 0.09 8.34% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59  ATILDLSCNK 48 -- -- 10.87 0.09 8.34% 
P21333 FLNA Filamin-A  VGTECGNQK 574 -- -- 10.79 0.09 8.37% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
HLYTLDGGDIINALCFSP
NR 240 -- YES 12.12 0.10 8.43% 
Q15417 CNN3 Calponin-3  DGIILCELINK 59 -- -- 11.20 0.10 8.52% 
Q9NZM1 MYOF Myoferlin  GLELQPQDNNGLCDPYIK 1574 -- -- 11.55 0.10 8.53% 
Q6PIU2 NCEH1 Neutral cholesterol ester hydrolase 1  
ICISGDSAGGNLAAALG
QQFTQDASLK 186 -- -- 12.25 0.10 8.53% 
Q9P289 MST4 Serine/threonine-protein kinase MST4  SIAVAEAACPGITDK 392 -- -- 13.31 -- 8.56% 
Q9Y490 TLN1 Talin-1  VQELGHGCAALVTK 1927 -- -- 12.57 0.11 8.58% 
Q00610 CLTC Clathrin heavy chain 1  HSSLAGCQIINYR 151 -- -- 11.41 0.10 8.63% 
Q9NQC3 RTN4 Reticulon-4  YSNSALGHVNCTIK 1101 -- YES 10.65 0.10 8.63% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1  GVAVLCTE 4644 -- -- 10.70 0.10 8.65% 
P14174 MIF Macrophage migration inhibitory factor  LLCGLLAER 81 -- YES 10.30 0.09 8.66% 
Q13813 SPTAN1 Spectrin alpha chain, non-erythrocytic 1  VNDVCTNGQDLIK 1930 -- -- 11.39 0.10 8.67% 
O75131 CPNE3 Copine-3  EALAQCVLAEIPQQVVGYFNTYK 506 -- -- 14.18 0.12 8.68% 
Q9UKK3 PARP4 Poly  LFACGIGSTANR 1002 -- -- 14.22 0.12 8.69% 
P23396 RPS3 40S ribosomal protein S3  GCEVVVSGK 134 -- YES 10.47 0.10 8.70% 
Q14696 MESDC2 LDLR chaperone MESD  CADVTLEGQVYPGK 180 -- -- 10.43 0.10 8.71% 
P40227 CCT6A T-complex protein 1 subunit zeta  
NAIDDGCVVPGAGAVE
VAMAEALIK 406 -- -- 10.55 0.10 8.73% 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1  LPADTCLLEFAR 330 -- -- 9.75 0.09 8.79% 
P21333 FLNA Filamin-A  DNGNGTYSCSYVPR 733 -- -- 10.57 0.10 9.00% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1  QDLADVVQVCEGK 4438 -- -- 10.28 0.10 9.04% 
P54136 RARS Arginine--tRNA ligase, cytoplasmic  
VLTAEELNAAQTSVAYG
CIK 502 -- -- 10.67 0.11 9.05% 
P63010 AP2B1 AP-2 complex subunit beta  ECHLNADTVSSK 857 -- -- 10.05 0.10 9.07% 
Q01518 CAP1 Adenylyl cyclase-associated protein 1  ALLVTASQCQQPAENK 93 -- YES 10.03 0.10 9.09% 
P36578 RPL4 60S ribosomal protein L4  GPCIIYNEDNGIIK 208 -- -- 14.04 0.13 9.10% 
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M  FNECGHVLYADIK 676 -- -- 10.09 -- 9.12% 
Q9NP72 RAB18 Ras-related protein Rab-18  LDNWLNELETYCTR 110 -- -- 9.87 0.10 9.15% 
P45880 VDAC2 Voltage-dependent anion-selective channel protein  
VC*EDLDTSVNLAWTSG
TNC*TR 210 -- -- 11.42 0.12 9.26% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al 
SPLTIC*YPEYTGSNTYEE
AAAYIQC*QFEDLNR 286 -- -- 9.75 0.11 9.42% 
O75131 CPNE3 Copine-3  SSPVEFECINEK 249 -- -- 9.58 0.11 9.49% 
Q15149 PLEC Plectin  VLSSSGSEAAVPSVCFLVPPPNQEAQEAVTR 992 -- -- 9.52 0.11 9.51% 
P55735 SEC13 Protein SEC13 homolog  FASGGCDNLIK 187 -- -- 9.36 0.11 9.59% 
P14649 MYL6B Myosin light chain 6B  ILYSQCGDVMR 89 -- -- 9.49 0.11 9.59% 
O75083 WDR1 WD repeat-containing protein 1  LATGSDDNCAAFFEGPPFK 170 -- -- 9.47 0.11 9.67% 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha NIAFFSTNCVEGTAR 249 -- -- 13.43 0.14 9.71% 
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O43747 AP1G1 AP-1 complex subunit gamma-1  ELLYFLDSCEPEFK 392 -- -- 13.58 0.14 9.77% 
Q9UL25 RAB21 Ras-related protein Rab-21  GIEELFLDLCK 177 -- -- 9.41 0.11 9.80% 
Q00610 CLTC Clathrin heavy chain 1  IHEGCEEPATHNALAK 870 -- -- 9.33 0.11 9.80% 
P15924 DSP Desmoplakin  NQCTQVVQER 1805 -- -- 12.87 -- 9.81% 
O00264 PGRMC1 Membrane-associated progesterone receptor componen GLATFCLDK 129 -- -- 11.22 0.13 9.81% 
Q9ULV4 CORO1C Coronin-1C  VTWDSSFCAVNPR 39 -- -- 9.39 0.11 9.82% 
E7ENX8 Uncharacterized protein  SFGAEEHEVCR 353 -- -- 9.33 0.11 9.83% 
P83731 RPL24 60S ribosomal protein L24  VELCSFSGYK 6 -- -- 9.26 0.11 9.83% 
P35579 MYH9 Myosin-9  EDQSILCTGESGAGK 172 -- YES 9.42 0.11 9.87% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3  NTPLCDSFVFR 429 -- -- 9.11 0.11 9.90% 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta  AVLLVGLCDSGK 73 -- -- 9.20 0.11 9.94% 
P18669 PGAM1 Phosphoglycerate mutase 1  YADLTEDQLPSCESLK 153 -- -- 11.12 0.13 10.00% 
P61981 YWHAG 14-3-3 protein gamma  NCSETQYESK 112 -- -- 10.91 0.13 10.09% 
P13639 EEF2 Elongation factor 2  YVEPIEDVPCGNIVGLVGVDQFLVK 466 -- -- 12.85 0.15 10.13% 
Q9Y490 TLN1 Talin-1  CTQDLGNSTK 1087 -- -- 9.15 0.12 10.14% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al IIHEDGYSEEECR 66 -- YES 9.20 0.12 10.16% 
Q9Y277 VDAC3 Voltage-dependent anion-selective channel protein  VCNYGLTFTQK 65 -- -- 13.40 0.15 10.21% 
O15031 PLXNB2 Plexin-B2  VLNCDTISQVK 1484 -- -- 8.88 0.12 10.23% 
P07237 P4HB Protein disulfide-isomerase  ITEFCHR 343 -- -- 8.85 0.12 10.24% 
P63010 AP2B1 AP-2 complex subunit beta  CLK 129 -- -- 8.86 0.12 10.26% 
Q03135 CAV1 Caveolin-1  VYSIYVHTVCDPLFEAVGK 156 -- YES 13.33 0.15 10.29% 
P09382 LGALS1 Galectin-1  EAVFPFQPGSVAEVCITFDQANLTVK 89 -- -- 8.76 0.12 10.31% 
P61106 RAB14 Ras-related protein Rab-14  SCLLHQFTEK 26 -- -- 8.60 0.12 10.37% 
P11216 PYGB Glycogen phosphorylase, brain form  
VFADYEAYMQCQAQV
DQLYR 784 -- -- 8.55 0.12 10.40% 
P30086 PEBP1 Phosphatidylethanolamine-binding protein 1  
APVAGTCYQAEWDDYV
PK 168 -- -- 8.41 0.12 10.50% 
P60174 TPI1 Triosephosphate isomerase  VPADTEVVCAPPTAYIDFAR 79 -- YES 8.73 0.12 10.50% 
P63010 AP2B1 AP-2 complex subunit beta  TAAVCVAK 144 -- -- 8.67 0.12 10.56% 
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B  DVIIADCGK 202 -- YES 8.37 0.12 10.70% 
Q01518 CAP1 Adenylyl cyclase-associated protein 1  TDGCHAYLSK 416 -- -- 8.34 0.12 10.71% 
P05388 RPLP0 60S acidic ribosomal protein P0  CFIVGADNVGSK 27 -- -- 8.34 0.12 10.71% 
Q9UBM7 DHCR7 7-dehydrocholesterol reductase  VIECSYTSADGQR 380 -- -- 8.35 0.12 10.72% 
P62888 RPL30 60S ribosomal protein L30  LVILANNCPALR 52 -- YES 8.76 0.13 10.78% 
P46777 RPL5 60S ribosomal protein L5  VGLTNYAAAYCTGLLLAR 100 -- YES 13.09 0.16 10.83% 
Q09666 AHNAK Neuroblast differentiation-associated protein AHNA 
EVFSSCSSEVVLSGDDEE
YQR 108 -- -- 13.08 0.16 10.84% 
O75131 CPNE3 Copine-3  VALNVSCANLLDK 15 -- -- 10.39 0.14 10.89% 
P61981 YWHAG 14-3-3 protein gamma  ELEAVCQDVLSLLDNYLIK 97 -- -- 18.99 0.22 10.92% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al IIHEDGYSEDECK 66 -- -- 8.24 0.13 10.98% 
P62424 RPL7A 60S ribosomal protein L7a  TCTTVAFTQVNSEDK 199 -- YES 9.34 0.14 10.98% 
P40925 MDH1 Malate dehydrogenase, cytoplasmic  VIVVGNPANTNCLTASK 137 -- YES 8.12 0.13 11.07% 
P60763 RAC3 Ras-related C3 botulinum toxin substrate 3  CVVVGDGAVGK 6 -- YES 8.47 0.13 11.07% 
P21333 FLNA Filamin-A  AHVVPCFDASK 1157 -- YES 7.95 0.13 11.15% 
Q13190 STX5 Syntaxin-5  TQEFLSACK 68 -- -- 12.98 0.17 11.22% 
O00429 DNM1L Dynamin-1-like protein  YIETSELCGGAR 361 -- -- 12.89 0.17 11.35% 
Q10567 AP1B1 AP-1 complex subunit beta-1  DCPLNAEAASSK 866 -- -- 7.95 0.13 11.36% 
Q15149 PLEC Plectin  LLEAQACTGGIIDPSTGER 4454 -- -- 8.28 0.13 11.37% 
P06730 EIF4E Eukaryotic translation initiation factor 4E  IAIWTTECENR 170 -- -- 10.01 0.15 11.38% 
P50991 CCT4 T-complex protein 1 subunit delta  ITGCASPGK 379 -- -- 8.00 0.13 11.44% 
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Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1  SACDTVDTWLDDTAK 4216 -- -- 10.04 0.15 11.47% 
Q9P0K7 RAI14 Ankycorbin  CPAESVDSSGK 110 -- -- 11.84 0.17 11.51% 
Q9HAV0 GNB4 Guanine nucleotide-binding protein subunit beta-4  TFVSGACDASSK 204 -- -- 7.61 0.13 11.56% 
P68104 EEF1A1 Elongation factor 1-alpha 1  NMITGTSQADCAVLIVAAGVGEFEAGISK 111 -- -- 10.12 0.14 11.57% 
P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma cat IYGFYDECK 140 -- -- 7.63 0.13 11.57% 
P62993 GRB2 Growth factor receptor-bound protein 2  VLNEECDQNWYK 32 -- -- 7.68 0.14 11.76% 
Q13418 ILK Integrin-linked protein kinase  FSFQCPGR 346 -- -- 7.48 0.14 11.85% 
P17987 TCP1 T-complex protein 1 subunit alpha  SLHDALCVVK 397 -- -- 7.30 0.14 11.97% 
P0CW22 RPS17L 40S ribosomal protein S17-like  VCEEIAIIPSK 35 -- YES 7.29 0.14 11.98% 
P14625 HSP90B1 Endoplasmin  GYEVIYLTEPVDEYCIQALPEFDGK 576 -- -- 7.53 0.14 12.01% 
Q14573 ITPR3 Inositol 1,4,5-trisphosphate receptor type 3  LGFVDVQNCISR 2668 -- -- 8.19 0.15 12.04% 
P30040 ERP29 Endoplasmic reticulum resident protein 29  
GQGVYLGMPGCLPVYD
ALAGEFIR 157 -- -- 7.51 0.14 12.05% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- FSPNSSNPIIVSCGWDK 168 -- -- 7.42 0.14 12.08% 
Q99832 CCT7 T-complex protein 1 subunit eta  CQVFEETQIGGER 345 -- -- 7.64 0.15 12.12% 
O00186 STXBP3 Syntaxin-binding protein 3  NHDNCDK 402 -- -- 12.61 0.19 12.27% 
Q06136 KDSR 3-ketodihydrosphingosine reductase  LISETTSVCK 245 -- -- 7.23 0.14 12.29% 
P07237 P4HB Protein disulfide-isomerase  EECPAVR 312 -- YES 7.14 0.14 12.31% 
P61158 ACTR3 Actin-related protein 3  YSYVCPDLVK 235 -- -- 7.31 0.14 12.31% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al DCGLF 352 -- YES 7.04 0.14 12.38% 
P35579 MYH9 Myosin-9  LQLQEQLQAETELCAEAEELR 896 -- -- 7.03 0.15 12.57% 
P55735 SEC13 Protein SEC13 homolog  VFIWTCDDASSNTWSPK 245 -- -- 6.95 0.15 12.66% 
O43747 AP1G1 AP-1 complex subunit gamma-1  FTCTVNR 539 -- -- 7.06 0.15 12.66% 
Q14195 DPYSL3 Dihydropyrimidinase-related protein 3  AITIASQTNCPLYVTK 248 -- -- 6.96 0.15 12.66% 
O43707 ACTN4 Alpha-actinin-4  ICDQWDALGSLTHSR 499 -- YES 6.89 0.15 12.76% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al EIYTHFTCATDTK 326 -- -- 7.02 0.15 12.84% 
P12931 SRC Proto-oncogene tyrosine-protein kinase Src  LTTVCPTSK 248 -- -- 6.92 0.15 12.86% 
P06733 ENO1 Alpha-enolase  SGETEDTFIADLVVGLCTGQIK 389 -- YES 6.81 0.15 12.93% 
P27348 YWHAQ 14-3-3 protein theta  YLAEVACGDDR 134 -- -- 6.80 0.15 12.94% 
P04075 ALDOA Fructose-bisphosphate aldolase A  ALANSLACQGK 339 -- YES 6.79 0.15 12.95% 
P68366 TUBA4A Tubulin alpha-4A chain  AVCMLSNTTAIAEAWAR 376 -- -- 6.78 0.15 12.97% 
P16435 POR NADPH--cytochrome P450 reductase  EVGETLLYYGCR 566 -- -- 6.71 0.15 13.01% 
Q15738 NSDHL Sterol-4-alpha-carboxylate 3-dehydrogenase, decarb FFLGDLCSR 86 -- -- 6.70 0.15 13.02% 
Q96AC1 FERMT2 Fermitin family homolog 2  GCEVTPDVNISGQK 426 -- YES 6.72 0.15 13.04% 
Q86UP2 KTN1 Kinectin  ECMAGTSGSEEVK 1105 -- -- 12.42 0.21 13.09% 
Q02543 RPL18A 60S ribosomal protein L18a  SSGEIVYCGQVFEK 64 -- -- 6.77 0.16 13.15% 
Q15149 PLEC Plectin  C*VEDPETGLC*LLPLTDK 3008 -- -- 6.76 0.15 13.16% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4  AGSDGESIGNCPFSQR 35 -- -- 6.68 0.16 13.23% 
P23528 CFL1 Cofilin-1  HELQANCYEEVK 139 -- -- 6.63 0.16 13.29% 
O95716 RAB3D Ras-related protein Rab-3D  CDLEDER 137 -- -- 6.85 0.16 13.36% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4  IEEFLEEVLCPPK 100 -- -- 6.51 0.16 13.43% 




201 -- -- 6.41 0.16 13.47% 
P08670 VIM Vimentin  QVQSLTCEVDALK 328 -- YES 6.56 0.16 13.52% 
P35579 MYH9 Myosin-9  LEEEQIILEDQNCK 988 -- -- 9.69 0.19 13.57% 
P09543 CNP 2,3-cyclic-nucleotide 3-phosphodiesterase  LDEDLAAYCR 111 -- -- 6.50 0.16 13.58% 
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Q96A33 CCDC47 Coiled-coil domain-containing protein 47  LNQENEHIYNLWCSGR 209 -- -- 7.68 0.19 13.62% 
Q15436 SEC23A Protein transport protein Sec23A  AVLNPLCQVDYR 74 -- -- 6.28 0.16 13.77% 
P49327 FASN Fatty acid synthase  TGGAYGEDLGADYNLSQVCDGK 2468 -- -- 6.39 0.16 13.78% 
Q13308 PTK7 Inactive tyrosine-protein kinase 7  NCLVSAQR 936 -- -- 6.25 0.16 13.79% 
P07437 TUBB Tubulin beta chain  LTTPTYGDLNHLVSATMSGVTTCLR 239 -- -- 6.18 0.16 13.86% 
P68366 TUBA4A Tubulin alpha-4A chain  SIQFVDWCPTGFK 347 -- YES 6.16 0.16 13.88% 
Q15437 SEC23B Protein transport protein Sec23B  IAGAIGPCVSLNVK 425 -- -- 6.23 0.17 14.05% 
Q9Y230 RUVBL2 RuvB-like 2  FVQCPDGELQK 227 -- -- 6.17 0.17 14.06% 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha NLEAVETLGSTSTICSDK 374 -- -- 6.19 0.17 14.07% 
P26038 MSN Moesin  EGILNDDIYCPPETAVLLASYAVQSK 117 -- -- 6.16 0.17 14.08% 
Q9H4G4 GLIPR2 Golgi-associated plant pathogenesis-related protei 
GQCGENLAWASYDQTG
K 63 -- -- 6.50 0.18 14.09% 
Q16658 FSCN1 Fascin  QIWTLEQPPDEAGSAAVCLR 61 -- -- 6.07 0.17 14.20% 
Q93050 ATP6V0A1 V-type proton ATPase 116 kDa subunit a isoform 1  ASLYPCPETPQER 247 -- -- 6.01 0.17 14.40% 
O94979 SEC31A Protein transport protein Sec31A  PDEFSALCDLLGTR 669 -- -- 12.11 0.24 14.42% 
O95487 SEC24B Protein transport protein Sec24B  CTLTNIPQTQALLNK 562 -- -- 6.05 0.17 14.44% 
P60763 RAC3 Ras-related C3 botulinum toxin substrate 3  AVLCPPPVK 178 -- -- 5.96 0.17 14.46% 
P61158 ACTR3 Actin-related protein 3  LGYAGNTEPQFIIPSCIAIK 34 -- -- 6.13 0.18 14.47% 
Q9UL25 RAB21 Ras-related protein Rab-21  VVLLGEGCVGK 29 -- -- 5.99 0.17 14.47% 
Q01518 CAP1 Adenylyl cyclase-associated protein 1  NSLDCEIVSAK 427 -- -- 6.05 0.17 14.49% 
P33176 KIF5B Kinesin-1 heavy chain  VFQSSTSQEQVYNDCAK 65 -- -- 5.67 0.15 14.51% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- YWLCAATGPSIK 249 -- -- 5.87 0.17 14.55% 
Q658P3 STEAP3 Metalloreductase STEAP3  QVPICGDQPEAK 168 -- -- 5.96 0.17 14.58% 
O75369 FLNB Filamin-B  SSFLVDCSK 2537 -- -- 5.85 0.17 14.58% 
P42330 AKR1C3 Aldo-keto reductase family 1 member C3  
WVDPNSPVLLEDPVLCA
LAK 242 -- -- 6.18 0.18 14.62% 
Q14247 CTTN Src substrate cortactin  HCSQVDSVR 112 -- -- 12.03 0.25 14.85% 
P21333 FLNA Filamin-A  VDINTEDLEDGTCR 2102 -- -- 7.67 0.19 14.87% 
P62829 RPL23 60S ribosomal protein L23  ISLGLPVGAVINCADNTGAK 28 -- YES 5.73 0.18 14.88% 
P63010 AP2B1 AP-2 complex subunit beta  DCEDPNPLIR 95 -- -- 5.80 0.18 14.90% 
P12814 ACTN1 Alpha-actinin-1  DGLGFCALIHR 180 -- -- 12.00 0.25 14.93% 
P35606 COPB2 Coatomer subunit beta  GVNCIDYYSGGDK 190 -- -- 8.64 0.21 15.05% 
Q02543 RPL18A 60S ribosomal protein L18a  DLTTAGAVTQCYR 109 -- YES 5.33 0.17 15.09% 
Q9Y3I0 C22orf28 tRNA-splicing ligase RtcB homolog  EHCEEYGR 193 -- -- 5.67 0.18 15.12% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al 
QLFALSCTAEEQGVLPD
DLSGVIR 112 -- YES 5.57 0.18 15.24% 
Q07065 CKAP4 Cytoskeleton-associated protein 4  
SSSSSSASAAAAAAAASS
SASCSR 100 -- YES 5.55 0.18 15.26% 
Q9UPT5 EXOC7 Exocyst complex component 7  GFNDGLEELCK 667 -- -- 11.95 0.26 15.27% 
P46776 RPL27A 60S ribosomal protein L27a  NQSFCPTVNLDK 70 -- -- 5.55 0.18 15.31% 
P60981 DSTN Destrin  CIIVEEGK 46 -- -- 5.42 0.19 15.64% 
P55735 SEC13 Protein SEC13 homolog  DVAWAPSIGLPTSTIASCSQDGR 234 -- -- 5.35 0.19 15.69% 
P14618 PKM Pyruvate kinase isozymes M1/M2  
AEGSDVANAVLDGADC
IMLSGETAK 358 -- -- 5.36 0.19 15.85% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59  VAGDC*LDEKQC*K 131 -- -- 5.48 0.19 15.87% 
P06733 ENO1 Alpha-enolase  TGAPCR 399 -- -- 5.33 0.19 15.89% 
O14936 CASK Peripheral plasma membrane protein CASK  DDLIPCK 633 -- -- 5.30 0.19 15.94% 
O75131 CPNE3 Copine-3  TIELSDDDFLGEC*EC*TLGQIVSSK 98 -- -- 5.29 0.19 16.00% 
P45880 VDAC2 Voltage-dependent anion-selective channel protein  
WNTDNTLGTEIAIEDQI
CQGLK 103 -- -- 5.42 0.20 16.02% 
P67870 CSNK2B Casein kinase II subunit beta  YQQGDFGYCPR 109 -- -- 5.22 0.19 16.04% 
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Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59  VAGDCLDEK 131 -- -- 5.20 0.19 16.05% 
Q8TC12 RDH11 Retinol dehydrogenase 11  FYNAGLAYCHSK 203 -- -- 5.61 0.20 16.07% 
O75369 FLNB Filamin-B  CLATGPGIASTVK 1617 -- -- 5.27 0.20 16.20% 
P62829 RPL23 60S ribosomal protein L23  ECADLWPR 125 -- YES 5.18 0.20 16.25% 
P21333 FLNA Filamin-A  THEAEIVEGENHTYCIR 2199 -- -- 5.17 0.20 16.28% 
Q96TA1 FAM129B Niban-like protein 1  HCNNGIPEDSK 194 -- -- 5.13 0.20 16.41% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X  
GADSLEDFLYHEGYACT
SIHGDR 468 -- -- 11.74 0.29 16.52% 
O75083 WDR1 WD repeat-containing protein 1  SIQCLTVHK 325 -- -- 5.04 0.20 16.64% 
P09382 LGALS1 Galectin-1  DSNNLCLHFNPR 43 -- YES 5.02 0.20 16.66% 
P50914 RPL14 60S ribosomal protein L14  CMQLTDFILK 54 -- -- 5.03 0.20 16.67% 
Q96CS3 FAF2 FAS-associated factor 2  NTLCAPEVISLINTR 194 -- -- 5.06 0.20 16.70% 
Q10567 AP1B1 AP-1 complex subunit beta-1  IQPGNPSCTDLELSLK 921 -- -- 4.94 0.20 16.76% 
P00338 LDHA L-lactate dehydrogenase A chain  VIGSGCNLDSAR 163 -- YES 4.96 0.20 16.77% 
P60981 DSTN Destrin  HECQANGPEDLNR 135 -- -- 4.93 0.20 16.77% 
P00558 PGK1 Phosphoglycerate kinase 1  DCVGPEVEK 99 -- -- 5.10 0.21 16.81% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X  WCDK 128 -- -- 5.17 0.21 16.83% 
Q9Y4P3 TBL2 Transducin beta-like protein 2  FEEAAGAAPCR 335 -- -- 5.00 0.21 16.85% 





ELGSECGIEFDEEK 145 -- -- 4.85 0.21 17.08% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  
ACGDSTLTQITAGLDPV
GR 25 -- -- 4.82 0.21 17.28% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- LWNTLGVCK 138 -- YES 4.77 0.21 17.35% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase  TGTLTTNQMSVCR 364 -- -- 6.46 0.24 17.38% 
P12814 ACTN1 Alpha-actinin-1  ICDQWDNLGALTQK 480 -- -- 4.75 0.21 17.38% 
Q9HBH5 RDH14 Retinol dehydrogenase 14  QAAECGPEPGVSGVGELIVR 97 -- -- 5.21 0.22 17.39% 
P29317 EPHA2 Ephrin type-A receptor 2  FTTEIHPSCVTR 612 -- -- 4.74 0.21 17.40% 
G3V599 CTAGE5 Cutaneous T-cell lymphoma-associated antigen 5  EATEAQSLEATCEK 666 -- -- 5.19 0.22 17.46% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  
VSCLGVTDDGMAVATG
SWDSFLK 317 -- -- 4.82 0.22 17.46% 
P08134 RHOC Rho-related GTP-binding protein RhoC  LVIVGDGACGK 16 -- YES 4.67 0.21 17.50% 
P21333 FLNA Filamin-A  VHSPSGALEECYVTEIDQDK 2378 -- -- 4.68 0.22 17.66% 
P29401 TKT Transketolase  QAFTDVATGSLGQGLGAACGMAYTGK 133 -- -- 4.69 0.22 17.68% 
Q13813 SPTAN1 Spectrin alpha chain, non-erythrocytic 1  CTELNQAWSSLGK 1314 -- -- 20.00 0.78 17.78% 
Q53EP0 FNDC3B Fibronectin type III domain-containing protein 3B  
ALNDGGYGPYSDVSEIT
TAAGPPGQCK 770 -- -- 11.54 0.32 17.84% 
P15311 EZR Ezrin  EGILSDEIYCPPETAVLLGSYAVQAK 117 -- -- 4.62 0.22 17.93% 
O60716 CTNND1 Catenin delta-1  NCDGVPALVR 450 -- -- 9.20 0.50 17.93% 
Q12904 AIMP1 Aminoacyl tRNA synthase complex-interacting multif 
IWEQIQPDLHTNDECVA
TYK 284 -- -- 4.58 0.22 17.99% 
P49327 FASN Fatty acid synthase  DGLLENQTPEFFQDVCK 1992 -- -- 4.76 0.23 18.02% 
P53675 CLTCL1 Clathrin heavy chain 2  LECSEELGDLVK 459 -- -- 18.79 0.54 18.08% 
P49327 FASN Fatty acid synthase  ADEASELACPTPK 2202 -- YES 11.52 0.33 18.13% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3  
WLC*TGDIGEFEPDGC*L
K 561 -- -- 4.50 0.22 18.14% 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44  VDCDQHSDIAQR 92 -- -- 4.45 0.23 18.38% 
Q15149 PLEC Plectin  VPLDVACAR 3295 -- -- 4.44 0.23 18.38% 
Q9Y4P3 TBL2 Transducin beta-like protein 2  FLASCGDR 391 -- -- 4.44 0.23 18.43% 
P11940 PABPC1 Polyadenylate-binding protein 1  ALYDTFSAFGNILSCK 128 -- YES 4.49 0.23 18.50% 
Q9H2U1 DHX36 Probable ATP-dependent RNA helicase DHX36  AESCGSGNSTGYQIR 284 -- -- 4.43 0.23 18.60% 
P42356 PI4KA Phosphatidylinositol 4-kinase alpha  DIAIDNICR 574 -- -- 4.66 0.25 18.63% 
P30101 PDIA3 Protein disulfide-isomerase A3  FIQENIFGICPHMTEDNK 244 -- -- 4.39 0.23 18.64% 
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Q9NZM1 MYOF Myoferlin  AASPSELTCPPGWEWEDDAWSYDINR 969 -- -- 4.42 0.23 18.66% 
P00558 PGK1 Phosphoglycerate kinase 1  ACANPAAGSVILLENLR 108 -- YES 4.37 0.23 18.69% 
P46940 IQGAP1 Ras GTPase-activating-like protein IQGAP1  
SPDVGLYGVIPECGETY
HSDLAEAK 660 -- -- 4.35 0.23 18.70% 
P13639 EEF2 Elongation factor 2  CELLYEGPPDDEAAMGIK 369 -- -- 4.66 0.24 18.82% 
Q9UGP8 SEC63 Translocation protein SEC63 homolog  APTLASLENCMK 366 -- -- 7.74 0.33 18.96% 
Q15149 PLEC Plectin  GCLDEETSR 3299 -- -- 4.27 0.24 19.01% 
P21333 FLNA Filamin-A  CAPGVVGPAEADIDFDIIR 810 -- YES 4.28 0.24 19.18% 
Q9NYB9 ABI2 Abl interactor 2  VADYCENNYIQSADK 33 -- -- 12.66 0.59 19.24% 
Q15418 RPS6KA1 Ribosomal protein S6 kinase alpha-1  PSNILYVDESGNPECLR 552 -- -- 4.20 0.24 19.33% 
P09382 LGALS1 Galectin-1  FNAHGDANTIVCNSK 61 -- YES 4.17 0.24 19.35% 
P63104 YWHAZ 14-3-3 protein zeta/delta  YDDMAACMK 25 -- -- 4.16 0.24 19.38% 
O75369 FLNB Filamin-B  VHSPSGAVEECHVSELEPDK 2333 -- -- 4.17 0.24 19.39% 
P62280 RPS11 40S ribosomal protein S11  CPFTGNVSIR 60 -- YES 4.11 0.24 19.46% 
O75369 FLNB Filamin-B  MDCQETPEGYK 2431 -- -- 4.63 0.25 19.57% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- YTVQDESHSEWVSCVR 153 -- -- 4.10 0.25 19.66% 
P17980 PSMC3 26S protease regulatory subunit 6A  C*TDDFNGAQC*K 387 -- -- 4.10 0.25 19.74% 
P21333 FLNA Filamin-A  LQVEPAVDTSGVQCYGPGIEGQGVFR 1260 -- -- 4.09 0.25 19.84% 
Q01813 PFKP 6-phosphofructokinase type C  NESCSENYTTDFIYQLYSEEGK 641 -- -- 4.06 0.25 19.89% 
P27816 MAP4 Microtubule-associated protein 4  
NVCLPPEMEVALTEDQ
VPALK 535 -- -- 4.04 0.25 19.95% 
P46821 MAP1B Microtubule-associated protein 1B  
GPAESPDEGITTTEGEGE
CEQTPEELEPVEK 905 -- -- 4.02 0.25 19.97% 
O15270 SPTLC2 Serine palmitoyltransferase 2  VLEEYGAGVCSTR 204 -- -- 4.01 0.25 19.99% 
Q8N5K1 CISD2 CDGSH iron-sulfur domain-containing protein 2  VVNEINIEDLCLTK 92 -- -- 4.07 0.26 20.19% 
Q6UX07 DHRS13 Dehydrogenase/reductase SDR family member 13  VVVVASAAHCR 174 -- -- 5.89 0.28 20.19% 
P21333 FLNA Filamin-A  VQVQDNEGCPVEALVK 717 -- -- 3.99 0.26 20.19% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  TFVSGACDASIK 204 -- -- 3.94 0.26 20.29% 
P62906 RPL10A 60S ribosomal protein L10a  FSVC*VLGDQQHC*DEAK 66 -- YES 3.91 0.26 20.36% 
O75083 WDR1 WD repeat-containing protein 1  CFSIDNPGYEPEVVAVHPGGDTVAIGGVDGNVR 438 -- -- 3.91 0.26 20.53% 
P27635 RPL10 60S ribosomal protein L10  LIPDGCGVK 195 -- -- 3.90 0.26 20.53% 
P00492 HPRT1 Hypoxanthine-guanine phosphoribosyltransferase  SYCNDQSTGDIK 106 -- -- 3.92 0.26 20.57% 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit LWDCETGK 81 -- -- 3.90 0.26 20.61% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- VWNLANCK 182 -- -- 3.78 0.27 20.95% 
P62330 ARF6 ADP-ribosylation factor 6  NWYVQPSCATSGDGLYEGLTWLTSNYK 155 -- -- 4.58 0.28 20.95% 
O75369 FLNB Filamin-B  IEYNDQNDGSCDVK 604 -- YES 3.77 0.27 20.96% 
P05388 RPLP0 60S acidic ribosomal protein P0  AGAIAPCEVTVPAQNTGLGPEK 119 -- YES 3.76 0.27 20.98% 
P21333 FLNA Filamin-A  SSFTVDCSK 2582 -- -- 3.85 0.27 21.12% 
P27348 YWHAQ 14-3-3 protein theta  YDDMATCMK 25 -- -- 3.75 0.27 21.18% 
Q9H299 SH3BGRL3 SH3 domain-binding glutamic acid-rich-like protein 
ATPPQIVNGDQYCGDYE
LFVEAVEQNTLQEFLK 71 -- -- 3.72 0.27 21.24% 
P42677 RPS27 40S ribosomal protein S27  LTEGCSFR 77 -- YES 3.70 0.27 21.28% 
Q96HE7 ERO1L ERO1-like protein alpha  HDDSSDNFCEADDIQSPEAEYVDLLLNPER 166 YES -- 3.66 0.27 21.37% 
P21333 FLNA Filamin-A  DGSCGVAYVVQEPGDYEVSVK 2293 -- -- 3.50 0.26 21.47% 
P62888 RPL30 60S ribosomal protein L30  VCTLAIIDPGDSDIIR 92 -- YES 3.67 0.28 21.52% 
P36578 RPL4 60S ribosomal protein L4  SGQGAFGNMCR 96 -- -- 3.67 0.28 21.58% 
P46821 MAP1B Microtubule-associated protein 1B  ASLTLFCPEEGDWK 190 -- -- 11.16 0.43 21.65% 
Q9Y2L5 TRAPPC8 Trafficking protein particle complex subunit 8  
NSIQNQESYEDGPCTITS
NK 265 -- -- 3.60 0.28 21.66% 
P68366 TUBA4A Tubulin alpha-4A chain  TIGGGDDSFTTFFCETGAGK 54 -- YES 3.68 0.28 21.73% 
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O15270 SPTLC2 Serine palmitoyltransferase 2  NTGSCQEAAAK 188 -- -- 3.63 0.28 21.75% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  LFVSGACDASAK 204 -- -- 3.90 0.33 21.98% 
P55060 CSE1L Exportin-2  ICEADR 85 -- -- 3.42 0.27 22.27% 
O43264 ZW10 Centromere/kinetochore protein zw10 homolog  NCLVYSIPTNSSK 346 -- -- 3.53 0.30 22.45% 
P21333 FLNA Filamin-A  AEISC*TDNQDGTC*SVSYLPVLPGDYSILVK 1912 -- -- 3.41 0.30 22.73% 
O43491 EPB41L2 Band 4.1-like protein 2  VTLLDGTEYSCDLEK 232 -- -- 3.40 0.30 22.77% 
Q07020 RPL18 60S ribosomal protein L18  GCGTVLLSGPR 134 -- YES 3.39 0.30 22.78% 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A  ITIADCGQLE 161 -- YES 3.44 0.30 22.81% 
Q16658 FSCN1 Fascin  DGNVTCER 80 -- -- 3.40 0.30 22.94% 
Q9Y490 TLN1 Talin-1  ASAGPQPLLVQSCK 956 -- -- 10.66 0.38 22.97% 
P50914 RPL14 60S ribosomal protein L14  ALVDGPCTQVR 42 -- -- 3.33 0.30 23.09% 
Q14573 ITPR3 Inositol 1,4,5-trisphosphate receptor type 3  
VILNPVNAGQPLHASN
YELSDNAGCK 207 -- -- 3.33 0.30 23.10% 
P30050 RPL12 60S ribosomal protein L12  EILGTAQSVGCNVDGR 141 -- -- 3.32 0.31 23.34% 
Q9BRR6 ADPGK ADP-dependent glucokinase  VLLCGPVGPK 178 -- -- 11.02 0.49 23.51% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4  DEFTNTCPSDK 234 -- -- 3.30 0.31 23.54% 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit HVLTGSADNSCR 76 -- -- 3.31 0.31 23.58% 
Q15436 SEC23A Protein transport protein Sec23A  ISGAIGPCVSLNSK 423 -- -- 3.25 0.31 23.61% 
P53621 COPA Coatomer subunit alpha  GNNVYCLDR 580 -- -- 3.20 0.32 23.90% 
P15880 RPS2 40S ribosomal protein S2  GCTATLGNFAK 229 -- YES 3.17 0.32 23.98% 
A1L0T0 ILVBL Acetolactate synthase-like protein  VLHDAQQQCR 608 -- -- 4.50 0.35 24.08% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5  ELAQQVQQVAAEYCR 191 -- YES 3.37 0.33 24.13% 
Q9H5V8 CDCP1 CUB domain-containing protein 1  DQVACLTFFK 587 -- -- 3.16 0.32 24.16% 
Q15436 SEC23A Protein transport protein Sec23A  PDLPPIQYEPVLCSR 61 -- -- 3.15 0.32 24.19% 
Q7L5N7 LPCAT2 Lysophosphatidylcholine acyltransferase 2  
TTSGGEWPQILVFPEGTC
TNR 223 -- -- 3.04 0.32 24.35% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
AEPPQCTSLAWSADGQ
TLFAGYTDNLVR 286 -- -- 3.06 0.33 24.58% 
P62249 RPS16 40S ribosomal protein S16  TATAVAHCK 25 -- YES 3.09 0.33 24.72% 
Q9Y490 TLN1 Talin-1  QELAVFCSPEPPAK 2161 -- -- 8.85 -- 24.80% 
P04439 HLA-A HLA class I histocompatibility antigen, A-3 alpha  AYLDGTCVEWLR 188 YES -- 0.31 2.88 75.23% 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5  IAEVDCTAER 381 -- -- 0.30 3.43 77.08% 
Q15165 PON2 Serum paraoxonase/arylesterase 2  EVESVDLPHCHLIK 42 YES -- 0.28 3.44 77.67% 
P07942 LAMB1 Laminin subunit beta-1  VDDIICDSR 190 -- -- 0.44 11.15 78.10% 
P01891 HLA-A HLA class I histocompatibility antigen, A-68 alpha AYLEGTCVEWLR 188 YES -- 0.27 3.79 79.08% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  FVCNDDVYSGPLK 1042 -- -- 0.26 3.97 79.71% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  FTCSESQVNSR 1476 -- -- -- 6.50 80.53% 
Q13162 PRDX4 Peroxiredoxin-4  EEECHFYAGGQVYPGEASR 51 -- -- 0.21 5.13 83.34% 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44  GTINFLHADCDK 301 YES -- -- 9.06 84.76% 
P23229 ITGA6 Integrin alpha-6  VVTCAHR 131 YES -- 0.17 6.03 85.67% 
P27797 CALR Calreticulin  HEQNIDCGGGYVK 105 YES -- 0.16 6.21 86.17% 
P20645 M6PR Cation-dependent mannose-6-phosphate receptor  TCDLVGEK 32 -- -- -- 12.05 87.82% 
O15230 LAMA5 Laminin subunit alpha-5  DDAAICTTEYSR 215 -- -- -- 12.31 88.71% 
P30044 PRDX5 Peroxiredoxin-5, mitochondrial  ALNVEPDGTGLTCSLAPNIISQL 204 YES -- -- 12.46 89.17% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  YVDGDLCPDGIR 1461 -- -- 0.13 9.41 89.55% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  VVSSCQEK 1282 -- -- 0.12 8.56 89.61% 
Q32P28 LEPRE1 Prolyl 3-hydroxylase 1  TQCAADFPWELDPDWSPSPAQASGAAALR 79 -- -- -- 12.93 90.32% 
P21589 NT5E 5-nucleotidase  TIVYLDGSSQSCR 353 YES -- -- 12.19 90.85% 
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Q13586 STIM1 Stromal interaction molecule 1  ATGTSSGANSEESTAAEFCR 49 -- -- 0.12 12.52 91.01% 
Q99470 SDF2 Stromal cell-derived factor 2  SATVCER 80 -- -- -- 10.73 91.16% 
P49257 LMAN1 Protein ERGIC-53  NNPAIVIIGNNGQIHYDHQNDGASQALASCQR 190 YES -- 0.09 11.89 92.14% 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5  
VDC*TAHSDVC*SAQGV
R 121 -- -- 0.09 12.65 92.38% 
O14672 ADAM10 Disintegrin and metalloproteinase domain-containin TITLQPGSPCNDFR 632 YES -- -- 14.28 92.38% 
Q12907 LMAN2 Vesicular integral-membrane protein VIP36  WTELAGCTADFR 202 YES -- 0.10 15.11 92.41% 
Q9Y282 ERGIC3 Endoplasmic reticulum-Golgi intermediate compartme NEGCQVYGFLEVNK 199 -- -- -- 14.35 92.46% 
P27797 CALR Calreticulin  LFPNSLDQTDMHGDSEYNIMFGPDICGPGTK 137 YES -- -- 14.17 92.65% 
P30101 PDIA3 Protein disulfide-isomerase A3  VDC*TANTNTC*NK 85 YES -- 0.08 13.01 92.73% 
O15031 PLXNB2 Plexin-B2  GNIFLTSYQYPFYDCR 615 -- -- -- 13.47 93.06% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  LSSDVCPTSDK 1270 -- -- 0.06 14.36 93.69% 
P20908 COL5A1 Collagen alpha-1(V) chain  DLQLC*HPDFPDGEYWVDPNQGC*SR 1645 YES -- -- 15.56 93.86% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  TASSVIELTCTK 2096 YES -- -- 16.79 94.19% 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2  AVTSANIQEFAGCK 367 YES -- -- 17.88 94.70% 
Q13445 TMED1 Transmembrane emp24 domain-containing protein 1  LCFDNSFSTISEK 106 -- -- -- 18.35 94.79% 
Q13740 ALCAM CD166 antigen  SSPSFSSLHYQDAGNYVCETALQEVEGLK 392 YES -- -- 18.65 94.89% 
Q13740 ALCAM CD166 antigen  QIGDALPVSCTISASR 354 YES -- -- 19.21 95.04% 
P60033 CD81 CD81 antigen  NNLCPSGSNIISNLFK 175 YES -- -- 19.55 95.13% 
P01137 TGFB1 Transforming growth factor beta-1  ALDTNYCFSSTEK 285 YES -- -- 19.91 95.22% 
P48509 CD151 CD151 antigen  VEGGCITK 208 -- -- -- 19.96 95.23% 
P09486 SPARC SPARC  YIPPCLDSELTEFPLR 155 YES -- 0.05 20.00 95.24% 
Q7Z7H5 TMED4 Transmembrane emp24 domain-containing protein 4  CFIEEIPDETMVIGNYR 41 -- -- 0.05 20.00 95.24% 
P13987 CD59 CD59 glycoprotein  FEHCNFNDVTTR 70 YES YES -- 20.00 95.24% 
P16070 CD44 CD44 antigen  ALSIGFETCR 77 YES YES -- 20.00 95.24% 
P13987 CD59 CD59 glycoprotein  ENELTYYC*C*K 88 YES YES -- 20.00 95.24% 
P48509 CD151 CD151 antigen  TVVALCGQR 192 -- YES -- 20.00 95.24% 
Q13443 ADAM9 Disintegrin and metalloproteinase domain-containin FGNCGFSGNEYK 553 -- -- -- 20.00 95.24% 
Q13443 ADAM9 Disintegrin and metalloproteinase domain-containin LVDAGEEC*DC*GTPK 428 -- -- -- 20.00 95.24% 
P61769 B2M Beta-2-microglobulin  SNFLNCYVSGFHPSDIEVDLLK 45 YES -- -- 20.00 95.24% 
P35613 BSG Basigin  SSEHINEGETAMLVCK 242 YES -- -- 20.00 95.24% 
P13987 CD59 CD59 glycoprotein  CWK 64 YES -- -- 20.00 95.24% 
Q9H5V8 CDCP1 CUB domain-containing protein 1  ISFLCDDLTR 401 -- -- -- 20.00 95.24% 
P55285 CDH6 Cadherin-6  VLDVNDNAPEFAEFYETFVCEK 497 -- -- -- 20.00 95.24% 
P08603 CFH Complement factor H  SCDNPYIPNGDYSPLR 267 YES -- -- 20.00 95.24% 
Q96S66 CLCC1 Chloride channel CLIC-like protein 1  
DVSPDLSC*ADEISEC*Y
HK 60 -- -- -- 20.00 95.24% 
Q9BT09 CNPY3 Protein canopy homolog 3  DTSCLAEQWSGK 206 YES -- -- 20.00 95.24% 
P39060 COL18A1 Collagen alpha-1(XVIII) chain  LTESYCETWR 1706 YES -- -- 20.00 95.24% 
P07858 CTSB Cathepsin B  ICEPGYSPTYK 211 YES -- -- 20.00 95.24% 
P27487 DPP4 Dipeptidyl peptidase 4  CQYYSVSFSK 454 YES -- -- 20.00 95.24% 
P27487 DPP4 Dipeptidyl peptidase 4  VTC*LSC*ELNPER 444 YES -- -- 20.00 95.24% 
O43854 EDIL3 EGF-like repeat and discoidin I-like domain-contai SELLGCTEEE 476 YES -- -- 20.00 95.24% 
P00533 EGFR Epidermal growth factor receptor  ACGADSYEMEEDGVR 311 YES -- -- 20.00 95.24% 
P00533 EGFR Epidermal growth factor receptor  FSNNPALCNVESIQWR 157 YES -- -- 20.00 95.24% 
P00533 EGFR Epidermal growth factor receptor  NLCYANTINWK 470 YES -- -- 20.00 95.24% 
P00533 EGFR Epidermal growth factor receptor  NYVVTDHGSCVR 307 YES -- -- 20.00 95.24% 
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P00533 EGFR Epidermal growth factor receptor  YSFGATCVK 291 YES -- -- 20.00 95.24% 
P29317 EPHA2 Ephrin type-A receptor 2  VEDAC*QAC*SPGFFK 273 -- -- -- 20.00 95.24% 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2  C*WGESSEDC*QSLTR 204 YES -- -- 20.00 95.24% 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2  NPQLCYQDTILWK 162 YES -- -- 20.00 95.24% 
Q96HE7 ERO1L ERO1-like protein alpha  DC*AVKPC*QSDEVPDGIK 99 YES -- -- 20.00 95.24% 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44  TPADCPVIAIDSFR 318 YES -- -- 20.00 95.24% 
Q9Y624 F11R Junctional adhesion molecule A  LSCAYSGFSSPR 50 YES -- -- 20.00 95.24% 
P02751 FN1 Fibronectin  C*DPVDQC*QDSETGTFYQIGDSWEK 555 YES -- -- 20.00 95.24% 
P02751 FN1 Fibronectin  GFNC*ESKPEAEETC*FDK 87 YES -- -- 20.00 95.24% 
P02751 FN1 Fibronectin  TFYSCTTEGR 374 YES -- -- 20.00 95.24% 
P02751 FN1 Fibronectin  WCGTTQNYDADQK 446 YES -- -- 20.00 95.24% 
Q92896 GLG1 Golgi apparatus protein 1  DDSELEGQVISCLK 970 -- -- -- 20.00 95.24% 
Q92896 GLG1 Golgi apparatus protein 1  FCENTQAGEGR 324 -- -- -- 20.00 95.24% 
Q92896 GLG1 Golgi apparatus protein 1  TETGQELEC*LQDHLDDLVVEC*R 659 -- -- -- 20.00 95.24% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  GC*PEDAAVC*AVDK 531 -- -- -- 20.00 95.24% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  
LSGAYLVDDSDPDTSLFI
NVCR 212 YES -- -- 20.00 95.24% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  
SNEHDDCQVTNPSTGH
LFDLSSLSGR 1516 YES -- -- 20.00 95.24% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  
TCSLSGEQQDVSIDLTPL
AQSGGSSYISDGK 328 YES -- -- 20.00 95.24% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  VQSSIAFLCGK 134 YES -- -- 20.00 95.24% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor  
YSDGDLTLIYFGGDECSS
GFQR 420 YES -- -- 20.00 95.24% 
Q16270 IGFBP7 Insulin-like growth factor-binding protein 7  
EDAGEYECHASNSQGQ
ASASAK 248 YES -- -- 20.00 95.24% 
Q16270 IGFBP7 Insulin-like growth factor-binding protein 7  GEGEPCGGGGAGR 71 -- -- -- 20.00 95.24% 
P26006 ITGA3 Integrin alpha-3  SETVLTCATGR 904 YES -- -- 20.00 95.24% 
P06756 ITGAV Integrin alpha-V  CQPIEFDATGNR 97 YES -- -- 20.00 95.24% 
P06756 ITGAV Integrin alpha-V  EPVGTCFLQDGTK 158 YES -- -- 20.00 95.24% 
P06756 ITGAV Integrin alpha-V  SQDIDADGQGFCQGGFSIDFTK 185 YES -- -- 20.00 95.24% 
P05556 ITGB1 Integrin beta-1  CDDLEALK 64 YES -- -- 20.00 95.24% 
P05556 ITGB1 Integrin beta-1  GCPPDDIENPR 75 YES -- -- 20.00 95.24% 
P07942 LAMB1 Laminin subunit beta-1  CGNTIPDDDNQVVSLSPGSR 643 -- -- -- 20.00 95.24% 
P11047 LAMC1 Laminin subunit gamma-1  EDGPWIPYQYYSGSCENTYSK 182 -- -- -- 20.00 95.24% 
P11047 LAMC1 Laminin subunit gamma-1  HNTYGVDCEK 316 YES -- -- 20.00 95.24% 
Q32P28 LEPRE1 Prolyl 3-hydroxylase 1  VVMDGVISDHECQELQR 483 -- -- -- 20.00 95.24% 
Q8IVL5 LEPREL1 Prolyl 3-hydroxylase 2  VLLDNVLSEEQCR 476 -- -- -- 20.00 95.24% 
Q9Y4K0 LOXL2 Lysyl oxidase homolog 2  FNAESQGCNHEEDAGVR 414 YES -- -- 20.00 95.24% 
Q9UBG0 MRC2 C-type mannose receptor 2  YLNWESDQPDNPSEENCGVIR 335 YES -- -- 20.00 95.24% 
Q9Y639 NPTN Neuroplastin  AEDSGEYHCVYHFVSAPK 218 YES -- -- 20.00 95.24% 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  NMGADLCR 369 -- -- -- 20.00 95.24% 
O15031 PLXNB2 Plexin-B2  DSQDPYC*GWC*VVEGR 486 YES -- -- 20.00 95.24% 
O15031 PLXNB2 Plexin-B2  LVECGSLFK 112 YES -- -- 20.00 95.24% 






SQALSGCEISISNETK 100 -- -- -- 20.00 95.24% 
Q9HCN8 SDF2L1 Stromal cell-derived factor 2-like protein 1  GGSEGGCPR 92 -- -- -- 20.00 95.24% 
Q9HCN8 SDF2L1 Stromal cell-derived factor 2-like protein 1  TGAELVTCGSVLK 38 -- -- -- 20.00 95.24% 
Q8WWI5 SLC44A1 Choline transporter-like protein 1  LVSGYDSYGNICGQK 69 -- -- -- 20.00 95.24% 
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Q99523 SORT1 Sortilin  PENSECDATAK 448 YES -- -- 20.00 95.24% 
P48307 TFPI2 Tissue factor pathway inhibitor 2  
TC*DAFTYTGC*GGNDN
NFVSR 183 YES -- -- 20.00 95.24% 
Q92544 TM9SF4 Transmembrane 9 superfamily member 4  TQLPYEYYSLPFCQPSK 64 -- -- -- 20.00 95.24% 
Q9NV96 TMEM30A Cell cycle control protein 50A  ECEPYR 157 -- -- -- 20.00 95.24% 
Q9NV96 TMEM30A Cell cycle control protein 50A  EIEIDYTGTEPSSPCNK 91 -- -- -- 20.00 95.24% 
Q96HE7 ERO1L ERO1-like protein alpha  YSEEANNLIEECEQAER 131 YES -- 0.04 20.00 95.54% 
Q32P28 LEPRE1 Prolyl 3-hydroxylase 1  TVTAEVQPQCGR 645 -- -- 0.04 20.00 96.16% 
Q14697 GANAB Neutral alpha-glucosidase AB  TC*EESSFC*K 41 YES -- 0.01 20.00 96.50% 
 
Table 2A-7. ReDiMe analysis to quantify changes in protein abundance following 
treatment with DMSO or Tg. Data was filtered for secretory pathway proteins that 
appeared in two replicates. Ratios were converted to log2(Tg:DMSO) and sorted 
by increasing levels of expression following Tg treatment. The 100 most abundant 
and 100 least abundant proteins following Tg treatment are shown. Localization 
of proteins was determined using Uniprot and GO annotated tabs on UniprotKB. 
Uniprot 
ID Protein Description 
Ratio H:L log2(Ratio) 
Average 
1 2 1 2 
P14136 GFAP Glial fibrillary acidic protein 0.21 0.3 -2.25 -1.74 -1.99 
P17661 DES Desmin 0.21 0.31 -2.25 -1.69 -1.97 
P08670 VIM Vimentin 0.33 0.26 -1.60 -1.94 -1.77 
P55072 VCP Transitional endoplasmic reticulum ATPase 0.36 0.3 -1.47 -1.74 -1.61 
P05121 SERPINE1 Plasminogen activator inhibitor 1 0.26 0.5 -1.94 -1.00 -1.47 
P13693 TPT1 Translationally-controlled tumor protein 0.39 0.52 -1.36 -0.94 -1.15 
P68400 CSNK2A1 Casein kinase II subunit alpha 0.5 0.43 -1.00 -1.22 -1.11 
P19784 CSNK2A2 Casein kinase II subunit alpha 0.44 0.5 -1.18 -1.00 -1.09 
P14618 PKM Pyruvate kinase isozymes M1/M2 0.49 0.45 -1.03 -1.15 -1.09 
Q06481 APLP2 Amyloid-like protein 2 0.43 0.53 -1.22 -0.92 -1.07 
O14579 COPE Coatomer subunit epsilon 0.41 0.59 -1.29 -0.76 -1.02 
Q12906 ILF3 Interleukin enhancer-binding factor 3 0.53 0.47 -0.92 -1.09 -1.00 
O15144 ARPC2 Actin-related protein 2/3 complex subunit 2 0.34 0.75 -1.56 -0.42 -0.99 
P35606 COPB2 Coatomer subunit beta 0.52 0.53 -0.94 -0.92 -0.93 
P31689 DNAJA1 DnaJ homolog subfamily A member 1 0.45 0.65 -1.15 -0.62 -0.89 
Q969G5 PRKCDBP Protein kinase C delta-binding protein 0.42 0.7 -1.25 -0.51 -0.88 
O15061 SYNM Synemin 0.66 0.47 -0.60 -1.09 -0.84 
P53618 COPB1 Coatomer subunit beta 0.54 0.62 -0.89 -0.69 -0.79 
P05067 APP Amyloid beta A4 protein 0.82 0.41 -0.29 -1.29 -0.79 
P60174 TPI1 Triosephosphate isomerase 0.59 0.58 -0.76 -0.79 -0.77 
P48444 ARCN1 Coatomer subunit delta 0.52 0.66 -0.94 -0.60 -0.77 
Q12905 ILF2 Interleukin enhancer-binding factor 2 0.61 0.61 -0.71 -0.71 -0.71 
P25786 PSMA1 Proteasome subunit alpha type-1 0.62 0.61 -0.69 -0.71 -0.70 
P53396 ACLY ATP-citrate synthase 0.62 0.64 -0.69 -0.64 -0.67 
P49773 HINT1 Histidine triad nucleotide-binding protein 1 0.5 0.8 -1.00 -0.32 -0.66 
P06744 GPI Glucose-6-phosphate isomerase 0.58 0.69 -0.79 -0.54 -0.66 
Q6NZI2 PTRF Polymerase I and transcript release factor 0.64 0.63 -0.64 -0.67 -0.66 
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P06737 PYGL Glycogen phosphorylase, liver form  0.56 0.74 -0.84 -0.43 -0.64 
P53621 COPA Coatomer subunit alpha 0.64 0.65 -0.64 -0.62 -0.63 
P55884 EIF3B Eukaryotic translation initiation factor 3 subunit 0.59 0.71 -0.76 -0.49 -0.63 
O00764 PDXK Pyridoxal kinase 0.61 0.69 -0.71 -0.54 -0.62 
P50395 GDI2 Rab GDP dissociation inhibitor beta 0.59 0.72 -0.76 -0.47 -0.62 
P00441 SOD1 Superoxide dismutase 0.62 0.7 -0.69 -0.51 -0.60 
P68366 TUBA4A Tubulin alpha-4A chain 0.63 0.69 -0.67 -0.54 -0.60 
Q86VP6 CAND1 Cullin-associated NEDD8-dissociated protein 1 0.43 1.02 -1.22 0.03 -0.59 
Q7KZF4 SND1 Staphylococcal nuclease domain-containing protein 0.7 0.63 -0.51 -0.67 -0.59 
Q71U36 TUBA1A Tubulin alpha-1A chain 0.65 0.68 -0.62 -0.56 -0.59 
O43491 EPB41L2 Band 4.1-like protein 2 0.52 0.86 -0.94 -0.22 -0.58 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit 0.7 0.64 -0.51 -0.64 -0.58 
P07900 HSP90AA1 Heat shock protein HSP 90-alpha 0.65 0.7 -0.62 -0.51 -0.57 
Q01518 CAP1 Adenylyl cyclase-associated protein 1 0.6 0.78 -0.74 -0.36 -0.55 
Q8IZP0 ABI1 Abl interactor 1 0.62 0.78 -0.69 -0.36 -0.52 
P07437 TUBB Tubulin beta chain 0.74 0.66 -0.43 -0.60 -0.52 
Q9BUF5 TUBB6 Tubulin beta-6 chain 0.68 0.72 -0.56 -0.47 -0.52 
P14868 DARS Aspartate--tRNA ligase, cytoplasmic  0.63 0.78 -0.67 -0.36 -0.51 
P08238 HSP90AB1 Heat shock protein HSP 90-beta 0.67 0.74 -0.58 -0.43 -0.51 
Q9Y678 COPG1 Coatomer subunit gamma-1 0.67 0.74 -0.58 -0.43 -0.51 
P62140 PPP1CB Serine/threonine-protein phosphatase PP1-beta cata 0.71 0.7 -0.49 -0.51 -0.50 
P28482 MAPK1 Mitogen-activated protein kinase 1 0.81 0.62 -0.30 -0.69 -0.50 
O15118 NPC1 Niemann-Pick C1 protein 0.6 0.84 -0.74 -0.25 -0.49 
Q16881 TXNRD1 Thioredoxin reductase 1, cytoplasmic  0.82 0.62 -0.29 -0.69 -0.49 
P50991 CCT4 T-complex protein 1 subunit delta 0.68 0.75 -0.56 -0.42 -0.49 
Q3ZCM7 TUBB8 Tubulin beta-8 chain 0.71 0.72 -0.49 -0.47 -0.48 
Q15042 RAB3GAP1 Rab3 GTPase-activating protein catalytic subunit 0.68 0.76 -0.56 -0.40 -0.48 
Q8TDD1 DDX54 ATP-dependent RNA helicase DDX54 0.68 0.76 -0.56 -0.40 -0.48 
P68371 TUBB4B Tubulin beta-4B chain 0.76 0.68 -0.40 -0.56 -0.48 
P49368 CCT3 T-complex protein 1 subunit gamma 0.74 0.7 -0.43 -0.51 -0.47 
Q9UH65 SWAP70 Switch-associated protein 70 0.57 0.92 -0.81 -0.12 -0.47 
Q13509 TUBB3 Tubulin beta-3 chain 0.78 0.68 -0.36 -0.56 -0.46 
P30530 AXL Tyrosine-protein kinase receptor UFO 0.69 0.78 -0.54 -0.36 -0.45 
Q9NPR2 SEMA4B Semaphorin-4B 0.71 0.78 -0.49 -0.36 -0.43 
P26599 PTBP1 Polypyrimidine tract-binding protein 1 0.66 0.84 -0.60 -0.25 -0.43 
P00338 LDHA L-lactate dehydrogenase A chain 0.64 0.88 -0.64 -0.18 -0.41 
O95347 SMC2 Structural maintenance of chromosomes protein 2 0.84 0.68 -0.25 -0.56 -0.40 
P11216 PYGB Glycogen phosphorylase, brain form  0.79 0.73 -0.34 -0.45 -0.40 
Q8IZH2 XRN1 5-3 exoribonuclease 1 0.5 1.17 -1.00 0.23 -0.39 
Q01813 PFKP 6-phosphofructokinase type C 0.72 0.83 -0.47 -0.27 -0.37 
Q5T4S7 UBR4 E3 ubiquitin-protein ligase UBR4 0.72 0.84 -0.47 -0.25 -0.36 
P61158 ACTR3 Actin-related protein 3 0.66 0.92 -0.60 -0.12 -0.36 
P21333 FLNA Filamin-A 0.75 0.81 -0.42 -0.30 -0.36 
P00558 PGK1 Phosphoglycerate kinase 1 0.79 0.77 -0.34 -0.38 -0.36 
P09493 TPM1 Tropomyosin alpha-1 chain 0.94 0.65 -0.09 -0.62 -0.36 
O75369 FLNB Filamin-B 0.71 0.87 -0.49 -0.20 -0.35 
P04792 HSPB1 Heat shock protein beta-1 0.83 0.75 -0.27 -0.42 -0.34 
Q99832 CCT7 T-complex protein 1 subunit eta 0.76 0.82 -0.40 -0.29 -0.34 
Q13418 ILK Integrin-linked protein kinase 0.82 0.77 -0.29 -0.38 -0.33 
Q96QK1 VPS35 Vacuolar protein sorting-associated protein 35 0.87 0.73 -0.20 -0.45 -0.33 
P46777 RPL5 60S ribosomal protein L5 0.88 0.73 -0.18 -0.45 -0.32 
P62136 PPP1CA Serine/threonine-protein phosphatase PP1-alpha cat 0.8 0.81 -0.32 -0.30 -0.31 
P12956 XRCC6 X-ray repair cross-complementing protein 6 0.73 0.89 -0.45 -0.17 -0.31 
Q13618 CUL3 Cullin-3 0.76 0.86 -0.40 -0.22 -0.31 
P18124 RPL7 60S ribosomal protein L7 0.84 0.78 -0.25 -0.36 -0.30 
P31949 S100A11 Protein S100-A11 0.72 0.91 -0.47 -0.14 -0.30 
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Q9UQ16 DNM3 Dynamin-3 0.62 1.06 -0.69 0.08 -0.30 
Q96FW1 OTUB1 Ubiquitin thioesterase OTUB1 0.7 0.94 -0.51 -0.09 -0.30 
O00231 PSMD11 26S proteasome non-ATPase regulatory subunit 11 0.68 0.97 -0.56 -0.04 -0.30 
Q14195 DPYSL3 Dihydropyrimidinase-related protein 3 0.83 0.8 -0.27 -0.32 -0.30 
Q6S8J3 POTEE POTE ankyrin domain family member E 0.73 0.91 -0.45 -0.14 -0.30 
P32969 RPL9P9 60S ribosomal protein L9 0.78 0.86 -0.36 -0.22 -0.29 
P22087 FBL rRNA 2-O-methyltransferase fibrillarin 0.8 0.84 -0.32 -0.25 -0.29 
Q9P2J5 LARS Leucine--tRNA ligase, cytoplasmic  0.75 0.9 -0.42 -0.15 -0.28 
Q15046 KARS Lysine--tRNA ligase 1.06 0.64 0.08 -0.64 -0.28 
P06756 ITGAV Integrin alpha-V 0.56 1.22 -0.84 0.29 -0.27 
P60709 ACTB Actin, cytoplasmic 1  0.76 0.9 -0.40 -0.15 -0.27 
P46459 NSF Vesicle-fusing ATPase 0.87 0.79 -0.20 -0.34 -0.27 
P07602 PSAP Proactivator polypeptide 0.68 1.02 -0.56 0.03 -0.26 
P04075 ALDOA Fructose-bisphosphate aldolase A 0.94 0.74 -0.09 -0.43 -0.26 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 0.81 0.86 -0.30 -0.22 -0.26 
P06753 TPM3 Tropomyosin alpha-3 chain 1.09 0.64 0.12 -0.64 -0.26 
P78344 EIF4G2 Eukaryotic translation initiation factor 4 gamma 2 0.72 0.97 -0.47 -0.04 -0.26 
Q8TC12 RDH11 Retinol dehydrogenase 11 2.05 1.65 1.04 0.72 0.88 
Q9HDC9 APMAP Adipocyte plasma membrane-associated protein 2.17 1.56 1.12 0.64 0.88 
Q9BRR6 ADPGK ADP-dependent glucokinase 1.71 1.98 0.77 0.99 0.88 
P07942 LAMB1 Laminin subunit beta-1 1.41 2.41 0.50 1.27 0.88 
Q15006 EMC2 ER membrane protein complex subunit 2 1.87 1.82 0.90 0.86 0.88 
Q15067 ACOX1 Peroxisomal acyl-coenzyme A oxidase 1 1.56 2.19 0.64 1.13 0.89 
P30519 HMOX2 Heme oxygenase 2 2.22 1.54 1.15 0.62 0.89 
Q13586 STIM1 Stromal interaction molecule 1 1.9 1.8 0.93 0.85 0.89 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosy 1.7 2.02 0.77 1.01 0.89 
Q7Z406 MYH14 Myosin-14 2.26 1.52 1.18 0.60 0.89 
P80303 NUCB2 Nucleobindin-2 1.92 1.79 0.94 0.84 0.89 
P61927 RPL37 60S ribosomal protein L37 1.9 1.81 0.93 0.86 0.89 
Q13724 MOGS Mannosyl-oligosaccharide glucosidase 1.58 2.19 0.66 1.13 0.90 
Q9Y4I1 MYO5A Unconventional myosin-Va 1.63 2.13 0.70 1.09 0.90 
O43896 KIF1C Kinesin-like protein KIF1C 1.55 2.24 0.63 1.16 0.90 
P50454 SERPINH1 Serpin H1 1.76 1.98 0.82 0.99 0.90 
Q9HCN8 SDF2L1 Stromal cell-derived factor 2-like protein 1 1.84 1.9 0.88 0.93 0.90 
Q10471 GALNT2 Polypeptide N-acetylgalactosaminyltransferase 2 2.44 1.44 1.29 0.53 0.91 
Q9H3N1 TMX1 Thioredoxin-related transmembrane protein 1 1.61 2.22 0.69 1.15 0.92 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  1.85 1.94 0.89 0.96 0.92 
Q16181 SEPT7 Septin-7 2.35 1.53 1.23 0.61 0.92 
P61513 RPL37A 60S ribosomal protein L37a 2.19 1.65 1.13 0.72 0.93 
P43307 SSR1 Translocon-associated protein subunit alpha 1.38 2.62 0.46 1.39 0.93 
O15460 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 1.83 2 0.87 1.00 0.94 
P49755 TMED10 Transmembrane emp24 domain-containing protein 10 1.96 1.87 0.97 0.90 0.94 
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B 1.68 2.22 0.75 1.15 0.95 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 2.04 1.84 1.03 0.88 0.95 
Q9H0U4 RAB1B Ras-related protein Rab-1B 2.15 1.75 1.10 0.81 0.96 
P07237 P4HB Protein disulfide-isomerase 1.84 2.06 0.88 1.04 0.96 
O75844 ZMPSTE24 CAAX prenyl protease 1 homolog 1.93 1.99 0.95 0.99 0.97 
P39656 DDOST Dolichyl-diphosphooligosaccharide--protein glycosy 1.96 1.98 0.97 0.99 0.98 
Q8WZ42 TTN Titin 1.89 2.09 0.92 1.06 0.99 
P14625 HSP90B1 Endoplasmin 2.05 1.93 1.04 0.95 0.99 
Q96A33 CCDC47 Coiled-coil domain-containing protein 47 1.96 2.02 0.97 1.01 0.99 
P27797 CALR Calreticulin 1.95 2.05 0.96 1.04 1.00 
P26885 FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2 2.11 1.91 1.08 0.93 1.01 
P46821 MAP1B Microtubule-associated protein 1B 2.11 1.91 1.08 0.93 1.01 
Q9Y4L1 HYOU1 Hypoxia up-regulated protein 1 2.03 2 1.02 1.00 1.01 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 2.42 1.69 1.28 0.76 1.02 
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P30101 PDIA3 Protein disulfide-isomerase A3 2.04 2.01 1.03 1.01 1.02 
Q00765 REEP5 Receptor expression-enhancing protein 5 2.16 1.9 1.11 0.93 1.02 
Q96HY6 DDRGK1 DDRGK domain-containing protein 1 2.39 1.72 1.26 0.78 1.02 
O60499 STX10 Syntaxin-10 2.05 2.01 1.04 1.01 1.02 
P48723 HSPA13 Heat shock 70 kDa protein 13 2.03 2.04 1.02 1.03 1.03 
P13667 PDIA4 Protein disulfide-isomerase A4 1.96 2.13 0.97 1.09 1.03 
Q14739 LBR Lamin-B receptor 2.13 1.96 1.09 0.97 1.03 
P46977 STT3A Dolichyl-diphosphooligosaccharide--protein glycosy 2 2.09 1.00 1.06 1.03 
Q14789 GOLGB1 Golgin subfamily B member 1 2.38 1.78 1.25 0.83 1.04 
Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3 1.86 2.28 0.90 1.19 1.04 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 1.92 2.23 0.94 1.16 1.05 
P0C0S5 H2AFZ Histone H2A.Z 1.75 2.46 0.81 1.30 1.05 
Q71UI9 H2AFV Histone H2A.V 1.75 2.46 0.81 1.30 1.05 
O60762 DPM1 Dolichol-phosphate mannosyltransferase 2.34 1.84 1.23 0.88 1.05 
Q13177 PAK2 Serine/threonine-protein kinase PAK 2 2.01 2.17 1.01 1.12 1.06 
O00116 AGPS Alkyldihydroxyacetonephosphate synthase, peroxisom 2.12 2.06 1.08 1.04 1.06 
Q9BVK6 TMED9 Transmembrane emp24 domain-containing protein 9 2.25 1.98 1.17 0.99 1.08 
O95302 FKBP9 Peptidyl-prolyl cis-trans isomerase FKBP9 2 2.24 1.00 1.16 1.08 
P14314 PRKCSH Glucosidase 2 subunit beta 2.16 2.08 1.11 1.06 1.08 
P11047 LAMC1 Laminin subunit gamma-1 1.9 2.38 0.93 1.25 1.09 
Q8NBJ5 GLT25D1 Procollagen galactosyltransferase 1 2.2 2.06 1.14 1.04 1.09 
Q9UGP8 SEC63 Translocation protein SEC63 homolog 2.18 2.09 1.12 1.06 1.09 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta 2.06 2.23 1.04 1.16 1.10 
P30040 ERP29 Endoplasmic reticulum resident protein 29 2.23 2.06 1.16 1.04 1.10 
Q969V3 NCLN Nicalin 2.08 2.22 1.06 1.15 1.10 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 2.34 1.98 1.23 0.99 1.11 
Q9H488 POFUT1 GDP-fucose protein O-fucosyltransferase 1 2.25 2.1 1.17 1.07 1.12 
Q13162 PRDX4 Peroxiredoxin-4 2.37 2.01 1.24 1.01 1.13 
Q15005 SPCS2 Signal peptidase complex subunit 2 2.41 2.02 1.27 1.01 1.14 
O95881 TXNDC12 Thioredoxin domain-containing protein 12 2.28 2.19 1.19 1.13 1.16 
Q8IVF2 AHNAK2 Protein AHNAK2 2.62 1.93 1.39 0.95 1.17 
Q15084 PDIA6 Protein disulfide-isomerase A6 2.46 2.06 1.30 1.04 1.17 
Q99470 SDF2 Stromal cell-derived factor 2 2.6 1.98 1.38 0.99 1.18 
Q9HD20 ATP13A1 Probable cation-transporting ATPase 13A1 1.89 2.73 0.92 1.45 1.18 
Q5JPE7 NOMO2 Nodal modulator 2 2.33 2.22 1.22 1.15 1.19 
Q9NYU2 UGGT1 UDP-glucose:glycoprotein glucosyltransferase 1 2.2 2.39 1.14 1.26 1.20 
O60493 SNX3 Sorting nexin-3 2.39 2.23 1.26 1.16 1.21 
Q86UE4 MTDH Protein LYRIC 2.46 2.19 1.30 1.13 1.21 
Q14696 MESDC2 LDLR chaperone MESD 2.95 1.84 1.56 0.88 1.22 
Q9UMX5 NENF Neudesin 2.72 2.08 1.44 1.06 1.25 
P11021 HSPA5 78 kDa glucose-regulated protein 2.51 2.38 1.33 1.25 1.29 
Q12797 ASPH Aspartyl/asparaginyl beta-hydroxylase 2.72 2.21 1.44 1.14 1.29 
Q9BWS9 CHID1 Chitinase domain-containing protein 1 2.66 2.37 1.41 1.24 1.33 
P51659 HSD17B4 Peroxisomal multifunctional enzyme type 2 2.72 2.43 1.44 1.28 1.36 
Q86SF2 GALNT7 N-acetylgalactosaminyltransferase 7 2.57 2.64 1.36 1.40 1.38 
Q92520 FAM3C Protein FAM3C 2.71 2.53 1.44 1.34 1.39 
Q86UP2 KTN1 Kinectin 2.62 2.62 1.39 1.39 1.39 
Q9Y4P3 TBL2 Transducin beta-like protein 2 2.82 2.51 1.50 1.33 1.41 
P55145 MANF Mesencephalic astrocyte-derived neurotrophic facto 2.94 2.42 1.56 1.28 1.42 
Q6ZXV5 TMTC3 Transmembrane and TPR repeat-containing protein 3 2.6 2.92 1.38 1.55 1.46 
O95292 VAPB Vesicle-associated membrane protein-associated pro 2.03 3.86 1.02 1.95 1.49 
Q8IVL5 LEPREL1 Prolyl 3-hydroxylase 2 2.92 2.79 1.55 1.48 1.51 
Q8TBA6 GOLGA5 Golgin subfamily A member 5 3.2 2.6 1.68 1.38 1.53 
Q9HBH5 RDH14 Retinol dehydrogenase 14 3.58 2.58 1.84 1.37 1.60 
Q96CS3 FAF2 FAS-associated factor 2 4.37 2.14 2.13 1.10 1.61 
P28288 ABCD3 ATP-binding cassette sub-family D member 3 3.68 2.55 1.88 1.35 1.62 
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Q70UQ0 IKBIP Inhibitor of nuclear factor kappa-B kinase-interac 4.33 2.2 2.11 1.14 1.63 
Q07065 CKAP4 Cytoskeleton-associated protein 4 3.52 2.77 1.82 1.47 1.64 
Q9UHI8 ADAMTS1 A disintegrin and metalloproteinase with thrombosp 3.56 2.8 1.83 1.49 1.66 
P39019 RPS19 40S ribosomal protein S19 3.67 2.92 1.88 1.55 1.71 
P22307 SCP2 Non-specific lipid-transfer protein 3.65 2.96 1.87 1.57 1.72 
O00429 DNM1L Dynamin-1-like protein 8.51 3.78 3.09 1.92 2.50 
 
Table 2A-8. ReDiMe analysis to quantify changes in protein abundance following 
treatment with DMSO or Tn. Data was filtered for secretory pathway proteins that 
appeared in two replicates. Ratios were converted to log2(Tn:DMSO) and sorted 
by increasing levels of expression following Tn treatment. The 100 most abundant 
and least abundant proteins following Tn treatment are shown. Localization of 
proteins was determined using Uniprot and GO annotated tabs on UniprotKB. 
Uniprot 
ID Protein Description 
Ratio 
(H:L) log2(Ratio) Average 
1 2 1 2 
P08133 ANXA6 Annexin A6 0.55 0.42 -0.86 -1.25 -1.06 
P09525 ANXA4 Annexin A4 0.5 0.54 -1.00 -0.89 -0.94 
Q9BTV4 TMEM43 Transmembrane protein 43 0.39 0.86 -1.36 -0.22 -0.79 
P11216 PYGB Glycogen phosphorylase, brain form  0.6 0.6 -0.74 -0.74 -0.74 
P31949 S100A11 Protein S100-A11 0.66 0.55 -0.60 -0.86 -0.73 
P50995 ANXA11 Annexin A11 0.7 0.52 -0.51 -0.94 -0.73 
Q9UKV5 AMFR E3 ubiquitin-protein ligase AMFR 0.62 0.61 -0.69 -0.71 -0.70 
P27487 DPP4 Dipeptidyl peptidase 4 0.56 0.68 -0.84 -0.56 -0.70 
Q96A33 CCDC47 Coiled-coil domain-containing protein 47 0.62 0.69 -0.69 -0.54 -0.61 
Q14696 MESDC2 LDLR chaperone MESD 0.71 0.63 -0.49 -0.67 -0.58 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2 0.6 0.76 -0.74 -0.40 -0.57 
Q29865 HLA-C HLA class I histocompatibility antigen, Cw-18 alph 0.77 0.6 -0.38 -0.74 -0.56 
Q29963 HLA-C HLA class I histocompatibility antigen, Cw-6 alpha 0.77 0.6 -0.38 -0.74 -0.56 
Q13724 MOGS Mannosyl-oligosaccharide glucosidase 0.52 0.89 -0.94 -0.17 -0.56 
P30504 HLA-C HLA class I histocompatibility antigen, Cw-4 alpha 0.78 0.6 -0.36 -0.74 -0.55 
O15533 TAPBP Tapasin 0.61 0.79 -0.71 -0.34 -0.53 
Q969H8 C19orf10 UPF0556 protein C19orf10 0.76 0.65 -0.40 -0.62 -0.51 
Q9HD20 ATP13A1 Probable cation-transporting ATPase 13A1 0.63 0.82 -0.67 -0.29 -0.48 
O15118 NPC1 Niemann-Pick C1 protein 0.69 0.75 -0.54 -0.42 -0.48 
O75955 FLOT1 Flotillin-1 0.72 0.73 -0.47 -0.45 -0.46 
Q99805 TM9SF2 Transmembrane 9 superfamily member 2 0.98 0.54 -0.03 -0.89 -0.46 
P04083 ANXA1 Annexin A1 0.76 0.7 -0.40 -0.51 -0.46 
P30533 LRPAP1 Alpha-2-macroglobulin receptor-associated protein 0.7 0.76 -0.51 -0.40 -0.46 
Q8N766 EMC1 ER membrane protein complex subunit 1 0.67 0.8 -0.58 -0.32 -0.45 
Q14332 FZD2 Frizzled-2 0.78 0.7 -0.36 -0.51 -0.44 
P10321 HLA-C HLA class I histocompatibility antigen, Cw-7 alpha 0.77 0.71 -0.38 -0.49 -0.44 
P18463 HLA-B HLA class I histocompatibility antigen, B-37 alpha 0.77 0.71 -0.38 -0.49 -0.44 
Q5BJH7 YIF1B Protein YIF1B 0.83 0.66 -0.27 -0.60 -0.43 
Q9NYT0 PLEK2 Pleckstrin-2 0.62 0.92 -0.69 -0.12 -0.40 
P04040 CAT Catalase 0.89 0.65 -0.17 -0.62 -0.39 
P37802 TAGLN2 Transgelin-2 0.62 0.94 -0.69 -0.09 -0.39 
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Q9Y6Y8 SEC23IP SEC23-interacting protein 0.82 0.72 -0.29 -0.47 -0.38 
P62820 RAB1A Ras-related protein Rab-1A 0.78 0.76 -0.36 -0.40 -0.38 
Q9P0K7 RAI14 Ankycorbin 0.76 0.78 -0.40 -0.36 -0.38 
Q15042 RAB3GAP1 Rab3 GTPase-activating protein catalytic subunit 0.71 0.84 -0.49 -0.25 -0.37 
P20908 COL5A1 Collagen alpha-1(V) chain 0.86 0.7 -0.22 -0.51 -0.37 
P30040 ERP29 Endoplasmic reticulum resident protein 29 0.86 0.7 -0.22 -0.51 -0.37 
Q6YHK3 CD109 CD109 antigen 0.71 0.85 -0.49 -0.23 -0.36 
P23469 PTPRE Receptor-type tyrosine-protein phosphatase epsilon 0.84 0.72 -0.25 -0.47 -0.36 
Q9Y4P3 TBL2 Transducin beta-like protein 2 0.56 1.08 -0.84 0.11 -0.36 
P30512 HLA-A HLA class I histocompatibility antigen, A-29 alpha 0.82 0.74 -0.29 -0.43 -0.36 
P13987 CD59 CD59 glycoprotein 0.76 0.8 -0.40 -0.32 -0.36 
P01891 HLA-A HLA class I histocompatibility antigen, A-68 alpha 0.77 0.79 -0.38 -0.34 -0.36 
P11166 SLC2A1 Solute carrier family 2, facilitated glucose trans 0.78 0.78 -0.36 -0.36 -0.36 
O00469 PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2  0.88 0.7 -0.18 -0.51 -0.35 
Q13501 SQSTM1 Sequestosome-1 0.79 0.78 -0.34 -0.36 -0.35 
P08195 SLC3A2 4F2 cell-surface antigen heavy chain 0.78 0.79 -0.36 -0.34 -0.35 
P01892 HLA-A HLA class I histocompatibility antigen, A-2 alpha  0.78 0.79 -0.36 -0.34 -0.35 
P10319 HLA-B HLA class I histocompatibility antigen, B-58 alpha 0.78 0.79 -0.36 -0.34 -0.35 
P16189 HLA-A HLA class I histocompatibility antigen, A-31 alpha 0.78 0.79 -0.36 -0.34 -0.35 
P18465 HLA-B HLA class I histocompatibility antigen, B-57 alpha 0.78 0.79 -0.36 -0.34 -0.35 
P30492 HLA-B HLA class I histocompatibility antigen, B-54 alpha 0.78 0.79 -0.36 -0.34 -0.35 
P30685 HLA-B HLA class I histocompatibility antigen, B-35 alpha 0.78 0.79 -0.36 -0.34 -0.35 
Q29940 HLA-B HLA class I histocompatibility antigen, B-59 alpha 0.78 0.79 -0.36 -0.34 -0.35 
P19338 NCL Nucleolin 0.87 0.71 -0.20 -0.49 -0.35 
P15151 PVR Poliovirus receptor 0.76 0.82 -0.40 -0.29 -0.34 
P19022 CDH2 Cadherin-2 0.81 0.77 -0.30 -0.38 -0.34 
Q13733 ATP1A4 Sodium/potassium-transporting ATPase subunit alpha 0.8 0.78 -0.32 -0.36 -0.34 
O00264 PGRMC1 Membrane-associated progesterone receptor componen 0.8 0.78 -0.32 -0.36 -0.34 
P29992 GNA11 Guanine nucleotide-binding protein subunit alpha-1 0.72 0.87 -0.47 -0.20 -0.34 
Q07000 HLA-C HLA class I histocompatibility antigen, Cw-15 alph 0.84 0.75 -0.25 -0.42 -0.33 
P61106 RAB14 Ras-related protein Rab-14 0.76 0.83 -0.40 -0.27 -0.33 
Q16643 DBN1 Drebrin 0.82 0.77 -0.29 -0.38 -0.33 
O15270 SPTLC2 Serine palmitoyltransferase 2 0.78 0.81 -0.36 -0.30 -0.33 
Q14165 MLEC Malectin 0.57 1.11 -0.81 0.15 -0.33 
P05556 ITGB1 Integrin beta-1 0.82 0.78 -0.29 -0.36 -0.32 
Q14573 ITPR3 Inositol 1,4,5-trisphosphate receptor type 3  0.8 0.8 -0.32 -0.32 -0.32 
Q99653 CHP1 Calcineurin B homologous protein 1 0.82 0.79 -0.29 -0.34 -0.31 
Q9Y6M7 SLC4A7 Sodium bicarbonate cotransporter 3 0.81 0.8 -0.30 -0.32 -0.31 
Q86UE4 MTDH Protein LYRIC 0.86 0.76 -0.22 -0.40 -0.31 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 0.79 0.83 -0.34 -0.27 -0.30 
P46977 STT3A Dolichyl-diphosphooligosaccharide--protein glycosy 0.7 0.94 -0.51 -0.09 -0.30 
Q6NZI2 PTRF Polymerase I and transcript release factor 0.88 0.75 -0.18 -0.42 -0.30 
Q9NZM1 MYOF Myoferlin 0.82 0.81 -0.29 -0.30 -0.30 
P05026 ATP1B1 Sodium/potassium-transporting ATPase subunit beta- 0.81 0.82 -0.30 -0.29 -0.30 
Q15599 SLC9A3R2 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 0.9 0.74 -0.15 -0.43 -0.29 
Q96HE7 ERO1L ERO1-like protein alpha 0.85 0.79 -0.23 -0.34 -0.29 
A0FGR8 ESYT2 Extended synaptotagmin-2 0.7 0.96 -0.51 -0.06 -0.29 
Q7Z3C6 ATG9A Autophagy-related protein 9A 0.76 0.89 -0.40 -0.17 -0.28 
Q9P0L0 VAPA Vesicle-associated membrane protein-associated pro 0.87 0.78 -0.20 -0.36 -0.28 
O95292 VAPB Vesicle-associated membrane protein-associated pro 0.73 0.93 -0.45 -0.10 -0.28 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al 0.8 0.85 -0.32 -0.23 -0.28 
P07099 EPHX1 Epoxide hydrolase 1 0.8 0.86 -0.32 -0.22 -0.27 
P30530 AXL Tyrosine-protein kinase receptor UFO 0.85 0.81 -0.23 -0.30 -0.27 
Q15836 VAMP3 Vesicle-associated membrane protein 3 0.82 0.84 -0.29 -0.25 -0.27 
P53675 CLTCL1 Clathrin heavy chain 2 0.75 0.92 -0.42 -0.12 -0.27 
Q01650 SLC7A5 Large neutral amino acids transporter small subuni 0.78 0.89 -0.36 -0.17 -0.26 
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Q16647 PTGIS Prostacyclin synthase 0.86 0.81 -0.22 -0.30 -0.26 
Q9H0U4 RAB1B Ras-related protein Rab-1B 0.67 1.04 -0.58 0.06 -0.26 
Q9UN37 VPS4A Vacuolar protein sorting-associated protein 4A 0.84 0.83 -0.25 -0.27 -0.26 
P04439 HLA-A HLA class I histocompatibility antigen, A-3 alpha  0.97 0.72 -0.04 -0.47 -0.26 
Q9P035 PTPLAD1 3-hydroxyacyl-CoA dehydratase 3 0.77 0.91 -0.38 -0.14 -0.26 
Q9Y639 NPTN Neuroplastin 0.9 0.78 -0.15 -0.36 -0.26 
P35613 BSG Basigin 0.78 0.9 -0.36 -0.15 -0.26 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 0.88 0.8 -0.18 -0.32 -0.25 
Q9Y2B0 CNPY2 Protein canopy homolog 2 0.88 0.8 -0.18 -0.32 -0.25 
Q92599 SEPT8 Septin-8 0.81 0.87 -0.30 -0.20 -0.25 
P53985 SLC16A1 Monocarboxylate transporter 1 0.86 0.82 -0.22 -0.29 -0.25 
P07355 ANXA2 Annexin A2 0.85 0.83 -0.23 -0.27 -0.25 
P60953 CDC42 Cell division control protein 42 homolog 0.85 0.83 -0.23 -0.27 -0.25 
P15880 RPS2 40S ribosomal protein S2 1.56 1.32 0.64 0.40 0.52 
P62269 RPS18 40S ribosomal protein S18 1.57 1.32 0.65 0.40 0.53 
Q71UM5 RPS27L 40S ribosomal protein S27-like 1.41 1.47 0.50 0.56 0.53 
P62841 RPS15 40S ribosomal protein S15 1.69 1.24 0.76 0.31 0.53 
O94979 SEC31A Protein transport protein Sec31A 1.59 1.32 0.67 0.40 0.53 
P14868 DARS Aspartate--tRNA ligase, cytoplasmic  1.35 1.56 0.43 0.64 0.54 
Q9UQB8 BAIAP2 Brain-specific angiogenesis inhibitor 1-associated 1.51 1.4 0.59 0.49 0.54 
P78344 EIF4G2 Eukaryotic translation initiation factor 4 gamma 2 1.45 1.48 0.54 0.57 0.55 
P48444 ARCN1 Coatomer subunit delta 1.45 1.48 0.54 0.57 0.55 
Q9ULV4 CORO1C Coronin-1C 1.54 1.4 0.62 0.49 0.55 
P27708 CAD CAD protein 1.43 1.51 0.52 0.59 0.56 
P38919 EIF4A3 Eukaryotic initiation factor 4A-III 1.36 1.62 0.44 0.70 0.57 
Q99536 VAT1 Synaptic vesicle membrane protein VAT-1 homolog 1.6 1.38 0.68 0.46 0.57 
Q02543 RPL18A 60S ribosomal protein L18a 1.55 1.43 0.63 0.52 0.57 
Q06787 FMR1 Fragile X mental retardation protein 1 1.5 1.48 0.58 0.57 0.58 
Q9H2U1 DHX36 Probable ATP-dependent RNA helicase DHX36 1.63 1.37 0.70 0.45 0.58 
Q01813 PFKP 6-phosphofructokinase type C 1.46 1.53 0.55 0.61 0.58 
Q13561 DCTN2 Dynactin subunit 2 1.57 1.43 0.65 0.52 0.58 
P35998 PSMC2 26S protease regulatory subunit 7 1.53 1.47 0.61 0.56 0.58 
Q13200 PSMD2 26S proteasome non-ATPase regulatory subunit 2 1.48 1.52 0.57 0.60 0.58 
P46783 RPS10 40S ribosomal protein S10 1.65 1.37 0.72 0.45 0.59 
P50914 RPL14 60S ribosomal protein L14 1.55 1.46 0.63 0.55 0.59 
Q8WX93 PALLD Palladin 1.59 1.43 0.67 0.52 0.59 
Q8WUW1 BRK1 Protein BRICK1 1.66 1.38 0.73 0.46 0.60 
P62280 RPS11 40S ribosomal protein S11 1.78 1.31 0.83 0.39 0.61 
P22234 PAICS Multifunctional protein ADE2 1.6 1.46 0.68 0.55 0.61 
P62906 RPL10A 60S ribosomal protein L10a 1.64 1.44 0.71 0.53 0.62 
P50552 VASP Vasodilator-stimulated phosphoprotein 1.64 1.45 0.71 0.54 0.62 
P26373 RPL13 60S ribosomal protein L13 1.66 1.44 0.73 0.53 0.63 
O60493 SNX3 Sorting nexin-3 1.44 1.66 0.53 0.73 0.63 
P62888 RPL30 60S ribosomal protein L30 1.87 1.28 0.90 0.36 0.63 
Q01518 CAP1 Adenylyl cyclase-associated protein 1 1.61 1.49 0.69 0.58 0.63 
Q00796 SORD Sorbitol dehydrogenase 1.6 1.5 0.68 0.58 0.63 
P46779 RPL28 60S ribosomal protein L28 1.78 1.35 0.83 0.43 0.63 
P06744 GPI Glucose-6-phosphate isomerase 1.75 1.38 0.81 0.46 0.64 
P18621 RPL17 60S ribosomal protein L17 1.58 1.53 0.66 0.61 0.64 
P62277 RPS13 40S ribosomal protein S13 1.62 1.5 0.70 0.58 0.64 
O00487 PSMD14 26S proteasome non-ATPase regulatory subunit 14 1.88 1.3 0.91 0.38 0.64 
Q07020 RPL18 60S ribosomal protein L18 1.8 1.36 0.85 0.44 0.65 
P62753 RPS6 40S ribosomal protein S6 1.06 2.31 0.08 1.21 0.65 
P62847 RPS24 40S ribosomal protein S24 1.66 1.48 0.73 0.57 0.65 
P17980 PSMC3 26S protease regulatory subunit 6A 1.67 1.49 0.74 0.58 0.66 
P62333 PSMC6 26S protease regulatory subunit 10B 1.77 1.41 0.82 0.50 0.66 
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P55884 EIF3B Eukaryotic translation initiation factor 3 subunit 1.48 1.69 0.57 0.76 0.66 
O43242 PSMD3 26S proteasome non-ATPase regulatory subunit 3 1.55 1.62 0.63 0.70 0.66 
P23526 AHCY Adenosylhomocysteinase 1.66 1.52 0.73 0.60 0.67 
O00231 PSMD11 26S proteasome non-ATPase regulatory subunit 11 1.57 1.61 0.65 0.69 0.67 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit 1.5 1.69 0.58 0.76 0.67 
Q12906 ILF3 Interleukin enhancer-binding factor 3 1.74 1.48 0.80 0.57 0.68 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 1.69 1.56 0.76 0.64 0.70 
P40429 RPL13A 60S ribosomal protein L13a 1.66 1.59 0.73 0.67 0.70 
P62745 RHOB Rho-related GTP-binding protein RhoB 2.25 1.2 1.17 0.26 0.72 
P53396 ACLY ATP-citrate synthase 1.68 1.61 0.75 0.69 0.72 
P61254 RPL26 60S ribosomal protein L26 1.56 1.74 0.64 0.80 0.72 
P61313 RPL15 60S ribosomal protein L15 1.64 1.67 0.71 0.74 0.73 
Q9UNM6 PSMD13 26S proteasome non-ATPase regulatory subunit 13 1.54 1.8 0.62 0.85 0.74 
P07814 EPRS Bifunctional glutamate/proline--tRNA ligase 1.78 1.56 0.83 0.64 0.74 
P48643 CCT5 T-complex protein 1 subunit epsilon 1.71 1.63 0.77 0.70 0.74 
P62195 PSMC5 26S protease regulatory subunit 8 1.77 1.58 0.82 0.66 0.74 
P60866 RPS20 40S ribosomal protein S20 1.83 1.54 0.87 0.62 0.75 
O00232 PSMD12 26S proteasome non-ATPase regulatory subunit 12 1.73 1.66 0.79 0.73 0.76 
Q02878 RPL6 60S ribosomal protein L6 2 1.46 1.00 0.55 0.77 
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 1.69 1.73 0.76 0.79 0.77 
P61513 RPL37A 60S ribosomal protein L37a 1.87 1.57 0.90 0.65 0.78 
P18124 RPL7 60S ribosomal protein L7 1.83 1.61 0.87 0.69 0.78 
Q15365 PCBP1 Poly(rC)-binding protein 1 1.82 1.62 0.86 0.70 0.78 
P26641 EEF1G Elongation factor 1-gamma 1.8 1.64 0.85 0.71 0.78 
Q9BY44 EIF2A Eukaryotic translation initiation factor 2A 1.73 1.73 0.79 0.79 0.79 
P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  1.71 1.76 0.77 0.82 0.79 
P27816 MAP4 Microtubule-associated protein 4 1.86 1.62 0.90 0.70 0.80 
P25787 PSMA2 Proteasome subunit alpha type-2 1.64 1.89 0.71 0.92 0.82 
P60174 TPI1 Triosephosphate isomerase 2.07 1.5 1.05 0.58 0.82 
P49207 RPL34 60S ribosomal protein L34 2.02 1.54 1.01 0.62 0.82 
O43237 DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2 1.84 1.7 0.88 0.77 0.82 
P13639 EEF2 Elongation factor 2 1.83 1.82 0.87 0.86 0.87 
P46778 RPL21 60S ribosomal protein L21 2.05 1.63 1.04 0.70 0.87 
P50991 CCT4 T-complex protein 1 subunit delta 1.83 1.83 0.87 0.87 0.87 
O95347 SMC2 Structural maintenance of chromosomes protein 2 1.94 1.73 0.96 0.79 0.87 
P54136 RARS Arginine--tRNA ligase, cytoplasmic  2.1 1.6 1.07 0.68 0.87 
Q12905 ILF2 Interleukin enhancer-binding factor 2 1.75 1.94 0.81 0.96 0.88 
P83731 RPL24 60S ribosomal protein L24 1.96 1.78 0.97 0.83 0.90 
P23396 RPS3 40S ribosomal protein S3 2.08 1.69 1.06 0.76 0.91 
P61247 RPS3A 40S ribosomal protein S3a 1.8 1.98 0.85 0.99 0.92 
P26599 PTBP1 Polypyrimidine tract-binding protein 1 1.92 1.86 0.94 0.90 0.92 
P63173 RPL38 60S ribosomal protein L38 2.06 1.74 1.04 0.80 0.92 
P62913 RPL11 60S ribosomal protein L11 2.34 1.54 1.23 0.62 0.92 
P32969 RPL9P9 60S ribosomal protein L9 2.01 1.82 1.01 0.86 0.94 
P68104 EEF1A1 Elongation factor 1-alpha 1 1.9 1.95 0.93 0.96 0.94 
P05386 RPLP1 60S acidic ribosomal protein P1 2.53 1.52 1.34 0.60 0.97 
P78371 CCT2 T-complex protein 1 subunit beta 2.06 1.94 1.04 0.96 1.00 
O60506 SYNCRIP Heterogeneous nuclear ribonucleoprotein Q 2.12 1.89 1.08 0.92 1.00 
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 2.05 1.99 1.04 0.99 1.01 
P50990 CCT8 T-complex protein 1 subunit theta 2.72 1.75 1.44 0.81 1.13 
P12956 XRCC6 X-ray repair cross-complementing protein 6 1.9 2.62 0.93 1.39 1.16 
P46821 MAP1B Microtubule-associated protein 1B 2.38 2.13 1.25 1.09 1.17 
Q05639 EEF1A2 Elongation factor 1-alpha 2 2.35 2.17 1.23 1.12 1.18 
P13693 TPT1 Translationally-controlled tumor protein 2.29 2.25 1.20 1.17 1.18 
P25398 RPS12 40S ribosomal protein S12 2.6 2.35 1.38 1.23 1.31 
P11940 PABPC1 Polyadenylate-binding protein 1 2.64 2.32 1.40 1.21 1.31 
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P62701 RPS4X 40S ribosomal protein S4, X isoform  2.94 2.25 1.56 1.17 1.36 
P13010 XRCC5 X-ray repair cross-complementing protein 5 2.66 2.67 1.41 1.42 1.41 
 
Table 2A-9. PANTHER GO Biological Processes enrichment analysis for the top 
100 most abundant proteins following Tg treatment. 
Analysis Type: 
PANTHER Overrepresentation Test (Released 
20190711) 
Annotation Version and Release Date: GO Ontology database  Released 2019-02-02 
Analyzed List: 
upload_1 (Homo 
sapiens)   
Reference List: Homo sapiens (all genes in database) 
Test Type: FISHER     
Correction: BONFERRONI    
       Protein Number   








P -value  
protein folding in endoplasmic reticulum (GO:0034975) 16 5 0.08 63.7 4.23E-04 
4-hydroxyproline metabolic process (GO:0019471) 15 4 0.07 54.36 1.73E-02 
protein hydroxylation (GO:0018126) 26 5 0.13 39.2 3.40E-03 
protein N-linked glycosylation via asparagine (GO:0018279) 33 5 0.16 30.89 9.76E-03 
peptidyl-asparagine modification (GO:0018196) 34 5 0.17 29.98 1.12E-02 
IRE1-mediated unfolded protein response (GO:0036498) 55 8 0.27 29.65 6.68E-06 
peptidyl-proline modification (GO:0018208) 58 7 0.28 24.6 2.61E-04 
endoplasmic reticulum unfolded protein response (GO:0030968) 100 12 0.49 24.46 2.46E-09 
cellular response to topologically incorrect protein (GO:0035967) 143 15 0.7 21.38 1.35E-11 
cell redox homeostasis (GO:0045454) 77 8 0.38 21.18 7.60E-05 
response to topologically incorrect protein (GO:0035966) 182 18 0.89 20.16 4.20E-14 
cellular response to unfolded protein (GO:0034620) 122 12 0.6 20.05 2.15E-08 
ERAD pathway (GO:0036503) 84 8 0.41 19.41 1.43E-04 
response to endoplasmic reticulum stress (GO:0034976) 242 23 1.19 19.37 1.39E-18 
response to unfolded protein (GO:0006986) 159 15 0.78 19.23 5.76E-11 
protein folding (GO:0006457) 226 18 1.11 16.24 1.47E-12 
protein N-linked glycosylation (GO:0006487) 76 6 0.37 16.09 2.67E-02 
peroxisome organization (GO:0007031) 79 6 0.39 15.48 3.29E-02 
regulation of response to endoplasmic reticulum stress (GO:1905897) 84 6 0.41 14.56 4.59E-02 
protein glycosylation (GO:0006486) 249 11 1.22 9.01 5.20E-04 
macromolecule glycosylation (GO:0043413) 249 11 1.22 9.01 5.20E-04 
glycosylation (GO:0070085) 261 11 1.28 8.59 8.21E-04 
glycoprotein biosynthetic process (GO:0009101) 311 11 1.53 7.21 4.44E-03 
glycoprotein metabolic process (GO:0009100) 373 12 1.83 6.56 3.47E-03 
protein targeting (GO:0006605) 352 11 1.73 6.37 1.43E-02 
oxidation-reduction process (GO:0055114) 960 21 4.71 4.46 7.98E-05 
peptidyl-amino acid modification (GO:0018193) 855 18 4.19 4.29 1.86E-03 
intracellular protein transport (GO:0006886) 989 19 4.85 3.92 3.25E-03 
cellular homeostasis (GO:0019725) 900 17 4.42 3.85 1.82E-02 
intracellular transport (GO:0046907) 1551 28 7.61 3.68 1.11E-05 
protein transport (GO:0015031) 1490 24 7.31 3.28 1.82E-03 
establishment of localization in cell (GO:0051649) 1803 29 8.84 3.28 6.91E-05 
peptide transport (GO:0015833) 1515 24 7.43 3.23 2.46E-03 
amide transport (GO:0042886) 1547 24 7.59 3.16 3.57E-03 
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cellular protein localization (GO:0034613) 1563 24 7.67 3.13 4.30E-03 
cellular macromolecule localization (GO:0070727) 1571 24 7.71 3.11 4.70E-03 
establishment of protein localization (GO:0045184) 1572 24 7.71 3.11 4.76E-03 
cellular response to stress (GO:0033554) 1669 25 8.19 3.05 3.70E-03 
protein localization (GO:0008104) 2111 28 10.36 2.7 7.22E-03 
vesicle-mediated transport (GO:0016192) 1917 25 9.4 2.66 4.46E-02 
cellular localization (GO:0051641) 2408 31 11.81 2.62 2.89E-03 
cellular protein metabolic process (GO:0044267) 3711 45 18.21 2.47 8.14E-06 
cellular protein modification process (GO:0006464) 3088 36 15.15 2.38 3.12E-03 
protein modification process (GO:0036211) 3088 36 15.15 2.38 3.12E-03 
protein metabolic process (GO:0019538) 4311 49 21.15 2.32 8.36E-06 
response to organic substance (GO:0010033) 2922 33 14.33 2.3 2.18E-02 
macromolecule modification (GO:0043412) 3298 36 16.18 2.23 1.61E-02 
transport (GO:0006810) 4472 46 21.94 2.1 1.50E-03 
establishment of localization (GO:0051234) 4593 46 22.53 2.04 2.42E-03 
organonitrogen compound metabolic process (GO:1901564) 5311 53 26.05 2.03 1.56E-04 
localization (GO:0051179) 5662 50 27.78 1.8 3.02E-02 
primary metabolic process (GO:0044238) 7492 61 36.75 1.66 1.25E-02 
metabolic process (GO:0008152) 8389 67 41.15 1.63 4.01E-03 
organic substance metabolic process (GO:0071704) 7841 62 38.47 1.61 2.75E-02 
cellular process (GO:0009987) 14425 91 70.76 1.29 4.55E-02 
Unclassified (UNCLASSIFIED) 3214 2 15.77 0.13 0.00E+00 
 
Table 2A-10. Filtered list of cysteine-containing peptides from secretory proteins 
identified in OxICAT analyses of DMSO and Tg treated samples. Each treatment 
was performed in triplicate and the data was filtered for peptides with ratios found 
in at least two of the replicates per treatment. Furthermore, the data was reduced 
to only peptides that displayed a statistically significant (p <0.05, unpaired t tests) 
difference in cysteine oxidation states. Data is displayed as percent oxidized and 
the average difference in percent oxidation (DMSO – Tg). Localization of proteins 
was determined using Uniprot and GO annotated tabs on UniprotKB. 
Uniprot 
ID Protein Description Peptide Sequence Residue 
Average Percent 
Oxidized Difference (DMSO - 
Tg) DMSO Tg 
P32004 L1CAM Neural cell adhesion molecule L1 CLAENSLGSAR 312 87.60% 11.18% 76.42% 
Q86TC9 MYPN Myopalladin NEAGIVSCTAR 1257 76.19% 11.18% 65.01% 
Q9Y4K0 LOXL2 Lysyl oxidase homolog 2 ASFC*LEDTEC*EGDIQK 657 95.24% 37.50% 57.74% 
P35241 RDX Radixin EAILNDEIYCPPETAVLLASYAVQAK 117 60.22% 22.83% 37.39% 




241 47.41% 10.75% 36.66% 
P60981 DSTN Destrin DCR 80 54.78% 18.62% 36.16% 
P55884 EIF3B Eukaryotic translation initiation factor 3 subunit YWLEEAECR 302 35.18% 5.90% 29.28% 
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1686 54.90% 28.18% 26.72% 
Q8WUY1 THEM6 UPF0670 protein THEM6 VVQHLCQR 168 43.43% 17.99% 25.44% 
P21333 FLNA Filamin-A IEC*DDKGDGSC*DVR 623 61.93% 36.58% 25.35% 
O00299 CLIC1 Chloride intracellular channel protein 1 EEFASTCPDDEEIELAYEQVAK 223 49.11% 28.07% 21.04% 
Q15437 SEC23B Protein transport protein Sec23B LAVSSAC 767 46.37% 26.79% 19.58% 
P05556 ITGB1 Integrin beta-1 LPQPVQPDPVSHCK 691 65.44% 48.45% 16.99% 
P62258 YWHAE 14-3-3 protein epsilon LIC*C*DILDVLDK 97 40.17% 23.51% 16.66% 
P21333 FLNA Filamin-A MDC*QEC*PEGYR 2476 62.12% 45.59% 16.53% 
Q8NBJ7 SUMF2 Sulfatase-modifying factor 2 CAADAGR 290 80.32% 65.84% 14.48% 
P15311 EZR Ezrin EGILSDEIYCPPETAVLLGSYAVQAK 117 32.57% 18.25% 14.32% 
P21333 FLNA Filamin-A CAPGVVGPAEADIDFDIIR 810 41.51% 27.28% 14.23% 
O75369 FLNB Filamin-B VHSPSGAVEECHVSELEPDK 2333 42.40% 28.21% 14.19% 
P30050 RPL12 60S ribosomal protein L12 HPHDIIDDINSGAVECPAS 162 48.51% 34.89% 13.62% 
P46940 IQGAP1 Ras GTPase-activating-like protein IQGAP1 
SPDVGLYGVIPECG
ETYHSDLAEAK 660 31.34% 18.20% 13.14% 
P26038 MSN Moesin EGILNDDIYCPPETAVLLASYAVQSK 117 29.53% 16.68% 12.85% 
P21333 FLNA Filamin-A VHSPSGALEECYVTEIDQDK 2378 36.47% 24.14% 12.33% 




1158 36.40% 24.10% 12.30% 
Q6JUT2 TIRAP3 TIR domain-containing adapter molecule 2 QCFYEDIAQGTK 0 88.34% 76.22% 12.12% 
Q96S66 CLCC1 Chloride channel CLIC-like protein 1 GQDPVSSPCG 550 44.24% 32.15% 12.09% 
P21333 FLNA Filamin-A YWPQEAGEYAVHVLCNSEDIR 649 36.88% 24.80% 12.08% 
P13010 XRCC5 X-ray repair cross-complementing protein 5 
ETVYCLNDDDETE
VLK 296 30.66% 19.05% 11.61% 
P49327 FASN Fatty acid synthase ADEASELACPTPK 2202 34.41% 23.04% 11.37% 




1353 40.57% 29.24% 11.33% 
P21333 FLNA Filamin-A VTYCPTEPGNYIINIK 2107 41.40% 30.40% 11.00% 




613 40.04% 29.10% 10.94% 
Q99943 AGPAT1 1-acyl-sn-glycerol-3-phosphate acyltransferase alp FTSGQCQVR 229 37.50% 26.57% 10.93% 
Q9UBI6 GNG12 Guanine nucleotide-binding protein G(I)/G(S)/G(O) 
ASADLMSYCEEHA
R 43 35.76% 25.18% 10.58% 
P09525 ANXA4 Annexin A4 FLTVLCSR 198 14.33% 4.15% 10.18% 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 DCPIK 344 34.97% 25.36% 9.61% 
P35998 PSMC2 26S protease regulatory subunit 7 LCPNSTGAEIR 377 17.23% 7.69% 9.54% 
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 QCVENADLPEGEK 112 30.50% 21.08% 9.42% 
Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3 YFSLPFCVGSK 66 83.66% 74.25% 9.41% 




274 67.56% 58.20% 9.36% 
Q16643 DBN1 Drebrin PPEIDITCWDADPVPEEEEGFEGGD 632 45.35% 36.02% 9.33% 
O94979 SEC31A Protein transport protein Sec31A SDQLQQAVQSQGFINYCQK 458 17.31% 8.16% 9.15% 
Q14151 SAFB2 Scaffold attachment factor B2 ILDILGETCK 224 32.80% 23.67% 9.13% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 DEFTNTCPSDK 234 27.71% 18.76% 8.95% 




71 37.25% 28.33% 8.92% 
Q10567 AP1B1 AP-1 complex subunit beta-1 YESVIATLCENLDSLDEPEAR 433 17.03% 8.11% 8.92% 
Q9BV81 EMC6 ER membrane protein complex subunit 6 GNAAVLDYCR 29 16.58% 7.86% 8.72% 
P35222 CTNNB1 Catenin beta-1 VAAGVLCELAQDK 619 16.35% 7.72% 8.63% 
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P57088 TMEM33 Transmembrane protein 33 LCLQSIAFISR 232 13.98% 5.46% 8.52% 
Q96CS3 FAF2 FAS-associated factor 2 LLQFQDLTGIESMDQCR 32 26.55% 18.07% 8.48% 




166 40.19% 31.76% 8.43% 
P17987 TCP1 T-complex protein 1 subunit alpha ICDDELILIK 357 27.22% 18.90% 8.32% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 IEEFLEEVLCPPK 100 24.21% 16.01% 8.20% 
P21333 FLNA Filamin-A LQVEPAVDTSGVQCYGPGIEGQGVFR 1260 34.93% 26.78% 8.15% 
P35579 MYH9 Myosin-9 QELEEICHDLEAR 917 19.80% 11.66% 8.14% 
P27348 YWHAQ 14-3-3 protein theta YDDMATCMK 25 33.97% 25.85% 8.12% 
Q9Y3I0 C22orf28 tRNA-splicing ligase RtcB homolog EHCEEYGR 193 25.43% 17.38% 8.05% 
Q9NP84 TNFRSF12A Tumor necrosis factor receptor superfamily member 
FTTPIEETGGEGCP
AVALIQ 122 41.94% 34.02% 7.92% 
P21333 FLNA Filamin-A VDINTEDLEDGTCR 2102 40.29% 32.38% 7.91% 
O75369 FLNB Filamin-B IEYNDQNDGSCDVK 604 44.81% 36.90% 7.91% 
O60361 NME2P1 Putative nucleoside diphosphate kinase SCAHDWVYE 130 31.64% 23.81% 7.83% 
O00232 PSMD12 26S proteasome non-ATPase regulatory subunit 12 
MVQQC*C*TYVEEI
TDLPIK 108 33.08% 25.27% 7.81% 
P60763 RAC3 Ras-related C3 botulinum toxin substrate 3 AVLCPPPVK 178 20.38% 12.76% 7.62% 
P07355 ANXA2 Annexin A2 ALLYLCGGDD 335 18.00% 10.41% 7.59% 
Q9H2G2 SLK STE20-like serine/threonine-protein kinase DLQLQCEANVR 1138 82.27% 74.88% 7.39% 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 SFLTAEDCFELGK 167 20.09% 12.89% 7.20% 
P60228 EIF3E Eukaryotic translation initiation factor 3 subunit LFIFETFCR 345 21.06% 13.86% 7.20% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al IIHEDGYSEDECK 66 19.04% 12.04% 7.00% 
P04439 HLA-A HLA class I histocompatibility antigen, A-3 alpha  
GGSYTQAASSDSA
QGSDVSLTACK 363 44.63% 37.68% 6.95% 
P63010 AP2B1 AP-2 complex subunit beta YESIIATLCENLDSLDEPDAR 433 17.31% 10.48% 6.83% 
Q9Y4L1 HYOU1 Hypoxia up-regulated protein 1 VEFEELCADLFER 352 23.77% 17.04% 6.73% 
Q00341 HDLBP Vigilin DCDPGSPR 940 38.50% 31.84% 6.66% 
Q9Y490 TLN1 Talin-1 CTQDLGNSTK 1087 17.61% 11.02% 6.59% 
P46821 MAP1B Microtubule-associated protein 1B TPDTSTYCYETAEK 2041 30.55% 24.09% 6.46% 
P26599 PTBP1 Polypyrimidine tract-binding protein 1 LSLDGQNIYNAC*C*TLR 250 28.38% 21.98% 6.40% 
O75935 DCTN3 Dynactin subunit 3 QFVQWDELLCQLEAATQVK 173 18.38% 12.32% 6.06% 
P61224 RAP1B Ras-related protein Rap-1b CDLEDER 118 25.33% 19.35% 5.98% 
O00743 PPP6C Serine/threonine-protein phosphatase 6 catalytic s 
GAFCDLVWSDPED
VDTWAISPR 192 32.06% 26.10% 5.96% 
Q9UKS6 PACSIN3 Protein kinase C and casein kinase substrate in ne 
IGLYPANYVECVG
A 421 32.54% 26.61% 5.93% 
Q96PD2 DCBLD2 Discoidin, CUB and LCCL domain-containing protein  
TDSCSSAQAQYDT
PK 725 40.10% 34.21% 5.89% 
P07900 HSP90AA1 Heat shock protein HSP 90-alpha CLELFTELAEDK 420 17.40% 11.52% 5.88% 
P50552 VASP Vasodilator-stimulated phosphoprotein SSSSVTTSETQPCTPSSSDYSDLQR 334 54.75% 48.88% 5.87% 




1133 35.47% 29.61% 5.86% 
O75369 FLNB Filamin-B CLATGPGIASTVK 1617 34.14% 28.33% 5.81% 
Q86Y82 STX12 Syntaxin-12 DFSSIIQTCSGNIQR 29 10.47% 4.76% 5.71% 
O00231 PSMD11 26S proteasome non-ATPase regulatory subunit 11 TTANAIYCPPK 202 16.71% 11.05% 5.66% 
P04439 HLA-A HLA class I histocompatibility antigen, A-3 alpha  
GGSYTQAASSDSA
QGSDVSLTACK 363 43.26% 38.05% 5.21% 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A ITIADCGQLE 161 33.78% 28.61% 5.17% 
P61981 YWHAG 14-3-3 protein gamma NCSETQYESK 112 16.30% 11.13% 5.17% 
P21333 FLNA Filamin-A VQVQDNEGCPVEALVK 717 29.59% 24.55% 5.04% 
Q9NZM1 MYOF Myoferlin CYVYQAR 1143 15.45% 10.43% 5.02% 
P50991 CCT4 T-complex protein 1 subunit delta AQDIEAGDGTTSVVIIAGSLLDSCTK 120 10.87% 5.86% 5.01% 
P04083 ANXA1 Annexin A1 ILVALCGGN 343 12.63% 7.69% 4.94% 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha CSSILLHGK 518 14.03% 9.09% 4.94% 
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Q96CS3 FAF2 FAS-associated factor 2 NTLCAPEVISLINTR 194 23.78% 18.96% 4.82% 
P63167 DYNLL1 Dynein light chain 1, cytoplasmic  NADMSEEMQQDSVECATQALEK 24 51.33% 46.57% 4.76% 
P55145 MANF Mesencephalic astrocyte-derived neurotrophic facto 
LCYYIGATDDAAT
K 75 18.73% 14.02% 4.71% 
P08670 VIM Vimentin QVQSLTCEVDALK 328 20.59% 15.99% 4.60% 
P63104 YWHAZ 14-3-3 protein zeta/delta YDDMAACMK 25 36.33% 31.84% 4.49% 
Q04917 YWHAH 14-3-3 protein eta NCNDFQYESK 112 10.15% 5.80% 4.35% 
P60763 RAC3 Ras-related C3 botulinum toxin substrate 3 CVVVGDGAVGK 6 12.12% 7.96% 4.16% 
P04075 ALDOA Fructose-bisphosphate aldolase A YASICQQNGIVPIVEPEILPDGDHDLK 178 12.64% 8.51% 4.13% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al 
ITHSPLTICFPEYTG
ANK 287 10.23% 6.22% 4.01% 
O43707 ACTN4 Alpha-actinin-4 ELPPDQAEYCIAR 879 19.12% 15.11% 4.01% 
Q12907 LMAN2 Vesicular integral-membrane protein VIP36 WTELAGCTADFR 202 74.25% 70.32% 3.93% 
P14618 PKM Pyruvate kinase isozymes M1/M2 AEGSDVANAVLDGADCIMLSGETAK 358 22.62% 18.73% 3.89% 
Q9ULV4 CORO1C Coronin-1C NDQCYDDIR 23 20.11% 16.24% 3.87% 
Q12907 LMAN2 Vesicular integral-membrane protein VIP36 NCIDITGVR 239 77.65% 73.94% 3.71% 
Q96CS3 FAF2 FAS-associated factor 2 LECLPPEPSPDDPESVK 349 23.00% 19.38% 3.62% 




286 12.68% 9.07% 3.61% 
Q93050 ATP6V0A1 V-type proton ATPase 116 kDa subunit a isoform 1 ASLYPCPETPQER 247 16.13% 12.54% 3.59% 
P15121 AKR1B1 Aldose reductase LIQYCQSK 200 18.26% 14.73% 3.53% 
P18124 RPL7 60S ribosomal protein L7 YGIICMEDLIHEIYTVGK 186 14.76% 11.25% 3.51% 




190 83.26% 79.76% 3.50% 




126 38.89% 35.41% 3.48% 
Q96HE7 ERO1L ERO1-like protein alpha YSEEANNLIEECEQAER 131 91.70% 88.25% 3.45% 
Q9Y230 RUVBL2 RuvB-like 2 FVQCPDGELQK 227 14.96% 11.53% 3.43% 
Q6DD88 ATL3 Atlastin-3 ELYENFCK 429 11.23% 7.91% 3.32% 
P60709 ACTB Actin, cytoplasmic 1  LCYVALDFEQEMATAASSSSLEK 217 10.14% 6.91% 3.23% 
P17987 TCP1 T-complex protein 1 subunit alpha SLHDALCVVK 397 13.97% 10.83% 3.14% 
P21333 FLNA Filamin-A DGSCGVAYVVQEPGDYEVSVK 2293 29.21% 26.14% 3.07% 
P21333 FLNA Filamin-A DNGNGTYSCSYVPR 733 18.43% 15.39% 3.04% 
P08758 ANXA5 Annexin A5 ALLLLCGEDD 316 10.90% 7.90% 3.00% 
P37235 HPCAL1 Hippocalcin-like protein 1 LLQCDPSSASQF 185 13.55% 10.60% 2.95% 
Q9HAV0 GNB4 Guanine nucleotide-binding protein subunit beta-4 
ADQELLLYSHDNII
CGITSVAFSK 271 7.65% 4.76% 2.89% 
P49368 CCT3 T-complex protein 1 subunit gamma TLIQNCGASTIR 455 10.91% 8.03% 2.88% 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha IISANGCK 211 17.87% 15.00% 2.87% 




137 86.51% 83.65% 2.86% 
P09525 ANXA4 Annexin A4 VLLVLCGGDD 315 7.66% 4.85% 2.81% 
Q9Y490 TLN1 Talin-1 VVAPTISSPVCQEQLVEAGR 732 9.37% 6.59% 2.78% 
P27797 CALR Calreticulin HEQNIDCGGGYVK 105 72.51% 69.74% 2.77% 
Q00610 CLTC Clathrin heavy chain 1 IHEGCEEPATHNALAK 870 12.88% 10.12% 2.76% 
P53618 COPB1 Coatomer subunit beta AAAQCYIDLIIK 284 7.73% 4.97% 2.76% 
Q9Y490 TLN1 Talin-1 VQELGHGCAALVTK 1927 13.37% 10.61% 2.76% 
P21333 FLNA Filamin-A THEAEIVEGENHTYCIR 2199 18.66% 15.97% 2.69% 
P09496 CLTA Clathrin light chain A LCDFNPK 218 13.03% 10.45% 2.58% 
Q99832 CCT7 T-complex protein 1 subunit eta INALTAASEAACLIVSVDETIK 511 12.47% 9.96% 2.51% 
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P53675 CLTCL1 Clathrin heavy chain 2 LECSEELGDLVK 459 8.29% 5.84% 2.45% 
P46782 RPS5 40S ribosomal protein S5 VNQAIWLLCTGAR 155 8.27% 5.89% 2.38% 
P63104 YWHAZ 14-3-3 protein zeta/delta DICNDVLSLLEK Bad ID 7.37% 5.05% 2.32% 
P29317 EPHA2 Ephrin type-A receptor 2 NILVNSNLVCK 753 8.75% 6.46% 2.29% 
Q9BZE1 MRPL37 39S ribosomal protein L37, mitochondrial  
NHIENQDECVLNV
ISHAR 153 38.06% 35.85% 2.21% 
P17987 TCP1 T-complex protein 1 subunit alpha IACLDFSLQK 236 7.91% 5.76% 2.15% 
O60716 CTNND1 Catenin delta-1 TPAILEASAGAIQNLCAGR 692 7.24% 5.16% 2.08% 
P21333 FLNA Filamin-A ATCAPQHGAPGPGPADASK 2543 21.87% 19.84% 2.03% 
P62829 RPL23 60S ribosomal protein L23 ECADLWPR 125 19.01% 17.07% 1.94% 
P09486 SPARC SPARC YIPPCLDSELTEFPLR 155 84.59% 82.66% 1.93% 
P60174 TPI1 Triosephosphate isomerase IIYGGSVTGATCK 255 20.17% 18.25% 1.92% 
P61247 RPS3A 40S ribosomal protein S3a LFCVGFTK 139 7.66% 5.76% 1.90% 
P68104 EEF1A1 Elongation factor 1-alpha 1 DGNASGTTLLEALDCILPPTR 234 8.89% 7.01% 1.88% 
P07355 ANXA2 Annexin A2 GLGTDEDSLIEIICSR 133 9.62% 7.77% 1.85% 
Q8N5K1 CISD2 CDGSH iron-sulfur domain-containing protein 2 VVNEINIEDLCLTK 92 25.71% 24.03% 1.68% 
P02786 TFRC Transferrin receptor protein 1 TDSTCR 363 84.69% 83.23% 1.46% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 AVYSTNCPVWEEAFR 522 6.98% 5.58% 1.40% 
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M ACQIFVR 653 7.93% 6.66% 1.27% 
P68366 TUBA4A Tubulin alpha-4A chain AYHEQLSVAEITNACFEPANQMVK 295 32.31% 31.06% 1.25% 
H3BN98 Uncharacterized protein FHEICSNLVK 109 5.09% 3.99% 1.10% 
Q92544 TM9SF4 Transmembrane 9 superfamily member 4 
TQLPYEYYSLPFCQ
PSK 64 94.63% 93.58% 1.05% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
ACADATLSQITNN
IDPVGR 25 9.41% 8.51% 0.90% 
Q9ULV4 CORO1C Coronin-1C DTICNQDER 456 5.12% 4.30% 0.82% 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
VPTANVSVVDLTC
R 247 7.70% 7.11% 0.59% 
O60716 CTNND1 Catenin delta-1 HIEWESVLTNTAGCLR 533 4.76% 5.22% -0.46% 
H3BN98 Uncharacterized protein ALC*DVGTAISC*SR 43 92.90% 93.38% -0.48% 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K GSDFDCELR 145 4.21% 4.81% -0.60% 
P07947 YES1 Tyrosine-protein kinase Yes LTTVCPTVK 255 10.83% 11.52% -0.69% 
P15153 RAC2 Ras-related C3 botulinum toxin substrate 2 YLECSALTQR 157 5.18% 6.04% -0.86% 
Q00610 CLTC Clathrin heavy chain 1 GQC*DLELINVC*NENSLFK 926 4.30% 5.18% -0.88% 
Q9NQC3 RTN4 Reticulon-4 YSNSALGHVNCTIK 1101 7.38% 8.27% -0.89% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al 
LWADHGVQACFG
R 140 4.40% 5.33% -0.93% 
P55884 EIF3B Eukaryotic translation initiation factor 3 subunit NLFNVVDCK 515 4.76% 5.72% -0.96% 




233 4.48% 5.49% -1.01% 
P13639 EEF2 Elongation factor 2 CLYASVLTAQPR 728 6.18% 7.20% -1.02% 
P00338 LDHA L-lactate dehydrogenase A chain DDVFLSVPCILGQNGISDLVK 293 5.73% 6.93% -1.20% 
P14618 PKM Pyruvate kinase isozymes M1/M2 GIFPVLCK 474 7.12% 8.36% -1.24% 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosy TEGSDLCDR 545 5.37% 6.62% -1.25% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 SSLQSQCLNEVLK 3712 5.41% 6.67% -1.26% 
Q15149 PLEC Plectin CRPDQLTGLSLLPLSEK 3336 8.11% 9.39% -1.28% 
P08195 SLC3A2 4F2 cell-surface antigen heavy chain WCSWSLSQAR 431 6.47% 7.79% -1.32% 
O15144 ARPC2 Actin-related protein 2/3 complex subunit 2 NCFASVFEK 120 3.65% 4.97% -1.32% 
P13639 EEF2 Elongation factor 2 YVEPIEDVPCGNIVGLVGVDQFLVK 466 11.54% 12.88% -1.34% 
Q9HBH5 RDH14 Retinol dehydrogenase 14 YFGDCK 306 39.51% 40.86% -1.35% 
Q15149 PLEC Plectin LLEAQACTGGIIDPSTGER 4454 10.17% 11.55% -1.38% 
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P62701 RPS4X 40S ribosomal protein S4, X isoform  ECLPLIIFLR 41 7.06% 8.47% -1.41% 
P46782 RPS5 40S ribosomal protein S5 AQCPIVER 66 4.90% 6.32% -1.42% 
Q9NRP0 OSTC Oligosaccharyltransferase complex subunit OSTC VPFLVLECPNLK 14 5.04% 6.48% -1.44% 
P21333 FLNA Filamin-A CSGPGLSPGMVR 1453 7.16% 8.60% -1.44% 
O75131 CPNE3 Copine-3 EALAQCVLAEIPQQVVGYFNTYK 506 7.12% 8.62% -1.50% 
P35579 MYH9 Myosin-9 CNGVLEGIR 694 6.09% 7.64% -1.55% 
P53992 SEC24C Protein transport protein Sec24C LLPVYLNCVLK 910 4.46% 6.12% -1.66% 
P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma cat 
TFTDC*FNC*LPIAA
IVDEK 155 18.74% 20.40% -1.66% 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosy 
VACITEQVLTLVN
K Bad ID 3.83% 5.50% -1.67% 
P30101 PDIA3 Protein disulfide-isomerase A3 VDC*TANTNTC*NK 85 84.84% 86.53% -1.69% 
O75718 CRTAP Cartilage-associated protein DSEAFCHR 84 93.54% 95.24% -1.70% 
Q9Y490 TLN1 Talin-1 AVAAGNSCR 2196 7.85% 9.61% -1.76% 
P21333 FLNA Filamin-A AHVVPCFDASK 1157 6.63% 8.39% -1.76% 
P09382 LGALS1 Galectin-1 DSNNLCLHFNPR 43 16.73% 18.49% -1.76% 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 
VDC*TAHSDVC*SA
QGVR 121 85.25% 87.02% -1.77% 
P09211 GSTP1 Glutathione S-transferase P ASCLYGQLPK 48 4.32% 6.11% -1.79% 
P63010 AP2B1 AP-2 complex subunit beta ECHLNADTVSSK 857 5.13% 6.96% -1.83% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 AGSDGESIGNCPFSQR 35 7.30% 9.15% -1.85% 
P61224 RAP1B Ras-related protein Rap-1b QWNNCAFLESSAK 141 5.50% 7.36% -1.86% 
P40429 RPL13A 60S ribosomal protein L13a CEGINISGNFYR 38 4.32% 6.18% -1.86% 
P42025 ACTR1B Beta-centractin ACYLSINPQK 222 5.41% 7.30% -1.89% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al IIHEDGYSEEECR 66 7.71% 9.62% -1.91% 
P17987 TCP1 T-complex protein 1 subunit alpha DCLINAAK 147 4.83% 6.77% -1.94% 
P51149 RAB7A Ras-related protein Rab-7a GADC*C*VLVFDVTAPNTFK 83 13.57% 15.52% -1.95% 
P68366 TUBA4A Tubulin alpha-4A chain SIQFVDWCPTGFK 347 9.91% 11.86% -1.95% 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta NTPSFLIACNK 179 6.79% 8.76% -1.97% 
P62913 RPL11 60S ribosomal protein L11 IAVHCTVR 72 17.43% 19.41% -1.98% 
P11940 PABPC1 Polyadenylate-binding protein 1 ALYDTFSAFGNILSCK 128 14.97% 16.96% -1.99% 
P05388 RPLP0 60S acidic ribosomal protein P0 NVASVCLQIGYPTVASVPHSIINGYK 226 9.22% 11.26% -2.04% 
P60953 CDC42 Cell division control protein 42 homolog YVECSALTQK 157 7.28% 9.33% -2.05% 





61 15.94% 18.02% -2.08% 
P68366 TUBA4A Tubulin alpha-4A chain AVCMLSNTTAIAEAWAR 376 9.92% 12.03% -2.11% 
P63167 DYNLL1 Dynein light chain 1, cytoplasmic  YNPTWHCIVGR 56 7.60% 9.71% -2.11% 
O60884 DNAJA2 DnaJ homolog subfamily A member 2 VIEPGCVR 308 9.20% 11.37% -2.17% 
P06733 ENO1 Alpha-enolase SGETEDTFIADLVVGLCTGQIK 389 13.76% 15.94% -2.18% 
P30050 RPL12 60S ribosomal protein L12 CTGGEVGATSALAPK 17 7.05% 9.27% -2.22% 
P46779 RPL28 60S ribosomal protein L28 NCSSFLIK 13 9.53% 11.76% -2.23% 
O60716 CTNND1 Catenin delta-1 NCDGVPALVR 450 4.47% 6.73% -2.26% 
P39023 RPL3 60S ribosomal protein L3 GCVVGTK 336 7.45% 9.71% -2.26% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 ATILDLSCNK 48 5.63% 7.92% -2.29% 
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 
TPEQCPSVVSLLSE
SYNPHVR 633 7.97% 10.29% -2.32% 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1 LPADTCLLEFAR 330 4.79% 7.16% -2.37% 
P15924 DSP Desmoplakin NQCTQVVQER 1805 11.42% 13.79% -2.37% 
P55735 SEC13 Protein SEC13 homolog VFIWTCDDASSNTWSPK 245 12.74% 15.12% -2.38% 
P23396 RPS3 40S ribosomal protein S3 GCEVVVSGK 134 6.63% 9.04% -2.41% 
P46777 RPL5 60S ribosomal protein L5 VGLTNYAAAYCTGLLLAR 100 6.39% 8.81% -2.42% 
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Q13724 MOGS Mannosyl-oligosaccharide glucosidase CWVALGAR 602 31.55% 33.99% -2.44% 
O75083 WDR1 WD repeat-containing protein 1 FVNCVR 194 5.36% 7.81% -2.45% 
Q14697 GANAB Neutral alpha-glucosidase AB TC*EESSFC*K 41 91.65% 94.12% -2.47% 
P07437 TUBB Tubulin beta chain TAVCDIPPR 354 9.60% 12.10% -2.50% 
P17931 LGALS3 Galectin-3 VIVCNTK 173 4.46% 7.00% -2.54% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
ACGDSTLTQITAG
LDPVGR 25 16.16% 18.72% -2.56% 
O43747 AP1G1 AP-1 complex subunit gamma-1 FTCTVNR 539 8.57% 11.13% -2.56% 
Q7L576 CYFIP1 Cytoplasmic FMR1-interacting protein 1 CFQPPIHQSLASS 1241 10.45% 13.03% -2.58% 
Q15149 PLEC Plectin AFCGFEDPR 4494 5.94% 8.53% -2.59% 




641 14.99% 17.59% -2.60% 
Q14764 MVP Major vault protein HYCTVANPVSR 59 6.56% 9.17% -2.61% 
P36578 RPL4 60S ribosomal protein L4 SGQGAFGNMCR 96 12.09% 14.73% -2.64% 
P21333 FLNA Filamin-A SSFTVDCSK 2582 20.42% 23.06% -2.64% 




207 21.78% 24.45% -2.67% 
Q15738 NSDHL Sterol-4-alpha-carboxylate 3-dehydrogenase, decarb FFLGDLCSR 86 8.96% 11.63% -2.67% 
Q96QK1 VPS35 Vacuolar protein sorting-associated protein 35 CYPDR 361 3.85% 6.58% -2.73% 
P55072 VCP Transitional endoplasmic reticulum ATPase GVLFYGPPGCGK 522 9.53% 12.27% -2.74% 
Q13190 STX5 Syntaxin-5 TQEFLSACK 68 14.50% 17.26% -2.76% 




641 4.76% 7.52% -2.76% 
P30041 PRDX6 Peroxiredoxin-6 DFTPVCTTELGR 47 23.51% 26.28% -2.77% 
O43865 AHCYL1 Putative adenosylhomocysteinase 2 GSSNFCVK 106 5.76% 8.60% -2.84% 
P30041 PRDX6 Peroxiredoxin-6 DINAYNCEEPTEK 91 37.14% 39.98% -2.84% 
P14868 DARS Aspartate--tRNA ligase, cytoplasmic  IGSCTQQDVELHVQK 130 4.87% 7.74% -2.87% 
Q14195 DPYSL3 Dihydropyrimidinase-related protein 3 GAPLVVICQGK 448 7.88% 10.75% -2.87% 
Q16658 FSCN1 Fascin LSCFAQTVSPAEK 121 11.08% 13.96% -2.88% 
P10586 PTPRF Receptor-type tyrosine-protein phosphatase F FISANLPCNK 1663 9.60% 12.53% -2.93% 
P57721 PCBP3 Poly(rC)-binding protein 3 INISEGNCPER 86 17.23% 20.18% -2.95% 
P60174 TPI1 Triosephosphate isomerase IAVAAQNCYK 104 13.42% 16.39% -2.97% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
HLYTLDGGDIINA
LCFSPNR 240 7.93% 10.93% -3.00% 




27 6.26% 9.27% -3.01% 
P07437 TUBB Tubulin beta chain NMMAACDPR 303 13.15% 16.19% -3.04% 
Q9HAV0 GNB4 Guanine nucleotide-binding protein subunit beta-4 TFVSGACDASSK 204 13.09% 16.16% -3.07% 
Q15149 PLEC Plectin C*VEDPETGLC*LLPLTDK 3008 14.14% 17.22% -3.08% 
Q9Y6Y8 SEC23IP SEC23-interacting protein CPGPLAVANGVVK 604 5.22% 8.32% -3.10% 
Q9Y6W5 WASF2 Wiskott-Aldrich syndrome protein family member 2 
SELECVTNITLANV
IR 27 7.09% 10.19% -3.10% 
Q02543 RPL18A 60S ribosomal protein L18a DLTTAGAVTQCYR 109 8.73% 11.88% -3.15% 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 
ESGSLSPEHGPVVV
HCSAGIGR 215 14.30% 17.48% -3.18% 
P62888 RPL30 60S ribosomal protein L30 LVILANNCPALR 52 7.70% 10.90% -3.20% 
P14174 MIF Macrophage migration inhibitory factor LLCGLLAER 81 7.05% 10.36% -3.31% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 GDGPICLVLAPTR 170 7.87% 11.24% -3.37% 
P49757 NUMB Protein numb homolog VSFCAPDR 117 9.59% 12.98% -3.39% 
O15031 PLXNB2 Plexin-B2 VLNCDTISQVK 1484 4.76% 8.17% -3.41% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 CDELTR 354 7.06% 10.48% -3.42% 
P55735 SEC13 Protein SEC13 homolog DVAWAPSIGLPTSTIASCSQDGR 234 17.18% 20.60% -3.42% 
P46776 RPL27A 60S ribosomal protein L27a NQSFCPTVNLDK 70 10.29% 13.72% -3.43% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase ANACNSVIK 471 9.56% 12.99% -3.43% 
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P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  
PGAIVIDCGINYVP
DDK 236 15.00% 18.48% -3.48% 
P21333 FLNA Filamin-A IVGPSGAAVPCK 1018 6.19% 9.70% -3.51% 
Q9Y2A7 NCKAP1 Nck-associated protein 1 NLITDIC*TEQC*TLSDQLLPK 618 7.07% 10.63% -3.56% 
P62424 RPL7A 60S ribosomal protein L7a TCTTVAFTQVNSEDK 199 7.76% 11.35% -3.59% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) LFVSGACDASAK 204 11.95% 15.55% -3.60% 
P63010 AP2B1 AP-2 complex subunit beta ITEYLCEPLR 123 5.37% 8.97% -3.60% 
A1L0T0 ILVBL Acetolactate synthase-like protein VLHDAQQQCR 608 7.55% 11.17% -3.62% 
P36578 RPL4 60S ribosomal protein L4 YAICSALAASALPALVMSK 125 5.55% 9.22% -3.67% 
P23396 RPS3 40S ribosomal protein S3 GLCAIAQAESLR 97 8.26% 11.93% -3.67% 
P35998 PSMC2 26S protease regulatory subunit 7 SVCTEAGMFAIR 389 9.85% 13.52% -3.67% 
P30086 PEBP1 Phosphatidylethanolamine-binding protein 1 
APVAGTCYQAEW
DDYVPK 168 19.76% 23.45% -3.69% 
P36578 RPL4 60S ribosomal protein L4 GPCIIYNEDNGIIK 208 5.38% 9.08% -3.70% 
O75131 CPNE3 Copine-3 TIELSDDDFLGEC*EC*TLGQIVSSK 98 13.58% 17.29% -3.71% 
P63220 RPS21 40S ribosomal protein S21 TYAICGAIR 56 9.54% 13.29% -3.75% 
P27635 RPL10 60S ribosomal protein L10 LIPDGCGVK 195 13.72% 17.56% -3.84% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 LQGATCNNNK 4570 10.18% 14.08% -3.90% 
P0CW22 RPS17L 40S ribosomal protein S17-like VCEEIAIIPSK 35 8.05% 11.96% -3.91% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) TFVSGACDASIK 204 14.17% 18.11% -3.94% 
P62829 RPL23 60S ribosomal protein L23 ISLGLPVGAVINCADNTGAK 28 10.24% 14.24% -4.00% 
O43815 STRN Striatin CYIASAGADALAK 765 9.27% 13.27% -4.00% 
P54136 RARS Arginine--tRNA ligase, cytoplasmic  VLTAEELNAAQTSVAYGCIK 502 5.60% 9.63% -4.03% 
O75369 FLNB Filamin-B SSFLVDCSK 2537 14.59% 18.67% -4.08% 
P42025 ACTR1B Beta-centractin YCFPNYVGR 34 6.44% 10.60% -4.16% 
P05388 RPLP0 60S acidic ribosomal protein P0 CFIVGADNVGSK 27 6.27% 10.46% -4.19% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
FSPNSSNPIIVSCG
WDK 168 7.03% 11.27% -4.24% 
Q9ULV4 CORO1C Coronin-1C VTWDSSFCAVNPR 39 8.37% 12.61% -4.24% 
P07437 TUBB Tubulin beta chain LTTPTYGDLNHLVSATMSGVTTCLR 239 10.48% 14.82% -4.34% 
P60709 ACTB Actin, cytoplasmic 1  CDVDIR 285 9.04% 13.38% -4.34% 
P50991 CCT4 T-complex protein 1 subunit delta ITGCASPGK 379 10.20% 14.55% -4.35% 
Q9HCN8 SDF2L1 Stromal cell-derived factor 2-like protein 1 TGAELVTCGSVLK 38 90.66% 95.01% -4.35% 
P61106 RAB14 Ras-related protein Rab-14 SCLLHQFTEK 26 5.37% 9.72% -4.35% 




604 23.59% 27.98% -4.39% 
Q9UKK3 PARP4 Poly LFACGIGSTANR 1002 6.66% 11.11% -4.45% 
P14625 HSP90B1 Endoplasmin LTESPCALVASQYGWSGNMER 645 17.05% 21.50% -4.45% 
P16435 POR NADPH--cytochrome P450 reductase EVGETLLYYGCR 566 8.77% 13.23% -4.46% 
P53675 CLTCL1 Clathrin heavy chain 2 DPHLACVAYER 918 7.88% 12.40% -4.52% 
P08134 RHOC Rho-related GTP-binding protein RhoC LVIVGDGACGK 16 10.63% 15.15% -4.52% 
P18669 PGAM1 Phosphoglycerate mutase 1 YADLTEDQLPSCESLK 153 9.62% 14.19% -4.57% 
Q8N5B7 CERS5 Ceramide synthase 5 SPCDSSSSNGANR 369 71.89% 76.47% -4.58% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase TGTLTTNQMSVCR 364 13.15% 17.73% -4.58% 
P07814 EPRS Bifunctional glutamate/proline--tRNA ligase 
YNVYPTYDFACPIV
DSIEGVTHALR 381 4.79% 9.40% -4.61% 
Q9ULV4 CORO1C Coronin-1C CEIAR 330 10.94% 15.63% -4.69% 
P48643 CCT5 T-complex protein 1 subunit epsilon VVNSCHR 181 4.30% 9.04% -4.74% 
P61158 ACTR3 Actin-related protein 3 DYEEIGPSICR 408 25.16% 29.92% -4.76% 
P50570 DNM2 Dynamin-2 CVDLVIQELINTVR 427 21.42% 26.18% -4.76% 
Q15437 SEC23B Protein transport protein Sec23B MVVPLACLLTPLK 40 7.09% 11.93% -4.84% 
P45880 VDAC2 Voltage-dependent anion-selective channel protein 
WNTDNTLGTEIAI
EDQICQGLK 103 11.99% 16.85% -4.86% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 
VGEATETALTCLV
EK 447 7.21% 12.09% -4.88% 
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P46776 RPL27A 60S ribosomal protein L27a SVGGACVLVA 144 16.90% 21.78% -4.88% 
O95487 SEC24B Protein transport protein Sec24B CTLTNIPQTQALLNK 562 6.83% 11.73% -4.90% 
P61158 ACTR3 Actin-related protein 3 YSYVCPDLVK 235 6.77% 11.74% -4.97% 
Q02543 RPL18A 60S ribosomal protein L18a SSGEIVYCGQVFEK 64 12.63% 17.61% -4.98% 
Q9NP72 RAB18 Ras-related protein Rab-18 TC*DGVQC*AFEELVEK 155 20.57% 25.56% -4.99% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X PCVVYGGADIGQQIR 298 8.34% 13.36% -5.02% 
Q2M2I8 AAK1 AP2-associated protein kinase 1 LQTGFTENEVLQIFC*DTC*EAVAR 156 18.00% 23.06% -5.06% 
P08134 RHOC Rho-related GTP-binding protein RhoC TCLLIVFSK 20 7.45% 12.57% -5.12% 
P55735 SEC13 Protein SEC13 homolog LATCSSDR 31 14.33% 19.46% -5.13% 
P39023 RPL3 60S ribosomal protein L3 VACIGAWHPAR 253 57.85% 63.05% -5.20% 
P29401 TKT Transketolase TVPFCSTFAAFFTR 386 5.40% 10.72% -5.32% 
Q8N0U8 VKORC1L1 Vitamin K epoxide reductase complex subunit 1-like ALCDLGPWVK 50 75.91% 81.23% -5.32% 
P13639 EEF2 Elongation factor 2 VTDGALVVVDC*VSGVC*VQTETVLR 131 30.97% 36.30% -5.33% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase ECVQPATK 997 19.45% 24.78% -5.33% 
P62280 RPS11 40S ribosomal protein S11 CPFTGNVSIR 60 7.28% 12.64% -5.36% 
P43034 PAFAH1B1 Platelet-activating factor acetylhydrolase IB subu LWDFQGFECIR 184 4.76% 10.13% -5.37% 
P25685 DNAJB1 DnaJ homolog subfamily B member 1 VSLEEIYSGCTK 179 4.46% 9.86% -5.40% 
P61158 ACTR3 Actin-related protein 3 LGYAGNTEPQFIIPSCIAIK 34 13.75% 19.29% -5.54% 
P45880 VDAC2 Voltage-dependent anion-selective channel protein 
VC*EDLDTSVNLA
WTSGTNC*TR 210 5.68% 11.27% -5.59% 
P50914 RPL14 60S ribosomal protein L14 CMQLTDFILK 54 8.72% 14.34% -5.62% 
P62244 RPS15A 40S ribosomal protein S15a CGVISPR 72 9.70% 15.40% -5.70% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X WCDK 128 10.99% 16.71% -5.72% 
P21333 FLNA Filamin-A VGTECGNQK 574 8.17% 13.91% -5.74% 
Q15286 RAB35 Ras-related protein Rab-35 WLHEINQNC*DDVC*R 110 18.18% 23.93% -5.75% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- YWLCAATGPSIK 249 7.71% 13.49% -5.78% 
P04222 HLA-C HLA class I histocompatibility antigen, Cw-3 alpha 
GGSC*SQAASSNSA
QGSDESLIAC*K 345 56.20% 62.04% -5.84% 
P30519 HMOX2 Heme oxygenase 2 GALEGSSCPFR 282 13.80% 19.65% -5.85% 
Q92747 ARPC1A Actin-related protein 2/3 complex subunit 1A IVTCGADR 70 12.31% 18.18% -5.87% 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  
FWTFETGC*TVC*D
EGLR 267 86.68% 92.59% -5.91% 
Q8IVL6 LEPREL2 Prolyl 3-hydroxylase 3 AVLDGLLTPAECGVLLQLAK 478 72.77% 78.79% -6.02% 
P21964 COMT Catechol O-methyltransferase GTVLLADNVICPGAPDFLAHVR 223 9.88% 15.91% -6.03% 
O00116 AGPS Alkyldihydroxyacetonephosphate synthase, peroxisom IVNLACK 226 20.36% 26.39% -6.03% 




133 11.07% 17.10% -6.03% 
P27708 CAD CAD protein ILALDCGLK 183 9.39% 15.47% -6.08% 
P00338 LDHA L-lactate dehydrogenase A chain VIGSGCNLDSAR 163 9.87% 16.02% -6.15% 
Q9NZN4 EHD2 EH domain-containing protein 2 IQLEHHISPGDFPDCQK 356 19.90% 26.10% -6.20% 
O95347 SMC2 Structural maintenance of chromosomes protein 2 FTQCQNGK 1174 5.66% 11.90% -6.24% 
Q15417 CNN3 Calponin-3 CASQAGMTAYGTR 173 16.48% 22.72% -6.24% 
Q9HD20 ATP13A1 Probable cation-transporting ATPase 13A1 
SPQENLVPCDVLL
LR 336 6.57% 12.84% -6.27% 
Q9H1C4 UNC93B1 Protein unc-93 homolog B1 PCPYEQAQGGDGPEEQ 583 13.41% 19.79% -6.38% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- VWNLANCK 182 12.97% 19.41% -6.44% 
P62249 RPS16 40S ribosomal protein S16 TATAVAHCK 25 10.94% 17.39% -6.45% 
O60504 SORBS3 Vinexin LCDDGPQLPTSPR 521 8.22% 14.69% -6.47% 
P62888 RPL30 60S ribosomal protein L30 TGVHHYSGNNIELGTACGK 85 16.20% 22.67% -6.47% 
Q99832 CCT7 T-complex protein 1 subunit eta YNFFTGCPK 364 5.85% 12.38% -6.53% 
	 276	
P61158 ACTR3 Actin-related protein 3 LPAC*VVDC*GTGYTK 8 29.14% 35.76% -6.62% 
O15143 ARPC1B Actin-related protein 2/3 complex subunit 1B IVTCGTDR 70 15.42% 22.12% -6.70% 




286 15.14% 21.86% -6.72% 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 HEASDFPCR 32 8.12% 14.85% -6.73% 
P30101 PDIA3 Protein disulfide-isomerase A3 FIQENIFGICPHMTEDNK 244 25.09% 31.96% -6.87% 
P14618 PKM Pyruvate kinase isozymes M1/M2 PVICATQMLESMIK 326 7.14% 14.04% -6.90% 
O15270 SPTLC2 Serine palmitoyltransferase 2 NTGSCQEAAAK 188 16.70% 23.66% -6.96% 
P30519 HMOX2 Heme oxygenase 2 CPFYAAEQDK 265 10.95% 17.91% -6.96% 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 PCTLSELE 528 48.13% 55.18% -7.05% 
Q13642 FHL1 Four and a half LIM domains protein 1 FWHDTCFR 65 45.64% 52.74% -7.10% 
Q7L576 CYFIP1 Cytoplasmic FMR1-interacting protein 1 CNEQPNR 98 12.46% 19.57% -7.11% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 GVEICIATPGR 221 6.91% 14.06% -7.15% 
P25398 RPS12 40S ribosomal protein S12 LGEWVGLCK 92 17.53% 24.72% -7.19% 
Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protei 
VAAASGHCGAFS
GSDSSR 919 13.56% 20.84% -7.28% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- LWNTLGVCK 138 9.27% 16.60% -7.33% 
Q8TAT6 NPLOC4 Nuclear protein localization protein 4 homolog FVALENISCK 188 23.65% 31.05% -7.40% 
P62701 RPS4X 40S ribosomal protein S4, X isoform  FDTGNLCMVTGGANLGR 181 4.76% 12.16% -7.40% 
P62273 RPS29 40S ribosomal protein S29 YGLNMCR 39 37.81% 45.25% -7.44% 
Q96A33 CCDC47 Coiled-coil domain-containing protein 47 
LNQENEHIYNLW
CSGR 209 13.94% 21.44% -7.50% 
O00154 ACOT7 Cytosolic acyl coenzyme A thioester hydrolase CVAALAR 100 18.03% 25.66% -7.63% 
Q15005 SPCS2 Signal peptidase complex subunit 2 SGGSGGC*SGAGGASNC*GTGSGR 17 64.15% 71.81% -7.66% 
O15269 SPTLC1 Serine palmitoyltransferase 1 YGVGTCGPR 133 8.80% 16.47% -7.67% 
P62266 RPS23 40S ribosomal protein S23 ITAFVPNDGCLNFIEENDEVLVAGFGR 90 13.54% 21.22% -7.68% 
P42330 AKR1C3 Aldo-keto reductase family 1 member C3 
WVDPNSPVLLEDP
VLCALAK 242 4.76% 12.54% -7.78% 
Q14694 USP10 Ubiquitin carboxyl-terminal hydrolase 10 TPSYSISSTLNPQAPEFILGCTASK 94 32.81% 40.60% -7.79% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
YTVQDESHSEWVS
CVR 153 12.74% 20.60% -7.86% 
Q92900 UPF1 Regulator of nonsense transcripts 1 WFCNGR 145 11.97% 20.01% -8.04% 
Q9Y4P3 TBL2 Transducin beta-like protein 2 YLATCADDR 108 16.80% 24.87% -8.07% 
P17980 PSMC3 26S protease regulatory subunit 6A C*TDDFNGAQC*K 387 21.27% 29.36% -8.09% 
P50914 RPL14 60S ribosomal protein L14 ALVDGPCTQVR 42 13.73% 21.87% -8.14% 
P13639 EEF2 Elongation factor 2 CELLYEGPPDDEAAMGIK 369 16.46% 24.60% -8.14% 
P32970 CD70 CD70 antigen LSFHQGCTIASQR 151 71.11% 79.29% -8.18% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 WLC*TGDIGEFEPDGC*LK 561 9.58% 17.77% -8.19% 
P39023 RPL3 60S ribosomal protein L3 TVFAEHISDECK 114 6.50% 14.71% -8.21% 
P62753 RPS6 40S ribosomal protein S6 LNISFPATGCQK 12 10.67% 18.90% -8.23% 
Q01082 SPTBN1 Spectrin beta chain, non-erythrocytic 1  PCDPQVIR 604 5.60% 13.86% -8.26% 
Q7L576 CYFIP1 Cytoplasmic FMR1-interacting protein 1 NFVGPPHFQVICR 918 37.32% 45.59% -8.27% 
Q15437 SEC23B Protein transport protein Sec23B IAGAIGPCVSLNVK 425 11.64% 19.92% -8.28% 
O15355 PPM1G Protein phosphatase 1G CSGDGVGAPR 13 14.66% 23.05% -8.39% 
P62888 RPL30 60S ribosomal protein L30 VCTLAIIDPGDSDIIR 92 13.74% 22.17% -8.43% 
O00116 AGPS Alkyldihydroxyacetonephosphate synthase, peroxisom GVQFAPFSTCR 565 9.07% 17.53% -8.46% 
Q07020 RPL18 60S ribosomal protein L18 GCGTVLLSGPR 134 14.56% 23.04% -8.48% 
Q15149 PLEC Plectin GCLDEETSR 3299 15.73% 24.26% -8.53% 
P11142 HSPA8 Heat shock cognate 71 kDa protein GPAVGIDLGTTYSCVGVFQHGK 17 7.43% 15.97% -8.54% 
P27816 MAP4 Microtubule-associated protein 4 CSLPAEEDSVLEK 635 31.97% 40.59% -8.62% 
P61160 ACTR2 Actin-related protein 2 VVVCDNGTGFVK 11 17.24% 26.21% -8.97% 
Q15436 SEC23A Protein transport protein Sec23A ISGAIGPCVSLNSK 423 13.69% 22.69% -9.00% 
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P00533 EGFR Epidermal growth factor receptor TPLLSSLSATSNNSTVACIDR 1049 54.46% 63.52% -9.06% 
P42677 RPS27 40S ribosomal protein S27 LTEGCSFR 77 10.92% 20.04% -9.12% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 
ELAQQVQQVAAE
YCR 191 22.90% 32.04% -9.14% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 STCIYGGAPK 200 13.88% 23.04% -9.16% 
Q13642 FHL1 Four and a half LIM domains protein 1 FTAVEDQYYC*VDC*YK 209 55.25% 64.45% -9.20% 
Q8IXB1 DNAJC10 DnaJ homolog subfamily C member 10 IGAVNCGDDR 186 78.97% 88.22% -9.25% 
Q9UHG3 PCYOX1 Prenylcysteine oxidase 1 LVCSGLLQASK 258 5.12% 14.39% -9.27% 
Q15149 PLEC Plectin VPLDVACAR 3295 13.33% 22.79% -9.46% 
Q9Y678 COPG1 Coatomer subunit gamma-1 SLPYNQPGTCYTLVALPK 706 14.37% 23.83% -9.46% 
P12268 IMPDH2 Inosine-5-monophosphate dehydrogenase 2 HGFCGIPITDTGR 140 7.75% 17.24% -9.49% 
O75122 CLASP2 CLIP-associating protein 2 VLCPIIQTADYPINLAAIK 1184 4.76% 14.27% -9.51% 
Q15436 SEC23A Protein transport protein Sec23A GPC*VSENEIGTGGTC*QWK 432 11.41% 20.97% -9.56% 
Q99439 CNN2 Calponin-2 CASQSGMTAYGTR 175 45.32% 54.90% -9.58% 
Q15436 SEC23A Protein transport protein Sec23A AVLNPLCQVDYR 74 15.25% 24.96% -9.71% 
P27635 RPL10 60S ribosomal protein L10 VDEFPLCGHMVSDEYEQLSSEALEAAR 49 35.59% 45.32% -9.73% 
Q6IQ22 RAB12 Ras-related protein Rab-12 FTDDTFC*EAC*K 68 50.17% 60.07% -9.90% 
O15143 ARPC1B Actin-related protein 2/3 complex subunit 1B 
STVLSLDWHPNNV
LLAAGSCDFK 162 14.01% 24.13% -10.12% 
P62280 RPS11 40S ribosomal protein S11 DVQIGDIVTVGECR 131 16.82% 27.09% -10.27% 
P10809 HSPD1 60 kDa heat shock protein, mitochondrial  AAVEEGIVLGGGCALLR 442 23.77% 34.05% -10.28% 




244 23.58% 33.98% -10.40% 
P50454 SERPINH1 Serpin H1 QHYNCEHSK 156 54.42% 64.90% -10.48% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 
VAGDC*LDEKQC*
K 131 16.86% 27.40% -10.54% 
Q86V48 LUZP1 Leucine zipper protein 1 NDC*TQLC*LSLNEER 134 26.38% 37.03% -10.65% 
Q7L5N7 LPCAT2 Lysophosphatidylcholine acyltransferase 2 
TTSGGEWPQILVFP
EGTCTNR 223 20.41% 31.35% -10.94% 
P49327 FASN Fatty acid synthase AFDTAGNGYCR 223 14.69% 25.64% -10.95% 
Q9Y6I9 TEX264 Testis-expressed sequence 264 protein LFTESCSISPK 68 14.02% 24.99% -10.97% 
P30040 ERP29 Endoplasmic reticulum resident protein 29 GQGVYLGMPGCLPVYDALAGEFIR 157 15.09% 26.15% -11.06% 
P61011 SRP54 Signal recognition particle 54 kDa protein TC*LIC*ADTFR 133 21.04% 32.18% -11.14% 
O43707 ACTN4 Alpha-actinin-4 CQLEINFNTLQTK 351 4.43% 15.63% -11.20% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 LLLCGGAPLSATTQR 450 12.17% 23.45% -11.28% 
P48444 ARCN1 Coatomer subunit delta NYCNIQVTK 479 14.87% 26.22% -11.35% 
P62633 CNBP Cellular nucleic acid-binding protein TSEVNCYR 158 54.69% 66.21% -11.52% 
P27797 CALR Calreticulin CKDDEFTHLYTLIVRPDNTYEVK 163 47.18% 58.79% -11.61% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 
SLPSVETLGC*TSVI
C*SDK 344 21.84% 33.53% -11.69% 
Q15436 SEC23A Protein transport protein Sec23A PDLPPIQYEPVLCSR 61 13.79% 25.64% -11.85% 
Q6NUM9 RETSAT All-trans-retinol 13,14-reductase  GACYGADHDLGR 534 27.99% 39.99% -12.00% 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  VGVDYEGGGCR 680 59.29% 71.62% -12.33% 
Q9H223 EHD4 EH domain-containing protein 4 LADC*DC*DGMLDEEEFALAK 493 23.43% 35.80% -12.37% 




61 27.77% 40.34% -12.57% 
P11216 PYGB Glycogen phosphorylase, brain form  LAACFLDSMATLGLAAYGYGIR 143 51.21% 63.80% -12.59% 
P00533 EGFR Epidermal growth factor receptor NGLQSCPIK 1058 51.00% 63.66% -12.66% 
Q15365 PCBP1 Poly(rC)-binding protein 1 LVVPATQCGSLIGK 109 20.76% 33.58% -12.82% 
Q15019 SEPT2 Septin-2 LTVVDTPGYGDAINC*RDC*FK 111 25.32% 38.35% -13.03% 
P57721 PCBP3 Poly(rC)-binding protein 3 LVVPASQCGSLIGK 141 19.74% 32.95% -13.21% 
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350 20.09% 33.32% -13.23% 
Q15019 SEPT2 Septin-2 LTVVDTPGYGDAINC*RDC*FK 111 25.87% 39.19% -13.32% 
P11766 ADH5 Alcohol dehydrogenase class-3 AGDTVIPLYIPQC*GEC*K 97 23.29% 36.67% -13.38% 
Q9Y281 CFL2 Cofilin-2 LLPLNDCR 80 9.73% 23.25% -13.52% 
O95159 ZFPL1 Zinc finger protein-like 1 LCNIPLASR 56 50.25% 64.10% -13.85% 
Q14571 ITPR2 Inositol 1,4,5-trisphosphate receptor type 2  TTC*FIC*GLER 2562 21.21% 35.17% -13.96% 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit HVLTGSADNSCR 76 15.70% 29.73% -14.03% 
P52209 PGD 6-phosphogluconate dehydrogenase, decarboxylating  
VGTGEPC*C*DWV
GDEGAGHFVK 170 21.84% 36.04% -14.20% 
Q8NCG7 DAGLB Sn1-specific diacylglycerol lipase beta AAC*VSC*PAQGVSSVDVA 658 51.33% 66.65% -15.32% 
P56192 MARS Methionine--tRNA ligase, cytoplasmic  SCPVVQSSQHLFLDLPK 441 12.37% 27.73% -15.36% 
Q8IWB7 WDFY1 WD repeat and FYVE domain-containing protein 1 VC*DSC*YDSIK 344 45.43% 60.85% -15.42% 
P21291 CSRP1 Cysteine and glycine-rich protein 1 DGEIYCK 167 40.59% 57.00% -16.41% 
Q9NR12 PDLIM7 PDZ and LIM domain protein 7 YAPSCAK 341 28.71% 45.71% -17.00% 
P49207 RPL34 60S ribosomal protein L34 AYGGSMCAK 83 45.61% 62.63% -17.02% 
Q9Y4P3 TBL2 Transducin beta-like protein 2 FVASCGFTPDVK 247 14.84% 31.93% -17.09% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 
VAGDC*LDEKQC*
K 131 16.01% 33.29% -17.28% 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta DTQTSITDSCAVYR 100 15.25% 32.71% -17.46% 
O15460 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 PCGSTEVD 529 49.87% 67.61% -17.74% 
P29323 EPHB2 Ephrin type-B receptor 2 GSCIANAEEVDVPIK 226 35.67% 53.79% -18.12% 
Q9Y6I9 TEX264 Testis-expressed sequence 264 protein CAVGSILSEGEESPSPELIDLYQK 94 17.69% 35.82% -18.13% 
Q9H488 POFUT1 GDP-fucose protein O-fucosyltransferase 1 VAYCFEVAAQR 126 76.82% 95.24% -18.42% 
P41091 EIF2S3 Eukaryotic translation initiation factor 2 subunit 
SCGSSTPDEFPTDIP
GTK 105 27.91% 48.10% -20.19% 
Q96HC4 PDLIM5 PDZ and LIM domain protein 5 FFAPECGR 479 18.75% 38.97% -20.22% 
P21291 CSRP1 Cysteine and glycine-rich protein 1 CSQAVYAAEK 122 34.17% 54.74% -20.57% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 VGAPLVC*C*EIK 503 17.40% 38.06% -20.66% 
P27708 CAD CAD protein VAEPELMGTPDGTCYPPPPVPR 1889 27.82% 48.61% -20.79% 
O60884 DNAJA2 DnaJ homolog subfamily A member 2 NVLC*SAC*SGQGGK 143 34.89% 55.90% -21.01% 
P62241 RPS8 40S ribosomal protein S8 LDVGNFSWGSEC*C*TR 71 17.58% 38.70% -21.12% 
O00469 PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2  
IFTENIVEQPCPDV
FWFPIFSEK 562 57.21% 78.62% -21.41% 
P31689 DNAJA1 DnaJ homolog subfamily A member 1 NVIC*DKC*EGR 134 36.67% 58.21% -21.54% 
P54136 RARS Arginine--tRNA ligase, cytoplasmic  NC*GC*LGASPNLEQLQEENLK 32 10.89% 32.49% -21.60% 
O00151 PDLIM1 PDZ and LIM domain protein 1 CGTGIVGVFVK 263 38.63% 60.25% -21.62% 
P30530 AXL Tyrosine-protein kinase receptor UFO DSC*SC*LTAAEVHPAGR 852 45.82% 68.60% -22.78% 
Q8NHP6 MOSPD2 Motile sperm domain-containing protein 2 CHTVESSK 442 10.83% 34.68% -23.85% 
Q9Y277 VDAC3 Voltage-dependent anion-selective channel protein VCNYGLTFTQK 65 6.79% 31.13% -24.34% 
P60981 DSTN Destrin CSTPEEIK 23 14.88% 40.80% -25.92% 
Q99523 SORT1 Sortilin CQGGVNPVR 723 64.75% 90.73% -25.98% 
Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protei LLVDADNCLHR 53 9.47% 43.08% -33.61% 
Q86WA8 LONP2 Lon protease homolog 2, peroxisomal  DGPSAGVTIVTCLASLFSGR 751 17.71% 51.45% -33.74% 
P09486 SPARC SPARC APLIPMEHCTTR 265 18.98% 55.41% -36.43% 
O95487 SEC24B Protein transport protein Sec24B VYAMCQIK 1103 17.27% 54.25% -36.98% 
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Table 2A-11. Filtered list of cysteine-containing peptides from secretory proteins 
identified in OxICAT analyses of DMSO and Tn treated samples. Each treatment 
was performed in triplicate and the data was filtered for peptides with ratios found 
in at least two of the replicates per treatment. Furthermore, the data was reduced 
to only peptides that displayed a statistically significant (p <0.05, unpaired t tests) 
difference in cysteine oxidation states. Data is displayed as percent oxidized and 
the average difference in percent oxidation (DMSO – Tn). Localization of proteins 
was determined using Uniprot and GO annotated tabs on UniprotKB. 
Uniprot 
ID Protein Description Peptide Sequence Residue 
Average Percent 
Oxidized Difference (DMSO - 
Tn)  DMSO Tn 
Q86TC9 MYPN Myopalladin NEAGIVSCTAR 1257 76.19% 29.43% 46.76% 
P07237 P4HB Protein disulfide-isomerase ITEFCHR 343 49.25% 12.54% 36.71% 
P39023 RPL3 60S ribosomal protein L3 VACIGAWHPAR 253 57.85% 26.41% 31.44% 




1686 54.90% 24.20% 30.70% 
P21333 FLNA Filamin-A IEC*DDKGDGSC*DVR 623 61.93% 31.27% 30.66% 
Q99943 AGPAT1 1-acyl-sn-glycerol-3-phosphate acyltransferase alp FTSGQCQVR 229 37.50% 13.47% 24.03% 
O00299 CLIC1 Chloride intracellular channel protein 1 
EEFASTCPDDEEIELAY
EQVAK 223 49.11% 27.07% 22.04% 
P62258 YWHAE 14-3-3 protein epsilon LIC*C*DILDVLDK 97 40.17% 20.91% 19.26% 
O75369 FLNB Filamin-B VHSPSGAVEECHVSELEPDK 2333 42.40% 24.04% 18.36% 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  VGVDYEGGGCR 680 59.29% 41.72% 17.57% 
P24666 ACP1 Low molecular weight phosphotyrosine protein phosp 
QLIIEDPYYGNDSDFET
VYQQCVR 146 52.12% 34.96% 17.16% 
P15311 EZR Ezrin EGILSDEIYCPPETAVLLGSYAVQAK 117 32.57% 15.60% 16.97% 
P21333 FLNA Filamin-A VTYCPTEPGNYIINIK 2107 41.40% 24.61% 16.79% 
P21333 FLNA Filamin-A VDINTEDLEDGTCR 2102 40.29% 23.76% 16.53% 
P30050 RPL12 60S ribosomal protein L12 HPHDIIDDINSGAVECPAS 162 48.51% 32.15% 16.36% 
Q16643 DBN1 Drebrin PPEIDITCWDADPVPEEEEGFEGGD 632 45.35% 29.59% 15.76% 
O75369 FLNB Filamin-B IEYNDQNDGSCDVK 604 44.81% 29.32% 15.49% 
P21333 FLNA Filamin-A VHSPSGALEECYVTEIDQDK 2378 36.47% 21.23% 15.24% 
P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  GCLELIK 152 39.80% 24.90% 14.90% 
Q96HE7 ERO1L ERO1-like protein alpha HDDSSDNFCEADDIQSPEAEYVDLLLNPER 166 40.19% 25.84% 14.35% 
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 QCVENADLPEGEK 112 30.50% 16.22% 14.28% 
P21333 FLNA Filamin-A CAPGVVGPAEADIDFDIIR 810 41.51% 27.30% 14.21% 
Q09666 AHNAK Neuroblast differentiation-associated protein AHNA 
GPFVEAEVPDVDLECP
DAK 1833 29.28% 15.28% 14.00% 
Q00341 HDLBP Vigilin DCDPGSPR 940 38.50% 24.52% 13.98% 




274 67.56% 53.79% 13.77% 
O75369 FLNB Filamin-B CLATGPGIASTVK 1617 34.14% 20.53% 13.61% 
P13010 XRCC5 X-ray repair cross-complementing protein 5 ETVYCLNDDDETEVLK 296 30.66% 17.13% 13.53% 
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Q96PD2 DCBLD2 Discoidin, CUB and LCCL domain-containing protein  TDSCSSAQAQYDTPK 725 40.10% 26.61% 13.49% 
P26038 MSN Moesin EGILNDDIYCPPETAVLLASYAVQSK 117 29.53% 16.34% 13.19% 
O00232 PSMD12 26S proteasome non-ATPase regulatory subunit 12 
MVQQC*C*TYVEEITDL
PIK 108 33.08% 19.89% 13.19% 
P46821 MAP1B Microtubule-associated protein 1B TPDTSTYCYETAEK 2041 30.55% 17.38% 13.17% 
P62913 RPL11 60S ribosomal protein L11 LC*LNIC*VGESGDR 21 28.97% 16.27% 12.70% 
Q14151 SAFB2 Scaffold attachment factor B2 ILDILGETCK 224 32.80% 20.14% 12.66% 
O75369 FLNB Filamin-B ALGALVDSC*APGLC*PDWESWDPQK 178 40.04% 27.61% 12.43% 
P04439 HLA-A HLA class I histocompatibility antigen, A-3 alpha  
GGSYTQAASSDSAQGS
DVSLTACK 363 43.26% 31.04% 12.22% 
Q9Y3I0 C22orf28 tRNA-splicing ligase RtcB homolog EHCEEYGR 193 25.43% 13.98% 11.45% 
P17987 TCP1 T-complex protein 1 subunit alpha ICDDELILIK 357 27.22% 15.85% 11.37% 




71 37.25% 25.94% 11.31% 
P35579 MYH9 Myosin-9 QELEEICHDLEAR 917 19.80% 8.63% 11.17% 
Q7L576 CYFIP1 Cytoplasmic FMR1-interacting protein 1 NFVGPPHFQVICR 918 37.32% 26.31% 11.01% 
O94979 SEC31A Protein transport protein Sec31A SDQLQQAVQSQGFINYCQK 458 17.31% 6.48% 10.83% 
O00743 PPP6C Serine/threonine-protein phosphatase 6 catalytic s 
GAFCDLVWSDPEDVDT
WAISPR 192 32.06% 21.25% 10.81% 
P60228 EIF3E Eukaryotic translation initiation factor 3 subunit LFIFETFCR 345 21.06% 10.62% 10.44% 
P53992 SEC24C Protein transport protein Sec24C LNEESGALLQC*ALLYTSC*AGQR 809 17.15% 6.71% 10.44% 
Q96CS3 FAF2 FAS-associated factor 2 NTLCAPEVISLINTR 194 23.78% 13.36% 10.42% 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 SFLTAEDCFELGK 167 20.09% 9.73% 10.36% 
P04439 HLA-A HLA class I histocompatibility antigen, A-3 alpha  
GGSYTQAASSDSAQGS
DVSLTACK 363 44.63% 34.59% 10.04% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 IEEFLEEVLCPPK 100 24.21% 14.60% 9.61% 
Q8N5K1 CISD2 CDGSH iron-sulfur domain-containing protein 2 VVNEINIEDLCLTK 92 25.71% 16.15% 9.56% 
P27816 MAP4 Microtubule-associated protein 4 NVCLPPEMEVALTEDQVPALK 535 23.61% 14.14% 9.47% 
P21333 FLNA Filamin-A VQVQDNEGCPVEALVK 717 29.59% 20.53% 9.06% 
P21333 FLNA Filamin-A LQVEPAVDTSGVQCYGPGIEGQGVFR 1260 34.93% 25.88% 9.05% 




1353 40.57% 31.71% 8.86% 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A ITIADCGQLE 161 33.78% 25.07% 8.71% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 SACDTVDTWLDDTAK 4216 20.04% 11.36% 8.68% 
O75935 DCTN3 Dynactin subunit 3 QFVQWDELLCQLEAATQVK 173 18.38% 9.76% 8.62% 




126 38.89% 30.37% 8.52% 
Q9Y2H6 FNDC3A Fibronectin type-III domain-containing protein 3A SNPSEVVEFTTCPDK 560 17.32% 8.84% 8.48% 




1133 35.47% 27.00% 8.47% 
P21333 FLNA Filamin-A AEISC*TDNQDGTC*SVSYLPVLPGDYSILVK 1912 31.32% 22.91% 8.41% 
Q9NP84 TNFRSF12A Tumor necrosis factor receptor superfamily member 
FTTPIEETGGEGCPAVA
LIQ 122 41.94% 33.60% 8.34% 
Q16658 FSCN1 Fascin DELFALEQSCAQVVLQAANER 260 21.29% 13.18% 8.11% 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 VDCDQHSDIAQR 92 26.40% 18.42% 7.98% 
Q9UBI6 GNG12 Guanine nucleotide-binding protein G(I)/G(S)/G(O) ASADLMSYCEEHAR 43 35.76% 27.87% 7.89% 
P18124 RPL7 60S ribosomal protein L7 YGIICMEDLIHEIYTVGK 186 14.76% 6.99% 7.77% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 DEFTNTCPSDK 234 27.71% 19.95% 7.76% 
P35222 CTNNB1 Catenin beta-1 VAAGVLCELAQDK 619 16.35% 8.78% 7.57% 
P07355 ANXA2 Annexin A2 ALLYLCGGDD 335 18.00% 10.44% 7.56% 
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P21333 FLNA Filamin-A DGSCGVAYVVQEPGDYEVSVK 2293 29.21% 21.80% 7.41% 
O75369 FLNB Filamin-B SSTETCYSAIPK 2501 28.78% 21.43% 7.35% 
Q9Y490 TLN1 Talin-1 CTQDLGNSTK 1087 17.61% 10.33% 7.28% 
P14618 PKM Pyruvate kinase isozymes M1/M2 AEGSDVANAVLDGADCIMLSGETAK 358 22.62% 15.39% 7.23% 
P60981 DSTN Destrin HECQANGPEDLNR 135 18.86% 11.63% 7.23% 
P61981 YWHAG 14-3-3 protein gamma ELEAVCQDVLSLLDNYLIK 97 12.75% 5.59% 7.16% 
P21333 FLNA Filamin-A ALGALVDSC*APGLC*PDWDSWDASK 205 29.79% 22.73% 7.06% 
Q9Y3Q3 TMED3 Transmembrane emp24 domain-containing protein 3 QCFHEEVEQGVK 40 69.19% 62.25% 6.94% 
Q99442 SEC62 Translocation protein SEC62 ESVVDYCNR 82 16.07% 9.16% 6.91% 
P35221 CTNNA1 Catenin alpha-1 AAAGEFADDPCSSVK 116 14.50% 7.61% 6.89% 
Q9ULV4 CORO1C Coronin-1C NDQCYDDIR 23 20.11% 13.28% 6.83% 
P21333 FLNA Filamin-A DNGNGTYSCSYVPR 733 18.43% 11.61% 6.82% 
P60174 TPI1 Triosephosphate isomerase IIYGGSVTGATCK 255 20.17% 13.40% 6.77% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al IIHEDGYSEDECK 66 19.04% 12.28% 6.76% 
O60716 CTNND1 Catenin delta-1 LVENC*VC*LLR 579 13.51% 6.77% 6.74% 
P07900 HSP90AA1 Heat shock protein HSP 90-alpha CLELFTELAEDK 420 17.40% 10.70% 6.70% 
P27816 MAP4 Microtubule-associated protein 4 PCSETSQIEDTPSSK 67 26.40% 19.73% 6.67% 
P49757 NUMB Protein numb homolog HTEVPTGTCPVDPFEAQWAALENK 611 21.80% 15.15% 6.65% 
P11142 HSPA8 Heat shock cognate 71 kDa protein VCNPIITK 603 12.18% 5.70% 6.48% 
P30153 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa reg DECPEVR 377 14.70% 8.30% 6.40% 
P04083 ANXA1 Annexin A1 ILVALCGGN 343 12.63% 6.38% 6.25% 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha CSSILLHGK 518 14.03% 7.82% 6.21% 
P15121 AKR1B1 Aldose reductase PAVNQIECHPYLTQEK 187 11.84% 5.64% 6.20% 
P07099 EPHX1 Epoxide hydrolase 1 NHGLSDEHVFEVICPSIPGYGFSEASSK 182 29.04% 23.02% 6.02% 
P61981 YWHAG 14-3-3 protein gamma NCSETQYESK 112 16.30% 10.31% 5.99% 
Q9NZM1 MYOF Myoferlin IYNCELENVAEFEGLTDFSDTFK 1483 10.12% 4.16% 5.96% 
P50991 CCT4 T-complex protein 1 subunit delta AQDIEAGDGTTSVVIIAGSLLDSCTK 120 10.87% 4.94% 5.93% 
O15460 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 PCGSTEVD 529 49.87% 44.00% 5.87% 
P27797 CALR Calreticulin CKDDEFTHLYTLIVRPDNTYEVK 163 47.18% 41.34% 5.84% 
P04075 ALDOA Fructose-bisphosphate aldolase A YASICQQNGIVPIVEPEILPDGDHDLK 178 12.64% 6.99% 5.65% 
P35579 MYH9 Myosin-9 CQHLQAEK 931 16.67% 11.02% 5.65% 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha IISANGCK 211 17.87% 12.30% 5.57% 
Q00610 CLTC Clathrin heavy chain 1 IHEGCEEPATHNALAK 870 12.88% 7.35% 5.53% 
P60174 TPI1 Triosephosphate isomerase VPADTEVVCAPPTAYIDFAR 79 21.40% 15.92% 5.48% 
Q6DD88 ATL3 Atlastin-3 ELYENFCK 429 11.23% 5.92% 5.31% 
Q9HCU5 PREB Prolactin regulatory element-binding protein CGAETQHEGLELR 128 29.13% 23.83% 5.30% 
P14625 HSP90B1 Endoplasmin GYEVIYLTEPVDEYCIQALPEFDGK 576 27.75% 22.67% 5.08% 
O95297 MPZL1 Myelin protein zero-like protein 1 DYTGCSTSESLSPVK 203 31.78% 26.72% 5.06% 
P60981 DSTN Destrin LGGSLIVAFEGCPV 163 26.99% 22.02% 4.97% 
P10301 RRAS Ras-related protein R-Ras ICSVDGIPAR 70 12.56% 7.66% 4.90% 
P78371 CCT2 T-complex protein 1 subunit beta SLHDALCVLAQTVK 395 9.58% 4.76% 4.82% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al 
SPLTIC*YPEYTGSNTYE
EAAAYIQC*QFEDLNR 286 12.68% 8.03% 4.65% 
Q9Y490 TLN1 Talin-1 VVAPTISSPVCQEQLVEAGR 732 9.37% 4.76% 4.61% 
P21333 FLNA Filamin-A THEAEIVEGENHTYCIR 2199 18.66% 14.10% 4.56% 
Q86SF2 GALNT7 N-acetylgalactosaminyltransferase 7 
TICTVPLIDVINGNTYEI
IPQGGGDEDGYAR 325 9.02% 4.76% 4.26% 
P60763 RAC3 Ras-related C3 botulinum toxin substrate 3 CVVVGDGAVGK 6 12.12% 7.86% 4.26% 
Q9UL25 RAB21 Ras-related protein Rab-21 GIEELFLDLCK 177 9.95% 5.72% 4.23% 
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P21333 FLNA Filamin-A ATCAPQHGAPGPGPADASK 2543 21.87% 17.65% 4.22% 
Q00610 CLTC Clathrin heavy chain 1 EVC*FAC*VDGK 1257 17.29% 13.07% 4.22% 
Q99832 CCT7 T-complex protein 1 subunit eta INALTAASEAACLIVSVDETIK 511 12.47% 8.29% 4.18% 
P05388 RPLP0 60S acidic ribosomal protein P0 AGAIAPCEVTVPAQNTGLGPEK 119 21.17% 17.21% 3.96% 
P60709 ACTB Actin, cytoplasmic 1  LCYVALDFEQEMATAASSSSLEK 217 10.14% 6.25% 3.89% 
Q13642 FHL1 Four and a half LIM domains protein 1 FTAVEDQYYC*VDC*YK 209 55.25% 51.37% 3.88% 
P08758 ANXA5 Annexin A5 ALLLLCGEDD 316 10.90% 7.07% 3.83% 
P62906 RPL10A 60S ribosomal protein L10a FSVC*VLGDQQHC*DEAK 66 19.98% 16.16% 3.82% 
Q9NYU2 UGGT1 UDP-glucose:glycoprotein glucosyltransferase 1 VFMNCQSK 1024 8.55% 4.76% 3.79% 
P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma cat IYGFYDECK 140 13.73% 9.97% 3.76% 
P13639 EEF2 Elongation factor 2 ETVSEESNVLCLSK 591 19.29% 15.55% 3.74% 
P13639 EEF2 Elongation factor 2 VTDGALVVVDC*VSGVC*VQTETVLR 131 30.97% 27.27% 3.70% 




201 13.96% 10.27% 3.69% 
P49368 CCT3 T-complex protein 1 subunit gamma TLIQNCGASTIR 455 10.91% 7.29% 3.62% 
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B DVIIADCGK 202 18.64% 15.16% 3.48% 
P23528 CFL1 Cofilin-1 HELQANCYEEVK 139 13.89% 10.42% 3.47% 
P14649 MYL6B Myosin light chain 6B ILYSQCGDVMR 89 17.04% 13.69% 3.35% 
P17987 TCP1 T-complex protein 1 subunit alpha IACLDFSLQK 236 7.91% 4.76% 3.15% 
Q9NP72 RAB18 Ras-related protein Rab-18 LDNWLNELETYCTR 110 9.46% 6.34% 3.12% 
P09525 ANXA4 Annexin A4 VLLVLCGGDD 315 7.66% 4.58% 3.08% 
Q9H2U1 DHX36 Probable ATP-dependent RNA helicase DHX36 AESCGSGNSTGYQIR 284 16.35% 13.31% 3.04% 
P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma cat 
TFTDC*FNC*LPIAAIVD
EK 155 18.74% 15.71% 3.03% 
P29317 EPHA2 Ephrin type-A receptor 2 NILVNSNLVCK 753 8.75% 5.78% 2.97% 
P07195 LDHB L-lactate dehydrogenase B chain ITVVGVGQVGMACAISILGK 36 9.56% 6.60% 2.96% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X 
GADSLEDFLYHEGYAC
TSIHGDR 468 19.52% 16.59% 2.93% 
P63104 YWHAZ 14-3-3 protein zeta/delta DICNDVLSLLEK Bad ID 7.37% 4.47% 2.90% 
P61247 RPS3A 40S ribosomal protein S3a LFCVGFTK 139 7.66% 4.76% 2.90% 
P05388 RPLP0 60S acidic ribosomal protein P0 NVASVCLQIGYPTVASVPHSIINGYK 226 9.22% 6.35% 2.87% 
P68104 EEF1A1 Elongation factor 1-alpha 1 DGNASGTTLLEALDCILPPTR 234 8.89% 6.04% 2.85% 
O75131 CPNE3 Copine-3 SDPLCVLFLNTSGQQWYEVER 31 8.05% 5.36% 2.69% 
P53675 CLTCL1 Clathrin heavy chain 2 LECSEELGDLVK 459 8.29% 5.61% 2.68% 
Q15149 PLEC Plectin LPLLAVCDYK 950 7.78% 5.10% 2.68% 
P00558 PGK1 Phosphoglycerate kinase 1 DCVGPEVEK 99 22.28% 19.64% 2.64% 
O60664 PLIN3 Perilipin-3 DIAQQLQATCTSLGSSIQGLPTNVK 341 8.11% 5.59% 2.52% 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 
ESGSLSPEHGPVVVHCS
AGIGR 215 14.30% 11.79% 2.51% 
P12235 SLC25A4 ADP/ATP translocase 1 YFAGNLASGGAAGATSLCFVYPLDFAR 129 7.02% 4.53% 2.49% 
O60716 CTNND1 Catenin delta-1 TPAILEASAGAIQNLCAGR 692 7.24% 4.76% 2.48% 
O43707 ACTN4 Alpha-actinin-4 EGLLLWCQR 173 7.08% 4.63% 2.45% 
Q9HAV0 GNB4 Guanine nucleotide-binding protein subunit beta-4 
ADQELLLYSHDNIICGI
TSVAFSK 271 7.65% 5.30% 2.35% 
P17987 TCP1 T-complex protein 1 subunit alpha VLCELADLQDK 76 10.94% 8.60% 2.34% 
Q07065 CKAP4 Cytoskeleton-associated protein 4 SSSSSSASAAAAAAAASSSASCSR 100 14.70% 12.37% 2.33% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al 
ITHSPLTICFPEYTGAN
K 287 10.23% 7.90% 2.33% 
O00116 AGPS Alkyldihydroxyacetonephosphate synthase, peroxisom IVNLACK 226 20.36% 18.07% 2.29% 
Q10567 AP1B1 AP-1 complex subunit beta-1 DCPLNAEAASSK 866 11.24% 9.02% 2.22% 
Q15149 PLEC Plectin CRPDQLTGLSLLPLSEK 3336 8.11% 5.91% 2.20% 
P60228 EIF3E Eukaryotic translation initiation factor 3 subunit 
FQYECGNYSGAAEYLY
FFR 141 7.02% 4.86% 2.16% 
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Q13162 PRDX4 Peroxiredoxin-4 EEECHFYAGGQVYPGEASR 51 84.89% 82.73% 2.16% 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase VPTANVSVVDLTCR 247 7.70% 5.58% 2.12% 
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M ACQIFVR 653 7.93% 5.83% 2.10% 
P40227 CCT6A T-complex protein 1 subunit zeta NAIDDGCVVPGAGAVEVAMAEALIK 406 9.85% 7.82% 2.03% 
P68366 TUBA4A Tubulin alpha-4A chain AYHEQLSVAEITNACFEPANQMVK 295 32.31% 30.31% 2.00% 
P07355 ANXA2 Annexin A2 GLGTDEDSLIEIICSR 133 9.62% 7.76% 1.86% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
ACADATLSQITNNIDP
VGR 25 9.41% 7.55% 1.86% 
P63010 AP2B1 AP-2 complex subunit beta TAAVCVAK 144 11.41% 9.66% 1.75% 
O94826 TOMM70A Mitochondrial import receptor subunit TOM70 
ILLDQVEEAVADFDECI
R 427 6.73% 5.05% 1.68% 
P21796 VDAC1 Voltage-dependent anion-selective channel protein YQIDPDACFSAK 232 6.80% 5.13% 1.67% 
P14923 JUP Junction plakoglobin LVQNCLWTLR 372 5.51% 3.84% 1.67% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
VSCLGVTDDGMAVAT
GSWDSFLK 317 17.41% 15.85% 1.56% 
P04083 ANXA1 Annexin A1 MYGISLCQAILDETK 324 5.84% 4.42% 1.42% 
P13639 EEF2 Elongation factor 2 IWCFGPDGTGPNILTDITK 651 6.42% 5.03% 1.39% 




61 15.94% 14.61% 1.33% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 GEGTGVLGSLSLPLSELLVADQLCLDR 890 5.42% 4.30% 1.12% 
P51149 RAB7A Ras-related protein Rab-7a AQAWCYSK 143 8.00% 6.88% 1.12% 
P63010 AP2B1 AP-2 complex subunit beta CVSTLLDLIQTK 391 5.31% 4.30% 1.01% 
P63167 DYNLL1 Dynein light chain 1, cytoplasmic  YNPTWHCIVGR 56 7.60% 6.59% 1.01% 
P35222 CTNNB1 Catenin beta-1 EDITEPAICALR 466 6.08% 5.09% 0.99% 
O75131 CPNE3 Copine-3 VALNVSCANLLDK 15 8.28% 7.30% 0.98% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al IIHEDGYSEEECR 66 7.71% 6.96% 0.75% 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 PCTLSELE 528 48.13% 47.45% 0.68% 
Q92544 TM9SF4 Transmembrane 9 superfamily member 4 TQLPYEYYSLPFCQPSK 64 94.63% 95.24% -0.61% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 GDGPICLVLAPTR 170 7.87% 8.59% -0.72% 
P62829 RPL23 60S ribosomal protein L23 ISLGLPVGAVINCADNTGAK 28 10.24% 10.98% -0.74% 
O60716 CTNND1 Catenin delta-1 NCDGVPALVR 450 4.47% 5.32% -0.85% 
P21333 FLNA Filamin-A SSFTVDCSK 2582 20.42% 21.40% -0.98% 
P0CW22 RPS17L 40S ribosomal protein S17-like VCEEIAIIPSK 35 8.05% 9.09% -1.04% 
P61224 RAP1B Ras-related protein Rap-1b QWNNCAFLESSAK 141 5.50% 6.55% -1.05% 
P00338 LDHA L-lactate dehydrogenase A chain DDVFLSVPCILGQNGISDLVK 293 5.73% 6.80% -1.07% 
P23396 RPS3 40S ribosomal protein S3 GLCAIAQAESLR 97 8.26% 9.34% -1.08% 
P14174 MIF Macrophage migration inhibitory factor LLCGLLAER 81 7.05% 8.21% -1.16% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- YTVQDESHSEWVSCVR 153 12.74% 13.98% -1.24% 
P46776 RPL27A 60S ribosomal protein L27a NQSFCPTVNLDK 70 10.29% 11.55% -1.26% 
O00299 CLIC1 Chloride intracellular channel protein 1 IGNCPFSQR 24 6.35% 7.65% -1.30% 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosy VACITEQVLTLVNK Bad ID 3.83% 5.17% -1.34% 
O75131 CPNE3 Copine-3 NCLNPQFSK 54 10.37% 11.80% -1.43% 
Q15149 PLEC Plectin GCLDEETSR 3299 15.73% 17.26% -1.53% 
P62244 RPS15A 40S ribosomal protein S15a CGVISPR 72 9.70% 11.27% -1.57% 
P50570 DNM2 Dynamin-2 LQDAFSSIGQSCHLDLPQIAVVGGQSAGK 27 6.26% 7.87% -1.61% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 CDELTR 354 7.06% 8.69% -1.63% 
P63010 AP2B1 AP-2 complex subunit beta ECHLNADTVSSK 857 5.13% 6.82% -1.69% 
P54136 RARS Arginine--tRNA ligase, cytoplasmic  VLTAEELNAAQTSVAYGCIK 502 5.60% 7.33% -1.73% 
P07437 TUBB Tubulin beta chain TAVCDIPPR 354 9.60% 11.35% -1.75% 
Q02543 RPL18A 60S ribosomal protein L18a SSGEIVYCGQVFEK 64 12.63% 14.38% -1.75% 
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P13489 RNH1 Ribonuclease inhibitor ELDLSNNCLGDAGILQLVESVR 409 5.49% 7.27% -1.78% 
P62888 RPL30 60S ribosomal protein L30 LVILANNCPALR 52 7.70% 9.50% -1.80% 
P50991 CCT4 T-complex protein 1 subunit delta ITGCASPGK 379 10.20% 12.00% -1.80% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 VAGDC*LDEKQC*K 131 16.86% 18.66% -1.80% 
Q14694 USP10 Ubiquitin carboxyl-terminal hydrolase 10 
TPSYSISSTLNPQAPEFIL
GCTASK 94 32.81% 34.62% -1.81% 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1 LPADTCLLEFAR 330 4.79% 6.63% -1.84% 
Q5JPE7 NOMO2 Nodal modulator 2 VSC*LDTC*GDLLVTLQSLSR 511 93.19% 95.07% -1.88% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- FSPNSSNPIIVSCGWDK 168 7.03% 8.92% -1.89% 
P16435 POR NADPH--cytochrome P450 reductase EVGETLLYYGCR 566 8.77% 10.73% -1.96% 
P62333 PSMC6 26S protease regulatory subunit 10B AVASQLDCNFLK 193 6.82% 8.78% -1.96% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- YWLCAATGPSIK 249 7.71% 9.69% -1.98% 
Q99832 CCT7 T-complex protein 1 subunit eta YNFFTGCPK 364 5.85% 7.86% -2.01% 
P05388 RPLP0 60S acidic ribosomal protein P0 CFIVGADNVGSK 27 6.27% 8.29% -2.02% 
P36578 RPL4 60S ribosomal protein L4 GPCIIYNEDNGIIK 208 5.38% 7.42% -2.04% 
P60709 ACTB Actin, cytoplasmic 1  CDVDIR 285 9.04% 11.09% -2.05% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 GVEICIATPGR 221 6.91% 9.02% -2.11% 
O75083 WDR1 WD repeat-containing protein 1 VCALGGSK 225 8.55% 10.71% -2.16% 
P21291 CSRP1 Cysteine and glycine-rich protein 1 DGEIYCK 167 40.59% 42.77% -2.18% 
Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protei 
VAAASGHCGAFSGSDS
SR 919 13.56% 15.85% -2.29% 
H3BN98 Uncharacterized protein ALC*DVGTAISC*SR 43 92.90% 95.24% -2.34% 
P36578 RPL4 60S ribosomal protein L4 SGQGAFGNMCR 96 12.09% 14.57% -2.48% 
P07437 TUBB Tubulin beta chain LTTPTYGDLNHLVSATMSGVTTCLR 239 10.48% 12.99% -2.51% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- LWNTLGVCK 138 9.27% 11.80% -2.53% 
P27635 RPL10 60S ribosomal protein L10 LIPDGCGVK 195 13.72% 16.29% -2.57% 
P30530 AXL Tyrosine-protein kinase receptor UFO YVLCPSTTPSPAQPADR 869 63.32% 66.02% -2.70% 
Q07020 RPL18 60S ribosomal protein L18 GCGTVLLSGPR 134 14.56% 17.31% -2.75% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
AEPPQCTSLAWSADGQ
TLFAGYTDNLVR 286 15.14% 17.90% -2.76% 
P48643 CCT5 T-complex protein 1 subunit epsilon VVNSCHR 181 4.30% 7.07% -2.77% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- VWNLANCK 182 12.97% 15.75% -2.78% 
Q13190 STX5 Syntaxin-5 TQEFLSACK 68 14.50% 17.28% -2.78% 
Q86V48 LUZP1 Leucine zipper protein 1 NDC*TQLC*LSLNEER 134 26.38% 29.18% -2.80% 
Q13418 ILK Integrin-linked protein kinase DFNEECPR 239 11.24% 14.06% -2.82% 
P21333 FLNA Filamin-A CSGPGLSPGMVR 1453 7.16% 9.99% -2.83% 




190 83.26% 86.19% -2.93% 
P00338 LDHA L-lactate dehydrogenase A chain VIGSGCNLDSAR 163 9.87% 12.82% -2.95% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 LQGATCNNNK 4570 10.18% 13.43% -3.25% 
P62266 RPS23 40S ribosomal protein S23 ITAFVPNDGCLNFIEENDEVLVAGFGR 90 13.54% 16.83% -3.29% 
P00533 EGFR Epidermal growth factor receptor TPLLSSLSATSNNSTVACIDR 1049 54.46% 57.76% -3.30% 
Q8N0U8 VKORC1L1 Vitamin K epoxide reductase complex subunit 1-like CSAALASR 58 79.25% 82.74% -3.49% 
P04439 HLA-A HLA class I histocompatibility antigen, A-3 alpha  AYLDGTCVEWLR 188 69.18% 72.68% -3.50% 
P04844 RPN2 Dolichyl-diphosphooligosaccharide--protein glycosy ACTYIR 72 86.96% 90.46% -3.50% 
P22307 SCP2 Non-specific lipid-transfer protein ALADAQIPYSAVDQAC*VGYVFGDSTC*GQR 61 27.77% 31.31% -3.54% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 LLLCGGAPLSATTQR 450 12.17% 15.77% -3.60% 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 
VDC*TAHSDVC*SAQG
VR 121 85.25% 88.85% -3.60% 
P50914 RPL14 60S ribosomal protein L14 CMQLTDFILK 54 8.72% 12.38% -3.66% 
Q32P28 LEPRE1 Prolyl 3-hydroxylase 1 TVTAEVQPQCGR 645 83.06% 86.73% -3.67% 
P62280 RPS11 40S ribosomal protein S11 CPFTGNVSIR 60 7.28% 10.98% -3.70% 
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P48444 ARCN1 Coatomer subunit delta NYCNIQVTK 479 14.87% 18.62% -3.75% 
Q8NFQ8 TOR1AIP2 Torsin-1A-interacting protein 2 ISHLVLPVQPVSSIEEQGCLF 468 72.08% 75.84% -3.76% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
LLLAGYDDFNCNIWD
AMK 294 5.60% 9.48% -3.88% 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 
VDC*TQHYELC*SGNQ
VR 247 89.15% 93.07% -3.92% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) TFVSGACDASIK 204 14.17% 18.34% -4.17% 
Q14697 GANAB Neutral alpha-glucosidase AB TC*EESSFC*K 41 91.65% 95.85% -4.20% 
P62280 RPS11 40S ribosomal protein S11 DVQIGDIVTVGECR 131 16.82% 21.19% -4.37% 
Q9H2G2 SLK STE20-like serine/threonine-protein kinase DLQLQCEANVR 1138 82.27% 86.69% -4.42% 
P42677 RPS27 40S ribosomal protein S27 LTEGCSFR 77 10.92% 15.40% -4.48% 
Q7L576 CYFIP1 Cytoplasmic FMR1-interacting protein 1 CNEQPNR 98 12.46% 16.96% -4.50% 
P29401 TKT Transketolase TVPFCSTFAAFFTR 386 5.40% 9.92% -4.52% 
Q15149 PLEC Plectin LLEAQACTGGIIDPSTGER 4454 10.17% 14.72% -4.55% 
P25398 RPS12 40S ribosomal protein S12 LGEWVGLCK 92 17.53% 22.12% -4.59% 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 TPADCPVIAIDSFR 318 89.60% 94.25% -4.65% 
P30041 PRDX6 Peroxiredoxin-6 DFTPVCTTELGR 47 23.51% 28.21% -4.70% 
P13639 EEF2 Elongation factor 2 STLTDSLVCK 41 12.81% 17.52% -4.71% 
P50914 RPL14 60S ribosomal protein L14 ALVDGPCTQVR 42 13.73% 18.53% -4.80% 
P41252 IARS Isoleucine--tRNA ligase, cytoplasmic  DSLPVC*PVDASGC*FTTEVTDFAGQYVK 350 20.09% 24.93% -4.84% 
P62249 RPS16 40S ribosomal protein S16 TATAVAHCK 25 10.94% 15.79% -4.85% 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 IAEVDCTAER 381 78.23% 83.15% -4.92% 
P61160 ACTR2 Actin-related protein 2 VVVCDNGTGFVK 11 17.24% 22.24% -5.00% 
Q15365 PCBP1 Poly(rC)-binding protein 1 LVVPATQCGSLIGK 109 20.76% 25.95% -5.19% 
Q15165 PON2 Serum paraoxonase/arylesterase 2 VLELDTLVDNLSIDPSSGDIWVGCHPNGQK 283 59.82% 65.22% -5.40% 
P67870 CSNK2B Casein kinase II subunit beta YQQGDFGYCPR 109 15.81% 21.23% -5.42% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 ILYLDSSEIC*FPTVPGC*PGAWDVDSENPQR 604 23.59% 29.04% -5.45% 
P30101 PDIA3 Protein disulfide-isomerase A3 FIQENIFGICPHMTEDNK 244 25.09% 30.56% -5.47% 
P55735 SEC13 Protein SEC13 homolog LATCSSDR 31 14.33% 19.89% -5.56% 
P21964 COMT Catechol O-methyltransferase GTVLLADNVICPGAPDFLAHVR 223 9.88% 15.48% -5.60% 
Q9Y277 VDAC3 Voltage-dependent anion-selective channel protein VCNYGLTFTQK 65 6.79% 12.40% -5.61% 




231 25.91% 31.55% -5.64% 
Q9Y6G9 DYNC1LI1 Cytoplasmic dynein 1 light intermediate chain 1 
DDSVVLPLGADTLTHN
LGIPVLVVCTK 244 23.58% 29.26% -5.68% 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit HVLTGSADNSCR 76 15.70% 21.42% -5.72% 
Q15436 SEC23A Protein transport protein Sec23A ISGAIGPCVSLNSK 423 13.69% 19.46% -5.77% 
O00592 PODXL Podocalyxin CEDLETQTQSEK 344 82.89% 88.82% -5.93% 
P57721 PCBP3 Poly(rC)-binding protein 3 LVVPASQCGSLIGK 141 19.74% 25.82% -6.08% 
P27797 CALR Calreticulin HEQNIDCGGGYVK 105 72.51% 78.71% -6.20% 
Q13586 STIM1 Stromal interaction molecule 1 ATGTSSGANSEESTAAEFCR 49 80.58% 86.88% -6.30% 
Q6NUM9 RETSAT All-trans-retinol 13,14-reductase  GACYGADHDLGR 534 27.99% 34.31% -6.32% 
P63220 RPS21 40S ribosomal protein S21 TYAICGAIR 56 9.54% 15.86% -6.32% 
P31689 DNAJA1 DnaJ homolog subfamily A member 1 NVIC*DKC*EGR 134 36.67% 43.01% -6.34% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase ECVQPATK 997 19.45% 26.00% -6.55% 
Q16629 SRSF7 Serine/arginine-rich splicing factor 7 GHYAYDCHR 119 20.15% 27.18% -7.03% 
P07814 EPRS Bifunctional glutamate/proline--tRNA ligase 
YNVYPTYDFACPIVDSI
EGVTHALR 381 4.79% 12.01% -7.22% 
Q15019 SEPT2 Septin-2 LTVVDTPGYGDAINC*RDC*FK 111 25.87% 33.25% -7.38% 
Q12907 LMAN2 Vesicular integral-membrane protein VIP36 WTELAGCTADFR 202 74.25% 81.72% -7.47% 
Q15019 SEPT2 Septin-2 LTVVDTPGYGDAINC*RDC*FK 111 25.32% 32.82% -7.50% 
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P30101 PDIA3 Protein disulfide-isomerase A3 VDC*TANTNTC*NK 85 84.84% 92.44% -7.60% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X DLMACAQTGSGK 223 5.54% 13.31% -7.77% 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 HAACPVLVGNK 503 66.32% 74.10% -7.78% 
P11216 PYGB Glycogen phosphorylase, brain form  TCFETFPDK 326 13.20% 21.00% -7.80% 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  
FWTFETGC*TVC*DEGL
R 267 86.68% 94.57% -7.89% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 VGAPLVC*C*EIK 503 17.40% 25.32% -7.92% 
P00533 EGFR Epidermal growth factor receptor NGLQSCPIK 1058 51.00% 59.39% -8.39% 
Q96HC4 PDLIM5 PDZ and LIM domain protein 5 FFAPECGR 479 18.75% 27.48% -8.73% 
P52209 PGD 6-phosphogluconate dehydrogenase, decarboxylating  
VGTGEPC*C*DWVGDE
GAGHFVK 170 21.84% 30.59% -8.75% 
Q15149 PLEC Plectin VPLDVACAR 3295 13.33% 22.16% -8.83% 
O14964 HGS Hepatocyte growth factor-regulated tyrosine kinase NCGQTVHDEVANK 75 7.76% 16.62% -8.86% 
O96005 CLPTM1 Cleft lip and palate transmembrane protein 1 VSFCPLSLWR 308 74.09% 82.97% -8.88% 
P49207 RPL34 60S ribosomal protein L34 AYGGSMCAK 83 45.61% 54.52% -8.91% 
Q15005 SPCS2 Signal peptidase complex subunit 2 SGGSGGC*SGAGGASNC*GTGSGR 17 64.15% 73.38% -9.23% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 NTPLCDSFVFR 429 7.71% 17.32% -9.61% 
P62633 CNBP Cellular nucleic acid-binding protein TSEVNCYR 158 54.69% 64.39% -9.70% 
P21291 CSRP1 Cysteine and glycine-rich protein 1 CSQAVYAAEK 122 34.17% 43.99% -9.82% 
P50454 SERPINH1 Serpin H1 QHYNCEHSK 156 54.42% 64.25% -9.83% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 STCIYGGAPK 200 13.88% 23.87% -9.99% 
P68104 EEF1A1 Elongation factor 1-alpha 1 PMCVESFSDYPPLGR 411 38.23% 48.30% -10.07% 
Q8IVL6 LEPREL2 Prolyl 3-hydroxylase 3 AVLDGLLTPAECGVLLQLAK 478 72.77% 83.23% -10.46% 
Q9Y6I9 TEX264 Testis-expressed sequence 264 protein 
CAVGSILSEGEESPSPEL
IDLYQK 94 17.69% 28.85% -11.16% 
P62241 RPS8 40S ribosomal protein S8 LDVGNFSWGSEC*C*TR 71 17.58% 30.22% -12.64% 
Q06830 PRDX1 Peroxiredoxin-1 HGEVCPAGWK 173 62.80% 75.53% -12.73% 
Q9Y4P3 TBL2 Transducin beta-like protein 2 FVASCGFTPDVK 247 14.84% 28.15% -13.31% 
O60884 DNAJA2 DnaJ homolog subfamily A member 2 NVLC*SAC*SGQGGK 143 34.89% 48.33% -13.44% 
Q99439 CNN2 Calponin-2 CASQSGMTAYGTR 175 45.32% 59.82% -14.50% 
P27348 YWHAQ 14-3-3 protein theta YLAEVACGDDR 134 10.79% 27.01% -16.22% 
P54136 RARS Arginine--tRNA ligase, cytoplasmic  NC*GC*LGASPNLEQLQEENLK 32 10.89% 29.17% -18.28% 
Q9UGP8 SEC63 Translocation protein SEC63 homolog NEPPLTCPYSLK 295 19.65% 38.68% -19.03% 
Q16658 FSCN1 Fascin LSCFAQTVSPAEK 121 11.08% 30.72% -19.64% 
O00469 PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2  
IFTENIVEQPCPDVFWF
PIFSEK 562 57.21% 77.41% -20.20% 
Q9NR12 PDLIM7 PDZ and LIM domain protein 7 YAPSCAK 341 28.71% 49.31% -20.60% 
Q93052 LPP Lipoma-preferred partner TYITDPVSAPCAPPLQPK 364 37.94% 58.89% -20.95% 
O15269 SPTLC1 Serine palmitoyltransferase 1 YGVGTCGPR 133 8.80% 29.96% -21.16% 
P62195 PSMC5 26S protease regulatory subunit 8 NIDINDVTPNCR 112 8.17% 29.51% -21.34% 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosy TEGSDLCDR 545 5.37% 29.57% -24.20% 
Q10567 AP1B1 AP-1 complex subunit beta-1 YESVIATLCENLDSLDEPEAR 433 17.03% 42.86% -25.83% 
Q01813 PFKP 6-phosphofructokinase type C TNCNVAVINVGAPAAGMNAAVR 411 8.46% 36.13% -27.67% 
P48739 PITPNB Phosphatidylinositol transfer protein beta isoform 
VVLPCSVQEYQVGQLY
SVAEASK 13 26.29% 63.60% -37.31% 





Table 3A-1. ReDiMe analysis to quantify changes in protein abundance in 
PDIA1KO or WT isolated ER. Data was filtered for secretory pathway proteins 
that appeared in two replicates. The 100 most abundant and 100 least abundant 
proteins following PDIA1KO are shown. Ratios were converted to 
log2(PDIA1KO:WT) and sorted by increasing levels of expression following 
PDIA1KO. Localization of proteins was determined using Uniprot and GO 
annotated tabs on UniprotKB. 
Uniprot ID Protein Description 
Ratio L:H log2(Ratio) 
Average 
1 2 1 2 
O15460 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 0.16 0.14 -2.65 -2.86 -2.76 
P07237 P4HB Protein disulfide-isomerase 0.15 0.15 -2.74 -2.76 -2.75 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 0.21 0.12 -2.27 -3.01 -2.64 
P00338 LDHA L-lactate dehydrogenase A chain 0.38 0.15 -1.40 -2.75 -2.07 
P02751 FN1 Fibronectin 0.18 0.41 -2.48 -1.27 -1.88 
Q9H6S3 EPS8L2 Epidermal growth factor receptor kinase substrate 0.33 0.25 -1.61 -1.98 -1.80 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 0.38 0.22 -1.40 -2.16 -1.78 
P15311 EZR Ezrin 0.30 0.29 -1.75 -1.79 -1.77 
P35580 MYH10 Myosin-10 0.39 0.29 -1.36 -1.80 -1.58 
O75369 FLNB Filamin-B 0.47 0.24 -1.08 -2.05 -1.57 
P35241 RDX Radixin 0.34 0.34 -1.55 -1.55 -1.55 
P26038 MSN Moesin 0.37 0.33 -1.45 -1.62 -1.53 
P35579 MYH9 Myosin-9 0.44 0.31 -1.19 -1.69 -1.44 
P06753 TPM3 Tropomyosin alpha-3 chain 0.50 0.29 -1.00 -1.77 -1.39 
O14950 MYL12B Myosin regulatory light chain 12B 0.46 0.33 -1.12 -1.58 -1.35 
P35749 MYH11 Myosin-11 0.43 0.36 -1.21 -1.49 -1.35 
P15144 ANPEP Aminopeptidase N 0.30 0.55 -1.73 -0.87 -1.30 
P53675 CLTCL1 Clathrin heavy chain 2 0.55 0.40 -0.87 -1.34 -1.10 
P09493 TPM1 Tropomyosin alpha-1 chain 0.59 0.40 -0.76 -1.31 -1.03 
P04075 ALDOA Fructose-bisphosphate aldolase A 0.56 0.43 -0.84 -1.22 -1.03 
P46783 RPS10 40S ribosomal protein S10 0.63 0.39 -0.67 -1.34 -1.00 
Q9BXF6 RAB11FIP5 Rab11 family-interacting protein 5 0.48 0.52 -1.05 -0.95 -1.00 
O75083 WDR1 WD repeat-containing protein 1 0.68 0.38 -0.56 -1.41 -0.98 
Q99439 CNN2 Calponin-2 0.37 0.69 -1.44 -0.53 -0.98 
P63104 YWHAZ 14-3-3 protein zeta/delta 0.73 0.35 -0.46 -1.50 -0.98 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.71 0.37 -0.50 -1.43 -0.97 
Q13813 SPTAN1 Spectrin alpha chain, non-erythrocytic 1  0.63 0.42 -0.67 -1.25 -0.96 
P46821 MAP1B Microtubule-associated protein 1B 1.28 0.21 0.36 -2.25 -0.95 
P53396 ACLY ATP-citrate synthase 0.87 0.31 -0.20 -1.67 -0.94 
P49368 CCT3 T-complex protein 1 subunit gamma 0.83 0.33 -0.27 -1.59 -0.93 
Q13200 PSMD2 26S proteasome non-ATPase regulatory subunit 2 1.00 0.28 0.00 -1.86 -0.93 
P60660 MYL6 Myosin light polypeptide 6 0.59 0.50 -0.77 -0.99 -0.88 
P68104 EEF1A1 Elongation factor 1-alpha 1 0.89 0.33 -0.17 -1.58 -0.88 
P62081 RPS7 40S ribosomal protein S7 0.96 0.31 -0.06 -1.69 -0.88 
P62195 PSMC5 26S protease regulatory subunit 8 0.82 0.36 -0.28 -1.46 -0.87 
P09382 LGALS1 Galectin-1 0.59 0.51 -0.77 -0.97 -0.87 
P07195 LDHB L-lactate dehydrogenase B chain 0.99 0.30 -0.02 -1.72 -0.87 
	 288	
P05388 RPLP0 60S acidic ribosomal protein P0 0.94 0.32 -0.10 -1.63 -0.86 
Q6P9B6 KIAA1609 TLD domain-containing protein KIAA1609 0.90 0.34 -0.16 -1.57 -0.86 
Q9BWD1 ACAT2 Acetyl-CoA acetyltransferase, cytosolic  0.89 0.34 -0.17 -1.55 -0.86 
Q04917 YWHAH 14-3-3 protein eta 0.64 0.48 -0.64 -1.07 -0.86 
P09651 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 0.96 0.32 -0.06 -1.65 -0.86 
P08238 HSP90AB1 Heat shock protein HSP 90-beta 0.66 0.46 -0.60 -1.11 -0.85 
Q15417 CNN3 Calponin-3 0.59 0.52 -0.76 -0.95 -0.85 
O43237 DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2 0.76 0.41 -0.40 -1.29 -0.85 
P29401 TKT Transketolase 1.21 0.26 0.27 -1.97 -0.85 
P62136 PPP1CA Serine/threonine-protein phosphatase PP1-alpha cat 0.47 0.66 -1.08 -0.60 -0.84 
P67936 TPM4 Tropomyosin alpha-4 chain 0.71 0.44 -0.49 -1.18 -0.83 
Q01082 SPTBN1 Spectrin beta chain, non-erythrocytic 1  0.64 0.49 -0.64 -1.02 -0.83 
Q06830 PRDX1 Peroxiredoxin-1 0.39 0.83 -1.34 -0.27 -0.81 
Q8WX93 PALLD Palladin 1.01 0.32 0.02 -1.63 -0.81 
Q12904 AIMP1 Aminoacyl tRNA synthase complex-interacting multif 1.53 0.22 0.61 -2.21 -0.80 
P08195 SLC3A2 4F2 cell-surface antigen heavy chain 0.53 0.62 -0.91 -0.68 -0.80 
P13010 XRCC5 X-ray repair cross-complementing protein 5 0.75 0.45 -0.42 -1.15 -0.78 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 0.97 0.35 -0.05 -1.51 -0.78 
P07737 PFN1 Profilin-1 0.66 0.52 -0.60 -0.95 -0.78 
P27348 YWHAQ 14-3-3 protein theta 0.78 0.44 -0.36 -1.17 -0.77 
P31947 SFN 14-3-3 protein sigma 0.73 0.48 -0.46 -1.07 -0.77 
P14618 PKM Pyruvate kinase isozymes M1/M2 0.78 0.45 -0.36 -1.16 -0.76 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 1.28 0.27 0.36 -1.87 -0.76 
P06493 CDK1 Cyclin-dependent kinase 1 0.48 0.73 -1.06 -0.46 -0.76 
Q01813 PFKP 6-phosphofructokinase type C 0.78 0.45 -0.35 -1.16 -0.76 
O43491 EPB41L2 Band 4.1-like protein 2 0.40 0.88 -1.31 -0.19 -0.75 
P31946 YWHAB 14-3-3 protein beta/alpha 0.73 0.49 -0.45 -1.04 -0.75 
P22392 NME2 Nucleoside diphosphate kinase B 0.84 0.43 -0.26 -1.23 -0.74 
P62140 PPP1CB Serine/threonine-protein phosphatase PP1-beta cata 0.54 0.67 -0.88 -0.57 -0.73 
P60763 RAC3 Ras-related C3 botulinum toxin substrate 3 0.41 0.90 -1.28 -0.16 -0.72 
P35998 PSMC2 26S protease regulatory subunit 7 1.10 0.34 0.14 -1.57 -0.71 
Q9H4M9 EHD1 EH domain-containing protein 1 0.94 0.40 -0.10 -1.32 -0.71 
Q16647 PTGIS Prostacyclin synthase 0.78 0.48 -0.36 -1.05 -0.71 
P33176 KIF5B Kinesin-1 heavy chain 1.02 0.37 0.03 -1.44 -0.71 
Q92974 ARHGEF2 Rho guanine nucleotide exchange factor 2 0.99 0.38 -0.02 -1.39 -0.71 
P18206 VCL Vinculin 1.09 0.35 0.12 -1.53 -0.70 
Q9BZF9 UACA Uveal autoantigen with coiled-coil domains and ank 1.18 0.32 0.23 -1.64 -0.70 
P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  1.04 0.36 0.05 -1.46 -0.70 
Q9NZN4 EHD2 EH domain-containing protein 2 0.89 0.43 -0.17 -1.21 -0.69 
P41252 IARS Isoleucine--tRNA ligase, cytoplasmic  1.45 0.27 0.54 -1.91 -0.69 
P49773 HINT1 Histidine triad nucleotide-binding protein 1 0.92 0.43 -0.13 -1.20 -0.67 
Q10567 AP1B1 AP-1 complex subunit beta-1 1.13 0.35 0.18 -1.50 -0.66 
P11166 SLC2A1 Solute carrier family 2, facilitated glucose trans 0.46 0.89 -1.13 -0.17 -0.65 
Q96TA1 FAM129B Niban-like protein 1 0.69 0.59 -0.53 -0.77 -0.65 
Q8IZP0 ABI1 Abl interactor 1 1.00 0.41 0.00 -1.30 -0.65 
O15118 NPC1 Niemann-Pick C1 protein 0.56 0.72 -0.82 -0.47 -0.65 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor 0.44 0.95 -1.20 -0.08 -0.64 
P61981 YWHAG 14-3-3 protein gamma 0.87 0.48 -0.20 -1.07 -0.64 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 0.53 0.77 -0.91 -0.37 -0.64 
Q96AC1 FERMT2 Fermitin family homolog 2 0.65 0.63 -0.61 -0.66 -0.64 
Q86SF2 GALNT7 N-acetylgalactosaminyltransferase 7 0.36 1.15 -1.47 0.20 -0.64 
O75319 DUSP11 RNA/RNP complex-1-interacting phosphatase 1.14 0.36 0.20 -1.46 -0.63 
Q15436 SEC23A Protein transport protein Sec23A 0.78 0.54 -0.36 -0.89 -0.63 
Q6NZI2 PTRF Polymerase I and transcript release factor 0.44 0.97 -1.20 -0.05 -0.63 
P18124 RPL7 60S ribosomal protein L7 0.73 0.59 -0.46 -0.77 -0.62 
Q13418 ILK Integrin-linked protein kinase 0.73 0.58 -0.45 -0.78 -0.62 
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Q9H4G4 GLIPR2 Golgi-associated plant pathogenesis-related protei 0.44 0.98 -1.20 -0.03 -0.62 
Q9Y6M7 SLC4A7 Sodium bicarbonate cotransporter 3 0.56 0.77 -0.84 -0.38 -0.61 
P07814 EPRS Bifunctional glutamate/proline--tRNA ligase 1.50 0.29 0.58 -1.81 -0.61 
P62263 RPS14 40S ribosomal protein S14 0.76 0.57 -0.40 -0.80 -0.60 
P13639 EEF2 Elongation factor 2 0.94 0.48 -0.10 -1.07 -0.58 
P53992 SEC24C Protein transport protein Sec24C 1.13 0.40 0.18 -1.33 -0.58 
Q05639 EEF1A2 Elongation factor 1-alpha 2 1.23 0.37 0.29 -1.44 -0.58 
P60174 TPI1 Triosephosphate isomerase 1.04 0.44 0.05 -1.19 -0.57 
P60953 CDC42 Cell division control protein 42 homolog 1.47 1.51 0.56 0.59 0.58 
Q12797 ASPH Aspartyl/asparaginyl beta-hydroxylase 1.55 1.43 0.64 0.52 0.58 
Q9P035 PTPLAD1 3-hydroxyacyl-CoA dehydratase 3 1.12 2.00 0.16 1.00 0.58 
Q15165 PON2 Serum paraoxonase/arylesterase 2 1.30 1.72 0.38 0.78 0.58 
P13637 ATP1A3 Sodium/potassium-transporting ATPase subunit alpha 1.26 1.79 0.33 0.84 0.59 
Q5JPE7 NOMO2 Nodal modulator 2 1.50 1.51 0.58 0.59 0.59 
P07355 ANXA2 Annexin A2 1.38 1.65 0.47 0.73 0.60 
Q9BVK6 TMED9 Transmembrane emp24 domain-containing protein 9 1.04 2.21 0.05 1.14 0.60 
Q14257 RCN2 Reticulocalbin-2 1.34 1.72 0.42 0.78 0.60 
Q53GQ0 HSD17B12 Estradiol 17-beta-dehydrogenase 12 1.53 1.51 0.61 0.59 0.60 
Q6YN16 HSDL2 Hydroxysteroid dehydrogenase-like protein 2 1.58 1.46 0.66 0.54 0.60 
Q96S66 CLCC1 Chloride channel CLIC-like protein 1 0.97 2.39 -0.05 1.26 0.60 
Q9BZF1 OSBPL8 Oxysterol-binding protein-related protein 8 1.24 1.87 0.31 0.90 0.61 
Q9H3N1 TMX1 Thioredoxin-related transmembrane protein 1 1.34 1.76 0.42 0.81 0.62 
Q96HY6 DDRGK1 DDRGK domain-containing protein 1 1.67 1.41 0.74 0.50 0.62 
P30533 LRPAP1 Alpha-2-macroglobulin receptor-associated protein 1.00 2.39 0.00 1.26 0.63 
Q8IVL5 LEPREL1 Prolyl 3-hydroxylase 2 1.14 2.10 0.20 1.07 0.63 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 1.13 2.15 0.18 1.10 0.64 
P80303 NUCB2 Nucleobindin-2 0.91 2.69 -0.14 1.43 0.64 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1.32 1.87 0.40 0.90 0.65 
P30519 HMOX2 Heme oxygenase 2 2.02 1.23 1.02 0.30 0.66 
Q9Y2Q3 GSTK1 Glutathione S-transferase kappa 1 1.28 1.95 0.36 0.97 0.66 
Q9UGP8 SEC63 Translocation protein SEC63 homolog 1.53 1.65 0.61 0.73 0.67 
Q9H5K3 SGK196 Protein kinase-like protein SgK196 1.45 1.76 0.54 0.81 0.67 
P14314 PRKCSH Glucosidase 2 subunit beta 1.13 2.26 0.18 1.18 0.68 
P30101 PDIA3 Protein disulfide-isomerase A3 1.40 1.83 0.49 0.87 0.68 
Q9Y4L1 HYOU1 Hypoxia up-regulated protein 1 1.71 1.51 0.77 0.59 0.68 
Q8IXB1 DNAJC10 DnaJ homolog subfamily C member 10 1.67 1.56 0.74 0.64 0.69 
Q86XL3 ANKLE2 Ankyrin repeat and LEM domain-containing protein 2 1.67 1.56 0.74 0.64 0.69 
P11216 PYGB Glycogen phosphorylase, brain form  1.89 1.39 0.92 0.47 0.70 
Q14573 ITPR3 Inositol 1,4,5-trisphosphate receptor type 3  1.23 2.15 0.29 1.10 0.70 
Q13131 PRKAA1 5-AMP-activated protein kinase catalytic subunit 2.18 1.21 1.12 0.28 0.70 
P06756 ITGAV Integrin alpha-V 1.32 2.00 0.40 1.00 0.70 
Q9BT09 CNPY3 Protein canopy homolog 3 1.50 1.79 0.58 0.84 0.71 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 1.47 1.83 0.56 0.87 0.72 
Q9Y282 ERGIC3 Endoplasmic reticulum-Golgi intermediate compartme 0.76 3.58 -0.40 1.84 0.72 
O95292 VAPB Vesicle-associated membrane protein-associated pro 1.58 1.72 0.66 0.78 0.72 
Q8N2K0 ABHD12 Monoacylglycerol lipase ABHD12 1.74 1.56 0.80 0.64 0.72 
Q5BJH7 YIF1B Protein YIF1B 1.53 1.79 0.61 0.84 0.73 
P51659 HSD17B4 Peroxisomal multifunctional enzyme type 2 1.67 1.65 0.74 0.73 0.73 
Q8IY17 PNPLA6 Neuropathy target esterase 1.74 1.59 0.80 0.67 0.74 
Q5SWX8 ODR4 Protein odr-4 homolog 1.78 1.56 0.83 0.64 0.74 
Q8NFQ8 TOR1AIP2 Torsin-1A-interacting protein 2 1.24 2.26 0.31 1.18 0.75 
P07602 PSAP Proactivator polypeptide 1.71 1.65 0.77 0.73 0.75 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 2.18 1.30 1.12 0.38 0.75 
Q96RQ1 ERGIC2 Endoplasmic reticulum-Golgi intermediate compartme 0.96 2.97 -0.06 1.57 0.75 
Q9P246 STIM2 Stromal interaction molecule 2 1.16 2.46 0.21 1.30 0.76 
Q9UBS4 DNAJB11 DnaJ homolog subfamily B member 11 1.53 1.87 0.61 0.90 0.76 
	 290	
Q9H1E5 TMX4 Thioredoxin-related transmembrane protein 4 1.07 2.69 0.10 1.43 0.76 
Q96CS3 FAF2 FAS-associated factor 2 1.45 2.00 0.54 1.00 0.77 
P08758 ANXA5 Annexin A5 1.43 2.05 0.51 1.03 0.77 
P11047 LAMC1 Laminin subunit gamma-1 1.24 2.39 0.31 1.26 0.79 
P61019 RAB2A Ras-related protein Rab-2A 1.28 2.32 0.36 1.22 0.79 
Q9P0L0 VAPA Vesicle-associated membrane protein-associated pro 1.78 1.69 0.83 0.75 0.79 
P50443 SLC26A2 Sulfate transporter 2.56 1.18 1.36 0.24 0.80 
P51149 RAB7A Ras-related protein Rab-7a 1.34 2.26 0.42 1.18 0.80 
Q9Y639 NPTN Neuroplastin 1.43 2.15 0.51 1.10 0.81 
O60635 TSPAN1 Tetraspanin-1 1.89 1.62 0.92 0.70 0.81 
Q9Y2H6 FNDC3A Fibronectin type-III domain-containing protein 3A 1.28 2.46 0.36 1.30 0.83 
Q32P28 LEPRE1 Prolyl 3-hydroxylase 1 2.56 1.23 1.36 0.30 0.83 
P27824 CANX Calnexin 1.53 2.10 0.61 1.07 0.84 
P53985 SLC16A1 Monocarboxylate transporter 1 1.85 1.79 0.89 0.84 0.86 
P30040 ERP29 Endoplasmic reticulum resident protein 29 1.89 1.76 0.92 0.81 0.87 
P06737 PYGL Glycogen phosphorylase, liver form  2.42 1.39 1.27 0.47 0.87 
P21796 VDAC1 Voltage-dependent anion-selective channel protein 1.32 2.61 0.40 1.38 0.89 
Q5JRA6 MIA3 Melanoma inhibitory activity protein 3 1.64 2.10 0.72 1.07 0.89 
P08670 VIM Vimentin 2.81 1.25 1.49 0.32 0.90 
P14625 HSP90B1 Endoplasmin 1.78 2.05 0.83 1.03 0.93 
P17661 DES Desmin 2.81 1.30 1.49 0.38 0.94 
P51572 BCAP31 B-cell receptor-associated protein 31 1.61 2.32 0.69 1.22 0.95 
P50454 SERPINH1 Serpin H1 2.02 1.87 1.02 0.90 0.96 
Q9BUN8 DERL1 Derlin-1 1.67 2.26 0.74 1.18 0.96 
P08240 SRPR Signal recognition particle receptor subunit alpha 2.07 1.83 1.05 0.87 0.96 
Q16270 IGFBP7 Insulin-like growth factor-binding protein 7 1.24 3.07 0.31 1.62 0.97 
Q9Y2B0 CNPY2 Protein canopy homolog 2 1.98 1.95 0.98 0.97 0.98 
Q9UHG3 PCYOX1 Prenylcysteine oxidase 1 1.61 2.46 0.69 1.30 0.99 
Q9NYU2 UGGT1 UDP-glucose:glycoprotein glucosyltransferase 1 2.35 1.76 1.23 0.81 1.02 
P07942 LAMB1 Laminin subunit beta-1 2.02 2.05 1.02 1.03 1.03 
Q96G01 BICD1 Protein bicaudal D homolog 1 1.67 2.53 0.74 1.34 1.04 
Q8WV24 PHLDA1 Pleckstrin homology-like domain family A member 1 1.78 2.39 0.83 1.26 1.04 
P16435 POR NADPH--cytochrome P450 reductase 1.98 2.15 0.98 1.10 1.04 
Q15392 DHCR24 Delta(24)-sterol reductase 1.74 2.53 0.80 1.34 1.07 
Q6UWP7 LCLAT1 Lysocardiolipin acyltransferase 1 1.85 2.39 0.89 1.26 1.07 
O75844 ZMPSTE24 CAAX prenyl protease 1 homolog 1.71 2.69 0.77 1.43 1.10 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta 2.42 2.00 1.27 1.00 1.14 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2 1.89 2.61 0.92 1.38 1.15 
O00264 PGRMC1 Membrane-associated progesterone receptor componen 1.89 2.61 0.92 1.38 1.15 
P60903 S100A10 Protein S100-A10 2.35 2.10 1.23 1.07 1.15 
Q9HD20 ATP13A1 Probable cation-transporting ATPase 13A1 1.93 2.61 0.95 1.38 1.17 
P11021 HSPA5 78 kDa glucose-regulated protein 2.29 2.32 1.20 1.22 1.21 
Q00765 REEP5 Receptor expression-enhancing protein 5 1.89 3.07 0.92 1.62 1.27 
P05106 ITGB3 Integrin beta-3 3.00 1.95 1.58 0.97 1.28 
Q13217 DNAJC3 DnaJ homolog subfamily C member 3 2.29 2.69 1.20 1.43 1.31 
Q8WUY1 THEM6 UPF0670 protein THEM6 2.49 2.53 1.31 1.34 1.33 
O75131 CPNE3 Copine-3 2.29 3.19 1.20 1.67 1.43 
Q9NV96 TMEM30A Cell cycle control protein 50A 2.42 3.19 1.27 1.67 1.47 
P51648 ALDH3A2 Fatty aldehyde dehydrogenase 3.00 2.69 1.58 1.43 1.51 
P07099 EPHX1 Epoxide hydrolase 1 3.48 3.44 1.80 1.78 1.79 
P09525 ANXA4 Annexin A4 3.48 3.58 1.80 1.84 1.82 




Table 3A-2. ReDiMe analysis to quantify changes in protein abundance in 
PDIA4KO or WT isolated ER. Data was filtered for secretory pathway proteins 
that appeared in two replicates. The 100 most abundant and 100 least abundant 
proteins following PDIA4KO are shown. Ratios were converted to 
log2(WT:PDIA4KO) and sorted by decreasing levels of expression following 
PDIA4KO. Localization of proteins was determined using Uniprot and GO 
annotated tabs on UniprotKB. 
Uniprot ID Protein Description 
Ratio L:H log2(Ratio) 
Average 
1 2 1 2 
P13667 PDIA4 Protein disulfide-isomerase A4 0.06 0.06 -4.18 -4.11 -4.15 
Q16270 IGFBP7 Insulin-like growth factor-binding protein 7 0.09 0.06 -3.42 -4.11 -3.77 
P41252 IARS Isoleucine--tRNA ligase, cytoplasmic  0.12 0.06 -3.11 -4.11 -3.61 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2 0.34 0.36 -1.58 -1.47 -1.52 
P08758 ANXA5 Annexin A5 0.38 0.45 -1.40 -1.14 -1.27 
O43707 ACTN4 Alpha-actinin-4 0.45 0.39 -1.16 -1.34 -1.25 
P12814 ACTN1 Alpha-actinin-1 0.42 0.49 -1.24 -1.03 -1.13 
Q15293 RCN1 Reticulocalbin-1 0.54 0.42 -0.89 -1.25 -1.07 
Q01650 SLC7A5 Large neutral amino acids transporter small subuni 0.50 0.46 -1.01 -1.12 -1.07 
P08195 SLC3A2 4F2 cell-surface antigen heavy chain 0.45 0.52 -1.14 -0.95 -1.04 
Q99805 TM9SF2 Transmembrane 9 superfamily member 2 0.60 0.41 -0.73 -1.29 -1.01 
Q9NVA2 SEPT11 Septin-11 0.39 0.64 -1.36 -0.65 -1.00 
Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3 0.56 0.46 -0.83 -1.13 -0.98 
Q14694 USP10 Ubiquitin carboxyl-terminal hydrolase 10 0.41 0.67 -1.28 -0.58 -0.93 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 0.73 0.39 -0.46 -1.35 -0.90 
Q14141 SEPT6 Septin-6 0.46 0.62 -1.11 -0.70 -0.90 
P46940 IQGAP1 Ras GTPase-activating-like protein IQGAP1 0.45 0.64 -1.14 -0.64 -0.89 
P00387 CYB5R3 NADH-cytochrome b5 reductase 3 0.73 0.40 -0.45 -1.31 -0.88 
P26599 PTBP1 Polypyrimidine tract-binding protein 1 0.54 0.57 -0.90 -0.82 -0.86 
P61619 SEC61A1 Protein transport protein Sec61 subunit alpha isof 0.57 0.54 -0.81 -0.88 -0.85 
P10301 RRAS Ras-related protein R-Ras 0.76 0.41 -0.40 -1.28 -0.84 
Q99832 CCT7 T-complex protein 1 subunit eta 0.56 0.57 -0.83 -0.82 -0.83 
P62070 RRAS2 Ras-related protein R-Ras2 0.56 0.57 -0.85 -0.80 -0.82 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 0.61 0.52 -0.71 -0.94 -0.82 
P35613 BSG Basigin 0.48 0.73 -1.05 -0.45 -0.75 
P16435 POR NADPH--cytochrome P450 reductase 0.73 0.50 -0.45 -1.01 -0.73 
Q13190 STX5 Syntaxin-5 0.64 0.57 -0.64 -0.81 -0.73 
Q8TED1 GPX8 Probable glutathione peroxidase 8 0.10 3.52 -3.25 1.81 -0.72 
Q07666 KHDRBS1 KH domain-containing, RNA-binding, signal transduc 0.69 0.54 -0.54 -0.90 -0.72 
P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  0.66 0.57 -0.60 -0.82 -0.71 
Q16647 PTGIS Prostacyclin synthase 0.61 0.61 -0.71 -0.71 -0.71 
O15173 PGRMC2 Membrane-associated progesterone receptor componen 1.02 0.37 0.03 -1.45 -0.71 
Q15907 RAB11B Ras-related protein Rab-11B 0.73 0.53 -0.46 -0.92 -0.69 
P09211 GSTP1 Glutathione S-transferase P 0.64 0.61 -0.65 -0.72 -0.69 
P06493 CDK1 Cyclin-dependent kinase 1 0.55 0.70 -0.86 -0.52 -0.69 
P02751 FN1 Fibronectin 1.07 0.37 0.09 -1.44 -0.67 
P49773 HINT1 Histidine triad nucleotide-binding protein 1 1.62 0.25 0.69 -2.02 -0.67 
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Q06481 APLP2 Amyloid-like protein 2 0.76 0.54 -0.39 -0.90 -0.64 
O43896 KIF1C Kinesin-like protein KIF1C 0.69 0.60 -0.54 -0.74 -0.64 
Q93050 ATP6V0A1 V-type proton ATPase 116 kDa subunit a isoform 1 0.89 0.47 -0.16 -1.10 -0.63 
P35241 RDX Radixin 0.60 0.69 -0.73 -0.53 -0.63 
P40227 CCT6A T-complex protein 1 subunit zeta 0.65 0.64 -0.62 -0.63 -0.63 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1 0.44 0.96 -1.19 -0.06 -0.63 
P60228 EIF3E Eukaryotic translation initiation factor 3 subunit 0.85 0.50 -0.23 -1.01 -0.62 
P15311 EZR Ezrin 0.60 0.71 -0.73 -0.50 -0.62 
O00592 PODXL Podocalyxin 1.04 0.41 0.05 -1.29 -0.62 
P05388 RPLP0 60S acidic ribosomal protein P0 0.60 0.72 -0.73 -0.48 -0.60 
Q15629 TRAM1 Translocating chain-associated membrane protein 1 0.61 0.72 -0.71 -0.48 -0.60 
P23528 CFL1 Cofilin-1 0.72 0.61 -0.48 -0.70 -0.59 
Q99653 CHP1 Calcineurin B homologous protein 1 1.10 0.40 0.14 -1.31 -0.58 
Q92599 SEPT8 Septin-8 0.64 0.70 -0.65 -0.51 -0.58 
P80303 NUCB2 Nucleobindin-2 0.59 0.77 -0.76 -0.38 -0.57 
Q92900 UPF1 Regulator of nonsense transcripts 1 0.85 0.54 -0.23 -0.90 -0.56 
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 0.82 0.57 -0.28 -0.81 -0.55 
P46781 RPS9 40S ribosomal protein S9 0.71 0.67 -0.50 -0.57 -0.54 
P29317 EPHA2 Ephrin type-A receptor 2 0.89 0.53 -0.16 -0.91 -0.54 
P51665 PSMD7 26S proteasome non-ATPase regulatory subunit 7 0.70 0.68 -0.51 -0.55 -0.53 
P50570 DNM2 Dynamin-2 0.86 0.56 -0.22 -0.84 -0.53 
P26038 MSN Moesin 0.64 0.75 -0.64 -0.41 -0.53 
P17931 LGALS3 Galectin-3 0.62 0.79 -0.69 -0.33 -0.51 
P61106 RAB14 Ras-related protein Rab-14 0.59 0.85 -0.77 -0.24 -0.51 
Q02818 NUCB1 Nucleobindin-1 0.59 0.85 -0.77 -0.24 -0.51 
O43852 CALU Calumenin 1.17 0.42 0.23 -1.23 -0.50 
O15270 SPTLC2 Serine palmitoyltransferase 2 0.69 0.73 -0.54 -0.46 -0.50 
Q92974 ARHGEF2 Rho guanine nucleotide exchange factor 2 0.53 0.97 -0.93 -0.05 -0.49 
O00571 DDX3X ATP-dependent RNA helicase DDX3X 0.70 0.73 -0.52 -0.45 -0.48 
P46782 RPS5 40S ribosomal protein S5 0.66 0.78 -0.60 -0.36 -0.48 
P06737 PYGL Glycogen phosphorylase, liver form  0.65 0.78 -0.61 -0.35 -0.48 
P80723 BASP1 Brain acid soluble protein 1 0.76 0.67 -0.39 -0.57 -0.48 
P13010 XRCC5 X-ray repair cross-complementing protein 5 0.65 0.80 -0.63 -0.32 -0.47 
Q12906 ILF3 Interleukin enhancer-binding factor 3 0.64 0.81 -0.64 -0.31 -0.47 
Q99439 CNN2 Calponin-2 0.80 0.65 -0.33 -0.62 -0.47 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 0.73 0.72 -0.46 -0.48 -0.47 
O00232 PSMD12 26S proteasome non-ATPase regulatory subunit 12 0.72 0.73 -0.48 -0.45 -0.46 
Q8N8S7 ENAH Protein enabled homolog 0.62 0.87 -0.69 -0.21 -0.45 
P01891 HLA-A HLA class I histocompatibility antigen, A-68 alpha 0.66 0.82 -0.60 -0.28 -0.44 
O75381 PEX14 Peroxisomal membrane protein PEX14 0.75 0.72 -0.41 -0.47 -0.44 
O00429 DNM1L Dynamin-1-like protein 0.71 0.77 -0.49 -0.38 -0.44 
P07099 EPHX1 Epoxide hydrolase 1 0.74 0.75 -0.44 -0.41 -0.42 
P49257 LMAN1 Protein ERGIC-53 0.70 0.80 -0.52 -0.32 -0.42 
P48643 CCT5 T-complex protein 1 subunit epsilon 0.81 0.69 -0.30 -0.54 -0.42 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 0.73 0.78 -0.46 -0.36 -0.41 
Q14764 MVP Major vault protein 0.75 0.77 -0.42 -0.38 -0.40 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosy 0.88 0.66 -0.18 -0.60 -0.39 
Q70UQ0 IKBIP Inhibitor of nuclear factor kappa-B kinase-interac 0.85 0.69 -0.24 -0.54 -0.39 
Q9NQC3 RTN4 Reticulon-4 0.69 0.85 -0.54 -0.24 -0.39 
P61019 RAB2A Ras-related protein Rab-2A 0.60 0.97 -0.74 -0.04 -0.39 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit 0.89 0.66 -0.16 -0.61 -0.39 
Q9H223 EHD4 EH domain-containing protein 4 0.83 0.71 -0.26 -0.50 -0.38 
Q6DD88 ATL3 Atlastin-3 0.88 0.67 -0.18 -0.58 -0.38 
P84098 RPL19 60S ribosomal protein L19 0.86 0.69 -0.22 -0.53 -0.38 
Q15417 CNN3 Calponin-3 0.88 0.67 -0.18 -0.57 -0.38 
Q9UHG3 PCYOX1 Prenylcysteine oxidase 1 0.84 0.71 -0.25 -0.50 -0.38 
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Q03135 CAV1 Caveolin-1 0.98 0.61 -0.03 -0.72 -0.37 
Q12907 LMAN2 Vesicular integral-membrane protein VIP36 0.82 0.73 -0.28 -0.45 -0.37 
P50914 RPL14 60S ribosomal protein L14 0.65 0.94 -0.63 -0.10 -0.36 
Q9NPR2 SEMA4B Semaphorin-4B 0.72 0.84 -0.47 -0.25 -0.36 
P02786 TFRC Transferrin receptor protein 1 1.09 0.56 0.12 -0.84 -0.36 
P29992 GNA11 Guanine nucleotide-binding protein subunit alpha-1 0.95 0.65 -0.08 -0.63 -0.35 
P18206 VCL Vinculin 0.79 0.78 -0.35 -0.35 -0.35 
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 1.67 0.96 0.74 -0.06 0.34 
P52594 AGFG1 Arf-GAP domain and FG repeat-containing protein 1 1.72 0.94 0.78 -0.10 0.34 
P40429 RPL13A 60S ribosomal protein L13a 1.11 1.45 0.15 0.54 0.34 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 1.45 1.12 0.53 0.16 0.35 
P62906 RPL10A 60S ribosomal protein L10a 1.31 1.23 0.39 0.30 0.35 
Q86SF2 GALNT7 N-acetylgalactosaminyltransferase 7 1.38 1.20 0.46 0.26 0.36 
Q8NFJ5 GPRC5A Retinoic acid-induced protein 3 1.96 0.84 0.97 -0.25 0.36 
P61163 ACTR1A Alpha-centractin 1.43 1.16 0.51 0.21 0.36 
Q15836 VAMP3 Vesicle-associated membrane protein 3 1.25 1.33 0.32 0.42 0.37 
Q8WWI5 SLC44A1 Choline transporter-like protein 1 1.07 1.57 0.09 0.65 0.37 
P20340 RAB6A Ras-related protein Rab-6A 1.03 1.66 0.04 0.73 0.38 
P30153 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa reg 1.62 1.08 0.69 0.12 0.41 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 1.28 1.38 0.36 0.47 0.41 
P62333 PSMC6 26S protease regulatory subunit 10B 1.67 1.06 0.74 0.09 0.41 
O75382 TRIM3 Tripartite motif-containing protein 3 1.18 1.51 0.24 0.59 0.42 
Q9UBI6 GNG12 Guanine nucleotide-binding protein G(I)/G(S)/G(O) 0.85 2.11 -0.24 1.08 0.42 
P30040 ERP29 Endoplasmic reticulum resident protein 29 1.02 1.76 0.03 0.81 0.42 
Q13162 PRDX4 Peroxiredoxin-4 1.38 1.32 0.46 0.40 0.43 
Q96AJ9 VTI1A Vesicle transport through interaction with t-SNARE 1.02 1.78 0.03 0.84 0.43 
O95881 TXNDC12 Thioredoxin domain-containing protein 12 1.59 1.15 0.67 0.20 0.44 
Q9NRW1 RAB6B Ras-related protein Rab-6B 0.91 2.04 -0.14 1.03 0.44 
Q9P0K7 RAI14 Ankycorbin 1.25 1.49 0.32 0.57 0.45 
P42677 RPS27 40S ribosomal protein S27 1.12 1.66 0.17 0.73 0.45 
Q08379 GOLGA2 Golgin subfamily A member 2 1.10 1.71 0.14 0.77 0.45 
P12268 IMPDH2 Inosine-5-monophosphate dehydrogenase 2 1.34 1.41 0.42 0.50 0.46 
Q9P2E9 RRBP1 Ribosome-binding protein 1 1.28 1.49 0.36 0.57 0.46 
Q86V48 LUZP1 Leucine zipper protein 1 1.62 1.21 0.69 0.27 0.48 
O00186 STXBP3 Syntaxin-binding protein 3 0.58 3.41 #### 1.77 0.49 
P26885 FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2 1.39 1.41 0.48 0.50 0.49 
Q9H0U4 RAB1B Ras-related protein Rab-1B 1.62 1.23 0.69 0.30 0.50 
Q9HBH5 RDH14 Retinol dehydrogenase 14 0.93 2.15 -0.10 1.10 0.50 
O43865 AHCYL1 Putative adenosylhomocysteinase 2 1.38 1.47 0.46 0.55 0.51 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 1.43 1.41 0.51 0.50 0.51 
P10809 HSPD1 60 kDa heat shock protein, mitochondrial  1.57 1.29 0.65 0.37 0.51 
Q9H270 VPS11 Vacuolar protein sorting-associated protein 11 hom 1.29 1.57 0.37 0.65 0.51 
Q00341 HDLBP Vigilin 1.34 1.53 0.42 0.61 0.52 
Q6UW68 TMEM205 Transmembrane protein 205 2.62 0.78 1.39 -0.35 0.52 
Q10471 GALNT2 Polypeptide N-acetylgalactosaminyltransferase 2 1.51 1.36 0.59 0.45 0.52 
P11021 HSPA5 78 kDa glucose-regulated protein 1.39 1.49 0.48 0.57 0.53 
P30101 PDIA3 Protein disulfide-isomerase A3 1.39 1.49 0.48 0.57 0.53 
Q00765 REEP5 Receptor expression-enhancing protein 5 1.47 1.41 0.55 0.50 0.53 
P48634 PRRC2A Protein PRRC2A 1.51 1.38 0.59 0.47 0.53 
P46776 RPL27A 60S ribosomal protein L27a 1.22 1.71 0.29 0.77 0.53 
P42892 ECE1 Endothelin-converting enzyme 1 1.45 1.47 0.53 0.55 0.54 
Q14696 MESDC2 LDLR chaperone MESD 1.04 2.07 0.05 1.05 0.55 
P53621 COPA Coatomer subunit alpha 1.28 1.68 0.36 0.75 0.55 
P07339 CTSD Cathepsin D 1.41 1.53 0.50 0.61 0.55 
P22392 NME2 Nucleoside diphosphate kinase B 1.17 1.84 0.23 0.88 0.55 
Q15149 PLEC Plectin 1.55 1.40 0.63 0.48 0.56 
	 294	
Q9Y5X1 SNX9 Sorting nexin-9 1.28 1.73 0.36 0.79 0.57 
Q9HDC9 APMAP Adipocyte plasma membrane-associated protein 0.94 2.37 -0.09 1.24 0.58 
P22307 SCP2 Non-specific lipid-transfer protein 1.08 2.07 0.11 1.05 0.58 
P68366 TUBA4A Tubulin alpha-4A chain 1.47 1.53 0.55 0.61 0.58 
Q9UBQ0 VPS29 Vacuolar protein sorting-associated protein 29 1.45 1.55 0.53 0.63 0.58 
P83731 RPL24 60S ribosomal protein L24 1.28 1.76 0.36 0.81 0.58 
P46783 RPS10 40S ribosomal protein S10 0.80 2.83 -0.33 1.50 0.59 
Q14254 FLOT2 Flotillin-2 1.69 1.33 0.76 0.42 0.59 
Q6NZI2 PTRF Polymerase I and transcript release factor 1.45 1.57 0.53 0.65 0.59 
Q13177 PAK2 Serine/threonine-protein kinase PAK 2 1.41 1.61 0.50 0.69 0.59 
Q15005 SPCS2 Signal peptidase complex subunit 2 1.36 1.68 0.44 0.75 0.60 
Q71U36 TUBA1A Tubulin alpha-1A chain 1.53 1.53 0.61 0.61 0.61 
P05067 APP Amyloid beta A4 protein 1.08 2.23 0.11 1.16 0.63 
P55145 MANF Mesencephalic astrocyte-derived neurotrophic facto 1.67 1.45 0.74 0.54 0.64 
Q8IVF2 AHNAK2 Protein AHNAK2 1.34 1.87 0.42 0.90 0.66 
P62847 RPS24 40S ribosomal protein S24 2.39 1.08 1.26 0.12 0.69 
P40763 STAT3 Signal transducer and activator of transcription 3 1.64 1.61 0.72 0.69 0.70 
P11413 G6PD Glucose-6-phosphate 1-dehydrogenase 3.06 0.87 1.61 -0.21 0.70 
O15460 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 1.51 1.76 0.59 0.81 0.70 
P68371 TUBB4B Tubulin beta-4B chain 1.75 1.55 0.80 0.63 0.72 
P07996 THBS1 Thrombospondin-1 1.83 1.53 0.87 0.61 0.74 
A0FGR8 ESYT2 Extended synaptotagmin-2 1.31 2.15 0.39 1.10 0.75 
P06744 GPI Glucose-6-phosphate isomerase 1.59 1.81 0.67 0.86 0.77 
Q14677 CLINT1 Clathrin interactor 1 1.57 1.84 0.65 0.88 0.77 
P11233 RALA Ras-related protein Ral-A 1.51 1.93 0.59 0.95 0.77 
P60174 TPI1 Triosephosphate isomerase 1.72 1.71 0.78 0.77 0.78 
P26373 RPL13 60S ribosomal protein L13 1.20 2.47 0.26 1.30 0.78 
Q71UM5 RPS27L 40S ribosomal protein S27-like 1.04 2.90 0.05 1.54 0.79 
P07437 TUBB Tubulin beta chain 1.72 1.78 0.78 0.84 0.81 
Q13509 TUBB3 Tubulin beta-3 chain 1.67 1.84 0.74 0.88 0.81 
P39019 RPS19 40S ribosomal protein S19 1.34 2.32 0.42 1.21 0.82 
P62917 RPL8 60S ribosomal protein L8 1.15 2.76 0.20 1.47 0.83 
P09382 LGALS1 Galectin-1 2.12 1.51 1.08 0.59 0.84 
Q9BUF5 TUBB6 Tubulin beta-6 chain 1.77 1.81 0.83 0.86 0.84 
Q14974 KPNB1 Importin subunit beta-1 1.80 1.81 0.85 0.86 0.85 
Q8WX93 PALLD Palladin 2.12 1.55 1.08 0.63 0.86 
Q06830 PRDX1 Peroxiredoxin-1 1.45 2.27 0.53 1.19 0.86 
P13987 CD59 CD59 glycoprotein 0.84 4.00 -0.25 2.00 0.87 
P62753 RPS6 40S ribosomal protein S6 1.72 2.00 0.78 1.00 0.89 
P09496 CLTA Clathrin light chain A 1.45 2.42 0.53 1.27 0.90 
Q8N2K0 ABHD12 Monoacylglycerol lipase ABHD12 2.00 1.76 1.00 0.81 0.91 
Q96JJ7 TMX3 Protein disulfide-isomerase TMX3 2.68 1.32 1.42 0.40 0.91 
P19022 CDH2 Cadherin-2 1.86 1.90 0.90 0.93 0.91 
Q8N5G2 TMEM57 Macoilin 1.67 2.27 0.74 1.19 0.96 
Q9Y314 NOSIP Nitric oxide synthase-interacting protein 2.44 1.71 1.29 0.77 1.03 
P11117 ACP2 Lysosomal acid phosphatase 1.67 2.70 0.74 1.43 1.08 
P17661 DES Desmin 1.64 2.76 0.72 1.47 1.09 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 2.34 2.23 1.23 1.16 1.19 
Q86W92 PPFIBP1 Liprin-beta-1 1.93 2.76 0.95 1.47 1.21 
Q03001 DST Dystonin 2.20 2.90 1.14 1.54 1.34 
P08670 VIM Vimentin 3.14 3.14 1.65 1.65 1.65 
P61254 RPL26 60S ribosomal protein L26 2.68 4.30 1.42 2.10 1.76 
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Table 3A-3. PANTHER GO Biological Processes enrichment analysis for the top 
100 most abundant proteins in PDIA1KO isolated ER. 
Analysis Type: 
PANTHER Overrepresentation Test 
(Released 20190711) 
Annotation Version and Release Date: 
GO Ontology database  Released 2019-07-
03 
Reference List: Homo sapiens (all genes in database) 
Test Type: FISHER    
Correction: BONFERRONI   
      
 Protein Number   









protein folding in endoplasmic reticulum (GO:0034975) 16 6 0.07 81.17 5.07E-06 
IRE1-mediated unfolded protein response (GO:0036498) 55 8 0.25 31.48 4.18E-06 
endoplasmic reticulum unfolded protein response (GO:0030968) 104 11 0.48 22.89 4.65E-08 
cellular response to unfolded protein (GO:0034620) 126 11 0.58 18.9 3.18E-07 
response to unfolded protein (GO:0006986) 162 14 0.75 18.71 6.42E-10 
cellular response to topologically incorrect protein (GO:0035967) 147 12 0.68 17.67 8.09E-08 
response to topologically incorrect protein (GO:0035966) 185 15 0.85 17.55 1.85E-10 
response to endoplasmic reticulum stress (GO:0034976) 252 19 1.16 16.32 1.58E-13 
regulation of response to endoplasmic reticulum stress (GO:1905897) 85 6 0.39 15.28 3.51E-02 
ERAD pathway (GO:0036503) 89 6 0.41 14.59 4.50E-02 
protein folding (GO:0006457) 226 12 1.04 11.49 8.80E-06 
endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888) 207 9 0.96 9.41 6.12E-03 
neutrophil degranulation (GO:0043312) 483 14 2.23 6.27 5.65E-04 
neutrophil activation involved in immune response (GO:0002283) 487 14 2.25 6.22 6.23E-04 
neutrophil mediated immunity (GO:0002446) 494 14 2.28 6.13 7.40E-04 
neutrophil activation (GO:0042119) 496 14 2.29 6.11 7.76E-04 
granulocyte activation (GO:0036230) 500 14 2.31 6.06 8.54E-04 
leukocyte degranulation (GO:0043299) 504 14 2.33 6.01 9.39E-04 
myeloid leukocyte mediated immunity (GO:0002444) 514 14 2.37 5.9 1.19E-03 
myeloid cell activation involved in immune response (GO:0002275) 518 14 2.39 5.85 1.30E-03 
endomembrane system organization (GO:0010256) 426 11 1.97 5.59 4.77E-02 
myeloid leukocyte activation (GO:0002274) 581 14 2.68 5.22 5.02E-03 
regulated exocytosis (GO:0045055) 696 16 3.22 4.98 1.33E-03 
leukocyte activation involved in immune response (GO:0002366) 619 14 2.86 4.9 1.05E-02 
cell activation involved in immune response (GO:0002263) 623 14 2.88 4.86 1.13E-02 
exocytosis (GO:0006887) 784 17 3.62 4.69 1.17E-03 
cellular homeostasis (GO:0019725) 897 19 4.14 4.58 2.75E-04 
export from cell (GO:0140352) 1032 20 4.77 4.19 4.73E-04 
secretion by cell (GO:0032940) 993 19 4.59 4.14 1.31E-03 
secretion (GO:0046903) 1108 19 5.12 3.71 6.77E-03 
intracellular transport (GO:0046907) 1522 25 7.03 3.56 1.85E-04 
lipid metabolic process (GO:0006629) 1196 19 5.53 3.44 2.07E-02 
vesicle-mediated transport (GO:0016192) 1950 29 9.01 3.22 8.85E-05 
establishment of localization in cell (GO:0051649) 1834 27 8.47 3.19 4.14E-04 
cellular protein localization (GO:0034613) 1598 23 7.38 3.12 7.82E-03 
cellular macromolecule localization (GO:0070727) 1606 23 7.42 3.1 8.52E-03 
cellular localization (GO:0051641) 2453 32 11.33 2.82 2.66E-04 
cellular catabolic process (GO:0044248) 1771 23 8.18 2.81 4.39E-02 
protein localization (GO:0008104) 2153 27 9.95 2.71 1.00E-02 
response to organic substance (GO:0010033) 2992 35 13.82 2.53 7.06E-04 
macromolecule localization (GO:0033036) 2489 29 11.5 2.52 1.57E-02 
transport (GO:0006810) 4521 52 20.89 2.49 5.07E-08 
establishment of localization (GO:0051234) 4653 52 21.5 2.42 1.58E-07 
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localization (GO:0051179) 5737 59 26.5 2.23 6.33E-08 
response to stress (GO:0006950) 3535 36 16.33 2.2 1.59E-02 
response to chemical (GO:0042221) 4455 44 20.58 2.14 1.16E-03 
Unclassified (UNCLASSIFIED) 3181 3 14.7 0.2 0.00E+00 
 
Table 3A-4. Filtered list of cysteine-containing peptides from secretory proteins 
identified in OxICAT analyses of WT and PDIA1KO isolated ER. Each treatment 
was performed in triplicate and the data was filtered for peptides with ratios found 
in at least two of the replicates per treatment. Furthermore, the data was reduced 
to only peptides that displayed a statistically significant (p <0.05, unpaired t tests) 
difference in cysteine oxidation states. Data is displayed as percent oxidized and 
the average difference in percent oxidation (WT – PDIA1KO). Localization of 
proteins was determined using Uniprot and GO annotated tabs on UniprotKB. 
Uniprot 
ID Protein Description Peptide Sequence Residue 
Percent Oxidized Difference 
(WT - 
PDIA1KO) WT PDIA1KO 
P05556 ITGB1 Integrin beta-1 CDDLEALK 64 95.24% 32.92% 62.32% 
Q9Y5R8 TRAPPC1 Trafficking protein particle complex subunit 1 NPLCPLGQTVQSELFR 115 38.32% 4.76% 33.55% 
Q9Y678 COPG1 Coatomer subunit gamma-1 FLGMHPCER 813 45.65% 13.97% 31.68% 
Q14764 MVP Major vault protein ALCLLLGPDFFTDVITIETADHAR 515 46.18% 19.77% 26.41% 
Q8WUY1 THEM6 UPF0670 protein THEM6 AHTVLAASCAR 104 42.07% 17.96% 24.11% 
O60701 UGDH UDP-glucose 6-dehydrogenase 
ISSINSISALCEATGAD
VEEVATAIGMDQR 241 38.03% 15.38% 22.65% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al DGGVQACFSR 139 24.35% 3.65% 20.70% 
Q15149 PLEC Plectin LECLQR 530 25.62% 5.45% 20.18% 
O75976 CPD Carboxypeptidase D DCTSK 1049 76.56% 56.54% 20.02% 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 HAACPVLVGNK 503 52.61% 37.29% 15.32% 
P14625 HSP90B1 Endoplasmin LTESPCALVASQYGWSGNMER 645 19.93% 6.84% 13.08% 
P60174 TPI1 Triosephosphate isomerase VPADTEVVCAPPTAYIDFAR 79 23.22% 11.20% 12.02% 
P14625 HSP90B1 Endoplasmin GYEVIYLTEPVDEYCIQALPEFDGK 576 23.56% 11.87% 11.69% 
Q99943 AGPAT1 1-acyl-sn-glycerol-3-phosphate acyltransferase alp FTSGQCQVR 229 27.69% 16.22% 11.47% 
P56192 MARS Methionine--tRNA ligase, cytoplasmic  
FVEGVC*PFC*GYEEA
R 405 34.41% 24.20% 10.21% 
O75608 LYPLA1 Acyl-protein thioesterase 1 LAGVTALSCWLPLR 144 14.33% 4.76% 9.57% 
P35998 PSMC2 26S protease regulatory subunit 7 LCPNSTGAEIR 377 42.15% 33.37% 8.79% 
P46459 NSF Vesicle-fusing ATPase C*PTDELSLTNC*AVVNEK 11 15.95% 7.38% 8.57% 
Q9NR12 PDLIM7 PDZ and LIM domain protein 7 GAIFC*PPC*YDVR 329 41.91% 34.07% 7.85% 
Q9Y4L1 HYOU1 Hypoxia up-regulated protein 1 VEFEELCADLFER 352 19.20% 12.32% 6.88% 
P30101 PDIA3 Protein disulfide-isomerase A3 
FIQENIFGICPHMTED
NK 244 29.17% 22.51% 6.67% 
O43402 EMC8 ER membrane protein complex subunit 8 YPHCAVNGLLVAEK 24 40.23% 33.67% 6.56% 
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P67936 TPM4 Tropomyosin alpha-4 chain EENVGLHQTLDQTLNELNCI 247 35.85% 29.68% 6.17% 
Q8NBJ5 GLT25D1 Procollagen galactosyltransferase 1 ALQAQEIECR 369 41.96% 35.94% 6.02% 
P01891 
HLA-A HLA class I 
histocompatibility antigen, A-68 
alpha 
GGSYSQAASSDSAQGS
DVSLTACK 363 30.47% 24.76% 5.71% 
P61224 RAP1B Ras-related protein Rap-1b CDLEDER 118 19.89% 14.29% 5.60% 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  VGVDYEGGGCR 680 70.14% 64.90% 5.24% 
P00558 PGK1 Phosphoglycerate kinase 1 DCVGPEVEK 99 24.29% 19.37% 4.92% 
Q14571 ITPR2 Inositol 1,4,5-trisphosphate receptor type 2  TTC*FIC*GLER 2562 27.68% 22.80% 4.87% 
P24390 KDELR1 ER lumen protein retaining receptor 1 
YLDLFTNYISLYNTCM
K 62 9.52% 5.09% 4.42% 
P01891 
HLA-A HLA class I 
histocompatibility antigen, A-68 
alpha 
GGSYSQAASSDSAQGS
DVSLTACK 363 28.33% 24.44% 3.89% 
Q13162 PRDX4 Peroxiredoxin-4 SINTEVVACSVDSQFTHLAWINTPR 148 25.75% 21.88% 3.87% 
P18669 PGAM1 Phosphoglycerate mutase 1 YADLTEDQLPSCESLK 153 12.08% 8.22% 3.86% 
P07099 EPHX1 Epoxide hydrolase 1 NHGLSDEHVFEVICPSIPGYGFSEASSK 182 19.97% 16.19% 3.78% 
P07947 YES1 Tyrosine-protein kinase Yes PENTPEPVSTSVSHYGAEPTTVSPCPSSSAK 42 18.72% 14.99% 3.73% 
P30530 AXL Tyrosine-protein kinase receptor UFO CWELNPQDR 785 10.77% 7.05% 3.72% 
Q9ULV4 CORO1C Coronin-1C NGSLICTASK 190 9.40% 5.70% 3.70% 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
IISNASC*TTNC*LAPL
AK 152 29.78% 26.16% 3.62% 
Q6PIU2 NCEH1 Neutral cholesterol ester hydrolase 1 
ICISGDSAGGNLAAAL
GQQFTQDASLK 186 11.17% 7.60% 3.57% 
Q8NHP6 MOSPD2 Motile sperm domain-containing protein 2 TSEDICLQLSR 471 32.34% 28.89% 3.45% 
P17858 PFKL 6-phosphofructokinase, liver type  
AAAYNLVQHGITNLC
VIGGDGSLTGANIFR 114 14.46% 11.17% 3.29% 
Q16658 FSCN1 Fascin QIWTLEQPPDEAGSAAVCLR 61 16.64% 13.39% 3.26% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al 
QLFALSCTAEEQGVLP
DDLSGVIR 112 11.68% 8.48% 3.20% 
P61077 UBE2D3 Ubiquitin-conjugating enzyme E2 D3 
VLLSIC*SLLC*DPNPD
DPLVPEIAR 107 14.71% 11.61% 3.09% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 IEEFLEEVLCPPK 100 13.37% 10.43% 2.94% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al IIHEDGYSEEECR 66 9.08% 6.31% 2.77% 
P60981 DSTN Destrin AVIFCLSADK 39 20.61% 17.89% 2.72% 
P12814 ACTN1 Alpha-actinin-1 ICDQWDNLGALTQK 480 9.04% 6.53% 2.51% 
P21333 FLNA Filamin-A VHSPSGALEECYVTEIDQDK 2378 18.32% 16.16% 2.16% 
Q13162 PRDX4 Peroxiredoxin-4 EEECHFYAGGQVYPGEASR 51 83.24% 81.16% 2.08% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al DCGLF 352 11.06% 8.98% 2.08% 
P27797 CALR Calreticulin HEQNIDCGGGYVK 105 72.84% 70.80% 2.05% 
P07900 HSP90AA1 Heat shock protein HSP 90-alpha CLELFTELAEDK 420 10.23% 8.39% 1.84% 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 VDCDQHSDIAQR 92 20.05% 18.26% 1.79% 
Q9ULV4 CORO1C Coronin-1C NDQCYDDIR 23 11.89% 10.17% 1.73% 
Q9Y3I0 C22orf28 tRNA-splicing ligase RtcB homolog NCWR 19 7.92% 6.23% 1.68% 
P21333 FLNA Filamin-A ALGALVDSC*APGLC*PDWDSWDASK 205 21.54% 20.04% 1.50% 
P07947 YES1 Tyrosine-protein kinase Yes LTTVCPTVK 255 12.17% 10.72% 1.44% 
P05388 RPLP0 60S acidic ribosomal protein P0 
NVASVCLQIGYPTVAS
VPHSIINGYK 226 7.98% 6.55% 1.44% 
Q96DX4 RSPRY1 RING finger and SPRY domain-containing protein 1 
VIPLEDPLGPAVITLLL
DECPLPTK 167 7.43% 6.02% 1.41% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
ACGDSTLTQITAGLDP
VGR 25 15.05% 13.70% 1.35% 
P61224 RAP1B Ras-related protein Rap-1b QWNNCAFLESSAK 141 7.10% 5.80% 1.30% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
ACADATLSQITNNIDP
VGR 25 7.82% 6.61% 1.21% 
P21333 FLNA Filamin-A TPCEEILVK 2601 13.74% 12.66% 1.09% 
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P00558 PGK1 Phosphoglycerate kinase 1 ACANPAAGSVILLENLR 108 22.66% 21.63% 1.03% 
P27797 CALR Calreticulin CKDDEFTHLYTLIVRPDNTYEVK 163 46.84% 45.86% 0.98% 
P61981 YWHAG 14-3-3 protein gamma ELEAVCQDVLSLLDNYLIK 97 6.01% 5.12% 0.89% 
P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma cat 
TFTDC*FNC*LPIAAIV
DEK 155 17.66% 16.79% 0.87% 
P61158 ACTR3 Actin-related protein 3 LGYAGNTEPQFIIPSCIAIK 34 13.83% 13.03% 0.80% 
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B DVIIADCGK 202 13.11% 12.59% 0.51% 
P21333 FLNA Filamin-A ATCAPQHGAPGPGPADASK 2543 16.43% 16.83% -0.40% 





VACITEQVLTLVNK 477 4.46% 5.04% -0.58% 
Q9UHB6 LIMA1 LIM domain and actin-binding protein 1 LLANQQVFHISCFR 414 27.90% 28.55% -0.65% 
P40429 RPL13A 60S ribosomal protein L13a CEGINISGNFYR 38 4.55% 5.26% -0.71% 
Q6DD88 ATL3 Atlastin-3 ELYENFCK 429 5.67% 6.40% -0.73% 
P21796 VDAC1 Voltage-dependent anion-selective channel protein YQIDPDACFSAK 232 4.91% 5.67% -0.76% 
Q99832 CCT7 T-complex protein 1 subunit eta 
INALTAASEAACLIVS
VDETIK 511 8.23% 9.10% -0.87% 
P62826 RAN GTP-binding nuclear protein Ran VC*ENIPIVLC*GNK 112 4.21% 5.16% -0.95% 
P08134 RHOC Rho-related GTP-binding protein RhoC TCLLIVFSK 20 9.99% 10.95% -0.96% 
P14618 PKM Pyruvate kinase isozymes M1/M2 GIFPVLCK 474 6.40% 7.40% -1.00% 




201 10.70% 11.81% -1.11% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 ATILDLSCNK 48 6.93% 8.10% -1.17% 
P05388 RPLP0 60S acidic ribosomal protein P0 CFIVGADNVGSK 27 7.94% 9.22% -1.28% 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2 NPQLCYQDTILWK 162 94.39% 95.70% -1.31% 
P07437 TUBB Tubulin beta chain TAVCDIPPR 354 10.31% 11.71% -1.40% 
Q9H3N1 TMX1 Thioredoxin-related transmembrane protein 1 FIITALPTIYHCK 106 12.58% 14.00% -1.41% 
P62820 RAB1A Ras-related protein Rab-1A CDLTTK 126 8.06% 9.48% -1.42% 
P62241 RPS8 40S ribosomal protein S8 NCIVLIDSTPYR 100 5.55% 7.11% -1.56% 
P13639 EEF2 Elongation factor 2 YVEPIEDVPCGNIVGLVGVDQFLVK 466 9.39% 11.03% -1.64% 
P00338 LDHA L-lactate dehydrogenase A chain VIGSGCNLDSAR 163 11.99% 13.70% -1.71% 
Q15149 PLEC Plectin CRPDQLTGLSLLPLSEK 3336 5.92% 7.66% -1.74% 
P21333 FLNA Filamin-A THEAEIVEGENHTYCIR 2199 11.54% 13.30% -1.76% 
P08670 VIM Vimentin QVQSLTCEVDALK 328 11.70% 13.48% -1.78% 
P51648 ALDH3A2 Fatty aldehyde dehydrogenase DILTAIAADLCK 50 4.76% 6.56% -1.80% 
P16152 CBR1 Carbonyl reductase DVCTELLPLIK 122 7.73% 9.54% -1.81% 
Q15149 PLEC Plectin GDECQLVGPAQPSHWK 965 9.61% 11.54% -1.93% 
P46779 RPL28 60S ribosomal protein L28 NCSSFLIK 13 7.57% 9.64% -2.07% 
P21964 COMT Catechol O-methyltransferase YLPDTLLLEECGLLR 207 5.36% 7.59% -2.23% 
Q15149 PLEC Plectin AFCGFEDPR 4494 4.46% 6.72% -2.26% 
P27816 MAP4 Microtubule-associated protein 4 
NVCLPPEMEVALTED
QVPALK 535 15.45% 17.78% -2.33% 
P29401 TKT Transketolase TVPFCSTFAAFFTR 386 8.90% 11.26% -2.36% 
P50991 CCT4 T-complex protein 1 subunit delta ITGCASPGK 379 9.41% 11.82% -2.41% 
P63010 AP2B1 AP-2 complex subunit beta ITEYLCEPLR 123 6.03% 8.45% -2.41% 
P36578 RPL4 60S ribosomal protein L4 GPCIIYNEDNGIIK 208 6.35% 8.81% -2.46% 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 
VDC*TAHSDVC*SAQG
VR 121 85.80% 88.28% -2.48% 
P20338 RAB4A Ras-related protein Rab-4A SCLLHQFIEK 28 32.89% 35.40% -2.51% 
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P62913 RPL11 60S ribosomal protein L11 IAVHCTVR 72 15.51% 18.04% -2.53% 
P62829 RPL23 60S ribosomal protein L23 ISLGLPVGAVINCADNTGAK 28 9.61% 12.19% -2.58% 
O60361 NME2P1 Putative nucleoside diphosphate kinase SCAHDWVYE 130 15.56% 18.17% -2.61% 
P0CW22 RPS17L 40S ribosomal protein S17-like VCEEIAIIPSK 35 7.03% 9.79% -2.76% 
P07437 TUBB Tubulin beta chain LTTPTYGDLNHLVSATMSGVTTCLR 239 13.13% 15.91% -2.78% 
P62906 RPL10A 60S ribosomal protein L10a FSVC*VLGDQQHC*DEAK 66 18.90% 21.68% -2.78% 
P46776 RPL27A 60S ribosomal protein L27a NQSFCPTVNLDK 70 10.66% 13.44% -2.79% 
P00533 EGFR Epidermal growth factor receptor NGLQSCPIK 1058 53.85% 56.76% -2.91% 
P62888 RPL30 60S ribosomal protein L30 TGVHHYSGNNIELGTACGK 85 19.52% 22.46% -2.94% 
Q9HCU5 PREB Prolactin regulatory element-binding protein CGAETQHEGLELR 128 21.63% 24.62% -2.99% 
P21333 FLNA Filamin-A IEC*DDKGDGSC*DVR 623 16.24% 19.26% -3.02% 
P62633 CNBP Cellular nucleic acid-binding protein GFQFVSSSLPDICYR 54 38.63% 41.65% -3.02% 
P30050 RPL12 60S ribosomal protein L12 HPHDIIDDINSGAVECPAS 162 24.45% 27.48% -3.03% 
P42025 ACTR1B Beta-centractin YCFPNYVGR 34 4.76% 7.87% -3.11% 
Q7Z7H5 TMED4 Transmembrane emp24 domain-containing protein 4 CFIEEIPDETMVIGNYR 41 85.50% 88.68% -3.18% 
P06733 ENO1 Alpha-enolase SGETEDTFIADLVVGLCTGQIK 389 13.89% 17.14% -3.25% 
P62266 RPS23 40S ribosomal protein S23 ITAFVPNDGCLNFIEENDEVLVAGFGR 90 15.89% 19.14% -3.25% 
P62701 RPS4X 40S ribosomal protein S4, X isoform  ECLPLIIFLR 41 6.50% 9.80% -3.30% 
Q15149 PLEC Plectin VPLDVACAR 3295 14.13% 17.47% -3.34% 
P54136 RARS Arginine--tRNA ligase, cytoplasmic  
VLTAEELNAAQTSVA
YGCIK 502 5.61% 8.96% -3.36% 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1 LPADTCLLEFAR 330 5.13% 8.59% -3.46% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 VAGDCLDEK 131 18.03% 21.50% -3.47% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 GDGPICLVLAPTR 170 6.30% 9.81% -3.51% 
O60884 DNAJA2 DnaJ homolog subfamily A member 2 NVLC*SAC*SGQGGK 143 35.00% 38.53% -3.53% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
HLYTLDGGDIINALCF
SPNR 240 7.40% 10.99% -3.59% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
TNHIGHTGYLNTVTV
SPDGSLCASGGK 207 16.73% 20.33% -3.59% 
Q96TA1 FAM129B Niban-like protein 1 HCNNGIPEDSK 194 12.66% 16.26% -3.60% 
P36578 RPL4 60S ribosomal protein L4 YAICSALAASALPALVMSK 125 6.18% 9.79% -3.61% 
P45880 VDAC2 Voltage-dependent anion-selective channel protein 
WNTDNTLGTEIAIED
QICQGLK 103 9.71% 13.33% -3.61% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X PCVVYGGADIGQQIR 298 7.70% 11.40% -3.70% 
P30101 PDIA3 Protein disulfide-isomerase A3 VDC*TANTNTC*NK 85 84.48% 88.21% -3.73% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 
WLC*TGDIGEFEPDGC
*LK 561 10.04% 13.78% -3.74% 
P11717 IGF2R Cation-independent mannose-6-phosphate receptor VVSSCQEK 1282 84.88% 88.63% -3.75% 
P50570 DNM2 Dynamin-2 LQDAFSSIGQSCHLDLPQIAVVGGQSAGK 27 6.45% 10.27% -3.82% 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  
FWTFETGC*TVC*DEG
LR 267 88.38% 92.21% -3.83% 
P08134 RHOC Rho-related GTP-binding protein RhoC LVIVGDGACGK 16 10.79% 14.64% -3.84% 
P09486 SPARC SPARC YIPPCLDSELTEFPLR 155 84.70% 88.62% -3.92% 
P00533 EGFR Epidermal growth factor receptor 
TPLLSSLSATSNNSTV
ACIDR 1049 53.05% 57.01% -3.96% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- YWLCAATGPSIK 249 9.94% 14.03% -4.09% 
P62888 RPL30 60S ribosomal protein L30 VCTLAIIDPGDSDIIR 92 14.00% 18.11% -4.11% 
P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic  GDLNDC*FIPC*TPK 143 7.56% 11.69% -4.13% 
Q15149 PLEC Plectin GCLDEETSR 3299 13.03% 17.17% -4.15% 
O95292 VAPB Vesicle-associated membrane protein-associated pro CVFELPAENDK 121 7.23% 11.43% -4.20% 
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Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 
VDC*TQHYELC*SGNQ
VR 247 88.88% 93.10% -4.22% 
Q9H553 ALG2 Alpha-1,3/1,6-mannosyltransferase ALG2  CAGDWLPR 70 9.88% 14.16% -4.28% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase ANACNSVIK 471 7.16% 11.47% -4.31% 
P07814 EPRS Bifunctional glutamate/proline--tRNA ligase 
YNVYPTYDFACPIVDS
IEGVTHALR 381 5.43% 9.77% -4.34% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
AEPPQCTSLAWSADG
QTLFAGYTDNLVR 286 14.75% 19.11% -4.36% 
Q14697 GANAB Neutral alpha-glucosidase AB TC*EESSFC*K 41 90.24% 94.65% -4.40% 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 TPADCPVIAIDSFR 318 87.68% 92.13% -4.45% 
P27824 CANX Calnexin C*ESAPGC*GVWQR 360 91.20% 95.70% -4.50% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 ELAQQVQQVAAEYCR 191 22.96% 27.49% -4.53% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase VGEATETALTCLVEK 447 5.73% 10.30% -4.57% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- LWNTLGVCK 138 10.93% 15.51% -4.57% 
P83731 RPL24 60S ribosomal protein L24 CESAFLSK 36 7.30% 11.88% -4.58% 
P07099 EPHX1 Epoxide hydrolase 1 FTPPLEDSCFHYGFNSNYLK 80 5.03% 9.68% -4.65% 
P50914 RPL14 60S ribosomal protein L14 CMQLTDFILK 54 10.46% 15.19% -4.72% 
Q15436 SEC23A Protein transport protein Sec23A ISGAIGPCVSLNSK 423 14.89% 19.64% -4.75% 
P45880 VDAC2 Voltage-dependent anion-selective channel protein WCEYGLTFTEK 76 4.76% 9.52% -4.76% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- VWNLANCK 182 12.47% 17.24% -4.77% 
Q15436 SEC23A Protein transport protein Sec23A 
GPC*VSENEIGTGGTC*
QWK 432 10.34% 15.30% -4.96% 
P62249 RPS16 40S ribosomal protein S16 TATAVAHCK 25 12.62% 17.62% -5.00% 
Q96GQ5 C16orf58 UPF0420 protein C16orf58 CIVSVAGGATR 201 9.28% 14.31% -5.03% 




190 83.12% 88.37% -5.25% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
YTVQDESHSEWVSCV
R 153 14.24% 19.60% -5.36% 
P27635 RPL10 60S ribosomal protein L10 LIPDGCGVK 195 11.53% 16.89% -5.37% 
P07814 EPRS Bifunctional glutamate/proline--tRNA ligase GSQFGQSC*C*LR 336 9.85% 15.24% -5.39% 
P27635 RPL10 60S ribosomal protein L10 MLSCAGADR 105 11.04% 16.48% -5.45% 
P15880 RPS2 40S ribosomal protein S2 GCTATLGNFAK 229 18.64% 24.11% -5.47% 
P50570 DNM2 Dynamin-2 CVDLVIQELINTVR 427 16.79% 22.28% -5.50% 
P32970 CD70 CD70 antigen LSFHQGCTIASQR 151 76.27% 81.84% -5.57% 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3 LLLCGGAPLSATTQR 450 11.47% 17.10% -5.63% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 VAGDCLDEK 131 18.48% 24.25% -5.77% 
Q15738 NSDHL Sterol-4-alpha-carboxylate 3-dehydrogenase, decarb FFLGDLCSR 86 7.79% 13.60% -5.82% 




61 8.83% 14.65% -5.82% 
Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protei 
VAAASGHCGAFSGSD
SSR 919 17.81% 23.70% -5.90% 
O60716 CTNND1 Catenin delta-1 SNAAAYLQHLCYR 394 7.07% 12.99% -5.92% 
Q9Y6I9 TEX264 Testis-expressed sequence 264 protein 
CAVGSILSEGEESPSPE
LIDLYQK 94 18.60% 24.52% -5.92% 
P26599 PTBP1 Polypyrimidine tract-binding protein 1 
LSLDGQNIYNAC*C*T
LR 250 18.59% 24.67% -6.08% 
P27635 RPL10 60S ribosomal protein L10 VDEFPLCGHMVSDEYEQLSSEALEAAR 49 39.13% 45.22% -6.09% 
Q01813 PFKP 6-phosphofructokinase type C NESC*SENYTTDFIYQLYSEEGKGVFDC*R 641 13.55% 19.65% -6.10% 
P42677 RPS27 40S ribosomal protein S27 LTEGCSFR 77 11.33% 17.53% -6.20% 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit HVLTGSADNSCR 76 20.13% 26.44% -6.30% 
Q6JUT2 TIRAP3 TIR domain-containing adapter molecule 2 FCFSNEFSTFTHK 0 74.43% 80.82% -6.38% 
P17980 PSMC3 26S protease regulatory subunit 6A C*TDDFNGAQC*K 387 19.39% 25.78% -6.40% 
P27708 CAD CAD protein ILALDCGLK 183 7.88% 14.43% -6.55% 
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Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 LQGATCNNNK 4570 6.43% 13.13% -6.69% 
P38606 ATP6V1A V-type proton ATPase catalytic subunit A FCPFYK 532 45.54% 52.55% -7.01% 
P27635 RPL10 60S ribosomal protein L10 SCGK 80 17.24% 24.29% -7.05% 
Q9H5V8 CDCP1 CUB domain-containing protein 1 ISFLCDDLTR 401 33.59% 40.78% -7.19% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X WCDK 128 7.05% 14.35% -7.30% 
Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protei 
VAQSIEDHHQEVIGFC
R 174 4.76% 12.07% -7.30% 
P62280 RPS11 40S ribosomal protein S11 DVQIGDIVTVGECR 131 18.26% 25.61% -7.35% 
P22307 SCP2 Non-specific lipid-transfer protein 
ALADAQIPYSAVDQA
C*VGYVFGDSTC*GQR 61 26.26% 33.70% -7.44% 
P09651 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 YHTVNGHNCEVR 175 6.89% 14.72% -7.83% 
Q15149 PLEC Plectin C*VEDPETGLC*LLPLTDK 3008 13.08% 20.94% -7.86% 
O00429 DNM1L Dynamin-1-like protein IIQHCSNYSTQELLR 446 4.76% 12.69% -7.92% 
P21964 COMT Catechol O-methyltransferase 
GTVLLADNVICPGAP
DFLAHVR 223 8.89% 16.85% -7.96% 
Q9ULV4 CORO1C Coronin-1C CEPIIMTVPR 343 25.49% 33.75% -8.25% 
P07602 PSAP Proactivator polypeptide HCLQTVWNK 48 36.71% 45.63% -8.92% 
P27816 MAP4 Microtubule-associated protein 4 CSLPAEEDSVLEK 635 25.08% 34.27% -9.19% 
Q8NFQ8 TOR1AIP2 Torsin-1A-interacting protein 2 
ISHLVLPVQPVSSIEEQ
GCLF 468 67.30% 76.68% -9.38% 
P41252 IARS Isoleucine--tRNA ligase, cytoplasmic  
DSLPVC*PVDASGC*FT
TEVTDFAGQYVK 350 16.42% 25.87% -9.45% 
O75369 FLNB Filamin-B SPFVVQVGEAC*NPNAC*R 450 10.49% 20.05% -9.55% 
P30530 AXL Tyrosine-protein kinase receptor UFO 
YVLCPSTTPSPAQPAD
R 869 60.31% 70.28% -9.97% 
P49207 RPL34 60S ribosomal protein L34 AYGGSMCAK 83 46.46% 56.54% -10.08% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 STCIYGGAPK 200 23.46% 33.73% -10.27% 
Q86V48 LUZP1 Leucine zipper protein 1 NDC*TQLC*LSLNEER 134 22.95% 33.38% -10.43% 
O96005 CLPTM1 Cleft lip and palate transmembrane protein 1 VSFCPLSLWR 308 73.58% 84.32% -10.74% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase ECVQPATK 997 15.60% 26.46% -10.86% 




201 54.35% 65.35% -11.01% 
P54136 RARS Arginine--tRNA ligase, cytoplasmic  
NC*GC*LGASPNLEQL
QEENLK 32 14.38% 25.41% -11.03% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 
SLPSVETLGC*TSVIC*S
DK 344 22.64% 33.71% -11.07% 
P04439 
HLA-A HLA class I 
histocompatibility antigen, A-3 
alpha  
AYLDGTCVEWLR 188 62.52% 73.59% -11.07% 
P04439 
HLA-A HLA class I 
histocompatibility antigen, A-3 
alpha  
AYLDGTCVEWLR 188 66.07% 77.16% -11.10% 





ACTYIR 72 82.81% 94.06% -11.25% 
Q00341 HDLBP Vigilin CDIIIISGR 948 13.30% 25.38% -12.08% 
O14964 HGS Hepatocyte growth factor-regulated tyrosine kinase VC*EPC*YEQLNR 212 36.99% 49.14% -12.15% 
Q8WVT3 TRAPPC12 Trafficking protein particle complex subunit 12 
PEQEPPVAEPVPVCTIF
SQR 160 5.44% 17.70% -12.27% 
P63010 AP2B1 AP-2 complex subunit beta YESIIATLCENLDSLDEPDAR 433 5.92% 18.20% -12.28% 
P61513 RPL37A 60S ribosomal protein L37a YTC*SFC*GK 39 27.36% 39.96% -12.61% 
Q8N2K0 ABHD12 Monoacylglycerol lipase ABHD12 
C*AAAGSSSSGSAAAA
LDADC*R 15 35.20% 48.19% -12.99% 
Q8NFQ8 TOR1AIP2 Torsin-1A-interacting protein 2 CLSHHVADAYTSSQK 310 67.02% 80.43% -13.40% 
P11216 PYGB Glycogen phosphorylase, brain form  TCFETFPDK 326 13.99% 27.39% -13.40% 
P54764 EPHA4 Ephrin type-A receptor 4 VIGVGEFGEVCSGR 636 27.19% 40.91% -13.73% 
P06733 ENO1 Alpha-enolase TGAPCR 399 12.80% 26.93% -14.13% 
P18031 PTPN1 Tyrosine-protein phosphatase non-receptor type 1 DCPIK 344 14.90% 29.36% -14.46% 
	 302	
P07237 P4HB Protein disulfide-isomerase EECPAVR 312 16.58% 31.17% -14.59% 
Q12907 LMAN2 Vesicular integral-membrane protein VIP36 WTELAGCTADFR 202 71.64% 87.45% -15.81% 
O75084 FZD7 Frizzled-7 VQCSPELR 94 14.46% 30.58% -16.12% 
Q9UI14 RABAC1 Prenylated Rab acceptor protein 1 NLGELCQR 64 17.83% 33.97% -16.14% 
Q15005 SPCS2 Signal peptidase complex subunit 2 
SGGSGGC*SGAGGAS
NC*GTGSGR 17 59.71% 76.15% -16.43% 
O95159 ZFPL1 Zinc finger protein-like 1 VTNLFCFEHR 16 19.95% 36.41% -16.46% 
Q8N5B7 CERS5 Ceramide synthase 5 SPCDSSSSNGANR 369 63.39% 80.50% -17.11% 
P08238 HSP90AB1 Heat shock protein HSP 90-beta CLELFSELAEDK 412 8.99% 26.60% -17.61% 
Q9UGP8 SEC63 Translocation protein SEC63 homolog NEPPLTCPYSLK 295 20.07% 37.74% -17.67% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 ILYLDSSEIC*FPTVPGC*PGAWDVDSENPQR 604 17.39% 37.35% -19.96% 
Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3 YFSLPFCVGSK 66 66.88% 88.24% -21.36% 
Q9NP72 RAB18 Ras-related protein Rab-18 TC*DGVQC*AFEELVEK 155 16.81% 39.55% -22.74% 
Q8NCG7 DAGLB Sn1-specific diacylglycerol lipase beta 
AAC*VSC*PAQGVSSV
DVA 658 49.19% 73.76% -24.57% 
O75369 FLNB Filamin-B APSVATVGSICDLNLK 2115 22.34% 50.74% -28.40% 
P32969 RPL9P9 60S ribosomal protein L9 PGVACSVSQAQK 134 10.68% 40.61% -29.93% 
Q7Z6Z7 HUWE1 E3 ubiquitin-protein ligase HUWE1 TPTEAPADCR 19 29.39% 64.80% -35.41% 
P55145 MANF Mesencephalic astrocyte-derived neurotrophic facto DSQICELK 117 59.16% 94.63% -35.47% 
P10586 PTPRF Receptor-type tyrosine-protein phosphatase F CDQYWPAR 1460 4.76% 41.64% -36.88% 
P08238 HSP90AB1 Heat shock protein HSP 90-beta FENLCK 564 5.24% 42.36% -37.12% 
P07237 P4HB Protein disulfide-isomerase ITEFCHR 343 15.52% 53.37% -37.84% 
 
Table 3A-5. Filtered list of cysteine-containing peptides from secretory proteins 
identified in OxICAT analyses of WT and PDIA4KO isolated ER. Each treatment 
was performed in triplicate and the data was filtered for peptides with ratios found 
in at least two of the replicates per treatment. Furthermore, the data was reduced 
to only peptides that displayed a statistically significant (p <0.05, unpaired t tests) 
difference in cysteine oxidation states. Data is displayed as percent oxidized and 
the average difference in percent oxidation (WT – PDIA4KO). Localization of 
proteins was determined using Uniprot and GO annotated tabs on UniprotKB. 
Uniprot 
ID Protein Description Peptide Sequence Residue 
Percent Oxidized Difference 
(WT - 
PDIA4KO) WT PDIA4KO 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2 VCYGLGMEHLR 342 89.03% 23.56% 65.47% 
P17858 PFKL 6-phosphofructokinase, liver type  VFANAPDSACVIGLK 708 50.29% 4.76% 45.52% 
Q14573 ITPR3 Inositol 1,4,5-trisphosphate receptor type 3  FCAGNPGNQALLHK 1236 59.74% 19.51% 40.22% 
Q9P273 ODZ3 Teneurin-3 PYCSLTK 10 80.45% 41.62% 38.83% 
P48449 LSS Lanosterol synthase DGTACAEVSR 609 43.36% 6.53% 36.83% 
Q9H7M9 C10orf54 Platelet receptor Gi24 GEVQTCSER 83 43.36% 6.54% 36.81% 
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Q9Y5R8 TRAPPC1 Trafficking protein particle complex subunit 1 NPLCPLGQTVQSELFR 115 38.32% 4.76% 33.55% 
Q96A65 EXOC4 Exocyst complex component 4 FVCK 489 39.88% 6.60% 33.28% 
Q9BUF5 TUBB6 Tubulin beta-6 chain EIVHIQAGQCGNQIGTK 12 38.48% 7.18% 31.30% 
P07858 CTSB Cathepsin B ICEPGYSPTYK 211 87.43% 56.52% 30.91% 
Q6PIU2 NCEH1 Neutral cholesterol ester hydrolase 1 TYILTCEHDVLR 345 47.65% 22.21% 25.44% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al DGGVQACFSR 139 24.35% 3.36% 20.99% 
Q96AC1 FERMT2 Fermitin family homolog 2 GCEVTPDVNISGQK 426 33.76% 13.55% 20.22% 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta DTQTSITDSCAVYR 100 39.48% 19.33% 20.15% 
Q9NR12 PDLIM7 PDZ and LIM domain protein 7 GAIFC*PPC*YDVR 329 41.91% 22.82% 19.10% 
Q99943 AGPAT1 1-acyl-sn-glycerol-3-phosphate acyltransferase alp FTSGQCQVR 229 27.69% 8.82% 18.87% 
Q15149 PLEC Plectin LECLQR 530 22.90% 6.28% 16.61% 
P14625 HSP90B1 Endoplasmin LTESPCALVASQYGWSGNMER 645 19.93% 4.76% 15.16% 
O75165 DNAJC13 DnaJ homolog subfamily C member 13 ADTVGLACEAINR 2110 18.22% 4.76% 13.45% 
Q13308 PTK7 Inactive tyrosine-protein kinase 7 LPQPEGCPSK 1032 25.10% 11.90% 13.20% 
P11766 ADH5 Alcohol dehydrogenase class-3 AGDTVIPLYIPQC*GEC*K 97 33.93% 20.79% 13.13% 
O43402 EMC8 ER membrane protein complex subunit 8 YPHCAVNGLLVAEK 24 40.23% 27.31% 12.92% 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  VGVDYEGGGCR 680 70.14% 57.83% 12.31% 
O15533 TAPBP Tapasin WASGLTPAQNCPR 115 26.89% 14.57% 12.31% 
Q14571 ITPR2 Inositol 1,4,5-trisphosphate receptor type 2  TTC*FIC*GLER 2562 27.30% 15.11% 12.20% 
P21333 FLNA Filamin-A VTYCPTEPGNYIINIK 2107 28.37% 16.28% 12.09% 
Q32P28 LEPRE1 Prolyl 3-hydroxylase 1 TVTAEVQPQCGR 645 84.76% 72.70% 12.06% 
P00558 PGK1 Phosphoglycerate kinase 1 DCVGPEVEK 99 24.29% 12.36% 11.93% 
P21291 CSRP1 Cysteine and glycine-rich protein 1 CSQAVYAAEK 122 37.77% 26.04% 11.73% 
O95159 ZFPL1 Zinc finger protein-like 1 LCNIPLASR 56 51.53% 39.90% 11.63% 
P14625 HSP90B1 Endoplasmin GYEVIYLTEPVDEYCIQALPEFDGK 576 23.56% 12.31% 11.26% 
P61011 SRP54 Signal recognition particle 54 kDa protein TC*LIC*ADTFR 133 26.05% 14.80% 11.25% 
P60174 TPI1 Triosephosphate isomerase VPADTEVVCAPPTAYIDFAR 79 23.22% 12.47% 10.76% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) LFVSGACDASAK 204 19.68% 9.05% 10.63% 
P27348 YWHAQ 14-3-3 protein theta YLAEVACGDDR 134 17.88% 7.54% 10.35% 
P04222 HLA-C HLA class I histocompatibility antigen, Cw-3 alpha 
GGSC*SQAASSNSAQGS
DESLIAC*K 345 53.64% 43.38% 10.26% 
O75369 FLNB Filamin-B CLATGPGIASTVK 1617 22.16% 12.07% 10.09% 
Q15942 ZYX Zyxin C*SVC*SEPIMPEPGR 504 34.99% 24.92% 10.08% 
P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2 
YSEDPTVPLPSETDGYVA
PLTCSPQPEYVNQPDVR 1133 24.80% 15.02% 9.79% 
Q9HCU5 PREB Prolactin regulatory element-binding protein CGAETQHEGLELR 128 21.63% 11.92% 9.71% 
P15311 EZR Ezrin EGILSDEIYCPPETAVLLGSYAVQAK 117 18.86% 9.46% 9.39% 
Q8NBJ5 GLT25D1 Procollagen galactosyltransferase 1 ALQAQEIECR 369 41.96% 32.83% 9.14% 
O00592 PODXL Podocalyxin CEDLETQTQSEK 344 86.64% 77.53% 9.11% 
P01891 HLA-A HLA class I histocompatibility antigen, A-68 alpha 
GGSYSQAASSDSAQGSD
VSLTACK 363 30.47% 21.36% 9.11% 
P62753 RPS6 40S ribosomal protein S6 LNISFPATGCQK 12 19.33% 10.27% 9.07% 
O15460 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 PCGSTEVD 529 54.01% 44.99% 9.02% 
Q99497 PARK7 Protein DJ-1 DVVICPDASLEDAK 53 30.11% 21.23% 8.88% 
P35998 PSMC2 26S protease regulatory subunit 7 LCPNSTGAEIR 377 42.15% 33.28% 8.87% 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 PCTLSELE 528 51.53% 42.68% 8.85% 
P30101 PDIA3 Protein disulfide-isomerase A3 FIQENIFGICPHMTEDNK 244 29.17% 20.36% 8.81% 
P50914 RPL14 60S ribosomal protein L14 ALVDGPCTQVR 42 23.52% 14.72% 8.80% 
Q15149 PLEC Plectin LLEAQACTGGIIDPSTGER 4454 13.20% 4.53% 8.67% 
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P32970 CD70 CD70 antigen LSFHQGCTIASQR 151 76.27% 67.68% 8.60% 
P60174 TPI1 Triosephosphate isomerase IIYGGSVTGATCK 255 16.34% 7.82% 8.52% 
P61158 ACTR3 Actin-related protein 3 LPAC*VVDC*GTGYTK 8 33.02% 24.87% 8.15% 
P01891 HLA-A HLA class I histocompatibility antigen, A-68 alpha 
GGSYSQAASSDSAQGSD
VSLTACK 363 28.33% 20.65% 7.68% 
O60884 DNAJA2 DnaJ homolog subfamily A member 2 NVLC*SAC*SGQGGK 143 35.00% 27.48% 7.52% 
Q13162 PRDX4 Peroxiredoxin-4 SINTEVVACSVDSQFTHLAWINTPR 148 25.75% 18.39% 7.36% 
P27797 CALR Calreticulin CKDDEFTHLYTLIVRPDNTYEVK 163 46.89% 39.55% 7.34% 
P00558 PGK1 Phosphoglycerate kinase 1 ACANPAAGSVILLENLR 108 22.66% 15.34% 7.32% 
Q9Y4L1 HYOU1 Hypoxia up-regulated protein 1 VEFEELCADLFER 352 19.20% 11.93% 7.27% 
P60763 RAC3 Ras-related C3 botulinum toxin substrate 3 AVLCPPPVK 178 15.57% 8.31% 7.25% 
O14964 HGS Hepatocyte growth factor-regulated tyrosine kinase VC*EPC*YEQLNR 212 36.99% 29.76% 7.23% 
Q8NBJ7 SUMF2 Sulfatase-modifying factor 2 CAADAGR 290 77.85% 70.64% 7.21% 
P26599 PTBP1 Polypyrimidine tract-binding protein 1 LSLDGQNIYNAC*C*TLR 250 18.59% 11.53% 7.06% 
P30530 AXL Tyrosine-protein kinase receptor UFO DSC*SC*LTAAEVHPAGR 852 38.02% 30.95% 7.06% 
P67870 CSNK2B Casein kinase II subunit beta YQQGDFGYCPR 109 17.93% 11.04% 6.89% 
P61158 ACTR3 Actin-related protein 3 DYEEIGPSICR 408 24.54% 17.66% 6.88% 
P68366 TUBA4A Tubulin alpha-4A chain AYHEQLSVAEITNACFEPANQMVK 295 29.15% 22.34% 6.81% 
Q15286 RAB35 Ras-related protein Rab-35 WLHEINQNC*DDVC*R 110 19.54% 12.80% 6.73% 
P07099 EPHX1 Epoxide hydrolase 1 NHGLSDEHVFEVICPSIPGYGFSEASSK 182 19.97% 13.29% 6.67% 
Q14151 SAFB2 Scaffold attachment factor B2 ILDILGETCK 224 18.40% 11.74% 6.66% 
Q13642 FHL1 Four and a half LIM domains protein 1 FWHDTCFR 65 41.29% 34.67% 6.62% 
Q8NHP6 MOSPD2 Motile sperm domain-containing protein 2 TSEDICLQLSR 471 32.34% 25.76% 6.58% 
Q9Y217 MTMR6 Myotubularin-related protein 6 TSQVCSLGSLLLDSYYR 347 11.73% 5.23% 6.50% 
Q8NFQ8 TOR1AIP2 Torsin-1A-interacting protein 2 
ISHLVLPVQPVSSIEEQG
CLF 468 67.30% 60.97% 6.33% 
P67936 TPM4 Tropomyosin alpha-4 chain EENVGLHQTLDQTLNELNCI 247 35.85% 29.52% 6.33% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 IEEFLEEVLCPPK 100 13.38% 7.21% 6.17% 
P09496 CLTA Clathrin light chain A LCDFNPK 218 11.01% 4.87% 6.15% 
Q9Y696 CLIC4 Chloride intracellular channel protein 4 DEFTNTCPSDK 234 14.00% 7.90% 6.10% 
P61077 UBE2D3 Ubiquitin-conjugating enzyme E2 D3 
VLLSIC*SLLC*DPNPDDP
LVPEIAR 107 14.71% 8.61% 6.10% 
Q99497 PARK7 Protein DJ-1 DPVQCSR 46 23.74% 17.69% 6.06% 
Q14694 USP10 Ubiquitin carboxyl-terminal hydrolase 10 
TAGQPEGGPGADFGQS
CFPAEAGR 254 36.94% 30.97% 5.97% 
Q16643 DBN1 Drebrin PPEIDITCWDADPVPEEEEGFEGGD 632 25.89% 20.05% 5.84% 
P21333 FLNA Filamin-A ALGALVDSC*APGLC*PDWDSWDASK 205 21.54% 15.86% 5.68% 
Q07020 RPL18 60S ribosomal protein L18 GCGTVLLSGPR 134 18.45% 12.77% 5.68% 
P55735 SEC13 Protein SEC13 homolog FASGGCDNLIK 187 13.44% 7.76% 5.67% 
P21291 CSRP1 Cysteine and glycine-rich protein 1 DGEIYCK 167 37.57% 31.91% 5.66% 
Q92520 FAM3C Protein FAM3C DNWVFCGGK 185 23.32% 17.69% 5.63% 
P17858 PFKL 6-phosphofructokinase, liver type  
AAAYNLVQHGITNLCVI
GGDGSLTGANIFR 114 16.07% 10.53% 5.54% 
Q9UBB4 ATXN10 Ataxin-10 DPSQVENLASSLQLITECFR 84 12.54% 7.03% 5.51% 
P14618 PKM Pyruvate kinase isozymes M1/M2 PVICATQMLESMIK 326 13.14% 7.72% 5.43% 
Q9Y3I0 C22orf28 tRNA-splicing ligase RtcB homolog EHCEEYGR 193 13.85% 8.45% 5.40% 
Q02809 PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  FWTFETGC*TVC*DEGLR 267 88.38% 83.05% 5.33% 
P07900 HSP90AA1 Heat shock protein HSP 90-alpha CLELFTELAEDK 420 10.23% 4.97% 5.27% 
P18669 PGAM1 Phosphoglycerate mutase 1 YADLTEDQLPSCESLK 153 12.08% 6.82% 5.25% 
P07858 CTSB Cathepsin B GQDHCGIESEVVAGIPR 319 34.56% 29.33% 5.23% 
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Q16658 FSCN1 Fascin QIWTLEQPPDEAGSAAVCLR 61 16.64% 11.49% 5.16% 
P09382 LGALS1 Galectin-1 FNAHGDANTIVCNSK 61 21.39% 16.28% 5.11% 
P21333 FLNA Filamin-A AEISC*TDNQDGTC*SVSYLPVLPGDYSILVK 1912 15.34% 10.39% 4.95% 
P05388 RPLP0 60S acidic ribosomal protein P0 AGAIAPCEVTVPAQNTGLGPEK 119 16.68% 11.73% 4.94% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
ACGDSTLTQITAGLDPV
GR 25 15.11% 10.33% 4.78% 
O00469 PLOD2 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2  
IFTENIVEQPCPDVFWFP
IFSEK 562 49.29% 44.67% 4.62% 
P61158 ACTR3 Actin-related protein 3 LGYAGNTEPQFIIPSCIAIK 34 13.83% 9.22% 4.61% 
Q06210 GFPT1 Glucosamine--fructose-6-phosphate aminotransferase CQNALQQVVAR 620 9.94% 5.36% 4.58% 
Q9Y3I0 C22orf28 tRNA-splicing ligase RtcB homolog NCWR 19 7.92% 3.38% 4.54% 
P13639 EEF2 Elongation factor 2 VTDGALVVVDC*VSGVC*VQTETVLR 131 29.98% 25.47% 4.52% 
P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma cat 
TFTDC*FNC*LPIAAIVDE
K 155 17.51% 13.01% 4.50% 
P14618 PKM Pyruvate kinase isozymes M1/M2 
AEGSDVANAVLDGADC
IMLSGETAK 358 17.05% 12.62% 4.43% 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A ITIADCGQLE 161 22.83% 18.41% 4.42% 
Q16658 FSCN1 Fascin DGNVTCER 80 18.35% 13.94% 4.41% 
P55735 SEC13 Protein SEC13 homolog VFIWTCDDASSNTWSPK 245 13.79% 9.40% 4.39% 
O75935 DCTN3 Dynactin subunit 3 QFVQWDELLCQLEAATQVK 173 13.06% 8.68% 4.38% 
P27816 MAP4 Microtubule-associated protein 4 
NVCLPPEMEVALTEDQ
VPALK 535 15.45% 11.11% 4.34% 
O75369 FLNB Filamin-B ALGALVDSC*APGLC*PDWESWDPQK 178 22.34% 18.06% 4.28% 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase IISNASC*TTNC*LAPLAK 152 29.78% 25.52% 4.26% 
Q9NZB2 FAM120A Constitutive coactivator of PPAR-gamma-like protei 
VAAASGHCGAFSGSDSS
R 919 17.81% 13.55% 4.26% 
P27635 RPL10 60S ribosomal protein L10 VDEFPLCGHMVSDEYEQLSSEALEAAR 49 39.36% 35.13% 4.23% 
P21333 FLNA Filamin-A ATCAPQHGAPGPGPADASK 2543 16.50% 12.34% 4.16% 
P17987 TCP1 T-complex protein 1 subunit alpha ICDDELILIK 357 13.46% 9.35% 4.11% 
P35579 MYH9 Myosin-9 QELEEICHDLEAR 917 10.52% 6.43% 4.09% 
Q9ULV4 CORO1C Coronin-1C NDQCYDDIR 23 11.89% 7.86% 4.04% 
P09486 SPARC SPARC YIPPCLDSELTEFPLR 155 84.70% 80.71% 3.99% 
P08670 VIM Vimentin QVQSLTCEVDALK 328 11.70% 7.74% 3.96% 
P07195 LDHB L-lactate dehydrogenase B chain ITVVGVGQVGMACAISILGK 36 8.75% 4.81% 3.94% 
Q01518 CAP1 Adenylyl cyclase-associated protein 1 TDGCHAYLSK 416 15.53% 11.60% 3.93% 
P60228 EIF3E Eukaryotic translation initiation factor 3 subunit LFIFETFCR 345 9.38% 5.47% 3.91% 
Q86V48 LUZP1 Leucine zipper protein 1 NDC*TQLC*LSLNEER 134 22.95% 19.12% 3.83% 
P55735 SEC13 Protein SEC13 homolog LATCSSDR 31 14.22% 10.44% 3.79% 
A1L0T0 ILVBL Acetolactate synthase-like protein PLCK 173 12.39% 8.62% 3.77% 
P09382 LGALS1 Galectin-1 DSNNLCLHFNPR 43 17.80% 14.07% 3.73% 
P30530 AXL Tyrosine-protein kinase receptor UFO YVLCPSTTPSPAQPADR 869 60.31% 56.62% 3.69% 
Q7Z7H5 TMED4 Transmembrane emp24 domain-containing protein 4 CFIEEIPDETMVIGNYR 41 85.98% 82.29% 3.69% 
P09758 TACSTD2 Tumor-associated calcium signal transducer 2 
PSEHALVDNDGLYDPD
CDPEGR 108 93.84% 90.19% 3.65% 
P07947 YES1 Tyrosine-protein kinase Yes PENTPEPVSTSVSHYGAEPTTVSPCPSSSAK 42 18.72% 15.13% 3.59% 
P61981 YWHAG 14-3-3 protein gamma NCSETQYESK 112 10.26% 6.74% 3.52% 
Q15436 SEC23A Protein transport protein Sec23A 
GPC*VSENEIGTGGTC*Q
WK 432 10.34% 6.83% 3.51% 
Q92544 TM9SF4 Transmembrane 9 superfamily member 4 TQLPYEYYSLPFCQPSK 64 95.24% 91.79% 3.45% 
Q15436 SEC23A Protein transport protein Sec23A AVLNPLCQVDYR 74 14.19% 10.75% 3.45% 
Q9UL25 RAB21 Ras-related protein Rab-21 GIEELFLDLCK 177 7.99% 4.56% 3.43% 
P21333 FLNA Filamin-A SPYTVTVGQAC*NPSAC*R 478 8.29% 4.89% 3.40% 
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P51149 RAB7A Ras-related protein Rab-7a GADC*C*VLVFDVTAPNTFK 83 14.38% 10.98% 3.40% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al 
SPLTIC*YPEYTGSNTYEE
AAAYIQC*QFEDLNR 286 8.90% 5.50% 3.40% 
P21333 FLNA Filamin-A SSFTVDCSK 2582 17.89% 14.50% 3.39% 
P21333 FLNA Filamin-A IEC*DDKGDGSC*DVR 623 16.24% 12.92% 3.31% 
O94979 SEC31A Protein transport protein Sec31A SCATFSSSHR 60 10.22% 6.97% 3.26% 
O60361 NME2P1 Putative nucleoside diphosphate kinase SCAHDWVYE 130 15.56% 12.31% 3.25% 
O00264 PGRMC1 Membrane-associated progesterone receptor componen GLATFCLDK 129 8.97% 5.73% 3.24% 
P11940 PABPC1 Polyadenylate-binding protein 1 ALYDTFSAFGNILSCK 128 15.50% 12.27% 3.23% 
P27797 CALR Calreticulin HEQNIDCGGGYVK 105 72.84% 69.63% 3.21% 
P07947 YES1 Tyrosine-protein kinase Yes LTTVCPTVK 255 12.17% 9.04% 3.12% 
P21333 FLNA Filamin-A TPCEEILVK 2601 13.74% 10.69% 3.05% 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 TPADCPVIAIDSFR 318 87.68% 84.64% 3.03% 
O96005 CLPTM1 Cleft lip and palate transmembrane protein 1 VSFCPLSLWR 308 73.58% 70.57% 3.01% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al IIHEDGYSEEECR 66 9.08% 6.11% 2.97% 
Q9Y6W5 WASF2 Wiskott-Aldrich syndrome protein family member 2 SELECVTNITLANVIR 27 10.25% 7.30% 2.95% 
P08134 RHOC Rho-related GTP-binding protein RhoC TCLLIVFSK 20 9.99% 7.08% 2.91% 




1353 16.80% 13.92% 2.88% 
P62820 RAB1A Ras-related protein Rab-1A CDLTTK 126 8.06% 5.18% 2.87% 
P12814 ACTN1 Alpha-actinin-1 ICDQWDNLGALTQK 480 9.04% 6.18% 2.87% 
Q14764 MVP Major vault protein HYCTVANPVSR 59 7.90% 5.07% 2.84% 
P18124 RPL7 60S ribosomal protein L7 YGIICMEDLIHEIYTVGK 186 8.15% 5.33% 2.82% 
Q96HE7 ERO1L ERO1-like protein alpha HDDSSDNFCEADDIQSPEAEYVDLLLNPER 166 26.22% 23.44% 2.78% 
P60709 ACTB Actin, cytoplasmic 1  CDVDIR 285 10.63% 7.86% 2.77% 
Q9H299 SH3BGRL3 SH3 domain-binding glutamic acid-rich-like protein 
ATPPQIVNGDQYCGDYE
LFVEAVEQNTLQEFLK 71 17.03% 14.28% 2.75% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al 
QLFALSCTAEEQGVLPD
DLSGVIR 112 11.68% 8.99% 2.68% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) TFVSGACDASIK 204 14.53% 11.85% 2.68% 
P62873 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
ACADATLSQITNNIDPV
GR 25 7.82% 5.15% 2.68% 
Q13162 PRDX4 Peroxiredoxin-4 EEECHFYAGGQVYPGEASR 51 83.24% 80.58% 2.66% 
P00533 EGFR Epidermal growth factor receptor 
TPLLSSLSATSNNSTVAC
IDR 1049 53.05% 50.41% 2.64% 
P14174 MIF Macrophage migration inhibitory factor LLCGLLAER 81 9.48% 6.86% 2.61% 
Q15149 PLEC Plectin GCLDEETSR 3299 13.03% 10.42% 2.60% 
Q9NZN4 EHD2 EH domain-containing protein 2 FMCAQLPNQVLESISIIDTPGILSGAK 138 10.56% 7.99% 2.57% 
O00299 CLIC1 Chloride intracellular channel protein 1 IGNCPFSQR 24 7.12% 4.56% 2.56% 
P40227 CCT6A T-complex protein 1 subunit zeta 
NAIDDGCVVPGAGAVE
VAMAEALIK 406 7.61% 5.09% 2.52% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
TNHIGHTGYLNTVTVSP
DGSLCASGGK 207 16.73% 14.23% 2.50% 
P23396 RPS3 40S ribosomal protein S3 GCEVVVSGK 134 7.28% 4.80% 2.49% 
O95292 VAPB Vesicle-associated membrane protein-associated pro CVFELPAENDK 121 7.23% 4.78% 2.46% 
P00338 LDHA L-lactate dehydrogenase A chain VIGSGCNLDSAR 163 12.01% 9.59% 2.42% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 LGTQTFCSR 370 6.98% 4.62% 2.37% 
P62906 RPL10A 60S ribosomal protein L10a FSVC*VLGDQQHC*DEAK 66 18.90% 16.54% 2.36% 
P62888 RPL30 60S ribosomal protein L30 VCTLAIIDPGDSDIIR 92 14.00% 11.66% 2.34% 
Q9HCU5 PREB Prolactin regulatory element-binding protein 
QPPPCYLTAWDGSNFLP
LR 280 17.10% 14.77% 2.33% 
P21333 FLNA Filamin-A LQVEPAVDTSGVQCYGPGIEGQGVFR 1260 13.83% 11.52% 2.30% 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 VDCDQHSDIAQR 92 20.05% 17.83% 2.22% 
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P68366 TUBA4A Tubulin alpha-4A chain SIQFVDWCPTGFK 347 10.48% 8.30% 2.17% 
P61224 RAP1B Ras-related protein Rap-1b QWNNCAFLESSAK 141 7.10% 4.94% 2.17% 
P15153 RAC2 Ras-related C3 botulinum toxin substrate 2 CVVVGDGAVGK 6 7.25% 5.13% 2.11% 
P07437 TUBB Tubulin beta chain TAVCDIPPR 354 10.31% 8.20% 2.11% 
P62888 RPL30 60S ribosomal protein L30 LVILANNCPALR 52 8.20% 6.15% 2.05% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al EIYTHFTCATDTK 326 10.66% 8.61% 2.04% 
P61981 YWHAG 14-3-3 protein gamma ELEAVCQDVLSLLDNYLIK 97 6.03% 3.99% 2.04% 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al IIHEDGYSEDECK 66 8.79% 6.78% 2.02% 
P62330 ARF6 ADP-ribosylation factor 6 NWYVQPSCATSGDGLYEGLTWLTSNYK 155 11.60% 9.62% 1.98% 
P68366 TUBA4A Tubulin alpha-4A chain AVCMLSNTTAIAEAWAR 376 11.44% 9.46% 1.97% 
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B DVIIADCGK 202 13.11% 11.14% 1.97% 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al DCGLF 352 11.06% 9.11% 1.94% 
P68104 EEF1A1 Elongation factor 1-alpha 1 DGNASGTTLLEALDCILPPTR 234 7.35% 5.42% 1.93% 
P05388 RPLP0 60S acidic ribosomal protein P0 NVASVCLQIGYPTVASVPHSIINGYK 226 7.98% 6.08% 1.91% 




201 10.70% 8.80% 1.90% 
P05388 RPLP0 60S acidic ribosomal protein P0 CFIVGADNVGSK 27 7.94% 6.05% 1.89% 
P62879 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
QTFIGHESDINAVAFFPN
GYAFTTGSDDATCR 250 9.56% 7.70% 1.86% 
P00338 LDHA L-lactate dehydrogenase A chain 
DDVFLSVPCILGQNGISD
LVK 293 6.49% 4.66% 1.83% 
Q96DX4 RSPRY1 RING finger and SPRY domain-containing protein 1 
VIPLEDPLGPAVITLLLD
ECPLPTK 167 7.43% 5.61% 1.82% 
P46776 RPL27A 60S ribosomal protein L27a NQSFCPTVNLDK 70 10.66% 8.86% 1.80% 
Q15149 PLEC Plectin CRPDQLTGLSLLPLSEK 3336 5.92% 4.15% 1.77% 
P09211 GSTP1 Glutathione S-transferase P ASCLYGQLPK 48 5.90% 4.15% 1.75% 
P30101 PDIA3 Protein disulfide-isomerase A3 VDC*TANTNTC*NK 85 84.35% 82.62% 1.73% 
Q9NP72 RAB18 Ras-related protein Rab-18 LDNWLNELETYCTR 110 6.32% 4.61% 1.72% 
P15153 RAC2 Ras-related C3 botulinum toxin substrate 2 YLECSALTQR 157 5.48% 3.84% 1.64% 
Q99832 CCT7 T-complex protein 1 subunit eta INALTAASEAACLIVSVDETIK 511 8.23% 6.60% 1.64% 
O95487 SEC24B Protein transport protein Sec24B CTLTNIPQTQALLNK 562 9.87% 8.26% 1.61% 
P13674 P4HA1 Prolyl 4-hydroxylase subunit alpha-1 SFLTAEDCFELGK 167 8.08% 6.47% 1.61% 
P62249 RPS16 40S ribosomal protein S16 TATAVAHCK 25 12.62% 11.02% 1.60% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 GEGTGVLGSLSLPLSELLVADQLCLDR 890 5.61% 4.02% 1.59% 
Q12904 AIMP1 Aminoacyl tRNA synthase complex-interacting multif MVILLCNLK 211 6.99% 5.42% 1.57% 
P04075 ALDOA Fructose-bisphosphate aldolase A 
YASICQQNGIVPIVEPEIL
PDGDHDLK 178 7.88% 6.31% 1.57% 
P15880 RPS2 40S ribosomal protein S2 GCTATLGNFAK 229 18.64% 17.10% 1.54% 
Q00610 CLTC Clathrin heavy chain 1 IHEGCEEPATHNALAK 870 7.29% 5.79% 1.51% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X 
GADSLEDFLYHEGYACT
SIHGDR 468 15.82% 14.34% 1.48% 
Q9UHG3 PCYOX1 Prenylcysteine oxidase 1 LVCSGLLQASK 258 5.93% 4.48% 1.45% 
P17987 TCP1 T-complex protein 1 subunit alpha DCLINAAK 147 6.28% 4.83% 1.45% 
P50570 DNM2 Dynamin-2 CVDLVIQELINTVR 427 16.79% 15.34% 1.45% 
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha LIIVEGCQR 705 6.60% 5.18% 1.42% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
AEPPQCTSLAWSADGQ
TLFAGYTDNLVR 286 14.75% 13.33% 1.42% 
P07355 ANXA2 Annexin A2 GLGTDEDSLIEIICSR 133 6.87% 5.51% 1.36% 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit HVLTGSADNSCR 76 20.13% 18.78% 1.36% 
P49257 LMAN1 Protein ERGIC-53 NNPAIVIIGNNGQIHYDHQNDGASQALASCQR 190 83.12% 81.79% 1.33% 
P21964 COMT Catechol O-methyltransferase LITIEINPDCAAITQR 145 9.06% 7.73% 1.33% 
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Q9Y490 TLN1 Talin-1 VVAPTISSPVCQEQLVEAGR 732 5.49% 4.21% 1.28% 
P08195 SLC3A2 4F2 cell-surface antigen heavy chain WCSWSLSQAR 431 5.11% 3.84% 1.28% 
Q14697 GANAB Neutral alpha-glucosidase AB TC*EESSFC*K 41 90.24% 88.99% 1.25% 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase VPTANVSVVDLTCR 247 6.25% 5.08% 1.18% 
P06733 ENO1 Alpha-enolase SGETEDTFIADLVVGLCTGQIK 389 13.89% 12.82% 1.07% 
P27635 RPL10 60S ribosomal protein L10 LIPDGCGVK 195 11.53% 10.46% 1.07% 
P29317 EPHA2 Ephrin type-A receptor 2 NILVNSNLVCK 753 5.27% 4.21% 1.06% 
P50914 RPL14 60S ribosomal protein L14 CMQLTDFILK 54 10.46% 9.53% 0.93% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 ATILDLSCNK 48 6.93% 6.01% 0.92% 
P60709 ACTB Actin, cytoplasmic 1  LCYVALDFEQEMATAASSSSLEK 217 7.28% 6.38% 0.90% 
P42677 RPS27 40S ribosomal protein S27 LTEGCSFR 77 11.59% 10.85% 0.74% 
Q6DD88 ATL3 Atlastin-3 ELYENFCK 429 5.67% 5.02% 0.65% 
O00571 DDX3X ATP-dependent RNA helicase DDX3X GCHLLVATPGR 317 6.92% 6.38% 0.54% 
P53992 SEC24C Protein transport protein Sec24C LLPVYLNCVLK 910 4.81% 4.30% 0.51% 
P0CW22 RPS17L 40S ribosomal protein S17-like VCEEIAIIPSK 35 7.03% 6.56% 0.47% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- VWNLANCK 182 12.47% 13.25% -0.78% 
P63010 AP2B1 AP-2 complex subunit beta TAAVCVAK 144 8.20% 9.32% -1.13% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase ANACNSVIK 471 7.16% 8.63% -1.47% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- YWLCAATGPSIK 249 9.91% 11.43% -1.52% 
Q9Y6I9 TEX264 Testis-expressed sequence 264 protein 
CAVGSILSEGEESPSPELI
DLYQK 94 18.60% 20.14% -1.55% 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 GDGPICLVLAPTR 170 6.30% 8.32% -2.02% 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 LQGATCNNNK 4570 6.43% 8.48% -2.05% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase VGEATETALTCLVEK 447 5.73% 7.95% -2.21% 
Q8N2G8 GHDC GH3 domain-containing protein VVGAYNQCPVVR 377 42.83% 45.05% -2.22% 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 
VDC*TAHSDVC*SAQGV
R 121 85.80% 88.21% -2.41% 
P63244 GNB2L1 Guanine nucleotide-binding protein subunit beta-2- 
HLYTLDGGDIINALCFSP
NR 240 7.34% 9.78% -2.45% 
P36578 RPL4 60S ribosomal protein L4 SGQGAFGNMCR 96 10.22% 12.69% -2.47% 
Q8NBS9 TXNDC5 Thioredoxin domain-containing protein 5 
VDC*TQHYELC*SGNQV
R 247 88.88% 91.59% -2.71% 
O00429 DNM1L Dynamin-1-like protein IIQHCSNYSTQELLR 446 4.76% 7.68% -2.92% 
Q15005 SPCS2 Signal peptidase complex subunit 2 
SGGSGGC*SGAGGASNC
*GTGSGR 17 59.71% 63.19% -3.48% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 AVYSTNCPVWEEAFR 522 5.05% 8.61% -3.55% 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 
SLPSVETLGC*TSVIC*SD
K 344 22.64% 26.38% -3.74% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 VAGDCLDEK 131 18.48% 22.72% -4.25% 
P62913 RPL11 60S ribosomal protein L11 IAVHCTVR 72 15.51% 20.05% -4.54% 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 ILYLDSSEIC*FPTVPGC*PGAWDVDSENPQR 604 17.39% 22.36% -4.97% 





ACTYIR 72 82.81% 88.01% -5.20% 
Q9UHB9 SRP68 Signal recognition particle 68 kDa protein LCESNR 173 39.93% 45.70% -5.77% 
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 VAGDCLDEK 131 18.03% 24.27% -6.24% 
Q9NP72 RAB18 Ras-related protein Rab-18 TC*DGVQC*AFEELVEK 155 16.76% 23.33% -6.56% 
Q6JUT2 TIRAP3 TIR domain-containing adapter molecule 2 FCFSNEFSTFTHK 0 74.43% 81.28% -6.85% 
Q8NCG7 DAGLB Sn1-specific diacylglycerol lipase beta 
AAC*VSC*PAQGVSSVD
VA 658 48.57% 56.44% -7.87% 
Q8N5B7 CERS5 Ceramide synthase 5 SPCDSSSSNGANR 369 63.39% 71.56% -8.17% 
O75131 CPNE3 Copine-3 EALAQCVLAEIPQQVVGYFNTYK 506 6.67% 14.85% -8.18% 
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P50991 CCT4 T-complex protein 1 subunit delta ITGCASPGK 379 9.41% 20.07% -10.66% 
P09525 ANXA4 Annexin A4 GAGTDEGCLIEILASR 108 8.88% 20.21% -11.33% 
P08581 MET Hepatocyte growth factor receptor 
SNSEIIC*C*TTPSLQQLN
LQLPLK 800 81.51% 94.02% -12.51% 
Q14764 MVP Major vault protein ALCLLLGPDFFTDVITIETADHAR 515 46.18% 59.96% -13.78% 
Q00341 HDLBP Vigilin DCVEAAK 855 21.15% 35.26% -14.11% 
A5YKK6 CNOT1 CCR4-NOT transcription complex subunit 1 YCDPVVLTYQAER 1541 14.23% 32.87% -18.64% 
Q6JUT2 TIRAP3 TIR domain-containing adapter molecule 2 FCFSNEFSTFTHK 0 15.78% 38.41% -22.64% 
P11216 PYGB Glycogen phosphorylase, brain form  TCFETFPDK 326 13.99% 38.48% -24.49% 
P36873 PPP1CC Serine/threonine-protein phosphatase PP1-gamma cat GNHECASINR 127 10.39% 40.62% -30.23% 
P10586 PTPRF Receptor-type tyrosine-protein phosphatase F CDQYWPAR 1460 4.76% 35.15% -30.39% 
O75534 CSDE1 Cold shock domain-containing protein E1 PGQQVATCVR 506 15.58% 49.41% -33.83% 
Q9BY67 CADM1 Cell adhesion molecule 1 CEASNIVGK 313 22.92% 61.72% -38.80% 
P08123 COL1A2 Collagen alpha-2(I) chain FTYTVLVDGCSK 1317 38.83% 81.65% -42.82% 
P30530 AXL Tyrosine-protein kinase receptor UFO TSSFSCEAHNAK 205 39.49% 95.24% -55.75% 
 
